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General Introduction
1.1. RATIONALE FOR THIS RESEARCH
Late life neuropsychiatric disorders
By 2050 we expect two billion persons over 65 years worldwide[1]. As the propor-
tion of the world’s population in the older ages continues to increase, the burden 
of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neuropsychiatric 
disorders increase as well. Th e percentage of persons with Alzheimer’s disease 
increases from 1 of 60-year-olds to about 30 of 85-year-olds [2].
Prevalence studies estimated that 24.3 million people have currently dementia 
worlwide, with 4.6 million new cases of dementia every year (one new case every 
7 seconds). Th e number of people aﬀ ected by dementia will double every 20 years 
to 81.1 million by 2040 [3].Th e prevalence of Parkinson’s disease in persons above 
65 years is 1.8 in Europe, with an increase from 0.6 in those aged 65 to 69 years 
to 2.6 in those 85 to 89 years [4].
Alzheimer’s disease is a progressive neurodegenerative disorder manifested by 
cognitive and memory deterioration leading to progressive impairment of ac-
tivities in daily living. Behavioral and psychotic symptoms of dementia (BPSD), 
including agitation, aggression, and psychoses, frequently occur in patients with 
dementia, particularly in advanced stages of the disease [5].
Parkinson’s disease is primarily considered a motor disease characterized by rest 
tremor, rigidity, bradykinesia and postural disturbances. However, neuropsychiat-
ric complications, including mood and anxiety disorders, fatigue, apathy, psycho-
sis, cognitive impairment, dementia, sleep disorders and addictions, frequently 
complicate the course of the illness [6].
Independent of these well deﬁ ned neurodegenerative diseases, a variety of 
psychiatric disturbances commonly occur in advanced age, ranging from depres-
sive symptoms to anxiety and psychotic disorders. Th e prevalence of depressive 
symptoms is 5–13, but depression in elderly is often under-diagnosed and under-
treated [7].
Anxiety disorders aﬀ ect up to 20 of the community-dwelling elderly [8]. 
Th e prevalence of psychotic symptoms (i.e. hallucinations and delusions) in the 
geriatric population ranges from 0.2 to 4.8 in an outpatient setting, and are as 
high as 10–63 in elderly living in nursing home [9].
Overall, late life neuropsychiatric disorders are disabling conditions that result 
in a lower quality of life of elderly patients and their caregivers, earlier institution-
alization, and excess mortality.
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Use of psychotropic drugs in elderly
Appropriate and judicious use of psychotropic drugs may dramatically improve 
the quality of life and functional status of many elderly patients with neuropsy-
chiatric disorders [10-12].
However, the decision to prescribe a psychotropic agent in elderly patients is a 
complex issue for a number of reasons. First, randomized clinical trials (RCTs) of 
psychotropic drugs in geriatric patients with mental illnesses are very scarce. Only 
recently a number of RCTs of mostly atypical antipsychotics have been conducted 
in demented patients [13]. Second, due to signiﬁ cant diﬀ erences in pharmacoki-
netic and pharmacodynamic proﬁ les, ﬁ ndings from RCTs of psychotropic drugs 
in younger persons may not be directly generalized to the geriatric population. 
Drug metabolism and clearance can be signiﬁ cantly reduced in older patients, as 
a result of impaired liver and renal functionality, which increases the potential for 
adverse drug reactions [14-16].
Th ird, the dose response eﬀ ect is diﬀ erent in older patients since not only phar-
macokinetics but also the pharmacodynamics change. Despite all these diﬃ  culties 
and the increased susceptibility to adverse drug reactions in elderly, one in ﬁ ve 
community-dwelling elderly persons receives currently psychotropic medications 
[17], and this rate is even higher in nursing home and long term facilities setting, 
where psychoactive agent overuse and disuse is the leading cause of preventable 
adverse drug reactions [18].
A brief overview of current knowledge and guidelines regarding the use and 
recommendations of speciﬁ c psychotropic drugs (antipsychotics, antidepressants 
and anti-Parkinson drugs) in elderly is presented below.
Antipsychotic drugs
Antipsychotic (AP) drugs (comprising conventional and atypical agents) are widely 
used in late life psychiatric disorders, such as psychoses, agitation and behavioral 
and psychological symptoms of dementia [19].
During the last two decades, the atypical antipsychotics, such as olanzapine, 
risperidone and quetiapine, have started to replace the older conventional anti-
psychotics, like phenothiazine (i.e. thioridazine and chlorpromazine) and buty-
rophenones (i.e. haloperidol) in the pharmacological management of psychotic 
disorders [20-21].
Several practice guidelines recommend atypical antipsychotics as the ﬁ rst line 
option in the treatment of chronic psychoses [22].
Reason is the better safety proﬁ le of atypicals as compared to conventional 
antipsychotics, especially regarding extrapyramidal adverse events [23].
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However, the increasing use of atypical antipsychotics has resulted in a grow-
ing number of safety alerts, especially regarding oﬀ -label use. Based on a pooled 
analysis of available randomized placebo-controlled clinical trials (RCTs), the 
UK Committee on Safety of Medicines (CSM) has highlighted a 3-fold increased 
risk of cerebrovascular events in elderly with dementia, who were treated with 
risperidone or olanzapine in March 2004 [24].
In April 2005, another warning was issued by the Food and Drug Administra-
tion (FDA) to inform health professionals about the results of a pooled analysis 
of 17 RCTs reporting a 1.7 times increased risk of all-cause mortality associated 
with atypical antipsychotic use in elderly dementia patients [25]. Cerebrovascular 
events, pneumonia and arrhythmias were the most frequently reported causes of 
death. In June 2008, the FDA extended this warning also to the typical anti-
psychotics [26].
Th ese safety alerts have ignited a very animated debate in the scientiﬁ c com-
munity. Some authors judged the warnings on atypical antipsychotics as unneces-
sarily alarming and potentially detrimental for elderly patients with dementia, in 
light of a possible more widespread use of conventional antipsychotics, as recently 
documented by a Canadian study [27].
Given the extent of use and the safety concerns, epidemiologic evidence on 
the use and the risks of antipsychotic drugs in the geriatric population is urgently 
needed.
Antidepressant drugs
Antidepressants (ADs) are frequently prescribed for the treatment of depressive 
symptoms and anxiety disorders in elderly. Initially, the tricyclic antidepressants 
(TCAs) were mainly used for these indications, despite TCAs have poorly toler-
ated in elderly, mostly due to their anticholinergic eﬀ ects.
Th e introduction of selective serotonin reuptake inhibitors (SSRIs) in the 80s 
has markedly changed the management of depression in elderly [28-29]. SSRIs, 
including sertraline, ﬂ uoxetine, paroxetine, ﬂ uvoxamine, citalopram, and escit-
alopram, are currently considered as ﬁ rst-line drugs in the treatment of late-life 
depression, due to similar eﬃ  cacy but more favorable tolerability, compared to 
other antidepressants [30-31]. However, concerns about the safety of SSRIs are 
growing, due to their anti-platelet activity which may increase the risk of bleeding 
[32-33].
SSRIs decrease intracellular contents of serotonin in platelets by blocking sero-
tonin transporter 5-HTT, thus inhibiting platelet function. Of particular interest 
is the relationship between antidepressant drug use and risk of both hemorrhagic 
and ischemic cerebrovascular events. Th ese associations are diﬃ  cult to study since 
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depression may be a risk factor and result of (minor) stroke [34]. Some previous 
studies failed to demonstrate an association between use of SSRIs and hemorrhagic 
stroke [35-37], while epidemiologic evidence on the risk of ischemic stroke in 
elderly patients is currently missing. Studying this relationship in an observational 
setting is complicated since elderly patients that are treated with antidepressants 
often have several cardiovascular risk factors and take many concomitant medica-
tions.
Polypharmacy may predispose elderly patients using antidepressants to develop 
drug-drug interactions. Older compounds, such as TCAs or Monoamine oxidase 
inhibitors (MAOIs), acting on a broad range of receptors and enzymes have a 
greater potential to interact pharmacodynamically with other medications aﬀ ect-
ing the same system(s) than newer agents (SSRIs) which have a more speciﬁ c 
mechanisms of action [38]. On the other hand, SSRI use in the elderly is associated 
with the possibility of clinically relevant pharmacokinetic interactions with other 
medications due to their inhibitory eﬀ ect on CYP enzymes. Th e diﬀ erential eﬀ ects 
of various SSRIs on CYPs are well characterized in vitro, with the potential to 
interact with other drugs being greater for ﬂ uvoxamine, ﬂ uoxetine and paroxetine 
and lower for sertraline, citalopram and escitalopram [39-40].
Th erefore, the potential for drug-drug interactions should guide the selection 
of an appropriate antidepressant in elderly. Comprehensive reviews of antidepres-
sant drug interactions in the elderly have been published, allowing for a better 
choice [41-42].
Anti-Parkinson drugs
Levodopa (L-Dopa) is the most eﬀ ective drug for the treatment of Parkinson’s 
disease (PD), although this medication is associated with limiting and poorly 
tolerated motor and non-motor side eﬀ ects, particularly, in the advanced stages 
of the disease [43]. Other anti-Parkinson drugs (APDs) are commonly used in 
clinical practice, either as monotherapy or as adjunctive therapy with L-Dopa, 
to delay or reduce its motor and non-motor complications and to maximise drug 
eﬀ ectiveness: ergot-derived (i.e. cabergoline, pergolide, and bromocriptine) and 
non ergot-derived (i.e. ropinirole and pramipexole) dopamine agonists (DAs), 
anticholinergic drugs, amantadine, selegiline and catecol-O-methyltraserase 
(COMT) inhibitors [44].
Dopamine agonists have been increasingly used as monotherapy in early PD to 
delay the start of L-Dopa treatment in the last decade [45]. Since 2002, a number 
of case reports of ﬁ brosis valvular heart disease associated with pergolide and there-
after also with cabergoline have been published. Th is association was conﬁ rmed by 
several prevalence echocardiographic studies in patients with Parkinson’s disease. 
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However, only one study looked at clinically diagnosed cardiac valve ﬁ brosis us-
ing data from an electronic health record database [46-49]. Laboratory studies 
indicate that the eﬀ ects of dopamine agonists may be linked to the activation of 
the serotonin 5-HT2B receptor [50].
Since some ergot derived DAs are strong agonists of 5-HT2B receptors, ﬁ brotic 
valvular damage is thought to occur through preferential activation of this recep-
tor expressed on heart valves.
As a consequence of the growing evidence about the risk of ﬁ brotic heart valve 
disease, pergolide was withdrawn from the US market, and cabergoline as well as 
pergolide are now second line treatment for PD in Europe, and their use requires 
monitoring [51].
On the basis of these health policy interventions, a dramatic impact on the 
prescribing pattern of anti-Parkinson drugs is expected in the following years.
1.2. AIM AND OUTLINE OF THE THESIS
Th e general objective of the research described in the present thesis was to ob-
tain a better understanding of the use and safety of antipsychotic (chapter 2), 
antidepressant (chapter 3), and anti-Parkinson drugs (chapter 4) in community 
dwelling elderly patients.
Speciﬁ cally, with respect to antipsychotic drugs, we ﬁ rst analysed the trends 
in prescriptions in Italy with a special focus on patients with dementia (chapter 
2.1). In the same setting it was measured if the safety warnings that have been 
issued by regulatory agencies changed the prescribing pattern of antipsychotics 
in elderly demented patients in the recent years (chapter 2.2). Th ese safety alerts, 
together with a growing number of observational studies, questioned the actual 
tolerability of atypical and typical antipsychotic use in elderly patients. To further 
assess the safety risks, we ﬁ rst investigated the risk of stroke associated with the 
use of diﬀ erent antipsychotic drugs in Italy by using the electronic health record 
database Health-Search/Th ales (HS) (chapter 2.3). Second, we analysed the risk 
of all cause mortality (chapter 2.4) and fatal and non-fatal pneumonia (chapter 
2.5) in association with atypical either typical antipsychotics in a cohort of elderly 
outpatients, using data from the Integrated Primary Care Information (IPCI), 
which is a Dutch general practice database. Finally, we conducted a comprehensive 
review of the the safety of atypical and typical antipsychotics in elderly demented 
patients (chapter 2.6).
Regarding antidepressant drugs, we analysed their prescribing pattern in adults 
and elderly persons in Italian general practice (chapter 3.1). Subsequently we as-
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sessed the potential association between ischemic stroke and use of SSRIs, TCAs 
and other antidepressants in a cohort of Dutch elderly outpatients (chapter 3.2). 
Finally, we reviewed the state of the art and the strategies to prevent drug-drug 
interactions in older patients (chapter 3.3).
Concerning anti-Parkinson drugs (APDs), in chapter 4.1 we described the 
prescribing pattern of APDs in Southern Italy, and, more in detail, we evaluated 
the burden of cardiovascular diseases in elderly with Parkinson’s disease who start 
a dopamine agonist agent (chapter 4.2). Finally, to provide new insights on the 
risk of ﬁ brotic valvular heart disease, we studied the association between ergot and 
non-ergot derived dopamine agonist use and cardiac valve regurgitation in elderly 
patients with Parkinson’s disease, using data from multiple electronic health record 
databases (Health Search/Th ales from Italy, IPCI from Th e Netherlands, THIN 
from United Kingdom) (chapter 4.3).
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Antipsychotic drugs in elderly: 
use and safety
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ABSTRACT
Objectives: To assess the antipsychotic use and the prevalence/incidence of anti-
psychotic drug users in Italy during the 1999-2002 years. To estimate the persis-
tence with antipsychotic medications and to measure their oﬀ -label use.
Methods: We selected 465,061 individuals registered at June 2002 in the lists of 
320 general practitioners, homogenously distributed throughout Italy, from the 
Health Search Database. We measured the antipsychotic drugs consumption, 
calculated as deﬁ ned daily dose (DDD) per 1,000 inhabitants per day. We also 
calculated the number of individuals receiving at least one antipsychotic prescrip-
tion, to estimate the annual prevalence and incidence of antipsychotics users. 
Among incident users, we evaluated the percentage of patients that were adherent 
to drug label indications and the average duration of treatment, estimated as 
Medical Possession Ratio (MPR).
Results: Atypical antipsychotic use has been continuously increased from 1999 to 
2002. Women, older people and patients aﬀ ected by psychotic disorders, other than 
schizophrenia, were more likely to receive antipsychotic prescriptions. Persistence 
to atypical drugs treatment (MPR=0.213 in 2002) appeared longer, compared to 
the typical ones (0.169). Th e percentage of patients adherent to drug label indica-
tions was signiﬁ cantly higher among typical antipsychotic users (P<0.001). Th e 
most common oﬀ -label use for atypical drug was senile dementia.
Conclusion: Atypical drugs use is continuously growing up along the years 1999-
2002, particularly in older people with dementia. Th e rapidly increasing use of 
this new class of antipsychotics highlights the need of a better evaluation about 
their safety proﬁ le, and a better deﬁ nition of their role in psychiatric treatments.
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INTRODUCTION
In the last decade the management of schizophrenia was modiﬁ ed by the market-
ing of second generation antipsychotics (SGAs). In diﬀ erent practice guidelines, 
SGAs have been considered as the ﬁ rst therapeutical option in schizophrenia 
[1-2] because they would provide a better safety proﬁ le with respect to traditional 
drugs. Several studies have reported that SGAs are associated to a reduction in the 
occurrence of extrapyramidal side-eﬀ ects, major adverse event in the antipsychotic 
treatment [3], despite the growing concern about the SGAs metabolic eﬀ ects, in-
cluding diabetes, hyperlipidemia and obesity [4]. However, the debate about the 
role for these medications still remains, because of their frequent use oﬀ -labelled 
[5]. Recently, the Committee on Safety of Medicines (CSM), after reviewing the 
available data from clinical trials of risperidone and olanzapine, has highlighted an 
increased risk of stroke in elderly patients with dementia who are treated with these 
drugs. In fact, although no atypical antipsychotic drug is licensed in Italy for the 
treatment of behavioural disturbances in dementia, risperidone and olanzapine are 
often used for such indication [6]. Nevertheless several previous studies reported 
a substantial increase of atypical antipsychotics prescriptions in primary care over 
the last years [7]. Particularly, a recent population-based study, performed in the 
UK from 1991 to 2000 [8], showed a continuously growing up consumption for 
such medications, partially attributable to the increased average annual duration 
of treatment. As far as Italy is concerned, few recent papers were published on 
this issue. Th e last study by Barbui et al [9] in the year 2000, reported a rate of 
oﬀ -label SGAs prescriptions of 52.
Th e present study was therefore performed to investigate possible changes in 
prescribing pattern for antipsychotic drugs in general practice during the years 
1999-2002, and to explore the duration of treatment, with the purpose to observe 
whether persistence could contribute in drug consumption variations. We have 
also estimated the oﬀ -label use for each antipsychotic drug.
METHODS
Data source
Primary care-based data were obtained by the Health Search Database (HSD), 
which was set up by the Italian College of General Practitioners (SIMG) in 1998. 
Characteristics of the database have been described in previous studies [10-11]. 
Brieﬂy, the HSD contains information about patient demographics, medical 
diagnoses coded according to the ninth edition of International Classiﬁ cation of 
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Diseases (ICD-9), drug prescriptions coded according to the Anatomical Chemical 
Classiﬁ cation system (ATC), hospital referrals, and diagnostic investigations from 
550 general practitioners (GPs) with a total patients population of over 800,000 
individuals. Every 3 months, the HSD is subject to a range of quality checks, par-
ticularly aimed to assess the completeness of all information collected. Physicians 
who fail to meet standard quality criteria are not considered for epidemiological 
studies [12].
Study population
For this study, we selected 465,061 patients registered at the end of June 2002 in 
the lists of 320 GPs, homogenously distributed throughout Italy (142 GPs from 
northern Italy, 60 from central, and 118 from southern) in order to include a num-
ber of patients proportional (0.9) to the size of their respective population.
We identiﬁ ed patients receiving at least one antipsychotic prescription, during 
the years 1999-2002. For each patient selected, the following information was 
included: age, gender, antipsychotic prescriptions, including brand name of the 
medication, ATC code, prescription date, number of prescribed packages, and 
indication codiﬁ ed by ICD-9.
We excluded from the study sample subjects aged <15 years, and patients 
without almost one year of recorded data in HSD before the ﬁ rst antipsychotic 
prescription (i.e. INDEX DATE).
Antipsychotic drugs
Antipsychotics were classiﬁ ed, according to the British National Formulary [8], 
into the following groups: (1) atypical, which consisted of clozapine, olanzapine, 
risperidone, and quetiapine; (2) typical, including all the other antipsychotic 
drugs. We excluded from the analysis amisulpride because until 2002 in Italy, it 
was exclusively used to treat dysthymia. Such compound was, in fact, classiﬁ ed as 
atypical antipsychotic after the end of the observation.
Drug utilization was expressed by using the deﬁ ned daily dose (DDD) per 
1,000 inhabitants per day, where DDD is the assumed average dose per day for a 
drug used for its main indication in adults [13]. Results have been standardized by 
age group according with Italian population reported by Italian Oﬃ  ce of National 
Statistics (ISTAT) in 2002 [14].
Prevalence/incidence of antipsychotic treatment
Prevalence and incidence of antipsychotic treatment were assessed by drug type 
and by molecule for each year. We considered an antipsychotic user as a patient 
who had at least one recorded antipsychotic prescription during the study period. 
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We measured the prevalence of antipsychotic treatment, deﬁ ned as the number of 
antipsychotic drugs users divided by the number of subjects alive and registered in 
the GP lists of the study population. We deﬁ ned “new user” as a patient receiving 
the ﬁ rst antipsychotic prescription without any recorded antipsychotic treatment 
in the previous year. Th e incidence rate was measured as the number of “new 
users” divided by the person-time free from antipsychotic drug use in the current 
year.
Analysis of persistence
Among new users, the persistence to antipsychotic drug therapy was annually 
quantiﬁ ed as a Medication Possession Ratio (MPR). MPR was calculated by di-
viding the cumulative duration of any antipsychotic treatment during follow-up 
(numerator) with the duration of “possible treatment” (denominator) [15]. Any 
subject who had an MPR greater than one had their records modiﬁ ed to reﬂ ect a 
maximum value of one [16].
Th e cumulative duration of each medication was calculated by dividing the 
total prescribed amount of antipsychotic drug with the recommended daily dose, 
according to the Italian Deﬁ ned Daily Doses. Th e duration of “possible treatment” 
corresponded to the number of days from the index date to the end of each year.
Adherence to drug label indications
Among new users, we analysed the indications (ICD-9 codes) linked to the ﬁ rst 
antipsychotic prescription being recorded. Th us, we compared such indications 
with those reported on drug label for each molecule in order to measure the 
percentage of adherence. Stratiﬁ cation by gender, age groups, and drug type was 
performed to observe factors associated with major adherence.
Statistical analysis
Chi-square test for proportions, with a signiﬁ cance level of P ≤ 0.05 was used for 
assessing the demographic variables more likely to be associated to an antipsychotic 
prescription, and for evaluating possible changes in the prescribing pattern during 
observation years. Th e same test was also used to explore diﬀ erences among drug 
types concerning prescription rate and adherence to indications.
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RESULTS
Antipsychotic prescriptions
Among neuropsychiatric drugs, antipsychotics (8.3 of total psychoactive drugs 
use) result the fourth drug category more prescribed during the year 2002 in the 
HSD, following antidepressants (45.7), anticonvulsivants (17.8), and sedatives/
hypnotics (17.4).
Antipsychotic use was relatively stable over the years 1999-2002 (Table 1). 
However, among the diﬀ erent therapeutic subgroups, atypical drugs consump-
tion varied from 10.5 of total antipsychotics in 1999 to 38.0 in 2002, whereas 
traditional medications use decreased during the 4-year study period. Out of 21 
diﬀ erent molecules being used, 10 accounted for almost 90 of total antipsychot-
ic consumption. Haloperidol was the most commonly prescribed drug during 
2002 (21.4), followed by olanzapine (19.8) and risperidone (13.0). Among 
traditional drugs, long-acting antipsychotics use remained stable over 4 years and 
accounted for only 9 of total antipsychotics use (data not shown).
Table 1. Use of antipsychotic drugs, stratifi ed by calendar year.
Molecules 1999 2000 2001 2002
DDD*/1,000 
inhab./day
% on
total
DDD*/1,000 
inhab./day
% on
total
DDD*/1,000 
inhab./day
% on
 total
DDD*/1,000 
inhab./day
% on 
total
Typical 1.53 89.5 1.26 81.3 1.25 68.7 1.19 62.0
Haloperidol 0.49 28.7 0.42 27.1 0.42 23.1 0.41 21.4
Clotiapine 0.14 8.2 0.12 7.7 0.12 6.6 0.13 6.8
Levosulpiride 0.16 9.4 0.13 8.4 0.13 7.1 0.10 5.2
Fluphenazine 0.12 7.0 0.10 6.5 0.10 5.5 0.10 5.2
Thioridazine 0.15 8.8 0.12 7.7 0.09 4.9 0.08 4.2
Chlorpromazine 0.06 3.5 0.05 3.2 0.06 3.3 0.06 3.1
Other typicals# 0.41 24.0 0.32 20.6 0.33 18.1 0.31 16.1
Atypical 0.18 10.5 0.29 18.7 0.57 31.3 0.73 38.0
Olanzapine 0.06 3.5 0.11 7.1 0.27 14.8 0.38 19.8
Risperidone 0.10 5.8 0.15 9.7 0.23 12.6 0.25 13.0
Quetiapine^ - - 0.01 0.6 0.03 1.6 0.06 3.1
Clozapine 0.02 1.2 0.02 1.3 0.04 2.2 0.04 2.1
Total 1.71 100.0 1.55 100.0 1.82 100.0 1.92 100.0
^ Molecule introduced in drug market starting from 2000.
*Italian DDD values expressed in grams: Haloperidol (0.008, os formulation; 0.0033, depot); Clotiapine (0.12); Levosulpiride (0.15); 
Fluphenazine (0.01, os; 0.001, parenteral); Thioridazine (0.3); Chlorpromazine (0.3, os; 0.1, parenteral); Olanzapine (0.01); Risperidone (0.005); 
Quetiapine (0.4); Clozapine (0.3);
#Other typicals: Levomeprazine (0.3), Promazine (0.3, os; 0.1, parenteral), Perphenazine (0.03, os; 0.01, parenteral; 0.007, depot), Pimozide 
(0.004), Trifl uoroperazine (0.02), Pericyazine (0.05), Zuclopenthixol (0.03, os; 0.015, depot), Bromperidol (0.01), Pipamperon (0.2).
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Description of study sample
Percentage of subjects treated with antipsychotic drugs was constant over the years 
(about 1.4 of total sample population). Among these, the number of patients 
receiving at least one prescription of both atypical and typical drugs in each year 
increased from 1.8 of total antipsychotic users in 1999 to 8.6 in 2002. Women 
and elders were more likely to receive typical antipsychotics, although, across the 
study years, the diﬀ erences in the patients demographics between the antipsychot-
ic groups tended to narrow (Table 2). Among typical users, percentage of males 
varied from 37.1 in 1999 to 40.5 in 2002 (P<0.001), while it dropped oﬀ  from 
48.9 to 45.9 among SGAs users. Similarly, typical users older than 65 years 
decreased from 54.0 in 1999 to 50.3 in 2002, whereas SGAs users varied from 
27.6 to 49.1 (P<0.001).
Table 2 also shows the main indications for antipsychotic prescription over the 
years, where psychosis disorders other than schizophrenia and aﬀ ective disorders 
reported the higher frequency. Interestingly, the percentage of patients with de-
mentia treated with atypical drugs, continuously increased along the study years 
(3.7 in 1999 vs. 19.8 in 2002).
Table 2. Demographic and clinical characteristics of patients in treatment with antipsychotic drugs, stratifi ed by drug type and calendar year.
1999
(N=4,505)
2000
(N=5,590)
2001
(N=6,081)
2002
(N=6,064)
Typicals
(N=4,284)
Atypicals
(N=221)
Typicals 
(N=5,034)
Atypicals
(N=556)
Typicals
(N=4,784)
Atypicals
(N=1,297)
Typicals
(N=4,490)
Atypicals
(N=1,574)
Gender (%)
Male 1,588 (37.1) 108 (48.9) 1,891 (37.6) 271 (48.7) 1,975 (41.3) 623 (48.0) 1,820 (40.5) 712 (45.2)
Female 2,696 (62.9) 113 (51.1) 3,143 (62.4) 285 (51.3) 2,809 (58.7) 674 (52.0) 2,670 (59.5) 862 (54.8)
Mean Age (DS) 65.5 (19.5) 52.1 (20.1) 65.6 (18.9) 52.6 (20.8) 64.5 (19.4) 57.9 (21.6) 63.6 (19.6) 60.1 (21.9)
Age groups (%)
15-29 159 (3.7) 34 (15.4) 203 (4.0) 74 (13.3) 212 (4.4) 124 (9.6) 231 (5.1) 156 (9.9)
30-49 846 (19.7) 90 (40.7) 929 (18.5) 187 (33.6) 1,008 (21.1) 394 (30.4) 998 (22.2) 415 (26.4)
50-64 968 (22.6) 36 (16.3) 1,127 (22.4) 88 (15.8) 1,061 (22.2) 186 (14.3) 1,002 (22.3) 230 (14.6)
65-79 1,083 (25.3) 37 (16.7) 1,396 (27.7) 107 (19.2) 1,191 (24.9) 295 (22.7) 1,111 (24.7) 387 (24.6)
≥80 1,228 (28.7) 24 (10.9) 1,369 (27.2) 90 (16.2) 1,312 (27.4) 298 (23.0) 1,148 (25.6) 386 (24.5)
Diagnostic groups (%)
Other or no diagnosis 961 (22.4) 27 (12.2) 929 (18.4) 42 (7.6) 808 (16.9) 78 (6.0) 658 (14.7) 91 (5.7)
Schizophrenia 296 (6.9) 71 (32.1) 344 (6.8) 134 (24.1) 354 (7.4) 259 (20.0) 332 (7.4) 294 (18.7)
Aff ective disorders 1,408 (32.9) 43 (19.4) 1,729 (34.3) 131 (23.5) 1,383 (28.9) 324 (24.9) 1,365 (30.4) 378 (24.0)
Other psychotic 
disorders *
1,245 (29.1) 72 (32.6) 1,497 (29.7) 173 (31.1) 1,607 (33.6) 398 (30.7) 1,533 (34.1) 501 (31.8)
Dementia 374 (8.7) 8 (3.7) 536 (10.6) 76 (13.7) 631 (13.2) 238 (18.4) 601 (13.4) 311 (19.8)
*Psychosis not otherwise specifi ed, paranoid disorders, reactive psychosis, personality disorders, alcohol or drug-related psychosis, 
psychosomatic disturbances.
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Prevalent and incident users
Prevalence of antipsychotic users resulted relatively stable over the years, varying 
from 13.7 (per 1,000 inhabitants) in 1999 to 12.9 in 2002 (Figure 1 a-b). Prevalence 
decreased among females (16.4 in 1999 vs. 14.6 in 2002), whereas it remained 
stable among males (10.9 in 1999 vs. 11.2 in 2002). Prevalence of typical drug users 
decreased from 13.0 in 1999 to 9.6 in 2002, whilst it increased approximately 5-fold 
for SGAs (0.7 in 1999 vs. 3.4 in 2002). Incidence rate of overall antipsychotic users 
was rather stable over the years (10.1 per 1,000 person-years in 1999 and in 2002). 
However, such trend substantially varied between the drug types with a decrease 
of typical users (9.7 in 1999 vs. 8.8 in 2002), and a slight increase of atypical users 
(0.4 in 1999 vs. 1.3 in 2002), as reported in ﬁ gures 2 a-b.
Figures 1 a-b. Prevalence of antipsychotic drugs users, stratifi ed by calendar year and drug type and gender
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Persistence to antipsychotic treatment
Th e overall persistence to antipsychotic treatment (MPR: 0.174 in 2002) decreased 
over the years (Table 3). Such evidence might be partially due to the observed de-
creasing persistence for SGAs (0.382 in 1999 vs. 0.213 in 2002), although over the 
years it remained higher than typicals (0.225 in 1999 vs. 0.169 in 2002). Compared 
to the old ages, a higher MPR (average: 0.393) was reported in patients aged 15-49, 
commonly atypical users and patients with schizophrenia.
Adherence to indications of use reported on drug label
Typical users showed a higher adherence compared to the atypical group (80.8 
vs. 36.3, P<0.001). No diﬀ erences were reported by gender and age groups. Th e 
Figure 2 a-b. Incidence of antipsychotic drug use per 1,000 Person/Years (P/Y) in females (A) and males (B), stratifi ed by calendar year and 
drug class.
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main oﬀ -label use for the SGAs was senile dementia (29.8 of total cases of non-
adherence), while the anxiety disorders not associated to any psychotic disorders 
was the most common oﬀ -label use related to the typical antipsychotics.
DISCUSSION
Th e results of the present study indicate that prevalence and incidence of anti-
psychotic treatments remain rather stable over the years 1999-2002. Th ese data 
diﬀ er from a study performed in the UK [8] in the years 1991-2000, where it was 
reported an increasing prevalence of antipsychotic use with a relative reduction of 
the incidence rate.
Such discrepancy might be partially aﬀ ected by the recent introduction in the 
drug market of SGAs. In our study an unchanged prevalence of typical users 
with a decreasing number of new users was shown. However, among atypical 
users the prevalence, but even the incidence, increased during the observed years. 
Th e DDD/1,000 inhabitants/day values for atypical drugs also showed a 4-fold 
increase from 1999 to 2002, while typical medications decreased of about one 
third over the years, thus conﬁ rming our hypothesis. Th is trend is also similar to 
that reported in a cross-sectional study conducted by Ashcroft et al [7], where 
atypical antipsychotics use resulted in a nearly 6-fold increase from 1997 to 2001 
in UK, whilst use of conventional antipsychotics decreased by 24. In the year 
2002, olanzapine and risperidone became the most common used antipsychotic 
drugs, partially in contrast to studies conducted in the US, where starting from 
Figure 3. Medical possession ratio of incident users, stratifi ed by calendar year, and drug type.
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1997 such drugs were the most widely prescribed [17]. Such evidence might be 
partially explained by the earlier launch of the above-mentioned medications in 
the US as compared to Italy.
Characteristics of antipsychotic drugs users
Women and patients >65 years old were more likely to receive an antipsychotic 
medication, particularly a traditional antipsychotic. According to the results from 
European Study of the Epidemiology of Mental Disorders (ESEMeD) Project 
[18], women would be twice as likely to suﬀ er mood and anxiety disorders as men. 
Since one third of patients treated with conventional antipsychotics were aﬀ ected 
by aﬀ ective disorders, the discrepancy in the demographic characteristics among 
two antipsychotic groups, may be explained by the diﬀ erent diagnostic distribu-
tion. Nevertheless, demographics of antipsychotic drugs users changed over the 
study period, with antipsychotic use resulting continuously increased among 
males and younger people (14-29 years). Such variation might be partially due to 
the increasing use of atypical medications, since these agents are more likely to 
be prescribed to men and younger people than conventional antipsychotics [19]. 
However, among atypical users, it was reported a statistically signiﬁ cant increase 
of mean age during 4 years, attributable to the rapidly increasing number of older 
people aﬀ ected by dementia (mean age: 81.1 ± 7.6).
Persistence to antipsychotic drugs treatment
A rather stable prevalence of antipsychotic use over the years with a decreasing 
incidence would suggest a slightly increasing average duration of antipsychotic 
treatment [8]. However, the study shows a decreasing trend of persistence to treat-
ment over the study period. In our analysis the patients who received SGAs are 
more likely to receive continuous antipsychotic therapy than those on conventional 
antipsychotics. Such evidence has been conﬁ rmed in a study from Germany [5]. 
Th e higher percentage of continuous users with atypical drugs could be a proxy 
for a more favourable side eﬀ ect proﬁ le. Another explanation may be correlated to 
the diﬀ erent distribution of diagnostic groups in the antipsychotic groups: SGAs 
are used to treat schizophrenia more than typical drugs, which, on the contrary, 
are mostly prescribed for acute psychosis associated to aﬀ ective disorders or other 
psychiatric diseases, according to our study and to German one [5].
Adherence to indications reported on drug label
Typical drugs users appear to be more adherent to drug label indications, compared 
to the patients receiving SGAs. Such ﬁ nding may be related to the fact that tradi-
tional medications have more indications reported on drug label with respect to the 
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atypical drugs. Surprisingly, among atypical users, the rate of elderly patients with 
dementia has been continuously increased along the study year, despite the recent 
debate on oﬀ -label use of SGAs. As previously mentioned, such patients should not 
be treated with these two agents not only because there is no speciﬁ c indication, 
but also for a documented increased risk of cerebrovascular accidents [20].
Limitations of the study
Th e present study was performed using computerized medical records from 
general practice in Italy. According to Kaye et al [8], the observed changes may 
not pertain directly to patients treated in other settings (for example, psychiatric 
inpatients or individual in nursing homes). Furthermore some antipsychotic drugs 
might be subject to major distribution directly from local psychiatric services thus 
avoiding general practitioners. Nevertheless, because GPs in Italy initiate anti-
psychotic treatment for some patients and continue treatments begun by specialist 
for other patients, we believe that these data are likely to be more representative 
of national trends than those from psychiatric hospitals or clinics. Moreover, we 
did not perform an analysis aimed to evaluate antipsychotic drugs politherapy, 
particularly the association between typical and atypical compounds, very com-
mon occurrence in daily clinical practice [21]. Th erefore, further studies addressed 
to investigate antipsychotic drugs politherapy in Italy are needed.
In conclusion, on the basis of the substantial increase of atypical antipsychotic 
drugs use in Italy from 1999 to 2002, and concerning the debate about the real 
safety proﬁ le and indication of use of the SGAs, we believe that eﬀ ectiveness and 
tolerability as well as the prescribing appropriateness of atypical antipsychotics 
should be carefully monitored, particularly among older patients.
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ABSTRACT
Introduction: Since 2004, safety alerts have been issued by European regulatory 
agencies regarding the risk of oﬀ -label use of atypical antipsychotics in elderly 
demented persons. We evaluated the antipsychotic drug prescribing pattern in the 
Italian general population and elderly demented outpatients, before and after the 
safety warnings.
Methods: A cohort study was conducted using the electronic medical records of 
the Italian general practice database “Health Search/Th ales” with information on 
about 1 million of subjects. One-year prevalence and incidence estimates were 
calculated for atypical and typical antipsychotic use. Th e monthly prevalence of 
both antipsychotic classes was also calculated in elderly demented patients.
Results: In the study population of 648,857 persons, 27,252 (4.2) patients re-
ceived at least one antipsychotic drug prescription. Th e prevalence of atypical 
antipsychotic use increased 3-times from 2000 to 2003 in the general population, 
remaining stable thereafter (3.4 per 1,000 in 2005). Use of typical antipsychotics 
decreased about one third in the same period, although it was still 3-times higher 
than atypicals in 2005 (10.9 per 1,000). Similar annual trends were observed in 
elderly patients, where use of atypical antipsychotics was more frequently for 
dementia than use of typicals (40.8 vs 23.7 in 2005).
Conclusion: In the last years, the prescribing pattern of antipsychotics changed 
in the Italian adult and elderly population. Compared to atypical antipsychotics, 
however, use of typical antipsychotics it is still three-times higher. Th e safety 
warnings seem to have partly inﬂ uenced the trend in the use of both typical and 
atypical antipsychotics in elderly dementia outpatients.
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INTRODUCTION
Antipsychotic drugs are commonly prescribed for the treatment of chronic mental 
illnesses and acute psychotic disorders associated to other psychiatric diseases, 
such as dementia, drug or alcohol abuse, depression or anxiety [1]. During the last 
two decades the marketing of the newer class of atypical antipsychotics changed 
the prescribing pattern of antipsychotics in general practice markedly, as reported 
in several US and European investigations [2-5]. Due to a supposed better safety 
proﬁ le, atypical antipsychotics, such as risperidone, olanzapine and quetiapine, 
have been increasingly prescribed in the treatment of psychiatric diseases. Th ese 
diseases included dementia and related psychotic disturbances, where the atypical 
replaced the typical antipsychotics, such as phenotiazines (e.g. thioridazine and 
chlorpromazine) and butyrophenones (e.g. haloperidol) [2-5].
Ashcroft et al reported a nearly six-fold increase in the use of atypical anti-
psychotics in the UK between 1997 and 2001, whilst the use of conventional 
antipsychotics decreased by 24 [3]. In the US, two atypical agents, olanzapine 
and risperidone, are the most widely prescribed antipsychotics since 1997 [4]. A 
previous Italian investigation reported a 5-fold increase in use of atypical anti-
psychotic medications for the treatment of behavioral and psychotic symptoms of 
dementia (BPSD) in primary care during 1999-2002, despite the oﬀ -label status 
of this indication [5]. In the last years, however, the safety proﬁ le of atypical and 
typical antipsychotics was questioned by the scientiﬁ c community and regula-
tory agencies. In March 2004, the European Committee on Safety of Medicines 
(CSM) recommended avoiding or switching the use of atypical antipsychotics in 
elderly with dementia, due to a 3-fold increased risk of cerebrovascular events [6]. 
On April 11, 2005, the Food and Drug Administration (FDA) warned healthcare 
providers about the increased all-cause mortality risk in elderly demented patients 
receiving atypical antipsychotics. Th is warning was thereafter extended to typical 
antipsychotics as well [7-8]. So far, only one Canadian study was performed to 
evaluate the eﬀ ect of these safety warnings on the antipsychotic prescribing pat-
tern [9]. Th is study demonstrated that the warnings had slowed down the increase 
in prescription of atypical antipsychotic drugs in patients with dementia but it 
had not changed the overall prescription rate of antipsychotics.
Th e aim of this drug utilization study was to evaluate how antipsychotic drug 
use changed in the general population, elderly and in elderly demented outpatients 
in the last years, after the issuing of the safety alerts.
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METHODS
Data source
For this study, the electronic medical records as kept in the Health Search/Th ales 
Database (HSD) were used. HSD was set up by the Italian College of General 
Practitioners (SIMG) in 1998 and currently captures data on more than 1 million 
patients from 800 general practitioners who are spread over the country. Charac-
teristics of the database have been described in previous studies [5, 10, 11]. Brieﬂ y, 
HSD contains information about patient demographics, medical diagnoses either 
coded according to the ninth edition of International Classiﬁ cation of Diseases-
Clinical Modiﬁ cation (ICD9-CM) or registered as clinical notes in free text, drug 
prescriptions coded according to the Anatomical Th erapeutic Chemical (ATC) 
classiﬁ cation system, hospital referrals, and diagnostic investigations.
HSD is subject to a range of quality checks, particularly aimed at assessing the 
completeness of all collected information. Physicians who fail to meet standard 
quality criteria are not considered for epidemiological studies [12].
Study population
For this study, we selected all the patients registered in the lists of 400 GPs who 
met the standard quality criteria. Th ese GPs are homogeneously distributed 
throughout Italy, so to include a number of patients that is proportional (about 
1) to the size of their respective population. Patients needed to be registered at 
least one year with the GP and be older than 15 since family pediatricians care for 
children until the age of 14 in Italy. Within the study sample, we identiﬁ ed all the 
patients receiving a ﬁ rst antipsychotic prescription (index date) during the years 
2000–2005 (no prescription in year prior). For each patient, the following infor-
mation was retrieved: age, gender, antipsychotic prescriptions, including brand 
name of the medication, ATC code, prescription date, and number of prescribed 
packages and indication of use.
Antipsychotic drugs
Antipsychotics were classiﬁ ed into the following groups: (1) atypicals, which con-
sisted of clozapine, olanzapine, risperidone, quetiapine and aripiprazole (marketed 
in Italy since 2005), and (2) typicals, including the following subgroups: phenotiaz-
ines, butyrophenones, benzamides and other typical antipsychotics (thioxanthene, 
diphenylbutylpiperidine derivatives, and clotiapine) [5]. We included amisulpride 
among benzamides because it belongs to this chemical subgroup, although it is 
considered as atypical antipsychotic in Italy since 2002. However, until that date 
amisulpride was mainly used for treating dysthymia.
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We also considered the long acting antipsychotics (haloperidol decanoate, ﬂ u-
phenazine decanoate, zuclopentixol decanoate, perphenazine enantate), separately. 
For each antipsychotic prescription, the coded indication of use directly linked to 
that prescription was identiﬁ ed. Th is indication of use was subsequently manually 
validated by two medical doctors through careful revision of all the clinical notes 
that were registered by GPs as free text. Finally, six diagnostic categories were 
created: 1) aﬀ ective disorders with psychoses, 2) behavioral and psychotic dis-
turbances of dementia, 3) schizophrenia, 4) anxiety disorders, 5) other psychotic 
disorders (i.e. delirium), and 6) not reported or not otherwise speciﬁ ed.
Data analysis
Patients who had at least one recorded antipsychotic prescription during the study 
period were classiﬁ ed as antipsychotic drug user. Th e annual prevalence of anti-
psychotic use was calculated by dividing the number of antipsychotic drug users 
per year by the number of subjects alive and registered in the GPs’ list during 
the entire observation year. One-year prevalence rates of overall and type speciﬁ c 
antipsychotic drug use were assessed, and the typical antipsychotic use was further 
stratiﬁ ed by diﬀ erent subgroups. All the rates were standardized for age according 
to the Italian population reported by Italian Oﬃ  ce of National Statistics (ISTAT) 
in 2005. Prevalence of use was expressed as rates per 1,000/10,000 inhabitants 
together with 95 Conﬁ dence Interval, as needed. Age speciﬁ c analyses were 
conducted for patients 65 years and older. In the elderly patients, the indication 
of use was further analysed. In demented elderly, we looked also at the yearly 
trend of antipsychotic drug use by single ingredient and the monthly trend in the 
prevalence of either atypical or typical antipsychotic use.
All the statistical analyses were conducted in SPSS/PC, version 13 (SPSS Inc, 
Chicago, Ill). Th e level of signiﬁ cance for all statistical tests was set at p-value 
below 0.05.
RESULTS
During the years 2000-2005, 27,252 (4.2) persons received at least one anti-
psychotic (AP) drug prescription in the study population, which comprised a 
total of 648,857 persons. In this population, the annual prevalence of AP use 
increased from 2000 to 2001, and decreased in the years thereafter (in 2005: 13.3; 
95 CI: 13.2-13.4 per 1,000 persons). In all the years, the prevalence of use of 
typical antipsychotics was much higher than that of atypicals Time trends in user 
rates diﬀ ered largely between atypical and typical antipsychotic drugs (Table 1). 
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Use of atypical drugs increased almost three-fold from 2000 [1.28 (1.18-1.38) per 
1,000] to 2003 [3.4 (3.3-3.6) per 1,000], but remained stable thereafter [in 2005: 
3.4 (3.2-3.5) per 1,000]. Use of typical antipsychotics reduced three-fold during 
the study years, but, despite the decrease, it remained approximately three-times 
higher than that of atypical agents in 2005: 10.9 (10.7-11.2) per 1,000 (Table 1).
Among typical antipsychotics, phenotiazines, butyrophenones and benzamides 
showed a similar prevalence of use in 2005, but the trends were quite diﬀ erent over 
time. Use of butyrophenones progressively increased, use of benzamides strongly 
decreased, while use of phenotiazines did not substantially change during the study 
years. Long acting antipsychotics accounted for around 5 of total antipsychotic 
use during the whole period. No signiﬁ cant diﬀ erences by gender in the observed 
trend between atypical and typical antipsychotics have been reported.
Elderly
Overall, 3,991 elderly patients (≥ 65 years) received at least one antipsychotic drug 
prescription in 2005, with a prevalence of use of 36.0 (34.0-38.0) per 1,000 persons 
per year, which is more than 3 times higher than in persons below 65 years.
In line with overall trends, use of atypical antipsychotics increased from 2000 
[1.8 (1.6-2.1) per 1,000] until 2003 [7.5 (7.0-8.0) per 1,000] in elderly, while the 
use of typical antipsychotics reduced by one third during the same period [31.9 
(30.9-33.0) per 1,000 in 2000 vs 24.8 (23.9-25.7) per 1,000 in 2003]. In the years 
thereafter, the user rates of atypicals and typicals remained mostly constant (Fig-
ure 1). Within the group of typical agents, the prevalence of butyrophenones use 
almost doubled from 2000 to 2005, while use of phenotiazines and even more 
that of benzamides tended to decrease (Figure 1). Th e distribution of indications 
of use in elderly patients, who received either atypical or typical antipsychotics, 
is shown in Figure 2a-b. Typicals were mainly used in the treatment of psychoses 
associated with aﬀ ective disorders (25.1 in 2005). On the other hand, the pro-
portion of typical antipsychotic users with dementia has been increasing since 
Table 1. Prevalence of antipsychotic drug use (per 1,000 inhabitants per year) in the Italian general population during the years 2000-2005
2000 2001 2002 2003 2004 2005
Antipsychotic type N. 
users
Prev. N. 
users
Prev. N. 
users
Prev. N. 
users
Prev. N. 
users
Prev. N. 
users
Prev.
Atypicals 655 1.28 1,476 2.75 1,781 3.26 1,880 3.41 1,884 3.34 1,952 3.36
Typicals 7,643 14.93 8,411 15.65 7,934 14.53 6,283 11.4 6,180 10.97 6,356 10.94
Phenotiazines 1,933 3.78 2,092 3.89 1,910 3.50 1,843 3.34 1,993 3.54 2,038 3.51
Butyrophenones 1,511 2.95 1,725 3.21 1,866 3.42 1,887 3.42 2,074 3.68 2,299 3.96
Benzamides 4,414 8.62 4,827 8.98 4,291 7.86 2,579 4.68 2,197 3.90 2,105 3.62
Others 488 0.95 546 1.02 578 1.06 582 1.06 548 0.97 624 1.07
Total 8,036 15.70 9,363 17.42 9,151 16.76 7,607 13.8 7,527 13.36 7,749 13.34
Gianluca BW.indd   42 25-May-09   11:23:12 AM
43
Antipsychotic drugs in elderly: use and safety
2003 (23.7 in 2005). Dementia and related disorders were the main indications 
of use for atypical antipsychotic users (40.8 in 2005), but this proportion has 
been declining starting from 2003. Some speciﬁ c sub-analyses were conducted 
in elderly demented patients to take a better look on use of typical and atypical 
antipsychotics (Figure 3-4). Th e monthly trend in the use of atypical and typical 
antipsychotics in elderly persons with dementia is reported in Figure 3. Th e preva-
lence of use of atypical agents in demented patients progressively increased from 
January 2000 [0.2 (0.05-0.7) per 10,000 elderly persons] until the beginning of 
2004 [9.7 (8.1-11.6) per 10,000], after which the increase slowed down. Conversely, 
the prevalence of use of typical antipsychotics decreased from 2001 [15.7 (13.5-18.2) 
per 10,000] until 2004 [10.7 (9.0-12.7) per 10,000], when its prevalence of use 
was almost overlapping that of atypical agents, then again slightly increasing in 
the following years, up to 12.1 (10.4-14.2) per 10,000 in December 2005. Analyses 
by active compound showed that haloperidol [27.8 (25.1-30.8) per 10,000 elderly 
persons], promazine [18.0 (15.8-20.4) per 10,000] and quetiapine [15.7 (13.7-18.0) 
per 10,000] were the most widely used antipsychotics in elderly patients for the 
treatment of behavioral and psychotic disorders of dementia in 2005 (Figure 4). 
Th e use of all of these medications for the treatment of dementia and related dis-
orders shows an increasing yearly trend. Indeed, prevalence of use of haloperidol 
has been raising about 70 in elderly patients due to dementia, while promazine 
doubled in this patient group from 2000 to 2005. In the atypical antipyschotics, 
use of quetiapine increased dramatically in elderly patients for the treatment of 
dementia and related disorders, particularly after the safety alert issue in 2004, 
whereas use of risperidone and olanzapine reduced signiﬁ cantly in these patients 
from 2004.
Figure 1. One-year prevalence of antipsychotic drug use (per 1.000 inhabitants) in community dwelling elderly during the years 2000-2005
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DISCUSSION
To our knowledge this is the ﬁ rst European drug utilization study that explored 
the trend in the use of atypical and typical antipsychotic drugs in both general 
population and more speciﬁ cally in elderly demented outpatients, before and 
after the safety warnings issued by European regulatory agencies in 2004 regard-
ing atypical antipsychotics. Our population-based study documented an almost 
Figure 2a-b. Distribution of indication of use in elderly patients receiving either atypical or typical antipsychotics
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three-fold increase in the use of atypical agents from 2000 to the end of 2003 in 
Italy, whilst this growth slowed down thereafter. Th e prevalence of use of typical 
antipsychotics reduced by one-third until 2003 and was stable during 2004-2005 
years. Th is trend was similar in elderly. A dramatic increase in the use of atypical 
agents in the general population, and particularly in elderly demented outpatients, 
starting from their marketing until 2002 was previously reported in Italy [5, 13], 
as well as in UK and US [3-4]. In Italy, national statistics have shown that the in-
crease in the use of atypicals slowed down after 2004, which is consistent with our 
ﬁ ndings. [14] Th e most likely explanation for the change in trend are the warnings 
Figure 3. Monthly trend in the prevalence of atypical and typical antipsychotic use in elderly outpatients because of dementia and related 
disorders
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Figure 4. Annual trend in the prevalence of use of individual medications* in elderly patients
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that were provided by the Italian Drug Agency, in line with other international 
agencies on the safety of atypical and typical antipsychotics in elderly demented 
patients [15]. However, despite these warnings more than 3 of Italian commu-
nity dwelling elderly patients received at least one antipsychotic drug prescription 
in 2005, with a large proportion of those that were treated for dementia and 
related disorders. Use of antipsychotics in elderly is risky, as these psychotropics 
are often misused and overused in geriatric patient [16]. Th e actual safety proﬁ le 
of antipsychotic drugs in elderly patients has been questioned due to a number 
of warnings issued by regulatory agencies about the risks associated with atypical 
agents in elderly patients with dementia. Th ese alerts have ignited a very animated 
and controversial debate in the scientiﬁ c community and an impact on prescrip-
tion rates of antipsychotic medications, not only among elderly patients with 
dementia, was expected [18]. Some health professionals were concerned that these 
warnings could be detrimental for older patients with dementia since atypical anti-
psychotic treatment could have been unnecessarily withheld, and clinicians would 
have adopted widespread use of conventional antipsychotic drugs [19]. Looking 
speciﬁ cally at elderly demented persons, our study seems to support the idea that 
the safety warnings slowed the growth in the use of atypical antipsychotics. Due to 
substitution of conventional agents, this did not reduce the overall user prevalence 
of antipsychotics due to substitution by conventional agents. Fukuda et al also 
reported that the safety alerts launched by regulatory agencies could lead to the 
replacement of atypical with typical agents and, on the basis of the assessment of a 
small group of Japanese psychiatric inpatients, this switching would not result in 
better clinical outcomes both in terms of eﬀ ectiveness and safety [20]. So far only 
one Canadian study had previously assessed the eﬀ ect of these alerts on the anti-
psychotic prescribing pattern, but it only looked at the antipsychotic use in elderly 
demented patients [9]. Th e Canadian prevalence rates are higher than the ones 
we found which may be explained by geographical and health care diﬀ erences. 
We may have a slight underestimation of antipsychotic use in our study as well, 
since a certain amount of antipsychotic drugs have been directly dispensed by 
psychiatric local services that are dedicated to the management of older patients 
with dementia in recent years, and these prescriptions would have been missing in 
the general practice database which was used in this study. In line with our study, 
however, the Canadians documented a signiﬁ cant decrease in the use of atypical 
agents in elderly patients with dementia after the safety alerts, while the overall 
prescription rate of antipsychotics was not reduced in these patients. Despite the 
decrease, however, about 40 of atypical antipsychotic users (compared to 25 
typical antipsychotics users) were still treated because of dementia and related 
disorders in 2005, after regulatory agencies warned health professionals against 
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the oﬀ -label use of atypical agents for this indication. Th is is in line with the 
oﬀ -label use reported in nursing homes in the US [21]. Haloperidol was the 
most frequently prescribed antipsychotic to elderly patients because of dementia 
and related disorders. A recent Cochrane review of this typical antipsychotic has 
shown that haloperidol could be eﬀ ective in the management of behavioural 
symptoms in dementia [22], while other reviews contrasted with these conclu-
sions [23]. Risperidone and olanzapine showed a declining trend starting from 
2004, in contrast to quetiapine whose utilization has been continuously increasing 
since its marketing in 2000. Th ese observed trends, with a reduction in the use 
only for those atypical agents (risperidone and olanzapine) that were speciﬁ cally 
mentioned in the safety alerts, would conﬁ rm an eﬀ ect of these warnings on the 
antipsychotic drug use.
Th is study should be interpreted with caution since it was performed using 
electronic health records from general practice in Italy. Th erefore, the observed 
changes in the prescribing pattern of antipsychotic drugs may not pertain di-
rectly to patients treated in other settings (e.g., psychiatric inpatients or elderly 
persons with mental illnesses that are residents in nursing homes) [24]. GPs in 
Italy initiate antipsychotic treatment for some patients and continue treatments 
begun by specialists for other patients. However, some antipsychotic drugs might 
have also been dispensed via direct distribution from local psychiatric services 
caring speciﬁ cally patients with dementia, thus bypassing general practitioners 
and, as a consequence, potentially leading to an underestimation of prevalence 
of antipsychotic use in our study. Direct distribution of antipsychotic drugs may 
vary on regional level and over time in Italy and aﬀ ects preferentially atypical anti-
psychotics. According to the Italian National report on dispensing of medicines, 
up to 50 of atypical antipsychotic prescriptions could be directly dispensed 
by psychiatric local services in the year 2005 [14]. Finally, indication of use was 
not reported and could not be identiﬁ ed for around 20 of antipsychotic users 
although it was manually validated through careful revision of the clinical diary 
by two medical doctors.
To conclude, this study shows that drug utilization studies can provide relevant 
information on the eﬀ ect of safety warnings that are launched by regulatory agen-
cies on the prescribing pattern of drugs. Th is study supports the view that antipsy-
chotics are frequently used in older people with psychiatric disorders, in particular 
dementia, despite the ongoing debate about their risks. Th e safety warnings that 
have been recently issued by regulatory agencies contributed to slow down the 
increasing trend in the use of atypical antipsychotics in Italian general population 
and at larger extent in elderly outpatients with dementia with a marginal shift 
towards typical antipsychotics in the last years.
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ABSTRACT
Th e purpose of the study was to investigate the risk of stroke with typical and 
atypical antipsychotics in elderly subjects, weighting for a number of known risk-
factors, including dementia. Data were retrospectively drawn from the primary 
care setting from the Health Search Database, which stores information on about 
1.5 of the total Italian population served by general practitioners. All elderly 
patients (65+ years) prescribed an antipsychotic in monotherapy from January 
2000 to June 2003 were selected for the study. A cohort of patients not exposed 
to antipsychotics was taken from the same database. Subjects who had previously 
had a stroke were excluded. Th e main outcome measure was the incidence of ﬁ rst-
ever stroke during exposure to an antipsychotic.Th e sample included non-users 
(69,939), users of atypicals (599), butyrophenones (749), phenotiazines (907), 
and substituted benzamides (1,968). Th e crude incidence of stroke in subjects 
not exposed to antipsychotics was 12.0/1000 person-years. Risk was signiﬁ cantly 
higher for those on butyrophenones (47.1/1000), phenotiazines (72.7/1000), and 
in the atypical antipsychotic group (47.4/1000). Substituted benzamides had an 
almost signiﬁ cant higher risk (25.0/1000). Cox regression modelling, weighting for 
demographic and clinical variables with non-users as the reference group, showed 
the risk for stroke was 5.79 times for phenotiazines, 3.55 times for butyrophenones, 
and 2.46 times for atypicals. Clinicians should be cautious in prescribing pheno-
tiazines and butyrophenones in elderly patients, since the risk for stroke would 
seem comparable or even greater then with atypicals.
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INTRODUCTION
A few years ago some double-blind trials in elderly patients with behavioural and 
psychological symptoms of dementia (BPSD) reported that individuals treated 
with risperidone or olanzapine were at higher risk for cerebrovascular events 
(CVEs) compared with subjects randomized to placebo (Street et al., 2000; 
Brodaty et al., 2003). Following on from these reports and reanalyses indicating 
that other atypicals were also associated with CVEs, some regulatory agencies 
issued speciﬁ c warnings against the use of some (FDA, 2003; EMEA, 2004; Com-
mittee on Safety of Medicines, 2004) or all (FDA, 2005) atypical antipsychotics 
in dementia patients. In the meanwhile, research on antipsychotics and stroke 
has broadened to include also typical antipsychotics and elderly subjects without 
dementia. In particular, large database studies reported a similar risk for stroke 
for both novel and older antipsychotics, and failed to demonstrate a preferential 
association between stroke and a given atypical compound (Hermann et al., 2004; 
Gill et al., 2005; Liperoti et al., 2005; Wang et al., 2005). Consequently a major 
dilemma arose (Lawlor, 2004; Mowat et al., 2004; Nelson, 2005; Shah and Shu, 
2005; Carson et al., 2006) about which was the best antipsychotic treatment for 
BPSD patients; those who stopped taking a novel antipsychotic may nevertheless 
be in need of another treatment, because the course of the disorder may be less 
benign than previously thought (Raju et al., 2005). Furthermore, evidence from 
the recent literature is often ﬂ awed by a number of factors. Typical antipsychot-
ics in general were grouped into a unitary broad class, irrespective from their 
belonging to diﬀ erent chemical groups (Hermann et al., 2004; Gill et al., 2005; 
Liperoti et al., 2005). Furthermore, the class of substituted benzamides was never 
evaluated, though these antipsychotics are widely prescribed in various, expecially 
European Countries. Furthermore, no recent studies have considered comparable 
unexposed subjects with details of other medical risk factors, or have excluded 
patients with a previous stroke (Hermann et al., 2004; Gill et al., 2005; Liperoti et 
al., 2005; Finkel et al., 2005; Formiga et al., 2005; Layton et al., 2005; Percudani 
et al., 2005).
Following on from these observations we investigated the risk for ﬁ rst-ever 
stoke in a general population of elderly patients, in cohorts exposed to butyro-
phenones, phenotiazines, and substituted benzamides. Risk ratios were compared 
with unexposed subjects and patients exposed to atypical antipsychotics.
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METHODS AND MATERIALS
Setting
Th e study included subjects from the Health Search Database (HSD), a comput-
erized system set up in the mid-1990s to collect data taken from the daily clinical 
activities of general practitioners (GPs). Th e characteristics of the database have 
been described in previous studies (Filippi et al., 2003a,b; Sacchetti et al., 2005; 
Triﬁ rò et al, 2005). Currently, the database contains information from 550 GPs 
from all over Italy with a total of about 800,000 patients, i.e. 1.5 of the Italian 
population. After extensive training on software use, GPs store data in real time 
and send them to a central server based in Florence, where a GPs association, the 
Società Italiana dei Medici di Medicina Generale, processes the data for research 
purposes. To ensure quality, every 3 months all the information collected in the 
database undergoes extensive monitoring with a scheduled feedback from admin-
istrators to users. Physicians who failed to meet standard quality criteria were not 
considered for this research, in agreement with the criteria set by Lawrenson et al. 
(1999). A unique identiﬁ cation number links all data to an individual patient who 
remains anonymous and no identifying details are available. Written informed 
consent to the processing of data was given by each patient to the treating phy-
sician. Information collected include patient demographics, medical diagnoses 
coded according to the ninth edition of International Classiﬁ cation of Diseases 
(ICD-9), drug prescriptions coded according to the Anatomical Chemical Clas-
siﬁ cation system (ATC), hospital referrals and results of diagnostic investigations. 
In the case of the death of a patient, a diagnosis is coded as the most reasonable 
cause of death. Th e HSD also generates a Chronic Disease Score (Von Korﬀ  et al., 
1992), that gives a total score according to the number of medication classes given 
to a patent.
Exposure defi nition
Th e study period spanned from January 1st, 2000 to June 30th 2003. Data were 
extracted in July 2003, and the GPs selected for this study (320) were those who 
had reported complete data at the end of the study period. Subjects were enrolled 
in the study when they were ﬁ rst prescribed an antipsychotic, and censoring (end 
of follow-up) was performed at the end of the study period, occurrence of the 
outcome (stroke, as deﬁ ned below), discontinuation of antipsychotic therapy, 
when the patient moved away from the GP practice, or death, whichever came 
ﬁ rst. For each prescription, the time of exposure was computed according to the 
criteria set by Strauss et al. (2004), adding an extra 30 days of carryover to the time 
covered by the daily prescription dose. After this time, individuals who did not 
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receive another antipsychotic prescription were censored. Patients were grouped 
into the following cohorts on the basis of exposure to antipsychotic medications 
during follow-up: (a) “non-users”, i.e. individuals who were never treated with 
antipsychotics throughout the time of their monitoring in the database; (b) users 
of atypical antipsychotics in monotherapy: olanzapine, risperidone, quetiapine, 
and clozapine (switchers with overlapping prescriptions were not included); 
(c) users of typical antipsychotics in monotherapy (both depot and non-depot 
formulations); (d) users of substituted benzamides (sulpiride, amisulpride). 
Aripiprazole was not licensed during the years under scrutiny, and ziprasidone 
is currently under registration in Italy: therefore these antipsychotics were not 
considered in the study. Inclusion criteria were the following: (i) age greater than 
64 years; (ii) no antipsychotics prescribed in the 3 months before study entry; (iii) 
no prescriptions of other antipsychotics during the observation period; (iv) more 
than 1 year of valid clinical history registered in the HSD. Exclusion criteria were: 
(i) previous cerebrovascular events (ICD9 codes: 430-8); (ii) cerebral tumours (191, 
225, 239.6); (iii) coagulopathy (284, 286-7); (iv) a diagnosis of stroke recorded the 
same day as the ﬁ rst antipsychotic prescription. Subjects were selected irrespective 
of a diagnosis of dementia.
Outcome defi nition
Th e primary outcome was a diagnosis of stroke recorded during the study period. 
Cases were identiﬁ ed through ICD9 codes (434.9, 438.0, 342, 342.0, 342.1 and 
342.9) or encoded medical problems described as “stroke,” “hemiparesis,” or 
“hemiplegia” registered in the HSD during the follow up. Validation studies have 
established an accuracy rate of 90 for the diagnosis of stroke based on these 
codes (Mayo et al., 1994; Filippi et al., 2003a; Leone et al., 2004).
Statistical analysis
Standard descriptive statistics were used to assess any possible clinical and de-
mographic diﬀ erence among exposure groups. Crude incidence rates of stroke 
were calculated for each study cohort by dividing the number of cases by the 
cumulative drug exposure, expressed as person-years.
To examine the independent eﬀ ect of the use of antipsychotics on the risk for 
stroke, a multivariate Cox proportional regression analysis was performed. Th e 
main advantages of Cox analysis are that it can weight for the eﬀ ects of covariates, 
other than exposure to an antipsychotic, and it can be applied when variable 
lengths of time of observation are produced by each subject. All analyses were 
performed with STATA 7.0 (STATA Corporation, Texas USA).
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RESULTS
Th e total sample consisted of 74,162 subjects, 69,939 non-users, 599 on atypicals, 
749 on butyrophenones, 907 on phenotiazines, and 1968 on substituted benz-
amides. Th e key sociodemographic and clinical features of the ﬁ ve cohorts are 
reported in Table 1, together with details of signiﬁ cant diﬀ erences. Overall, the 
most frequent diseases were hypertension, diagnosed in more than half of the 
subjects, and diabetes, dyslipidemia, obesity, COPD, diagnosed in about one-
sixth of the sample.
Dementia was diagnosed in 17.5 of those on antipsychotics. Th e more com-
mon speciﬁ c psychiatric diagnoses were ‘other’ psychotic disorders (36.1) and 
aﬀ ective disorders (13.3), while schizophrenia was diagnosed only in 0.9 of 
those prescribed an antipsychotic. Th e crude incidence of stroke in subjects not 
exposed to antipsychotics was 12.0/1000 person-years (CI 11.5-12.5). When com-
pared to this estimate, risk was signiﬁ cantly higher in those on butyrophenones 
(47.1/1000; CI 22.1-88.8), phenotiazines (72.7/1000; CI 43.3-107.7), and in the 
atypical antipsychotic group (47.4/1000; CI 23.4-86.5). Substituted benzamides 
had an almost signiﬁ cant higher risk (25.0/1000; CI 12.0-34.1) (Table 2). Th e mean 
interval from ﬁ rst prescription to new-onset stroke was 103.3 days (SD 112.7) in 
atypicals, 57.5 (SD 22.2) in butyrophenones, 21.3 (SD 18.8) in phenotiazines, and 
120.5 (SD 119.6) in substituted benzamides (F=0.30, p=n.s.).
At univariate analysis stroke was associated with some of the sociodemographic 
and clinical variables: higher age, male sex, a Chronic Disease Score higher than 5, 
a diagnosis of Parkinson disease, and the use of anticoagulants (Table 3). Demen-
tia, per se, had only a weak eﬀ ect on stroke risk, and also aﬀ ective disorders were 
not associated to the risk.
In order to weight for the eﬀ ect of those variables who had a diﬀ erential dis-
tribution in the cohorts all variables in Table 1 were entered in the Cox analysis 
(including dementia and psychiatric indication of use).
Two multivariate models were applied. In the ﬁ rst model the reference group 
was made up of subjects not exposed to antipsychotics (default risk=1). Th e risk 
of stroke was again higher for the group of phenotiazines (5.79 times; CI 3.07-
10.9), butyrophenones (3.55; CI 1.56-8.07), and atypicals (2.46; CI 1.07-5.65) when 
compared to unexposed subjects. Th e group of substituted benzamides had an 
almost signiﬁ cantly higher risk (2.2; CI 0.98-4.90). Th e second model took atypi-
cal users as the reference group (default risk=1), and allowed us to compare typical 
vs. atypical antipsychotic drugs, while weighing for the same covariates entered in 
the previous model. Phenotiazines had a signiﬁ cantly higher risk (2.34) for stroke 
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Table 1. Demographic and clinical characteristics of diff erent exposure cohorts
Variable Non-Users Butyrophenones Phenothiazines
Subst. 
Benzamides
Atypicals
p
N=69,939 (%) N=749 (%) N=907 (%) N=1,968 (%) N=599 (%)
Mean age (SD) 75.7 (7.9) 81.9 (8.7) 82.6 (8.9) 75.4 (7.2) 79.8 (7.9) ** a
Females 40,220 (57.5) 484 (64.6) 547 (60.3) 1,466 (74.5) 371 (61.9) ** b
Chronic Disease Score
1-5 40,816 (58.4) 585 (78.1) 685 (75.5) 1,556 (79.1) 452 (75.5) ** b
> 5 29,123 (41.6) 164 (21.9) 222 (24.5) 412 (20.9) 147 (24.5)
Diseases aff ecting risk 
of stroke
Hypertension 40,624 (58.1) 407 (54.3) 503 (55.5) 1,208 (61.4) 337 (56.3) n.s.
History of coronary 
Heart Diseases
6,469 (9.2) 84 (11.2) 127 (14.0) 167 (8.5)  75 (12.5)
** b
Heart failure  2,512 (3.6) 51 (6.8) 59 (6.5) 52 (2.6)  31  (5.2) ** b
Atrial Fibrillation  3,983 (5.7) 56 (7.5) 65 (7.2) 89 (4.5)  33  (5.5) * b
Other arrhythmias  3,213 (4.6) 33 (4.4) 39 (4.3) 79 (4.0)  30  (5.0) n.s.
Diabetes mellitus 10,913 (15.6) 116 (15.5) 154 (17.0) 250 (12.7)  97 (16.2) * b
Dyslipidemia 14,198 (20.3) 77 (10.3) 94 (10.4) 387 (19.7)  79 (13.2) ** b
COPD 10,340 (14.8) 126 (16.8) 168 (18.5) 270 (13.7) 105 (17.5) ** b
Pneumonia  3,506 (5.0) 30 (4.0) 44 (4.9) 70 (3.6)  46  (7.7) ** b
Dementia  1,215 (1.7) 211 (28.2) 227 (25.0) 64 (3.3) 235 (39.2) ** b
Parkinson’s disease  1,503 (2.1) 97 (13.0) 83 (9.2) 57 (2.9) 118 (19.7) ** b
Malignant neoplasm  3,361 (4.8) 26 (3.5) 27 (3.0) 40 (2.0)  14  (2.3) ** b
Obesity  9,711 (13.9) 80 (10.7) 85 (9.4) 286 (14.5)  69 (11.5) ** b
Concurrent use of 
medications
Anticoagulants 23,376 (33.4) 161 (21.5) 205 (22.6) 405 (20.6) 160 (26.7) ** b
Diuretics 19,371 (27.7) 154 (20.6) 210 (23.2) 287 (14.6)  90 (15.0) ** b
Beta-blockers 10,283 (14.7) 19 (2.5) 41 (4.5) 187 (9.5)  28  (4.7) ** b
ACE-inhibitors 25,061 (35.8) 167 (22.3) 199 (21.9) 507 (25.8) 151 (25.2) ** b
Calcium-channel 
blockers
18,541 (26.5) 91 (12.1) 135 (14.9) 331 (16.8)  77 (12.9)
** b
Angiotensin receptor 
blockers
 5,562  (8.0) 14 (1.9) 27 (3.0) 86 (4.4)  17  (2.8)
** b
Benzodiazepines 12,382 (17.7) 159 (21.2) 188 (20.7) 542 (27.5) 148 (24.7) ** b
Sympathicomimetic 
drugs
 8,345 (11.9) 33 (4.4) 35 (3.9) 89 (4.5)  24  (4.0)
** b
Psychiatric indication 
of use
Schizophrenia 14 (1.9) 6 (0.7) 2 (0.1)  18  (3.0) ** c
Other Psychotic 
Disorders
401 (53.5) 431 (47.5) 334 (17.0) 359 (59.9)
** c
Aff ective Disorders 56 (7.5) 46 (5.1) 386 (19.6)  74 (12.5) ** c
Other or no diagnosis 278 (37.1) 423 (46.6) 1,239 (63.0) 148 (24.7) ** c
* p<0.05; ** p<0.01
a F, 5,74162 d.f.;
b Chi2, 4 d.f.
c Chi2, 3 d.f.
n.s. = not signifi cant
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when compared to atypical antipsychotics. No signiﬁ cant interactions between 
antipsychotic class and other variables were found.
DISCUSSION
Th e main ﬁ ndings of this study can be summarised as follows. When compared to 
antipsychotic-free controls, elderly patients taking antipsychotics in monotherapy 
were at higher risk for ﬁ rst-ever stroke. Th e increased incidence of stroke involved 
all the chemical families of antipsychotics we tested, although the association 
was only near to signiﬁ cance for substituted benzamides. Among the users of 
antipsychotics, the unadjusted and adjusted stroke risk of patients treated with 
phenotiazines exceeded that found in subjects exposed to atypical antipsychotics. 
Th e increased risk of stroke associated with antipsychotic medications was not 
Table 2. Incidence of stroke among persons taking antipsychotic medications and unexposed subjects
Treatment group
Mean days of 
follow-up (SD)
Cases of stroke
Years of follow-up
(per 1,000)
Crude incidence per 
1000 PY
(95% CI)
UNEXPOSED 1,069 (327) 2,459 205.0 12.0 (11.5-12.5)
BUTYROPHENONES 87 (87) 8 0.17 47.1 (22.1-88.8)
PHENOTHIAZINES 82 (47) 16 0.22 72.7 (43.3-107.7)
OTHER TYPICALSa 106 (119) 1 0.04 25.0 (2.3-116.6)
SUBSTITUTED BENZAMIDESb 124 (121) 14 0.67 20.9 (12.0-34.1)
ATYPICALS 117 (112) 9 0.19 47.4 (23.4-86.5)
a thioxanthenes, diphenylbutylpiperidine derivative, dibenzothiazepine;
b sulpiride, amisulpride.
Table 3. Sociodemographic variables, illnesses and treatments associated with stroke
Variables
Crude incidence
per 1,000 PY (95% CI)
p value a
AGE GROUPS < 0.001
65-80 9.8 (9.3-10.3)
≥ 80 19.6 (18.4-20.8)
GENDER < 0.001
Males 13.6 (12.8-14.4)
Females 11.2 (10.6-11.8)
CHRONIC DISEASE SCORE < 0.001
1-5 10.1 (9.5-10.6)
> 5 14.9 (14.1-15.7)
CO-MORBIDITIES
Parkinson’s disease 24.3 (20.0-29.3) < 0.001
CONCURRENT MEDICATIONS
Anticoagulants 20.4 (19.4-21.5) <0.001
a Chi square, 1 d.f.
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conﬁ ned to patients with dementia but was present in all the cohorts that were 
prescribed these drugs: antipsychotic users remained at higher risk for stroke 
even after controlling for dementia and other relevant confounders. Th is rather 
generalised association between the use of antipsychotic drugs and stroke was not 
unexpected on the basis of the pre-existing literature involving non demented 
patients treated with these compounds. For example, schizophrenia patients were 
reported to have an abnormally high prevalence of transient cerebral ischemia 
(Curkendall et al., 2004), their actual and 10-year risk of stroke (McCreadie, 2003; 
Curkendall et al., 2004) was almost two-fold that of the general population, and 
they presented an excess of cerebrovascular mortality (Brook, 1985; Allebech, 1986; 
Osby et al., 2000; Joukamaa et al., 2001). In turn, patients with depression or 
bipolar disorder were found to have abnormally high risk of dying from cere-
brovascular accidents (Schwalb, 1987; Zhenge et al., 1997; Schwalb and Schwalb; 
Osby et al., 2001; Angst et al., 2002).
Th ese results substantially agree with other observational studies which have 
generally failed to ﬁ nd a diﬀ erence in the risk of stroke when users of atypical 
antipsychotics are compared to users of typicals (Hermann et al., 2004; Gill et al., 
2005; Layton et al., 2005). However, in our sample the majority of patients were 
treated with typical antipsychotics; in previous reports (Hermann et al., 2004; Gill 
et al., 2005; Liperoti et al., 2005; Formiga et al., 2005) the majority of the patients 
were treated with atypical compounds. Th e low number of subjects (or person-
years) in our atypical cohort is explained by the restrictions placed by the Italian 
Table 4. Risk of stroke in diff erent treatment groups
Unadjusted Risk Ratio
(95% CI)
Adjusted Risk Ratioa
(95% CI)
Model I
Unexposed subjects as the reference group
 NON-USE 1:00 1.0
 BUTYROPHENONES 3.32 (1.64-6.70) 3.55 (1.56-8.07)
 PHENOTHIAZINES 5.26 (3.26-8.89) 5.79 (3.07-10.90)
 ATYPICAL ANTIPSYCHOTICS 2.07 (1.07-3.99) 2.46 (1.07-5.65)
 SUBSTITUTED BENZAMIDES 1.58 (0.92-2.69) 2.20 (0.98-4.90)
Model II
Subjects exposed to atypicals as the reference group
 ATYPICAL ANTIPSYCHOTICS 1:00
 NON-USERS 0.65 (0.33-1.26) 0.40 (0.17-0.92)
 BUTYROPHENONES 1.55 (0.60-4.04) 1.44 (0.55-3.76)
 PHENOTHIAZINES 2.57 (1.13-5.84) 2.34 (1.01-5.41)
 SUBSTITUTED BENZAMIDES 1.08 (0.47-2.52) 0.89 (0.33-2.38)
a Cox proportional hazard regression analysis adjusted for age, gender, Chronic Disease Score, medical illnesses (dementia, Parkinson’s disease, 
hypertension, ischemic heart diseases, heart failure, atrial fi brillation, diabetes, dyslipidemia, COPD, recent history of pneumonia, malignant 
neoplasm, obesity), psychiatric indication of use for an antipsychotic, use of drugs during follow-up (benzodiazepines, diuretics, CCBs, ACE-
inhibitors, beta-blockers, anticoagulants, angiotensin receptor blokers, sympathicomimetic drugs).
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legislation on the prescription of atypical antipsychotics by general practitioners. 
Indeed, only after the indication of a psychiatrist working in the public mental 
health service can a novel antipsychotic be prescribed by a primary care doctor.
Some strengths and weaknesses of our study must be discussed. Th is is the ﬁ rst 
study that reports estimates of stroke on a general elderly population unexposed 
to antipsychotics, taken from the same general practitioners database as the pa-
tients exposed to these drugs. Some recent studies on the general population have 
investigated the crude annual incidence rate of ﬁ rst-ever stroke. Th is was reported 
to be 1.74/1000 in a German study (Kolominsky-Rabas et al., 1988), 1.79/1000 in 
a south-Italian study (Di Carlo et al., 2003), and 2.8/1000 in a Scottish study 
(Syme et al., 2005). All these studies were based on the total population, including 
newborns. Since our study investigated only elderly patients, we re-ran the selec-
tion on the total population served by general practitioners (i.e. subjects aged 14 
or more) and found an annual crude incidence rate of 2.77/1000 person-years 
which compares well with that found by other studies based on case register data. 
A second novelty of the study is the independent evaluation of the two most pre-
scribed classes of typical antipsychotics, namely phenotiazines and butyrophe-
nones: no other studies have so far performed this dissection although renewed 
interest in the use of older antipsychotics has emerged after recommendations 
from the regulatory agencies (FDA, 2003; EMEA, 2004; Committee on Safety of 
Medicines, 2004; FDA, 2005). Furthermore, the investigation of an association 
between substituted benzamides and stroke was deﬁ nitely original. Data on sub-
stituted benzamides should however not only require replication, but also possible 
speciﬁ c subanalyses. Although sulpiride and amisulpride belong to the same 
chemical group and share a selective antagonist activity on dopamine receptors, it 
cannot be indeed completely dismissed that these two substituted benzamides 
diﬀ er in their clinical proﬁ le: the label of atypical antipsychotic appears fully justi-
ﬁ ed for amisulpride (Leucht et al., 2002; Mota Neto et al., 2007), but questionable 
for sulpiride (Soares et al., 2007), as the superiority of this last compound on 
ﬁ rst-generation antipsychotics is actually evidence-based for movement disorders 
and only anecdotal for negative symptoms. Th anks to the many variables coded in 
the general practitioners database we could adjust the estimated risks for many, 
possibly confounding variables. Th is is now highly advisable, given the evidence 
emerging from the re-analysis of randomised controlled trials that identiﬁ ed pre-
existing vascular risk factors in subjects who developed stroke while in therapy 
(Smith and Beier, 2004; De Deyn et al, 2005). In particular, in our study the esti-
mates of risk were weighted for thirteen diseases (including dementia) and eight 
types of treatment (including antihypertensives and anticoagulants). Th e majority 
of these variables constitute well-established risk factors for stroke (Elkind and 
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Sacco, 1988; Sacco et al., 1997; Davis et al., 1998; Goldstein, 2000; Lindsberger 
and Grau, 2003; Humphries and Morgan, 2004). We dealt with diﬀ erences be-
tween cohorts by adjusting in the Cox analysis for potential confounders, as was 
done in some other studies on stroke and antipsychotics (Hermann et al., 2004; 
Gill et al., 2005). Another statistical approach could have been the propensity 
score matching, but we relied on Cox regression modelling for the real advantages 
of the propensity score matching is still debated and it seems to give results similar 
to conventional multivariate methods (Sturmer et al., 2006; Shah et al., 2005). We 
excluded subjects with a previous stroke in order to focus on true incidence and 
not recurrent stroke, thus contributing new data on fìrst-ever stroke. Th e adop-
tion of these strict exclusion criteria is both a strength and a weakness of the study: 
the risk estimate was undoubtedly associated with antipsychotic exposure but it 
did not allow analysis of subjects with prior cerebrovascular events. Some distor-
tions in the identiﬁ cation of cases with stroke could also have occurred in the 
study as stroke leading to hospital admission might have been recorded in the 
database after actual occurrence. We believe, however, that such potential misclas-
siﬁ cation would be scarcely inﬂ uential because there is no reason to assume a 
preferential concentration of patients with a delayed registration of the event in a 
given cohort. Although cerebrovascular adverse events reported in randomised 
controlled trials of atypical antipsychotics consisted of both transient ischemic 
attacks (TIA) and stroke, we focused exclusively on stroke, similar to other studies 
(Hermann et al., 2004; Gill et al., 2005). However, a recent study reported that 
about 70 of TIA episodes occur within a week prior to stroke, suggesting that a 
stroke diagnosis might capture previous TIAs (Johnstone et al., 2000; Hill et al., 
2004; Rothwell and Warlow, 2005). Also, our study was a retrospective analysis of 
a very large clinical set, so that a chart diagnosis of stroke was the principal out-
come measure. Although a previous reliability study has shown for this measure a 
90 accuracy (Leone et al., 2004), diagnoses were based only on the ICD-9 codes, 
and not on structured evaluations as in RCTs. Sub-analyses targeted to assess the 
possible eﬀ ects of the dose and duration of antipsychotic treatment on stroke in-
cidence were not addressed; the inﬂ uence of these putative sources of variation 
seems dubious, however, as the increased risk for cerebrovascular events reported 
in BPSD clinical trials did not appear associated with dose and duration of olan-
zapine or risperidone treatment (Street et al, 2000; Brodaty et al, 2003). Th e 
sample study included a relatively small proportion of patients with dementia. 
Patients with this diagnosis represented from 3.3 to 39.2  of antipsychotic users 
and only 1.7 of non users. Given the low number of incident cases, a stratiﬁ ed 
analysis for this variable was not performed. Anyway, dementia was entered in the 
Cox regression, so that risk ratios were weighted for this variable. No data were 
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available on other factors known to be associated with stroke such as smoking 
habits, bad diet, and physical exercise, but these data are probably out of the reach 
of very large databases in the primary care setting, and this information was not 
present in all the major studies published recently. Waiting for speciﬁ c research 
aimed at resolving the complex interplay of factors contributing to stroke, it re-
mains that the increased risk for stroke in patients receiving antipsychotic medica-
tion should not be ascribed solely to antipsychotic drugs. For instance, it may 
simply be that those prescribed drugs are predisposed to stroke because of un-
healthy lifestyles, diﬃ  culties to look for health care, inadequate management of 
predisposing morbidities, and inability to cope with protective health behaviours, 
all of which are often present in the clinical conditions treated with an antipsy-
chotic. Also, the possibility of a diathesis facilitating stroke shared by patients 
with dementia, schizophrenia or mood disorders cannot be dismissed: reports 
(Wada-Isoe et al., 2004, Zhang et al., 2002, Garver et al., 2003, O’Brien et al., 
2004) of abnormal interleukin 6 levels in all these groups could support this hy-
pothesis, given the possible association of this pro-inﬂ ammatory cytokine with 
stroke (Chamorro, 2004, Dziedzic et al., 2004). In the meanwhile, clinicians 
should systematically identify the presence of cerebrovascular predisposing factors 
whenever they are planning a treatment with antipsychotics irrespective of the 
speciﬁ c diagnosis. Subsequently, the physician should carefully evaluate alterna-
tive treatment strategies for high-risk patients. For individuals with a recognised 
cerebrovascular vulnerability who need treatment with antipsychotics, the choice 
of drug should consider the global aspects of eﬃ  cacy and tolerability; suﬃ  cient 
evidence to favour some compounds over others on the potential for stroke or 
related accidents is still not available. Our data would suggest special caution with 
phenotiazines, while the risk associated with substituted benzamides should be 
further investigated.
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ABSTRACT
Purpose: To estimate the association between use of typical and atypical anti-
psychotics and all-cause mortality in a population of demented outpatients.
Methods: Th e study cohort comprised all demented patients older than 65 years 
and registered in the Integrated Primary Care Information (IPCI) database, dur-
ing 1996-2004. First, mortality rates were calculated during use of atypical and 
typical antipsychotics. Second, we assessed the association between use of atypical 
and typical antipsychotics and all-cause mortality through a nested case-control 
study in the cohort of demented patients. Each case was matched to all eligible 
controls at the date of death by age and duration of dementia. Odds ratios were 
estimated through conditional logistic regression analyses.
Results: Th e crude mortality rate was 30.1 (95 CI: 18.2-47.1) and 25.2 (21.0-29.8) 
per 100 person-years during use of atypical and typical antipsychotics, respectively. 
No signiﬁ cant diﬀ erence in risk of death was observed between current users of 
atypical and typical antipsychotics (OR= 1.3; 95 CI: 0.7-2.4). Both types of anti-
psychotics were associated with a signiﬁ cantly increased risk of death as compared 
to non-users (OR= 2.2, 1.2-3.9 for atypical antipsychotics; OR=1.7, 1.3-2.2 for 
typical antipsychotics).
Conclusions: Conventional antipsychotic drug should be included in the FDA’s 
Public Health advisory, which currently warns only of the increased risk of death 
with the use of atypical antipsychotics in elderly demented persons.
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INTRODUCTION
In the treatment of behavioral and psychotic symptoms in demented patients 
(BPSD), atypical antipsychotics have tended to replace typical antipsychotics, de-
spite their oﬀ -label use for this indication.1-2 Atypical antipsychotics are supposed 
to have a better safety proﬁ le than typical antipsychotics, especially with regards to 
extrapyramidal symptoms 3. However, recently, concern has been raised about the 
safety of atypical antipsychotics in older demented adults. Pooled data from several 
clinical trials showed a 3-fold increase in risk of cerebrovascular events (CVEs) in 
patients with BPSD, who were treated with olanzapine or risperidone, compared 
to placebo 4-5. In addition, a 2-fold increase in all-cause mortality was observed in 
demented patients who were treated with olanzapine6. As a consequence, the Com-
mittee on Safety of Medicines (CSM) has recommended avoiding the use of atypical 
antipsychotics in elderly with BPSD in March 2004 6. On April 11, 2005, the Food 
and Drug Administration (FDA) has issued another public health advisory to warn 
healthcare providers against the oﬀ -label use of atypical antipsychotic medications 
in elderly with BPSD because of an increased mortality risk7. No warning was 
issued for the typical antipsychotics, although the FDA is now considering it, since 
some data would suggest a similar increase in mortality risk also for these drugs7.
To date, several articles have been published on predictors of mortality in patients 
with dementia8-10. However, only one observational study has been performed to 
speciﬁ cally explore the association between antipsychotic use and risk of all-cause 
mortality in elderly persons, but this was not limited to demented patients.11
In light of the warnings expressed by FDA and CSM regarding atypical anti-
psychotics, we aimed to compare the risk of all-cause mortality between users of 
typical and atypical antipsychotics by means of a nested case control study in a 
cohort of demented patients.
METHODS
Setting
In the Netherlands, all persons have their own general practitioner who ﬁ les all 
relevant medical details on their patients from primary care visits, hospital admis-
sions and visits to outpatient clinics. For this study, data were retrieved from the 
Integrated Primary Care Information (IPCI) database, a longitudinal general prac-
tice research database set up in 1992 and containing data from electronic medical 
records from a group of 150 general practitioners (GPs) in the Netherlands. Details 
of the database have been previously described 12-13. Brieﬂ y, the database contains 
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the complete medical records of approximately 500,000 patients with an age and 
gender distribution representative of the Netherlands. Th e electronic records 
contain coded and anonymous data on patient demographics, reasons for visits 
(in free text), signs and symptoms, diagnoses (using the International Classiﬁ ca-
tion for Primary Care 14 and free text) from general practitioners and specialists, 
referrals, hospitalizations, as well as drug prescriptions, including product name 
+ anatomical therapeutic chemical classiﬁ cation (ATC code), dispensed quantity, 
dosage regimen and indication. To maximize completeness of the data, general 
practitioners participating in the IPCI project are not allowed to maintain a sys-
tem of paper-based records, aside from the electronic medical records. Th e system 
complies with European Union guidelines on the use of medical data for medical 
research and has been proven valid for pharmaco-epidemiological research 12. Th e 
Scientiﬁ c and Ethical Advisory Board of the IPCI project approved the study.
Study cohort
Th e study cohort comprised all patients 65 years or older, who were aﬀ ected by 
dementia and had at least 1 year of medical history recorded in the database, 
during the study period (1996-2004). Subjects were followed from the latest of 
the following dates: one year of valid database history, age 65 year or diagnosis 
of dementia until the earliest of the following censoring dates: death, latest avail-
ability of data, transferring out of the General Practitioner (GP) practice or end 
of study period.
Cases and controls
Th e primary study outcome was all-cause mortality. All potential deaths were 
reviewed by two medically trained persons, blinded to exposure and unaware of 
the study objective, in order to assess the date of death (index date).
For the nested case control study, we matched to each case all eligible controls 
in the study cohort on year of birth, duration of dementia and index date.
Exposure defi nition
For each antipsychotic drug prescription, we calculated the prescription length by 
dividing the total number of prescribed units (capsules/tablets) by the prescribed 
number of units per day. For calculation of mortality rates during treatment with 
antipsychotic drugs, we used days of exposure plus a carry-over of 60 days, as 
denominator. Exposure days were calculated separately for atypical antipsychotics, 
typical antipsychotics and combinations (overlapping use). Carry-over was con-
sidered only if there were gaps between consecutive prescriptions or if there was 
no subsequent prescription.
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For nested case-control analysis, exposure at the index date was classiﬁ ed, ac-
cording to antipsychotic use, in one of the following mutually exclusive groups: 
current use, past use and non-use. A patient was classiﬁ ed as a current user if the 
index date fell during the duration of antipsychotic treatment or within a maxi-
mum of 60 days after the end of the last prescription 15. A person was classiﬁ ed 
as past user if the antipsychotic treatment was discontinued more than 60 days 
before the index date. If patients had no prescription for an antipsychotic drug 
prior to the index date during the study period, they were classiﬁ ed as nonusers. If 
persons had used more than one type of antipsychotic, they were classiﬁ ed as com-
bined current users if both types of antipsychotics were currently used, otherwise 
current exposure of one class overruled past exposure. In a sub-analysis, switchers 
from atypical to typical or vice versa were studied separately. Among current users 
of both antipsychotic types the eﬀ ect of daily dose (< or ≥ than 0.5 deﬁ ned daily 
dose (DDD) equivalents 16 was evaluated. Th e DDD is the recommended average 
maintenance dosage of a drug for an adult for the main indication, as deﬁ ned by 
the World Health Organization.
Other Covariates
Th ere are many potential risk factors for death in demented patients. We considered 
as potential confounders: history of cardio- and cerebrovascular diseases (angina 
pectoris, myocardial infarction, heart failure, atrial ﬁ brillation, peripheral arterial 
disease, stroke and transient ischemic attack), pneumonia, chronic obstructive 
pulmonary diseases (COPD), diabetes mellitus, cancer and Parkinson’s disease or 
parkinsonism, home-bound lifestyle, and concomitant use at the index date of 
antibiotics, corticosteroids, sympathicomimetics, cardiovascular drugs (digoxin, 
diuretics, calcium channel-blockers, beta-blockers, ACE inhibitors, angiotensin 
receptor blockers, anticoagulants, lipid lowering drugs) and psychotropic medica-
tions (SSRI and Tricyclic antidepressants, lithium, opioids, benzodiazepines).
Statistical analysis
As a ﬁ rst step, we calculated the crude mortality rates for each type of antipsychotic 
by dividing the number of deaths by the accumulated amount of drug exposure. 
In the case-control analysis, the univariate association between each risk factor and 
death was estimated through conditional logistic regression. All covariates that 
were signiﬁ cantly (p < 0.05) associated with mortality were evaluated as potential 
confounders in the ﬁ nal analyses.
In order to evaluate the association between use of typical and atypical anti-
psychotics and all-cause mortality, a conditional logistic regression analysis was 
conducted using two diﬀ erent reference categories: non-use of antipsychotics 
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and current use of typical antipsychotics. As confounders, we retained all risk 
factors that were signiﬁ cantly associated with death and changed the risk estimate 
for current use of any antipsychotic type more than 5 17. Eﬀ ect modiﬁ cation 
was explored by stratifying for age, gender and type of dementia although it was 
anticipated that the study had not enough power.
RESULTS
Cohort
Th e study cohort comprised 2,385 elderly patients with dementia: 772 (32.4) 
with Alzheimer’s disease, 320 (13.4) with vascular dementia and 1,293 (54.2) 
with mixed or unspeciﬁ ed dementia. Of these, 680 (28.5) and 78 (3.3) had 
received prescriptions for typical and atypical antipsychotics after dementia di-
agnosis, respectively, and 63 (2.6) had received both types of drugs, 39 of those 
started with typical antipsychotics and switched to atypical drugs, mostly because 
of extrapyramidal symptoms.
Th e amount of accumulated exposure was of 56.5 person-years (PY) for use of 
atypical antipsychotics, 500.8 PY for typical antipsychotics and 12.1 PY for combined 
use. During follow-up, 407 persons died. Th e crude mortality rates during current 
use of atypical, typical and overlapping use of atypical and typical antipsychotics 
were 30.1 (18.2-47.1), 25.2 (21.0-29.8) and 16.5 (3.3-53.0) per 100 PY, respectively.
Nested case-control study
Of the 407 deaths that occurred during follow-up, 398 (97.8) could be matched 
on year of birth, duration of dementia and index date to one or more controls. 
Male gender and advanced age (>85 years) were positively associated with death as 
well as a variety of cardiovascular diseases (Table 1). Recent history of pneumonia, 
current use of antibiotics and opioids were factors strongly associated with death. 
Baseline characteristics of controls that were currently exposed to atypical or 
typical antipsychotics were compared to assess diﬀ erences between these treat-
ment groups. Patients treated with typical antipsychotics were more likely to be 
aﬀ ected by heart failure and chronic obstructive pulmonary diseases, and to have 
suﬀ ered prior events of stroke and myocardial infarction in comparison to users 
of atypical antipsychotic. On the other hand, users of atypical antipsychotics were 
more often treated with other psychotropic medications (benzodiazepines and 
antidepressants) than users of typical antipsychotics (data not shown). Table 2 
shows the association between use of antipsychotics and all-cause mortality. With 
reference to non-use, current use of both atypical (ORadj: 2.2, 95 CI: 1.2-3.9) 
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and typical antipsychotic drugs (1.7, 1.3-2.2) were associated with a signiﬁ cantly 
increased risk of death. In comparison to current use of typical antipsychotics, the 
risk of death was similar in current users of atypical antipsychotics (1.3, 0.7-2.4).
Table 1. Characteristics of cases and controls
Covariate
Cases
N=398 (%)
Controls
N=4,023 (%)
Unadjusted Matched 
Odds Ratio
(95% CI)
Mean Age (SD), years 85.3 (6.5) 84.5 (5.0) -
Age groups, years Matched
65-75 32 (8.0) 167 (4.2)
76-85 162 (40.7) 2,145 (53.3)
> 85 204 (51.3) 1,711 (42.5)
Gender (male) 145 (36.4) 1,073 (26.7) 1.7 (1.3 – 2.1)
Smoking 39 (9.8) 381 (9.5) 1.1 (0.8 – 1.6)
Cardiovascular diseases
Hypertension 249 (62.6) 2,543 (63.2) 1.1 (0.9 – 1.3)
Angina 61 (15.3) 533 (13.2) 1.2 (0.9 – 1.6)
Myocardial Infarction 45 (11.3) 251 (6.2) 2.1 (1.5 – 2.9)
TIA 59 (14.8) 311 (7.7) 2.1 (1.5 – 2.8)
Stroke 60 (15.1) 360 (8.9) 1.8 (1.3 – 2.5)
Heart Failure 128 (32.2) 673 (16.7) 2.3 (1.8 – 2.9)
Atrial Fibrillation 46 (11.6) 400 (9.9) 1.3 (0.9 – 1.8)
Peripheral Arterial Disease 22 (5.5) 157 (3.9) 1.5 (0.9 – 2.4)
Other diseases
Pneumonia (one year prior) 23 (5.8) 43 (1.1) 5.3 (3.1 –9.1)
COPD 70 (17.6) 449 (11.2) 1.8 (1.3 –2.4)
Parkinson(ism) 52 (13.1) 316 (7.9) 1.9 (1.4 – 2.6)
Diabetes Mellitus 84 (21.1) 749 (18.6) 1.3 (1.0-1.6)
Cancer 66 (16.6) 468 (11.6) 1.6 (1.2 – 2.1)
Concomitant medications
Diuretics 144 (36.2) 1,189 (29.6) 1.4 (1.1 – 1.7)
Digoxin 61 (15.3) 447 (11.1) 1.5 (1.1 – 2.1)
CCB 22 (5.5) 326 (8.1) 0.7 (0.4 – 1.1)
Beta-blockers 44 (11.1) 531 (13.2) 0.8 (0.6 – 1.2)
Angiotensin Receptor Blockers 12 (3.0) 94 (2.3) 1.2 (0.7 – 2.3)
Ace-inhibitors 63 (15.8) 575 (14.3) 1.2 (0.9 – 1.6)
Anticoagulants 135 (33.9) 1,394 (34.7) 1.0 (0.8 – 1.3)
Lipid lowering drugs 4 (1.0) 91 (2.3) 0.5 (0.2 – 1.3)
SSRI 18 (4.5) 302 (7.5) 0.7 (0.4 – 1.1)
Tricyclic antidepressant 11 (2.8) 133 (3.3) 0.9 (0.5 – 1.7)
Opioids 75 (18.8) 71 (1.8) 11.1 (7.7 – 16.0)
Benzodiazepines 113 (28.4) 1,012 (25.2) 1.2 (1.0 – 1.5)
Corticosteroids 33 (8.3) 148 (3.7) 2.4 (1.6 – 3.6)
Antibiotics 81 (20.4) 295 (7.3) 3.1 (2.3 – 4.1)
Values are numbers (percentages) unless stated otherwise.
Legend: TIA= Transient Ischemic Attack; PAD= Peripheral Arterial Disease; COPD= Chronic Obstructive Pulmonary Disease; CCB= Calcium 
Channel Blocker; SSRI= Selective Serotonin Re-uptake Inhibitor.
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Among current users of both atypical and typical antipsychotics, we observed 
a strong eﬀ ect of dose on the association with death. Concerning atypical anti-
psychotics, the risk of death increased also with increasing duration of use (data 
not shown). An analysis on the individual atypical antipsychotics showed some 
heterogeneity among them, with the strongest for olanzapine but we had limited 
power to assess diﬀ erences (Table 2).
Sub-analyses targeted to explore whether the association between use of atypical 
antipsychotics and death diﬀ ered by gender, age, type of dementia and switching 
from one antipsychotic type to another one are shown in table 3. Gender (females) 
and advanced age (≥ 80 years old) seemed to modify the risk of death for current 
users of atypical antipsychotics, as compared to use of typical antipsychotics, but 
none of these interactions was signiﬁ cant. Th e risk of death associated with use 
of atypical antipsychotics, as compared to typical antipsychotics, was higher in 
patients starting directly on atypical medications (1.7, 0.8-3.3) than in patients 
who switched from typical medications to atypical ones (0.8, 0.1-8.2).
Table 2. Association between antipsychotic drug use and death in persons with dementia.
Antipsychotic use
Cases
N= 398 (%)
Controls
N= 4,023 (%)
OR unadjusted
(95% CI)
OR adjusted^
(95% CI)
Non-use 214 (53.8) 2,721 (67.6) 1.0 (ref ) 1.0 (ref )
Atypical antipsychotic use
Current* 18 (4.5) 99 (2.5) 2.2 (1.3-3.7) 2.2 (1.2-3.9)
Olanzapine 3 (0.8) 5 (0.1) 6.0 (1.3-27.0) 6.7 (1.4-32.1)
Risperidone 13 (3.3) 89 (2.2) 1.8 (1.0-3.3) 1.7 (0.9-3.4)
Clozapine 2 (0.5) 7 (0.2) 2.5 (0.4-14.7) 1.8 (0.3-11.2)
Quetiapine 1 (0.3) 0 No data No data
Past 3 (0.8) 38 (0.9) 1.2 (0.4-4.1) 1.4 (0.4-5.2)
Typical antipsychotic use
Current 110 (27.6) 732 (18.2) 1.8 (1.4-2.3) 1.7 (1.3-2.2)
Past 46 (11.6) 402 (10.0) 1.4 (1.0-2.0) 1.4 (0.9-2.0)
Combined antipsychotic use
Current 2 (0.5) 14 (0.3) 1.8 (0.4-8.5) 1.8 (0.4-8.7)
Past 5 (1.3) 17 (0.4) 2.9 (1.0-8.3) 3.0 (0.9-9.9)
Current typical use 110 (27.6) 732 (18.2) 1.0 (ref ) 1.0 (ref )
Current atypical use 18 (4.5) 99 (2.5) 1.2 (0.7-2.1) 1.3 (0.7-2.4)
Legend: CI= confi dence interval; OR= odds ratio.
^OR matched and additionally adjusted for gender and factors changing the risk estimate for antipsychotic users by more than 5% (Heart 
failure, COPD, Parkinson(ism), home-bound lifestyle, benzodiazepines, antibiotics). *Current use of diff erent atypical antipsychotics is not 
mutually exclusive.
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DISCUSSION
In this study, we found no diﬀ erence in the risk of death between atypical and 
typical antipsychotic use in elderly outpatients with dementia. Th e use of atypical 
and typical antipsychotics was similarly associated with a signiﬁ cant and dose-
related increase in risk of all-cause mortality compared to non-users. Our ﬁ nding 
on atypical antipsychotics is consistent with the public health advisory that was 
recently issued by FDA 7. Health care providers were informed about the results 
of a pooled analysis of seventeen placebo-controlled studies that showed a 1.7 fold 
increased risk of death during use of atypical antipsychotics. Data on typical anti-
psychotics from clinical trials for this indication are limited but are consistent with 
a similar increase in the risk of death 7. Our study results underline that the risk 
of death is similarly elevated in users of typical antipsychotics. Th e FDA did not 
mention eﬀ ects of dose and duration. In our study, the risk of death increased with 
increasing daily dose for both antipsychotic types and with increasing duration of 
use for atypical antipsychotics. In general, a positive dose-response supports a 
causal eﬀ ect. A recently published meta-analysis of randomized placebo-controlled 
trials of atypical antipsychotics in patients with dementia 18 highlighted that use of 
these newer antipsychotics for relatively brief periods (8-12 weeks) may be associ-
Table 3. Risk of death in subgroups of current users of atypical and typical antipsychotics.
Variables
Current use of 
antipsychotic drug
Cases
N= 398 (%*)
Controls
N=4,023 (%*)
OR adjusted^
(95% CI)
Males
atypical 3 (0.8) 24 (0.6) 0.4 (0.1-2.8)
typical 35 (8.8) 179 (4.4) 1.0 (ref )
Females
atypical 15 (3.8) 75 (1.9) 1.6 (0.7-3.3)
typical 75 (18.8) 553 (13.7) 1.0 (ref )
65-79 years old
atypical 5 (1.3) 21 (0.5) 0.8 (0.2-2.9)
typical 18 (4.5) 83 (2.1) 1.0 (ref )
 ≥80 years old
atypical 13 (3.3) 78 (1.9) 1.4 (0.7-2.7)
typical 92 (23.1) 649 (16.1) 1.0 (ref )
Alzheimer’s disease
atypical 4 (1.0) 28 (0.7) 0.9 (0.2-4.4)
typical 41 (10.3) 302 (7.5) 1.0 (ref )
Vascular dementia
atypical 3 (0.8) 23 (0.6) 0.6 (0.1-10.2)
typical 17 (4.3) 106 (2.6) 1.0 (ref )
Mixed/unspecifi ed dementia
atypical 11 (2.8) 48 (1.2) 1.7 (0.8-4.1)
typical 52 (13.1) 324 (8.1) 1.0 (ref )
Switchers
atypical 2 (0.5) 29 (0.7) 0.8 (0.1-8.2)
typical 2 (0.5) 12 (0.3) 1.0 (ref )
Non-switchers
atypical 16 (4.0) 70 (1.7) 1.7 (0.8-3.3)
typical 108 (27.1) 720 (17.9) 1.0 (ref )
^OR adjusted for gender, Parkinson(ism), heart failure, COPD, home-bound lifestyle, concomitant use of benzodiazepines and antibiotics.
*Percentage based on total cases and controls, including those not exposed to antipsychotics, past users of any antipsychotic type and users of 
combination.
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ated with a small increased risk of death as compared with placebo. In line with 
our results, it is also highlighted that this eﬀ ect may not be limited to atypical 
drugs and may be associated also with haloperidol and other antipsychotics that 
have not been tested for this indication of use 18. Prior to our investigation, only 
one US observational study11 had explored the association between antipsychotic 
medication use and risk of all-cause death in elderly patients, independent of the 
presence of dementia. Th e results from that study also suggest that conventional 
antipsychotic medications are at least as likely as atypical agents to increase the 
risk of death among elderly persons. In light of previous alerts4-5 and scientiﬁ c evi-
dences from other observational studies19-22, however, further evaluations should 
be performed to more precisely establish whether diﬀ erences in the risk of well-
deﬁ ned fatal event, such as stroke or arrhythmias, may be reported between users 
of atypical and typical antipsychotics. Although exploratory and underpowered, 
our sub-analyses suggested that certain subgroups of atypical and typical anti-
psychotic users would have diﬀ erent risks of death related to antipsychotic drug 
use. In particular, the risk of death was higher in females than males for atypical 
antipsychotics, compared to users of typical antipsychotics. Gender as a risk factor 
of death in demented patients is controversial 9,23-24. Patients starting directly with 
atypical antipsychotics were at higher risk of death compared to those switching 
from typical to atypical antipsychotics. Future studies should provide also more 
data on the diﬀ erential risk in users of antipsychotics who are switchers and non-
switchers.
To our knowledge, this is the ﬁ rst observational study speciﬁ cally comparing 
the eﬀ ect of atypical and typical antipsychotic drugs on all-cause mortality in a 
cohort of elderly patients who have been diagnosed with dementia. Th e strength 
of this study is the information on many confounders, dementia, dose and dura-
tion of antipsychotic drug use and the possibility to review reason for switching. 
However, several limitations of our study warrant caution. In any observational 
study, selection bias, information bias and residual confounding should be consid-
ered as alternative explanations for the study ﬁ nding. Selection bias was minimal 
as all data were obtained from prospectively collected medical records that are 
maintained for patient care purposes. Information bias by misclassiﬁ cation of the 
outcome will be minimal since death is consistently registered by GPs 15. A previous 
study on the IPCI database has shown that the incidence of sudden cardiac death 
is in line with estimates from other sources 25. Studies on mortality and inﬂ uenza 
vaccination in the IPCI database additionally underlined the validity of the data 
on mortality26. Misclassiﬁ cation of exposure may have occurred since we used 
outpatient prescription data and had no information whether the antipsychotic 
drug prescriptions were actually ﬁ lled and taken. It is likely, however, that such 
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exposure misclassiﬁ cation will be evenly distributed among cases and controls and, 
therefore, the actual risk may be underestimated. To limit exposure misclassiﬁ ca-
tion due to inpatient prescriptions, we excluded all patients who transferred out 
of the GP practice (e.g. to a nursing home or long-term care facility). Many risk 
factors for death were considered in our study, even though residual confounding 
due to unmeasured confounders or severity of disease cannot be excluded. Opioids 
are often given in the end-stage of life to alleviate pain in terminally ill patients. 
Since this variable can be considered a proxy of death rather than a confounder of 
the association between use of antipsychotics and death, we did not include use 
of opioids in the multivariate analysis. Inclusion of opioids in the model did not 
change the association between atypicals and typicals and risk of death.
To summarize, our study shows that both types of antipsychotic drugs are associ-
ated with an increased and dose-related risk of death in elderly demented persons, 
which is consistent with results from placebo-controlled trials. Since behavioral 
and psychotic symptoms requiring antipsychotic treatment may themselves be 
predictors of mortality within older demented patients27, however, confounding 
by indication may explain at least part of that association. On the other hand, the 
main study ﬁ nding is that patients with dementia who are currently treated with 
typical antipsychotics in an outpatient setting have a similar risk of death as users 
of atypical antipsychotics.
Th erefore, our data supports the fact that conventional antipsychotic drugs 
should be included in the FDA’s Public Health advisory, which currently warns 
only of the increased risk of death with the use of atypical antipsychotics in elderly 
demented persons.
REFERENCES
 1. Triﬁ ro G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic pre-
scribing pattern among Italian general practitioners: a population-based study during 
the years 1999-2002. Eur J Clin Pharmacol 2005; 61: 47-53.
 2. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. Th e use of 
atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64: 1106-12.
 3. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with 
second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychia-
try 2004; 161: 414-25.
 4. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of 
risperidone for the treatment of aggression, agitation, and psychosis of dementia. J 
Clin Psychiatry 2003; 64: 134-43.
 5. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in 
dementia trials. CMAJ 2004; 170: 1395.
Gianluca BW.indd   77 25-May-09   11:23:15 AM
Chapter 2
78
 6. Committee on Safety of Medicines. Latest News. 9 March 2004. Atypical antipsy-
chotic drugs and stroke. Available at: www.mca.gov.uk/aboutagency/regframework/
csm/csmhome.htm. Accessed May 09, 2005.
 7. FDA Public Health Advisory. Deaths with Antipsychotics in Elderly Patients with 
Behavioural Disturbances. Available at: http://www.fda.gov/cder/drug/advisory/anti-
psychotics.htm. Accessed 10/04/2005.
 8. Ostbye T, Hill G, Steenhuis R. Mortality in elderly Canadians with and without 
dementia: a 5-year follow-up. Neurology 1999; 53: 521-6.
 9. Schaufele M, Bickel H, Weyerer S. Predictors of mortality among demented elderly 
in primary care. Int J Geriat Psychiatry 1999; 14: 946-956.
 10. Suh GH, Yeon BK, Shah A, Lee JY. Mortality in Alzheimer’s disease: a compara-
tive prospective Korean study in the community and nursing homes. Int J Geriat 
Psychiatry 2005; 20: 26-34.
 11. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart 
MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medica-
tions. N Engl J Med. 2005; 353: 2335-41.
 12. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on 
electronic patient records: the IPCI project. Methods Inf Med 1999; 38: 339-44.
 13. Van der Lei J, Duisterhout JS, Westerhof HP, et al. Th e introduction of computer-
based patient records in Th e Netherlands. Ann Intern Med 1993; 119: 1036-41.
 14. Lamberts H, Wood M, Hofmans-Okkes IM. International primary care classiﬁ ca-
tions: the eﬀ ect of ﬁ fteen years of evolution. Fam Pract 1992; 9: 330-9.
 15. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden 
cardiac death. Arch Intern Med. 2004; 164: 1293-7.
 16. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index With 
DDDs. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 
2002.
 17. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public 
Health 1989; 79: 340-9.
 18. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug 
treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 
2005; 294: 1934-43.
 19. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, Bernabei R. Con-
ventional and atypical antipsychotics and the risk of hospitalization for ventricular 
arrhythmias or cardiac arrest. Arch Intern Med. 2005; 165: 696-701.
 20. Ray WA, Meredith S, Th apa PB, Meador KG, Hall K, Murray KT. Antipsychotics 
and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001; 58: 1161-7.
 21. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, Bernabei R. Cere-
brovascular events among elderly nursing home patients treated with conventional or 
atypical antipsychotics. J Clin Psychiatry. 2005; 66: 1090-6.
 22. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of 
ischemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445.
 23. Bracco L, Gallato R, Grigoletto F, et al. Factors aﬀ ecting course and survival in Al-
zheimer’s disease. A 9-year longitudinal study. Arch Neurol 1994; 51: 1213-9.
Gianluca BW.indd   78 25-May-09   11:23:15 AM
79
Antipsychotic drugs in elderly: use and safety
 24. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Prognostic factors 
in very old demented adults: a seven-year follow-up from a population-based survey 
in Stockholm. J Am Geriatr Soc 1998; 46: 444-52.
 25. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC. 
Th e incidence of sudden cardiac death in the general population. J Clin Epidemiol 
2004; 57: 98-102.
 26. Voordouw AC, Sturkenboom MC, Dieleman JP, et al. Annual revaccination against 
inﬂ uenza and mortality risk in community-dwelling elderly persons. JAMA 2004; 
292: 2089-95.
 27. Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type de-
mentia. Ann Intern Med 1990; 113: 429-34.
Gianluca BW.indd   79 25-May-09   11:23:15 AM
Gianluca BW.indd   80 25-May-09   11:23:15 AM
2.5.  Fatal and non fatal community acquired pneumonia 
associated with antipsychotic drug use in elderly 
patients
Submitted for publication
Gianluca Trifi rò1,2,3, MD, Elif F. Sen1, MSc, Achille P. Caputi 2,3, professor, Giovanni 
Gambassi 4, professor, Vincenzo Bagnardi, PhD 5-6, Jose Brea, PhD 7, Miriam C.J.M. 
Sturkenboom1, professor
1. Pharmacoepidemiology unit, Departments of Medical Informatics and Epidemiology & 
Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands;
2. Department of Clinical and Experimental Medicine and Pharmacology – University of 
Messina, Messina – Italy;
3. IRCCS Centro Neurolesi ‘Bonino-Pulejo’, Messina, Italy;
4. Centro Medicina Invecchiamento - Universita’ Cattolica Sacro Cuore, Rome – Italy;
5. Department of Statistics, University of Milano-Bicocca, Milan, Italy;
6. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy;
7. Industrial Pharmacology Institute - Department of Pharmacology - School of Pharmacy - 
Universidad de Santiago de Compostela – Spain.
Gianluca BW.indd   81 25-May-09   11:23:15 AM
Chapter 2
82
ABSTRACT
Context: Recently, the Food and Drug Administration highlighted that mortality 
is increased during use of antipsychotics in elderly dementia patients and pneu-
monia is one of the most frequently reported causes of death. Th e alert regarded 
atypical antipsychotics but was recently extended also to typical antipsychotics.
Objective: To evaluate whether use of typical or atypical antipsychotics is associ-
ated with fatal/non-fatal pneumonia in elderly patients.
Design, Setting and Participants: A population based nested case-control study 
was conducted in a cohort of antipsychotic (AP) drug users who were 65 years or 
older during the years 1996-2006 in the Dutch Integrated Primary Care Informa-
tion (IPCI) medical record database. Cases were all patients with an incident fatal 
or non-fatal community-acquired pneumonia. Up to 20 controls were matched to 
each case on age, gender and index date. Exposure to AP was categorized by type, 
recency and daily dose of use and the association with pneumonia was assessed 
using conditional logistic regression.
Main outcome measure: Association between fatal/non-fatal community acquired 
pneumonia and antipsychotic use.
Results: 258 incident cases of pneumonia were matched to 1,686 controls. Sixty-
four (24.8) of the cases died within 30 days and were considered fatal cases. 
Current use of either atypical (OR: 2.64; 95 CI: 1.51-4.61) or typical (OR: 1.74; 
95 CI: 1.22-2.49) antipsychotics was associated with a increase in the risk of 
pneumonia compared to past use of any antipsychotic. Th e linear trend of dosage 
was signiﬁ cant for both current users of atypical and typical antipsychotics. Only 
atypical antipsychotics were associated with a signiﬁ cant increase in the risk of 
fatal pneumonia (OR: 5.5, 95 CI: 1.5-20.6).
Conclusion: Th e use of either atypical or typical antipsychotics in elderly patients 
appears to be associated in a dose-dependent fashion with the development of 
community-acquired pneumonia.
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INTRODUCTION
Antipsychotic (AP) drugs, which are generally distinguished in typical (conven-
tional) and atypical (newer) agents, are widely used in geriatric psychiatric disorders, 
such as aﬀ ective psychoses, agitation and behavioral and psychological symptoms 
of dementia [1-2]. Although antipsychotics are eﬀ ective for some indications, they 
are often over- and misused in elderly patients and recently their safety proﬁ le was 
questioned by the Food and Drug Administration (FDA) [1]. In 2005 the FDA 
informed health professionals about the results of a pooled analysis of placebo-
controlled clinical trials, reporting a 70 increased risk in all-cause mortality 
in elderly demented patients who were treated with atypical antipsychotics [3]. 
According to the FDA alert, pneumonia was one of the most frequently reported 
causes of death [3]. Although the warning focused on atypical antipsychotics, the 
FDA underlined that a similar increased risk could not be excluded for the typical 
antipsychotics. Subsequent observational studies conﬁ rmed this suspicion since 
they found that mortality was elevated in elderly patients receiving either atypical 
or typical antipsychotic drugs [4-6]. In June 2008, the FDA extended the warning 
about the increased risk of all-cause mortality also to the typical antipsychotics, 
when used oﬀ -label in elderly dementia patients [7].
Th e mechanism behind the demonstrated increase in mortality is not clear and 
the question remains whether antipsychotics may increase the risk of pneumonia 
and thereby mortality. Th is is not easy to assess since the baseline risk of fatal 
pneumonia is already high in elderly patients with psychiatric diseases [8].
To our knowledge, two studies (one in the Netherlands and one in US) have 
evaluated the association between antipsychotic drug use and pneumonia, but 
both studies captured only hospitalized pneumonia [9-10]. Compared to non-
users, the Dutch study showed a 3-fold increased risk of pneumonia in atypical 
users and a 60 increase in users of typical antipsychotics [9]. Th e U.S. study that 
included a cohort of patients hospitalized for pneumonia found that use of typical 
antipsychotics was associated with a 50 increased risk of mortality in inpatients 
with pneumonia [10].
To further explore the association between atypical and typical antipsychotic 
drug use and the risk of fatal/non-fatal community-acquired pneumonia we 
conducted a case control study nested in a cohort of elderly outpatients receiving 
antipsychotic drugs.
Gianluca BW.indd   83 25-May-09   11:23:15 AM
Chapter 2
84
METHODS
Setting
For this study, data were retrieved from the Integrated Primary Care Informa-
tion (IPCI) database, a longitudinal general practice research database set up 
in 1992 and containing data from electronic medical records from a group of 
200 general practitioners (GPs) in the Netherlands. All Dutch inhabitants are 
registered with their own GP. Th e GP is the gatekeeper to all further care and ﬁ les 
all relevant medical details from primary care visits, hospital admissions and visits 
to outpatient clinics. Details of the IPCI database have been previously described 
[11]. Brieﬂ y, the database contains the complete medical records of approximately 
800,000 patients. Th e age and gender distribution of the IPCI population is rep-
resentative of the whole country. Th e electronic records contain anonymous data 
on patient demographics, reasons for visits (in free text), signs and symptoms, 
diagnoses (using the International Classiﬁ cation for Primary Care and free text) 
[12] from the GPs and the specialists, along with referrals, hospitalizations, as well 
as drug prescriptions, including product name + anatomical therapeutic chemical 
classiﬁ cation (ATC code), dispensed quantity, dosage regimen and indication of 
use [13]. To maximize completeness of the data, GPs participating in the IPCI 
project are not allowed to maintain any paper-based records. Th e system complies 
with European Union guidelines on the use of medical data for medical research 
and has been proven valid for pharmacoepidemiological research [14]. Th e Scien-
tiﬁ c and Ethical Advisory Board of the IPCI project approved the study (Study 
Protocol N. 07/05).
Study cohort
Th e source population comprised all patients who were registered in the IPCI 
database and were 65 years or older during the study period (January 1, 1996 - 
December 31, 2006). Th e study cohort included all elderly patients that received 
a ﬁ rst antipsychotic drug prescription during the study years. Cohort members 
were followed from the cohort entry date until the earliest of the following events: 
pneumonia, death, moving out of the practice area or end of the study period. 
Persons, who were diagnosed with lung cancer, either before or during the obser-
vation period, were excluded.
Identifi cation and Ascertainment of Pneumonia
Cases were all persons with a ﬁ rst ascertained community-acquired pneumonia 
during follow-up. Pneumonia was identiﬁ ed through searches of coded diagnoses 
and narratives in the electronic medical record [15]. Th e electronic medical records 
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of all potential patients were reviewed manually by two medically trained research-
ers (E.F.S, G.T.) who were blinded towards the exposure. Cases were classiﬁ ed as 
certain (either conﬁ rmed by a specialist or diagnosed by chest X-ray) or possible 
(diagnosed by GPs on the basis of respiratory sign/symptoms). For unresolved 
cases, a third medical doctor arbitrated. All of the remaining potential cases were 
excluded. Th e date of ﬁ rst speciﬁ c symptoms related to pneumonia (i.e. fever, 
respiratory signs/symptoms) was deﬁ ned as the index date (ID). Pneumonia was 
considered fatal if the person died within 30 days after ID [16].
Controls
By using incidence density sampling, up to 20 controls (individuals alive and 
disease-free at index date) from the cohort of new users of antipsychotic drugs 
were matched to each case on the year of birth, gender and index date.
Exposure defi nition
For the estimate of the association between antipsychotic drugs and pneumonia, 
we created exposure categories based on drug type, timing, dose and duration 
of use. Antipsychotic drug use was obtained from the prescription ﬁ les and the 
length of treatment was calculated based on the dispensed number of units and 
the dosing regimen. In detail, we calculated the duration as the total number of 
units per prescription divided by the prescribed daily number of these units. Anti-
psychotic drugs were grouped in: 1) Atypical antipsychotics: clozapine, olanzapine, 
risperidone, quetiapine; 2) Typical antipsychotics, divided in Butyrophenones, 
Phenothiazines, and Others (Benzamides, Th ioxanthene and Diphenylbutylpip-
eridine derivatives); 3) Combination of atypical and typical antipsychotics, in case 
of concomitant use. Exposure to antipsychotic drug types was categorized by time 
since last use. Drug use was deﬁ ned as current if the prescription duration covered 
the index date or ended 30 days or less (carry-over eﬀ ect) prior to that, as recent 
if the end of the last prescription was between 30 and 180 days prior to the index 
date, and as past if the last prescription ended more than 180 days before ID. If 
patients had used more than one type of antipsychotic drug, current exposure of 
one class overruled past exposure of the other, unless they were concomitantly 
used. Among current users of antipsychotic drugs, we studied the risk of fatal 
and non-fatal pneumonia for the most widely prescribed compounds, by daily 
dosage (≤ or > median DDD) and by diﬀ erent durations of use (≤ 7, ≤ 30 and ≤ 
60 days).
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Covariates
As covariates, we considered age, gender, calendar time (matching variables), 
indication of use of antipsychotic drugs (behavioral and psychological symptoms 
of dementia, psychoses associated to aﬀ ective disorders, anxiety disorders, includ-
ing agitation and sleep disorders, and other psychotic disturbances) as obtained 
from the electronic medical record, smoking, home bound lifestyle (deﬁ ned as 
receiving at least 2 visits from GP at home within 1 month prior to index date), 
cardiovascular diseases (heart failure, hypertension, angina, history of myocardial 
infarction, cardiac arrhythmias), history of cerebrovascular disorders, Parkinson’s 
disease (identiﬁ ed as diagnosis and/or anti-Parkinson drug use), chronic obstruc-
tive pulmonary disease (COPD), diabetes mellitus, chronic renal disease, chronic 
liver disease, cancer (except for lung cancer). With respect to medications, we 
looked at any prior use of cardiovascular drugs (diuretics, digoxin, ACE-inhibitors, 
sartanes, calcium-channel blockers, beta-blockers, lipid-lowering drugs, aspirin 
and other antiplatelet drugs, anticoagulants), gastric acid-suppressive drugs, and 
concomitant use (within 3 months prior to the index date) of antibiotics, systemic 
corticosteroids, respiratory drugs (nasal and throat preparations, drugs for obstruc-
tive airway diseases, cough and cold preparations, antihistamines for systemic use 
and other respiratory system products), and psychotropic drugs (benzodiazepines, 
tricyclic antidepressants, selective serotonin reuptake inhibitors, opioids and 
anticonvulsants).
Data Analysis
To reduce confounding by indication a nested case control analysis was conducted 
in a cohort of new users of antipsychotic drugs. We selected new users of anti-
psychotics for two reasons: 1) to calculate crude incidence rates of pneumonia in 
users of atypical and typical antipsychotics; 2) to avoid bias due to depletion of 
susceptible patients: if the risk of pneumonia changes over time bias is introduced 
by prevalent users since not all of their time at risk is observed [9]. Crude incidence 
rates of pneumonia in users of atypical and typical antipsychotics were calculated 
by dividing the number of cases by the corresponding persons-months of exposure 
(PMs). Relative risks of community acquired pneumonia were estimated as odds 
ratio (OR) by using conditional logistic regression analysis, while adjusting for all 
covariates that were signiﬁ cantly (p < .05) associated with pneumonia in the uni-
variate analysis. Relative risks (plus 95 conﬁ dence intervals [CIs]) were calculated 
for typical and atypical antipsychotics by comparing current use to past use of 
any antipsychotics; in current users, the eﬀ ects of the most commonly prescribed 
individual medications, and the eﬀ ect of dose (in deﬁ ned daily dose equivalents) 
and duration of use were estimated. Moreover, a linear trend across the dosage 
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strata was tested including dosage as ordinal variable in the conditional logistic 
regression model. In order to directly compare the eﬀ ect of atypical and typical 
antipsychotics, an analysis was conducted that assessed the eﬀ ects of current use 
of atypicals by using current use of typical agents as reference group. Since one 
of the potential explanations of a diﬀ erential eﬀ ect on pneumonia between the 
antipsychotic classes could be the diﬀ erences in anti-histaminergic eﬀ ects, a post-
hoc analysis was conducted that used current use of butyrophenones as reference 
group since these antipsychotics have the lowest aﬃ  nity for the anti-histaminergic 
receptor H1 (see Table 5). To evaluate the association between use of antipsychotics 
and fatal pneumonia, all the above mentioned analyses were repeated in a dataset 
that comprised only the fatal cases of pneumonia (deﬁ ned as those events leading 
to death within 30 days from the onset) and their matched controls. A sensitivity 
analysis was conducted that deﬁ ned fatal pneumonia as death occurring within 7 
days after the onset of pneumonia. Moreover, to compare our ﬁ ndings with those 
from previous publications that included only hospitalized pneumonia, we per-
formed a sensitivity analysis restricted to pneumonia cases requiring hospitaliza-
tion and their matched controls. Several sensitivity analyses were also conducted 
in order to rule out the impact of potential protopathic and information biases. 
Severe pneumonia may induce delirium and trigger subsequent antipsychotic drug 
use in elderly patients [17]. If the date of onset of pneumonia is not deﬁ ned with 
certainty that might result in a protopathic bias, i.e. a drug which is used to treat 
prodromic symptoms of the outcome may falsely be considered to actually cause 
the outcome [18]. To explore whether the association between antipsychotic drugs 
and pneumonia was distorted due to protopathic bias, we performed an analysis 
that excluded all patients who began the treatment within 7 days prior to the 
index date. To rule out possible outcome misclassiﬁ cation and inspect ascertain-
ment bias a sensitivity analysis was conducted excluding all pneumonia cases that 
were judged to be only possible.
Th e number of pneumonia cases attributable to use of atypical and typical 
antipsychotics was calculated by multiplying the adjusted attributable risk per-
centage ((OR-1)/OR) with the incidence rate (in Person-Months) and the average 
duration of use in months [15].
All conditional logistic regression analyses were conducted in SPSS/PC, version 
13 (SPSS Inc, Chicago, Ill). Th e level of signiﬁ cance for all statistical tests was set 
at p-value below 0.05.
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RESULTS
Th e study cohort comprised 2,560 elderly patients who received a ﬁ rst antipsy-
chotic medication prescription during the follow-up period (Figure 1). Among 
those, 2,263 (88.4) started with typical antipsychotics, 277 (10.8) with atypicals 
(20 patients received a combination of atypical and typical antipsychotics). Th e 
mean duration of use was 154 and 128 days for atypical and typical antipsychotics, 
respectively. After cohort entry 264 patients suﬀ ered a ﬁ rst pneumonia. Th e inci-
dence rates of pneumonia were 1.12 and 0.78 cases per 100 person-months (PMs) 
among current users of atypical and typical antipsychotics, respectively (Table 1). 
Figure 1. Selection of incident cases of community acquired pneumonia and matched controls by using Integrated Primary Care Information 
(IPCI) database.
2,636 new users of 
antipsychotics
258 incident 
cases of 
pneumonia
IPCI population: 
72,863 patients 65 
years and older
Broad search through 
codes and free text 
622 patients with 
potential incident 
pneumonia  
358 cases excluded 
because judged 
false positive  
Final study 
cohort: 2,560
76 patients excluded due 
to lung cancer 
Medical record validation 
1,686 controls, 
matched on 
age, gender and 
index date 
- 64 cases of fatal 
pneumonia; 
- 57 cases leading 
to hospitalization. 
6 cases could not be 
matched 
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Pneumonia rates were comparable between past use of atypical and typical anti-
psychotic drugs. Of the 264 cases, 258 could be matched to 1,686 controls on age, 
gender and index date. Fifty-seven cases (22.1) were hospitalized for pneumonia 
and 64 (24.8) were considered fatal (Figure 1). Cases were more likely to be home 
bound and to be diagnosed with chronic obstructive pulmonary diseases, diabetes 
mellitus and arrhythmias (Table 2). Chronic use of anticoagulants and concomi-
tant use of antibiotics, corticosteroids, tricyclic antidepressants and opioids were 
also risk factors for pneumonia in this cohort. Th e indications for antipsychotic 
drug use were not associated with pneumonia. Current use of atypical (OR: 2.64; 
95 CI: 1.51-4.61) and typical (OR: 1.74; 95 CI: 1.22-2.49) antipsychotics was 
associated with an increased risk of pneumonia when compared to past use (Table 
3). Th e increased risk disappeared after stopping medication as recent use of 
antipsychotics was not associated with an increased risk of pneumonia anymore. 
Current use of atypical antipsychotics was associated with a non-signiﬁ cant 50 
higher risk of pneumonia compared to current use of typical antipsychotics (OR: 
1.52, 95 CI: 0.87-2.64). Analyses of chemical subgroups of typical antipsychotics 
showed some heterogeneity. Use of butyrophenones was associated with only a 
slightly increased risk of pneumonia (OR: 1.56; 95 CI: 1.07-2.29) while the use 
of phenothiazines was associated with a four-fold increased risk (OR: 4.32, 95 
CI: 1.57-11.87) (Table 3). Adjustment for frequency of use of diﬀ erent subtypes in 
determining the class eﬀ ect for typical antipsychotics showed that the overall class 
eﬀ ect remained approximately the same (OR: 2.03; 95 CI: 1.20-3.45). Analysis 
of individual drugs showed that risperidone (OR: 3.30; 95 CI: 1.84-5.93) was 
associated with the highest risk of pneumonia (Table 4). Th e daily dosage of either 
atypical or typical antipsychotics was generally very low in current users (median: 
0.15 DDD). Patients receiving higher doses (above median) of either atypical or 
Table 1. Incidence rate (IR) of pneumonia by exposure to antipsychotic drugs.
Antipsychotic exposure Cases of pneumonia
Person months (PM) 
exposure
IR (per 100 PM)
Atypical antipsychotics (N=277)
Current use 22 1,967 1.12
Recent use 15 1,649 0.91
Past use 8 1,829 0.44
Typical antipsychotics (N=2,263)
Current use 76 9,689 0.78
Recent use 79 10,461 0.76
Past use 62 15,001 0.41
Combination of both types (N=20)
Current use 1 131 0.76
Recent use 1 94 1.06
Past use - 162 -
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Table 2. Characteristics of cases and controls.
Covariates Cases
N=258 (%)
Controls
N= 1,686 (%)
Odds Ratio
(95% CI)
P-value
Gender Matching factor
Males 116 (45.0) 457 (27.1)
Mean Age (SD) 83.7 (7.5) 83.2 (5.9) Matching factor
Smoking 38 (14.7) 193 (11.4) 1.24 (0.82-1.88) .13
Home bound lifestyle 38 (14.7) 107 (6.3) 2.11 (1.35-3.29) < .001
Cardiovascular diseases
Angina 49 (19.0) 355 (21.1) 0.79 (0.55-1.14) .45
History of myocardial infarction 5 (1.9) 37 (2.2) 0.72 (0.28-1.87) .79
History of cerebrovascular events 45 (17.4) 233 (13.8) 1.26 (0.92-1.72) .11
Heart Failure 56 (21.7) 269 (16.0) 1.24 (0.87-1.78) .05
Arrhythmias 36 (14.0) 165 (9.8) 1.54 (1.03-2.31) .04
Hypertension 45 (17.4) 381 (22.6) 0.79 (0.55-1.13) .06
Other diseases potentially related to pneumonia
Swallowing problems 7 (2.7) 47 (2.8) 0.81 (0.33-2.00) .95
COPD 49 (19.0) 190 (11.3) 1.62 (1.12-2.36) < .001
Diabetes Mellitus 58 (22.5) 282 (16.7) 1.52 (1.08-2.15) .02
Chronic renal disease 7 (2.7) 38 (2.3) 1.07 (0.46-2.47) .65
Chronic hepatic diseases 10 (3.9) 52 (3.1) 1.30 (0.61-2.76) .50
Cancer (except for lung cancer) 36 (14.0) 188 (11.2) 1.23 (0.81-1.87) .20
Parkinson’s disease 30 (11.6) 135 (8.0) 1.45 (0.92-2.30) .05
Indication for antipsychotic drug use .001
BPSD 80 (31.0) 607 (36.0) 0.84 (0.59-1.19)
Aff ective psychoses 11 (4.3) 136 (8.1) 0.55 (0.28-1.09)
Anxiety disorders* 75 (29.1) 347 (20.6) 1.34 (0.93-1.91)
Other psychotic disorders 87 (33.7) 509 (30.2) 1.00
Not reported 5 (1.9) 87 (5.2) 0.40 (0.16-1.02)
Use of cardiovascular drugs
Antihypertensive drugs 141 (54.7) 936 (55.5) 1.00 (0.76-1.33) .80
Digoxin 26 (10.1) 132 (7.8) 1.44 (0.90-2.29) .22
Antiplatelet drugs 79 (30.6) 459 (27.2) 1.22 (0.89-1.66) .26
Anticoagulants 42 (16.3) 171 (10.1) 2.19 (1.48-3.24) .003
Lipid lowering drugs 15 (5.8) 86 (5.1) 1.34 (0.75-2.40) .63
Use of gastric acid suppressive drugs 45 (17.4) 244 (14.5) 1.26 (0.87-1.82) .21
Concomitant use of:
Respiratory drugs 31 (12.0) 158 (9.4) 1.27 (0.82-1.97) .18
Corticosteroids 17 (6.6) 43 (2.6) 2.75 (1.48-5.11) < .001
Antibiotics 52 (20.2) 219 (13.0) 1.66 (1.16-2.38) .002
Psychotropic drugs
Opioids 20 (7.8) 61 (3.6) 2.41 (1.35-4.31) .002
Benzodiazepines 57 (22.1) 335 (19.9) 1.23 (0.88-1.72) .41
Anticonvulsants 1 (0.4) 32 (1.9) 0.17 (0.03-1.30) .19
TCA 15 (5.8) 43 (2.6) 2.40 (1.27-4.51) .003
SSRI 12 (4.7) 69 (4.1) 1.30 (0.68-2.48) .82
Legend: COPD=Chronic Obstructive Pulmonary Disease; BPSD= Behavioural and Psychological Symptoms of Dementia; Respiratory drugs= 
Cough and cold preparation, Antihistamines for systemic use, Nasal and throat preparations, Drugs for obstructive airways diseases and other 
respiratory system products; TCA=Tricyclic antidepressant; SSRI= Selective Serotonin Reuptake Inhibitor.*including sleep disorders and agitation.
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typical antipsychotics were those with the highest risk of pneumonia (Table 4). 
Th e linear trend of dosage was signiﬁ cant for both current users of atypical (p 
< .005) and typical antipsychotics (p < .001). Th ere was no clear pattern of the 
duration of use, however, the highest risk was observed during the ﬁ rst week of 
treatment (Table 4). Th ere was no signiﬁ cant eﬀ ect modiﬁ cation by presence of 
behavioral and psychological symptoms of dementia (BPSD) or concomitant use 
of benzodiazepines, SSRIs or TCAs. Exclusion of patients with BPSD did not 
remove the association between current use of atypical (OR: 3.33; 95 CI: 1.37-
8.08) or typical antipsychotics (OR: 1.85; 95 CI: 1.17-2.93) and pneumonia. Use 
of atypical but not that of typical antipsychotics was associated with fatal pneu-
monia (OR: 5.5; 95 CI: 1.5-20.6) (Table 3). If a fatal event was deﬁ ned as death 
occurring within 7 days rather than within 30 days, the risk estimate for atypical 
antipsychotics was 3.8 (95 CI: 0.67-21.0). If cases were limited to pneumonia 
requiring hospitalization, only the use of atypical antipsychotics was associated 
with pneumonia (OR: 6.3, 95 CI: 2.0-19.5). Various sensitivity analyses were 
Table 3. Association between use of antipsychotic drugs and pneumonia in the cohort of new users of antipsychotic drugs.
Fatal and non-fatal pneumonia Fatal pneumonia
Antipsychotic 
exposure
Cases
N=258 
(%)
Controls
N=1,686 
(%)
Matched OR
(95% CI)
Adj^ OR
(95% CI)
Cases
N=64 
(%)
Controls
N=401 
(%)
Matched OR
(95% CI)
Adj^ OR
(95% CI)
Current use
Atypical
28 
(10.9)
100 (5.9)
2.99
(1.76-5.09)
2.64
(1.51-4.61)
7 (10.9) 19 (4.7)
3.78
(1.19-11.98)
5.46
(1.45-20.56)
Typical
105 
(40.7)
517 
(30.7)
1.90
(1.34-2.70)
1.74
(1.22-2.49)
26 (40.6) 139 (34.7)
1.83
(0.88-3.77)
1.61
(0.72-3.56)
Butyrophenones
77 
(29.8)
429 
(25.4)
1.62
(1.11-2.36)
1.56
(1.07-2.29)
21 (32.8) 117 (29.2)
1.80
(0.85-3.82)
1.42
(0.61-3.27)
Phenothiazines 9 (3.5) 13 (0.8)
4.00
(1.44-11.14)
4.32
(1.57-11.9)
1 (1.6) 2 (0.5) - -
Others* 19 (7.4) 75 (4.4)
2.24
(1.20-4.16)
2.12
(1.14-3.98)
4 (6.3) 20 (5.0)
1.77
(0.51-6.20)
2.36
(0.62-8.97)
Combination of 
atypical and typical
4 (1.6) 8 (0.5)
4.52
(1.12-18.21)
5.35
(1.33-21.5)
- 2 (0.5) - -
Recent Use
Atypical 5 (1.9) 39 (2.3)
1.41 (0.48-
4.17)
1.33 (0.44-
4.03)
- 5 (1.2) - -
Typical
46 
(17.8)
279 
(16.5)
1.56 (1.02-
2.39)
1.28 (0.82-
2.00)
17 (26.6) 82 (20.4)
1.82 (0.81-
4.09)
1.36 (0.56-
3.33)
Combination of 
atypical and typical
1 (0.4) 2 (0.1) - - - - -
Past Use of any AP
69 
(26.7)
741 
(44.0)
Reference 
Group
Reference 
Group
14 (21.9) 154 (38.4)
Reference 
Group
Reference 
Group
^Adjusted for diabetes mellitus, COPD, arrhythmias, home bound lifestyle, indication of use of antipsychotics and any prior use of 
anticoagulants and concomitant use of corticosteroids, antibiotics, TCA and opioids; * Thioxanthene, Diphenylbutylpiperidine and Benzamides 
derivatives.
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conducted to estimate the eﬀ ect size of possible misclassiﬁ cation of exposure or 
outcome. Varying the current use window by diminishing the carry-over period 
from 30 to 20, 10 or 0 days resulted in a slightly reduced risk for current users 
of atypical antipsychotics (OR from 2.64 to 2.24 in 0 days carry-over), while no 
changes were observed for current users of typical antipsychotics. Exclusion of 
cases in which pneumonia was classiﬁ ed only as possible (diagnosis from GP based 
on signs/symptoms consistent with pneumonia, without further ascertainment) 
slightly reduced the eﬀ ect estimates, particularly for typical antipsychotics [OR: 
2.13 (95 CI: 1.96-3.92) and 1.36 (95 CI: 0.92-2.00) for current users of atypical 
and typical antipsychotics, respectively]. To verify the existence of protopathic bias, 
we performed a sensitivity analysis excluding all patients who started antipsychotic 
therapy within 7 days prior to the pneumonia onset but the risk estimates did not 
change substantially [OR: 2.50 (95 CI: 1.37-4.54) and 1.49 (95 CI: 1.02-2.18) 
for current users of atypical and typical antipsychotics, respectively]. In the elderly 
patients using antipsychotics in this study, the adjusted attributable risk is 62 for 
Table 4. Dose, duration and individual drug response analysis for the association between current use of antipsychotics and the risk of 
pneumonia*.
Cases
 N= 258 
(%)
Controls
N=1,686 (%)
Crude OR
(95% CI)
Adjusted^ OR
(95% CI)
By dosage#
Current use of Atypical APs
≤ 0.15 DDD 6 (2.3) 30 (1.8) 1.88 (0.71-4.98) 1.42 (0.48-4.17)
> 0.15 DDD 22 (8.5) 70 (4.2) 3.55 (1.97-6.38) 3.31 (1.80-6.11)
Current use of Typical APs
≤ 0.15 DDD 60 (23.3) 329 (19.5) 1.72 (1.15-2.55) 1.53 (1.02-2.29)
> 0.15 DDD 45 (17.4) 188 (11.2) 2.20 (1.40-3.45) 2.12 (1.33-3.49)
By duration of use
Current use of Atypical APs
≤ 7 days 13 (5.0) 33 (2.0) 4.62 (2.18-9.74) 3.89 (1.75-8.64)
≤ 30 days 23 (8.9) 64 (3.8) 3.68 (2.07-6.54) 3.22 (1.75-5.93)
≤ 60 days 26 (10.1) 86 (5.1) 3.29 (1.91-5.69) 2.96 (1.66-5.25)
Current use of Typical APs
≤ 7 days 49 (19.0) 170 (10.1) 2.63 (1.70-4.06) 2.29 (1.46-3.60)
≤ 30 days 80 (31.0) 319 (18.9) 2.20 (1.52-3.21) 2.01 (1.36-2.95)
≤ 60 days 90 (34.9) 403 (23.9) 2.02 (1.41-2.90) 1.85 (1.27-2.68)
By active compound**
Current use of:
Risperidone 26 (10.1) 71 (4.2) 3.63 (2.09-6.32) 3.30 (1.84-5.93)
Olanzapine 5 (1.9) 23 (1.4) 2.41 (0.83-7.00) 2.08 (0.69-6.24)
Pipamperon 46 (17.8) 276 (16.4) 1.55 (1.01-2.38) 1.50 (0.97-2.33)
Haloperidol 40 (15.5) 161 (9.5) 2.43 (1.53-3.86) 2.03 (1.25-3.28)
Zuclopenthixol 11 (4.3) 39 (2.3) 2.19 (0.99-4.85) 2.00 (0.88-4.51)
*Past use of any antipsychotic drugs was the reference category; ^Adjusted for diabetes mellitus, COPD, arrhythmias, home bound lifestyle, 
indication of use of antipsychotics and any prior use of anticoagulants and concomitant use of corticosteroids, antibiotics, TCA and opioids; # 
linear trend across the 3 dosage strata is signifi cant for both current users of atypical (p <.005) and typical antipsychotics (p < .001), ** Only the 
drugs with more than 3 users for each cell in two by two tables have been considered. The use of individual drugs was not mutually exclusive.
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atypical and 43 for typical antipsychotics. Th erefore, 0.69 pneumonia cases per 
100 person-months of atypical antipsychotic exposure can be directly attributed to 
the medication, while the ﬁ gure is 0.33 pneumonia cases per 100 person-months 
for typical antipsychotics. Since the average duration of use was 5.1 person-months 
for atypical and 4.2 person-months for typical antipsychotics, this translates into 
the following number needed to harm (NNH): 29 for atypical antipsychotics and 
73 for typical antipsychotics. NNH represents the number of patients that should 
be treated with either atypical or typical antipsychotics to observe 1 case of pneu-
monia. Table 5 shows the aﬃ  nity of diﬀ erent antipsychotics for H1 histaminergic 
(H1) and cholinergic receptors. Overall, aﬃ  nity to H1 histaminergic receptor of 
antipsychotics is higher than aﬃ  nity to cholinergic receptors. In particular, look-
ing at mean values of all the compounds included in each subgroup, atypical 
Table 5. Affi  nity values (pKi) of diff erent antipsychotics for H1 histaminergic (H1) and cholinergic receptors, based on literature search [31-36]^
Atypical antipsychotic H1 MUSC M1 M2 M3
 Clozapine 8.70±0.53 7.61±0.40 8.22±0.61 7.08±0.44 7.59±0.30
 Olanzapine 8.85±0.73 7.75±0.54 8.15±0.38 7.32±0.34 7.36±0.43
 Quetiapine 7.89±0.71 6.03±0.68 6.86±0.06 6.20±0.00 5.40±0.50
 Risperidone 7.86±0.81 4.94±0.46 5.18±0.52 5.21±0.42 5.07±0.52
Typical antipsychotic      
 Phenothiazines  
 Chlorpromazine 8.10±0.50 7.01±0.68 7.21±0.35 6.56±0.35 7.22±0.09
 Fluphenazine 7.68±0.59 5.72±0.60 5.49±0.28 5.66±0.66 5.84±0.11
 Perphenazine 8.10±0.60 5.70±0.79 5.77 5.54 5.73
 Prochlorperazine 7.72±0.51 6.04±0.34 6.11 5.85
 Thioridazine 7.77±0.42 7.79±0.26 8.19±0.41 7.58±0.71 7.61±0.26
 Trifl uoperazine 7.20±0.20 5.89±0.06 5.89 5.66 6.00
 Mesoridazine 8.74 7.22±0.00 7.80±0.24 7.17±0.64 7.55
 Levomepromazine 8.69 7.37 6.58 7.41
 Periciazine 7.16* 6.09*
 Butyrophenones      
 Bromperidol 6.01±0.12 5.36±0.49 5.12 5.74 5.15
 Haloperidol 6.07±0.45 5.15±0.45 5.51±0.53 5.28±0.38 5.15±0.53
 Benperidol 6.69* 6.30*
 Droperidol 5.60*
 Others      
 Pimozide 6.45 5.86
 Sulpiride 4.14 4.37
 Flupenthixol 9.06* 5.32*
 Zuclopenthixol 7.40* 6.10*
 Tiapride 8.00* 4.50*
 Penfl uridol 5.47*
Legend: H1=histamine-1 receptor subtype; MUSC=muscarinic non-selective; M1=muscarinic-1 receptor subtype; M2=muscarinic-2 receptor 
subtype; M3=muscarinic-3 receptor subtype.
^ When more than one data was available mean ± SD was reported, while the cell was left empty when no data were available. Values labeled 
with * are referred to affi  nity values at rat receptors.
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antipsychotics, similarly to phenothiazines, have the highest aﬃ  nity to H1 recep-
tor while butyrophenones have the lowest aﬃ  nity. When compared to current use 
of butyrophenones (lowest H1 aﬃ  nity), a non-statistically signiﬁ cant increase in 
the risk of pneumonia was observed in antipsychotic groups with the highest H1 
aﬃ  nity: atypical antipsychotics (OR: 1.74; 95 CI: 0.99-3.07) and phenothiazines 
(OR: 2.60; 95 CI: 0.92-7.33). Moreover, combining atypical antipsychotics and 
phenothiazines, which have similar H1 -receptor aﬃ  nity, showed a signiﬁ cantly 
increased association with pneumonia for these drugs as compared to butyrophe-
nones (OR: 1,90, 95 CI: 1.13-3.21).
DISCUSSION
Th is study shows that the use of either atypical or typical antipsychotics in commu-
nity-dwelling elderly is associated with the development of community acquired 
pneumonia. Exposure to antipsychotic drugs is associated with an increased risk 
of fatal/non-fatal pneumonia in a dose-dependent fashion; the risk is high early 
after the beginning of the treatment but it rapidly disappears upon withdrawal of 
medication. Atypical antipsychotics are also associated with fatal pneumonia and 
hospitalized pneumonia. Although our design was diﬀ erent, the conclusion of 
this study are in line with those of a previous Dutch investigation which reported 
an increased risk of hospitalized pneumonia shortly after the initiation of anti-
psychotic drugs, especially with atypical agents (adj. OR: 3.1, 95 CI: 1.9–5.1; 
comparator=non use) [9].. Partly in contrast, a small incompletely reported U.S. 
study including data Medicaid patients found no signiﬁ cant diﬀ erence in the risk 
of hospitalized pneumonia between the two classes of antipsychotics (after 30 
days therapy, typical versus atypical antipsychotics: OR=1.11; 95 CI: 0.76-1.63) 
[19]. However, in this study published as letter to editor, hospitalized pneumo-
nia was not the main outcome. Th e possible mechanisms by which exposure to 
antipsychotics could be associated with the development of pneumonia remain 
speculative. Use of typical antipsychotics may be a risk factor for aspiration pneu-
monia, as a result of extrapyramidal eﬀ ects, such as akinesia [20]. On the contrary, 
atypical antipsychotics are markedly less likely to cause extrapyramidal adverse 
events, including akinesia, particularly when used at the low dosages, as reported 
in this study [21-22]. In light of the observed increased risk of pneumonia in both 
atypical and typical antipsychotics, therefore mechanisms other than extrapyra-
midal adverse events may play a role in the antipsychotic-induced pneumonia. 
Th e histamine-1 receptor blocking eﬀ ect and the anticholinergic action of anti-
psychotics have been proposed as alternative explanations for the occurrence of 
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pneumonia [9]. Th e anticholinergic eﬀ ect of antipsychotics can induce dryness 
of the mouth, possibly leading to impaired oro-pharyngeal bolus transport and 
thereby to aspiration pneumonia. Th is hypothesis could also explain why the 
use of tricyclic antidepressants (agents with marked anticholinergic eﬀ ects) was 
a strong risk factor for pneumonia in our study. On the other hand, excessive 
sedation as a result of histamine-1 receptor blocking in the central nervous system 
is a well-known cause of swallowing problems, which could facilitate aspiration 
pneumonia [23]. In line with this hypothesis, our study showed a higher risk of 
pneumonia for atypical antipsychotics and phenothiazines compared to butyro-
phenones, with the latter ones being the antipsychotics with the lowest aﬃ  nity for 
antihistaminergic receptor H1. Moreover, some antipsychotics are known to have 
direct or indirect eﬀ ects on the immune system [24]. Most speciﬁ cally, clozapine 
has been proven to induce neutropenia in up to 3 of patients and agranulocytosis 
in approximately 1 of patients, thus increasing the risk for infections, such as 
pneumonia [25]. Although less well-evidenced, leukopenia and neutropenia have 
also been associated with use of the atypical antipsychotics, such as risperidone 
and olanzapine, as well as with typical antipsychotics [26-27].
Another important ﬁ nding of this study was the high fatality rate and the strong 
association between atypical antipsychotic use and fatal community-acquired 
pneumonia [14]. Yet, the presence of neuropsychiatric disease is a strong risk 
factor for mortality among patients with pneumonia [28]. Likewise pneumonia 
is an independent predictor of death in very old patients with neuropsychiatric 
conditions (mean age of our study sample: 83 years) [29]. With regard to the 
association between fatal pneumonia and antipsychotics, Barnett et al reported 
higher fatality rates in users of typical antipsychotics, in contrast to our study 
[10]. Since that study was not nested in an antipsychotic drug user cohort, but in 
a cohort of inpatients with pneumonia, the results are diﬃ  cult to compare and 
may be subject to confounding by severity, illness or co-morbidity, as the authors 
acknowledged.
Strength and limitations
Th e strength of this study is the availability of information on many potential 
confounders, indication of use, dose and duration of antipsychotic drug use. 
Moreover, we studied pneumonia resulting in hospitalization as well as those 
cared for in outpatient setting. However, several limitations of our study merit 
consideration. As in any observational study, selection bias, information bias and 
residual confounding should be considered as alternative explanations for the 
ﬁ ndings. Selection bias was unlikely as all the data were obtained from prospec-
tively collected medical records that are maintained for patient care purposes. 
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Information bias by misclassiﬁ cation of the outcome is similarly unlikely since 
all pneumonia cases were retrieved from the medical records and reviewed by 
medically trained researchers blinded towards the exposure. Exclusion of those 
cases for which pneumonia was considered only possible (those cases diagnosed by 
GPs based on symptoms but no objective assessment) similarly reduced the eﬀ ect 
estimate by 20 both for atypical as well as typical antipsychotics. Ascertainment 
of disease was associated with antipsychotic drug use (being lower in users since 
aspiration pneumonia is a known side eﬀ ect), but not diﬀ erential between atypi-
cal and typical antipsychotics. Misclassiﬁ cation of exposure may have occurred 
since we used outpatient prescription data and had no information about actual 
ﬁ lling and use of the medications. However, due to the way data were collected 
it is very unlikely that such a misclassiﬁ cation would have been diﬀ erential be-
tween cases and controls and, therefore, the actual risk may have possibly been 
underestimated. Confounding was addressed in the design and analysis phases. 
In order to minimize the eﬀ ect of confounding by indication, the whole study 
was conducted in a cohort of new users of antipsychotic drugs and past use was 
chosen as reference category. To explore the eﬀ ect of confounding by dementia 
severity we conducted a sensitivity analysis which excluded BPSD patients, and 
this did not yield diﬀ erent eﬀ ect estimates. Th e incidence rates of pneumonia were 
similar during past use of atypical and typical antipsychotics, which supports the 
notion that confounding by indication between two classes was minimal. Many 
risk factors for pneumonia were considered in our study. Nevertheless, residual 
confounding due to unmeasured covariates or severity of disease can never be 
excluded. However, only strong and highly prevalent risk factors would be able 
to explain the study ﬁ ndings and it is unlikely that these covariates have been 
omitted. Despite the fact that the mechanisms by which antipsychotics may cause 
pneumonia are unlikely to diﬀ er in diﬀ erent settings we should warn against 
generalization of these results to patients living in nursing homes or long term 
care facilities since these were not included in this study.
In conclusion, our study shows that the use of either atypical or typical antipsy-
chotics in elderly outpatients is associated with the development of community-
acquired pneumonia in a dose-dependent fashion and early after the beginning of 
treatment in elderly outpatients. Use of atypical antipsychotics appears also to be 
associated with fatal cases of pneumonia. Th ese study ﬁ ndings should be observed 
also in light of the ongoing discussion about the eﬀ ectiveness of antipsychotics in 
elderly patients. In particular, Th e Clinical Antipsychotic Trials of Intervention 
Eﬀ ectiveness-Alzheimer’s Disease (CATIE-AD) showed that antipsychotics may 
be eﬀ ective for some symptoms included in the BPSD, but would not improve the 
quality of life in patients with Alzheimer’s disease [30].
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ABSTRACT
With the progressive aging of the population in Western Countries, the number 
of patients aﬀ ected by dementia is rapidly increasing. Treatment of dementia ad-
dresses two main clinical manifestations: cognitive deterioration and “behavioral 
and psychological symptoms of dementia” (BPSD). What should be considered 
the most appropriate pharmacological treatment for BPSD has remained question-
able due to the availability of only a limited number of trials that have evaluated 
comparatively eﬀ ectiveness and safety of diﬀ erent treatments. Despite this lack of 
information, antipsychotic drugs, especially atypical agents, have been increas-
ingly utilized in clinical practice in the last decade. Th is article reviews all the 
evidences concerning the safety of both atypical and conventional antipsychotics 
used in the treatment of BPSD in elderly patients with dementia. As regard new 
safety issues, results from meta-analyses of clinical trials and observational studies 
report overall a similarly increased risk in all-cause mortality and cerebrovascular 
adverse events in users of both atypical and conventional antipsychotics. On 
the other hand, safety issues speciﬁ cally related to antipsychotic types consist of 
cardiotoxicity, namely proarrhytmic activity, and extrapyramidal symptoms for 
conventional antipsychotics, and metabolic eﬀ ects (i.e. increased risk of diabetes 
and obesity) for atypical antipsychotics, as largely described in both clinical trials 
and thereafter observational investigations.
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INTRODUCTION
Epidemiology of Dementia
Th e progressive aging of the population is associated with an increase of patients 
aﬀ ected by dementia. At present time, in the United States, the prevalence of de-
mentia is estimated to be around 20-30 among community dwelling individuals 
over 80 years, and up to 60-80 among elderly in nursing homes. Th is translates 
in about 4 millions of individuals currently aﬀ ected by Alzheimer’s disease only 
in the United States with a new case diagnosed every 72 seconds [1]. Dementia is 
growingly becoming a critical issue for any health care system, especially in western 
countries. Indeed, dementia causes progressive disability and it is an independent 
predictor of mortality. Th e expected lifetime for dementia patients is estimated to 
be between 5 and 12 years after initial diagnosis [1]. Treatment addresses two main 
clinical manifestations: cognitive deterioration and “behavioral and psychological 
symptoms of dementia” (BPSD). BPSD is a complex of symptoms – sometime 
clustered – and main clinical features include hallucinations, delusions, agitation, 
wandering and aggression or abuse. Virtually all patients with dementia will de-
velop changes in behaviour and personality [2]. Th e nature and frequency of these 
symptoms might vary over the course of the illness, and the relation to the severity 
of the disease is not univocal. BPSD are generally more troubling and challenging 
than cognitive decline since they result in an increased caregiver burden, an accel-
erated cognitive deterioration, earlier institutionalization and excess mortality [3].
Management of BPSD
Treatment of BPSD should initially consider all of non pharmacological means. 
Should this approach be unsuccessful, physicians should rely upon the use of 
medications. Th e only class of drugs with some evidence of eﬃ  cacy is that of 
antipsychotics. Th ese medications are generally classiﬁ ed as either conventional 
or atypical antipsychotics [4]. Th e latter were introduced in the ’90s and were 
called atypical because supposedly devoid of extrapyramidal side eﬀ ects. Indeed, 
atypical antipsychotics present with a receptor binding proﬁ le that is extremely 
more complex and diversiﬁ ed than conventional agents. In 2006, Ballard and 
Waite [5] completed a review for the Cochrane Collaboration concluding that 
risperidone and olanzapine have a modest eﬃ  cacy in reducing aggression and 
psychosis but neither should be routinely used because of their serious adverse 
events. Increasingly, safety concerns have ignited a controversial debate about the 
risk-beneﬁ t ratio of these agents. More recently, a meta-analysis of 7 studies on 
atypical antipsychotics (risperidone, olanzapine or quetiapine) for the treatment 
of BPSD was published [6]. It documented no statistically or clinically signiﬁ cant 
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diﬀ erences in eﬀ ectiveness between atypical antipsychotics and placebo. Th is 
ﬁ nding was conﬁ rmed by the CATIE-AD investigators who also reported that 
the placebo group had signiﬁ cantly lower health costs than patients on either 
risperidone, olanzapine or quetiapine [7]. Likewise, there is insuﬃ  cient evidence 
to suggest that psychotropic medications other than antipsychotics represent an 
overall eﬀ ective and safer treatment alternative for BPSD [8].
Off -label use of antipsychotics
Either conventional or atypical antipsychotics are not approved for the treatment 
of BPSD with the only exception of haloperidol. So, the use of these agents for 
this indication should be considered oﬀ -label, despite being endorsed by institu-
tion like the American Academy of Neurology. Accordingly, risperidone is cur-
rently approved for the treatment of one or more symptoms of BPSD in over 30 
countries [9]. Certainly, recent years have witnessed an increased utilization of 
antipsychotics and in particular of atypical agents in view of a supposed better risk 
proﬁ le and tolerability relative to conventional agents. Studies from United King-
dom and Canada have reported an increase in overall antipsychotic prescribing to 
older patients in long term care facilities [10-12]. Other investigations have shown 
that atypical antipsychotics have become the agents more commonly prescribed 
[13]. In Italy, a drug utilization study has documented a 5-fold increased use of 
atypical agents for the treatment of BPSD between 1999 and 2004 [14].
Warnings and safety alerts
Th e trend toward a rapidly increasing utilization of atypical antipsychotics has been 
paralleled by the release of several warnings and safety alerts concerning the risks 
associated with their oﬀ -label use in elderly with BPSD. With an unprecedented 
move, the manufacturer of risperidone in October 2002 notiﬁ ed all Canadian 
healthcare professionals that an increased rate of cerebrovascular events among 
risperidone users relative to placebo was becoming evident in drug-sponsored 
clinical trials [15]. In March 2004, the UK Committee on Safety of Medicines 
(CSM) through a Dear Doctor Letter [16] has recommended avoiding atypical 
antipsychotic administration to elderly demented individuals with behavioural 
disturbances, particularly in patients with a high baseline risk of stroke. Informa-
tion about harm was available for olanzapine and risperidone. However, a similar 
warning has been recently issued also by the manufacturer of aripiprazole [17]. On 
April 2005, an oﬃ  cial warning was issued by the Food and Drug Administration 
(FDA)[18] to inform health professionals about the results of a pooled analysis of 
17 RCTs reporting a 1.7 times increased risk of all-cause mortality associated with 
atypical antipsychotic use in elderly with BPSD, compared to placebo with an 
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increased risk evident in 15 of 17 trials analyzed. FDA has documented a similar 
increased risk of death with conventional antipsychotics use but has refrained 
from adding a warning in the Summary of Product Characteristics because data 
about conventional antipsychotics were based on only one trial with haloperidol. 
Th ese alerts have ignited a very animated debate in the scientiﬁ c community. 
Some authors judge the warnings on atypical antipsychotics as unnecessarily 
alarming and potentially detrimental for patients with dementia [19]. Th ey reason 
that avoidance of these pharmacological agents could lead to a more widespread 
use of conventional antipsychotics. Other researchers instead are concerned that 
there is no clear evidence to support a greater beneﬁ ts with atypical relative to con-
ventional antipsychotics [20]. Th is review will thoroughly evaluate the currently 
available data on the potential risks associated with the use of antipsychotics. We 
will review as separate issues: all-cause mortality, cerebrovascular events, cardiac 
eﬀ ects, vascular eﬀ ects, metabolic abnormalities, extrapyramidal symptoms and 
hyperprolactinemia.
ALL-CAUSE MORTALITY
In April 2005, the results of a meta-analysis including 17 placebo-controlled stud-
ies of four drugs (olanzapine, risperidone, quetiapine and aripiprazole) were made 
available [18]. Th e studies were, on average, 10 weeks in duration and enrolled 
a combined 5,106 elderly patients with dementia. Th e ﬁ ndings revealed a 4.5 
mortality rate among patients who had been treated with atypical antipsychotics, 
compared with 2.6 among patients on placebo. It is noteworthy that already in 
2004, based on a pooled analysis of randomized clinical trials (RCTs) the Euro-
pean Medicines Agency (EMEA) had issued a warning about a two-fold increased 
risk of all-cause mortality associated with olanzapine. Th e exact mechanism for 
the increased risk has yet to be identiﬁ ed. However, despite a substantial variabil-
ity, causes of death were primarily cardiac (i.e. heart failure or sudden death) or 
infectious (i.e. pneumonia). A recent re-analysis of olanzapine trial data found no 
signiﬁ cant diﬀ erences in mortality between olanzapine and conventionals agents 
[22]. Likewise, FDA claimed that a similar increased risk of death could also be 
reported for conventional antipsychotics, although limited availability of RCTs 
could not allow a precise risk estimate. In fact, a new meta-analysis of RCTs [23] 
found that a conventional antipsychotic, haloperidol, for which comparable data 
could be accrued was associated with about two-fold increased mortality versus 
placebo, a risk even higher than that associated with the use of atypical agents. 
In light of the uncertainty about the actual risk of all-cause mortality associated 
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with either atypical or conventional antipsychotics, and in consideration of sub-
stantial limits of the trials, a number of observational studies [9, 24-32] have been 
completed in the last few years. A US retrospective cohort study [24] based on a 
health insurance database found that conventional antipsychotics were associated 
with a signiﬁ cantly higher risk of mortality than were atypical antipsychotics at 
all intervals studied (≤180 days: RR=1.37; 95 CI: 1.27-1.49; <40 days: RR=1.56; 
1.37-1.78; 40-79 days: RR=1.37; 1.19-1.59; and 80-180 days: RR=1.27; 1.14-1.41) and 
in all subgroups deﬁ ned according to the presence or absence of dementia or 
nursing home residency. Th e greatest increase in risk occurred soon after therapy 
was initiated and with higher dosages of conventional antipsychotics. Such ﬁ nd-
ing was conﬁ rmed by a population-based, retrospective cohort study carried out 
using the administrative health care database in Ontario [25]. Authors reported 
that relative to atypical antipsychotic use, conventional antipsychotic use was 
associated with a higher risk for death in both short and long term treatment 
of community-dwelling elderly with dementia. Similarly, Liperoti et al. [32] has 
documented that among residents of nursing homes in 5 US states, conventional 
antipsychotics were associated with a 22 increased risk of all-cause mortality 
relative to atypical agents. Not all of the observational studies have supported 
these conclusions. A case control study nested in a cohort of elderly outpatients 
with dementia was conducted using data from Dutch general practice database 
[26]. Th is investigation reported no statistically signiﬁ cant diﬀ erences in the risk 
of all-cause mortality between users of atypical and conventional antipsychotics, 
while both antipsychotic classes were associated with a signiﬁ cantly higher and 
dose-dependent risk of dying, compared to placebo. Another study reported that 
the adjusted mortality risk for atypicals was similar to that for conventional anti-
psychotics [28]. In general, it remains controversial whether data available should 
be interpreted as describing a class eﬀ ect, as claimed by FDA, or the risk of death 
may vary across diﬀ erent ingredients [29]. However, not an enough number of 
patients have been studied in RCTs to adequately explore the risk of death associ-
ated with individual antipsychotics use, nor observational studies could ﬁ ll the 
gap. Th e only exception is for risperidone for which a meta-analysis of 6 RCTs 
(N=1,721), was carried out [9]. Th e pooled analysis found a not signiﬁ cant and 
dose-independent increase in mortality compared to placebo (mortality rate: 4.0 
vs. 3.1; RR=1.21, 0.76-2.06). More recently, Liperoti et al. [32] using the SAGE 
(Systematic Assessment of Geriatric drugs use via Epidemiology) database have 
completed a study comparing each atypical antipsychotics to haloperidol and to 
other conventional agents. Relative to risperidone users, risk of all cause mortality 
was not diﬀ erential among other atypicals users while was higher for haloperidol 
users [32].
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To summarize, observational studies carried out after the warnings launched 
by regulatory agencies conﬁ rmed that an increased risk of all-cause mortality is 
associated with antipsychotic use in elderly with dementia, compared to non us-
ers. Conventional antipsychotics have a similar, if not higher risk of death than 
atypical agents (Table 1). Risk of death is increased early after beginning of treat-
ment and seems explained by an excess mortality from cardiovascular causes and 
pneumonia.
CEREBROVASCULAR EVENTS
A pooled analysis of RCTs has documented an increased risk for transient ischemic 
attacks (TIA) and stroke of about 3-fold with risperidone and olanzapine, com-
pared to placebo [33-35]. Despite a substantial uncertainty about the diagnostic 
accuracy of either TIA or stroke in the trials considered, a warning was issued and 
extended to all atypical antipsychotics. In the scientiﬁ c community, some authors 
judged this alert as inappropriate because no comparative data between atypi-
cal and conventional was available. Moreover, the causal relation appeared to be 
extremely diﬃ  cult to establish in most cases. Nevertheless, a number of potential 
mechanisms have been postulated to explain a possible increased incidence of 
stroke with the use of atypical antipsychotics in elderly persons with dementia [36, 
37]. Atypical antipsychotics could induce orthostatic hypotension, as a result of 
antagonism at alpha-adrenergic receptors. Elderly with a pre-existing cerebrovas-
cular disease might experience a TIA or CVAE as a consequence of hypotension 
aggravating the deﬁ cit in cerebral perfusion. Alternatively, after an episode of 
orthostatic hypotension, there could be a rebound excess of catecholamines with 
vasoconstriction and aggravation of cerebral vascular insuﬃ  ciency. Other puta-
tive mechanisms proposed include hyperprolactinemia and thromboembolism. 
Beyond the biological plausibility, several recently published observational studies 
[38-45] have explored the comparative risk of stroke associated with both atypical 
and conventional antipsychotics (Table 2). Th ese population-based, observational 
studies were performed through administrative databases [38-41, 43, 44], general 
practice database [45], or through prescription event monitoring methodology 
[42]. Most of these studies selected elderly patients [38, 43, 45] eventually living 
in nursing home [39], while only Gill et al. [40] and Barnett et al. [44] looked 
speciﬁ cally at older adults with a diagnosis of dementia. In all of the studies, 
outcome was any case of CVAEs, including both transient ischemic attack and 
stroke, resulting in hospital admission (all, except for Sacchetti et al. [45] and 
Layton et al. [42]), or as collected in general practitioners’ records [45] or through 
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Table 2. List of observational studies on the risk of cerebrovascular adverse events associated to antipsychotic drugs that have been published 
so far.
Author [Ref] Study Design - 
Population
Outcome Exposure Main fi ndings
Herrmann et al. [45] Population based 
retrospective cohort 
study – 11,400 subjects 
> 65 years from 
administrative healthcare 
database in Ontario
Hospital 
admission due to 
stroke
Use of risperidone, 
olanzapine and typical 
antipsychotics
a)Adjusted relative risk vs. 
conventional antipsychotic:
-risperidone: 1.4 (0.7-2.8)
-olanzapine:1.1 (0.5-2.3)
Gill et al. [47] Population based 
retrospective cohort 
study – 32,710 subjects ≥ 
65 years with dementia 
from administrative 
healthcare database in 
Ontario
Hospital 
admission due to 
ischemic stroke
New users of atypical 
(risperidone, quetiapine 
and olanzapine) and 
typical antipsychotics
a)Adjusted relative
 risk of atypical vs typical:
1.01 (0.81-1.26);
b) subanalyses for selected 
population confi rmed this 
fi nding.
Liperoti et al. [46] Case-control study- 
residents of nursing 
homes in 6 U.S. states 
(SAGE database) with 
dementia
Hospital 
admission for 
stroke or transient 
ischemic attack
Current use of atypical 
and conventional 
antipsychotics and non 
use
Adjusted odds ratio (vs non 
use):
- risperidone: 0.87 ( 0.67-1.12)
- olanzapine 1.32 (0.83-2.11)
- other atypicals: 1.57 (0.65-3.82)
- conventional: 1.24 (0.95-1.63).
Finkel et al. [48] Retrospective cohort 
study- Medicaid data
New case of 
acute inpatient 
admission for 
cerebrovascular 
events
Incident use of 
atypical antipsychotics 
(risperidone, olanzapine, 
quetiapine and 
ziprasidone) and 
haloperidol
a)Adjusted relative risk vs. 
risperidone:
-olanzapine: 1.05 (0.63-1.73)
-quetiapine:0.66 (0.23-1.87)
-haloperidol:1.91 (1.02-3.60)
Layton et al. [49] Prescription event 
monitoring study 
through data from UK 
National Health Service
Any 
cerebrovascular 
events within fi rst 
180 days therapy
Incident use of 
risperidone, quetiapine 
and olanzapine
a)Adjusted relative risk vs. 
olanzapine:
- risperidone: 1.2 (0.5-3.0)
- quetiapine: 2.1 (0.6-7.7)
b) dementia is strong risk factor
Percudani et al. [50] Case control study – 
35,604 patients ≥ 65 
years from administrative 
healthcare database in 
Lombardy, Italy
Hospital 
admission 
due to any 
cerebrovascular 
events
Previous use (as 
monotherapy) of atypical 
(risperidone, olanzapine, 
quetiapine and clozapine) 
and typical antipsychotics
Adjusted OR of atypical vs 
conventional:
- 1.42 (1.24-1.64)
Barnett et al. [51] Retrospective cohort 
study- 14,029 subjects 
≥ 65 years with 
dementia from Veteran 
Administration and 
Medicare database
Hospital 
admission 
due to any 
cerebrovascular 
events
Incident use of atypical 
and typical antipsychotic 
and non use
a)Adjusted relative risk vs. 
non use:
 - typical: 1.29 (0.48-3.47)
 - atypical:1.20 (0.83-1.74)
Sacchetti et al. [52] Retrospective cohort 
study- 74,162 elderly 
patients from Italian 
general practice database
First ever stroke Incident use of atypical 
antipsychotics, 
butyrophenones, 
phetioazines, benzamides 
and non use
a)Adjusted relative risk vs. 
non use:
-atypical: 2.46 (1.07-5.65)
-butyrophenones: 3.55 (1.56-
8.07)
-phetioazines: 5.79 (3.07-10.9)
-benzamides: 2.2 (0.98-4.90)
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questionnaires [42]. In summary, these studies suggested no increased risk of 
stroke with atypicals compared to conventional antipsychotics. Indeed, data seem 
to suggest that CVAE risk might actually be even lower for atypical antipsychotics 
than for conventional agents [46]. Interestingly, diﬀ erential risk was reported for 
subgroups of conventional antipsychotic like phenotiazines and butyrophenones. 
Th e latter agents would be linked to a higher risk of stroke compared to atypi-
cal antipsychotics and benzamides and other older antipsychotics, as reported in 
studies where data were analysed in a disaggregated fashion [45]. Concerning 
atypical antipsychotics, although only few observational investigations examined 
accurately the risk of CVAE associated to the individual ingredients, no signiﬁ cant 
diﬀ erences would be highlighted. Unfortunately, observational investigations 
were not able to assess accurately the relation between dose and duration of use 
of antipsychotic drugs and the occurrence of stroke. Data from the trials showed 
that all of risperidone and olanzapine users who developed CVAE were aﬀ ected 
by a number of vascular risk factors (atrial ﬁ brillation, hypertension, diabetes and 
hyperlipidaemia) that were either poorly treated or untreated [37]. In general, an 
underlying condition of vascular dementia was associated with a greater likelihood 
of cerebrovascular adverse events. Vascular dementia and history of CVAE were 
strong risk factors, according to the results of sub-analyses performed in some ob-
servational studies [39, 44]. Another issue is that the higher CVAE risk in elderly 
with dementia who use both conventional and atypical antipsychotic compared 
with non users could be partly explained by confounding by indication. Indeed, 
cognitive impairment, regardless of underlying aetiology, has been demonstrated 
to be a strong predictor of ischemic stroke independent of vascular risk factors 
[47]. In addition, individuals with Alzheimer’s disease seem to be more likely 
to die from cerebrovascular disease than normal elderly subjects thus supporting 
potential for confounding by indication [48].
CARDIAC EFFECTS
Atypical antipsychotics may cause cardiac adverse eﬀ ects including sinus tachy-
cardia, atrial and ventricular extrasystoles, QTc interval prolongation, T wave 
inversion, ST segment depression, and atrioventricular blocks [49]. One area of 
recent interest, concern, and controversy is the clinical eﬀ ect and meaning of 
changes in the rate corrected QT interval [50]. Th e Pﬁ zer/FDA study [51]. was the 
most extensive cardiac safety study related to the QTc intervals of antipsychotics 
ever conducted. Most cardiologists think that a QTc reading of more than 500 
milliseconds puts a patient at signiﬁ cant risk for torsade de pointes, ventricular 
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ﬁ brillation, and sudden death [52-57]. In the Pﬁ zer/FDA study, all the novel anti-
psychotics, when used alone, showed a QTc reading of less than 500 milliseconds 
(FDA) including ziprasidone [51]. Th e mean QTc increase from baseline with 
ziprasidone was signiﬁ cant (6-10 milliseconds throughout the dosing level) and 
greater than the other atypicals. From greatest to least risk of QTc prolongation, 
Pﬁ zer/FDA showed that thioridazine had the greatest danger of prolonging the 
QTc, followed in descending order by ziprasidone, quetiapine, risperidone, olan-
zapine, and haloperidol. As a result of this study, thioridazine received a “black box” 
warning and ziprasidone was approved with a label warning of the potential risks 
for prolongation of the QTc interval [58,59]. Almost all of the data concerning the 
cardiac eﬀ ects of atypical antipsychotics have been generated either in preclinical 
pharmacologic studies or in young-adult patients with psychiatric conditions. 
Deleterious cardiac eﬀ ects of antipsychotic medications have been well described 
with older antipsychotic medications. Some (e.g., phenothiazines) have been 
associated with an increased risk of ventricular arrhythmias, cardiac arrest, and 
sudden death [58,59]. Th e literature includes several case series in schizophrenic 
patients treated with thioridazine hydrochloride [60-62], haloperidol [63], and 
other conventional antipsychotics [64]. More recently, epidemiologic studies [65, 
66] have conﬁ rmed a direct relationship between conventional antipsychotics 
and the risk of sudden death and this has been attributed to the QT-prolonging 
properties of conventional antipsychotics [67, 68].
Experience with atypical antipsychotics is evolving but, in general, they appear 
to be more “cardiosafe” than conventional medications. Despite experimental 
evidence that some atypical antipsychotics can also prolong QT interval [64] only 
clozapine has been linked to serious cardiac problems [69]. A single epidemiologic 
study on schizophrenic patients has suggested an increased risk of ventricular ar-
rhythmias and cardiac arrest associated with risperidone, a ﬁ nding not endorsed 
by the authors of that study [65]. Indeed, risperidone has a minimal eﬀ ect on 
QT interval [64] and the only reported case of sudden death was not due to 
ventricular arrhythmias [70]. It is important to consider the cardiovascular eﬀ ects 
of antipsychotic medications also in older patients with dementia and cardiovas-
cular comorbidities. Recently, Liperoti et al conducted a case control study among 
nursing home residents in 6 US states using the SAGE database [71]. Th e 649 
cases included residents hospitalized for cardiac arrest (40.6), paroxysmal ven-
tricular tachycardia (34.5), and ventricular ﬂ utter or ﬁ brillation (24.9). After 
control for potential confounders, users of conventional antipsychotics showed an 
86 increase in the risk of hospitalization for ventricular arrhythmias or cardiac 
arrest (odds ratio, 1.86; 95 conﬁ dence interval, 1.27-2.74) relative to nonusers. 
Among residents receiving conventional antipsychotics, those with cardiac disease 
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were 3.27 times (95 conﬁ dence interval, 1.95-5.47) more likely to be hospitalized 
for ventricular arrhythmias and cardiac arrest, compared with nonusers without 
cardiac disease. Th ere was no increased risk associated with the use of atypical 
antipsychotics (odds ratio, 0.87; 95 conﬁ dence interval, 0.58-1.32). Th ere are 
other infrequent or rare cardiac events linked to the use of antipsychotics. Some of 
the atypicals report congestive heart failure as a direct cardiac eﬀ ect. Th is eﬀ ect has 
been reported infrequently (1/100–1/1000) with olanzapine and rarely (<1/1000) 
with clozapine and quetiapine [72] . Th e vasodilator eﬀ ects of the atypicals may 
counteract any major hemodynamic deterioration. However, therapeutic doses of 
antipsychotics do not seem to have important eﬀ ects on myocardial function.
VASCULAR EFFECTS
Hypotension is a major and frequent side eﬀ ect encountered with atypicals. Th e 
atypicals that most commonly cause hypotension, from the greatest to the lowest 
frequency, include clozapine (9), quetiapine (7), risperidone (5), and olanzap-
ine (5); the least hypotensive (1) eﬀ ects are reported with ziprasidone or halo-
peridol [72]. Likewise, some antipsychotics can cause or exacerbate hypertension. 
Atypical antipsychotic medications that cause hypertension, with greater to lower 
frequency, include clozapine (4), olanzapine (2), ziprasidone (1); the lowest 
risk of hypertension (1) is caused by risperidone and quetiapine [72]. A possible 
association between venous thromboembolism (VTE) and the use of antipsychot-
ic agents was ﬁ rst suggested in the 1950s after the introduction of phenothiazines 
[73]. Since then, several case studies [74-76] have supported the notion of an 
increased risk of VTE with conventional antipsychotic agents. Recently, Zornberg 
and Jick [77] documented a 7-fold increase in the risk of idiopathic VTE among 
users of conventional antipsychotic agents who were younger than 60 years and 
free of major risk factors. A similar thromboembolic eﬀ ect of conventional anti-
psychotic agents has been observed also among individuals with risk factors for 
VTE [78]. As for atypical antipsychotic agents, information on the risk of VTE 
has historically been limited to clozapine [79-81]. Th is association is primarily 
supported by results of a large record-linkage study in which a 5-fold increase in 
lethal pulmonary embolism was found [58]. More recently, 3 cases of VTE have 
been reported among elderly patients treated with olanzapine [82] and 1 case in a 
young man with a psychotic disorder [83]. Finally, a possible association between 
risperidone and massive pulmonary thromboembolism has been suggested from a 
review of autopsy records in a Japanese population [84]. Despite these suggestions, 
clear evidence of a possible thromboembolic eﬀ ect of antipsychotic agents is lack-
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ing. Most studies have been conducted on small samples with inadequate control 
for confounders. Moreover, elderly patients, who are among the most common re-
cipients of antipsychotic medications, have been systematically excluded. A single 
study among adults 65 years and older compared the eﬀ ect of antipsychotic agents 
on the risk of VTE relative to that of thyroid replacement therapy and found only 
a slightly increased risk with butyrophenones [85]. Recently, Liperoti et al. [86], 
conducted a retrospective cohort study to estimate the eﬀ ect of atypical and con-
ventional antipsychotic agents on the risk of hospitalization for VTE among elderly 
patients living in nursing homes in 5 US states. She identiﬁ ed 539 hospitalizations 
for VTE; venous thrombosis accounted for 77.6 and pulmonary embolism for 
22.4. Th e occurrence of VTE hospitalizations started early (30-60 days) and was 
distributed throughout the entire follow-up time. After adjusting for all poten-
tial confounders, the rate of hospitalization for VTE was increased for users of 
atypical antipsychotic agents, including risperidone (adjusted hazard ratio [HR], 
1.98; 95 CI, 1.40-2.78), olanzapine (adjusted HR, 1.87; 95 CI, 1.06-3.27), and 
clozapine/quetiapine (adjusted HR, 2.68; 95 CI, 1.15-6.28). Instead, no increased 
rate of hospitalization for VTE was associated with phenothiazines (adjusted HR, 
1.03; 95 CI, 0.60-1.77) or other conventional medications (adjusted HR, 0.98; 
95 CI, 0.52-1.87). A much smaller case-control study in a cohort of patients 68 
years of age has documented a similar point estimate for atypical antipsychotics 
but also an odds ratio of 4.1 for conventional agents [87]. Th e mechanisms by 
which antipsychotic medications may contribute to VTE remain to be established 
conclusively. Although conventional agents have been associated with enhanced 
aggregation of platelets [88], atypical antipsychotic agents have not been tested 
systematically. Recent in vitro data coming from the manufacturer do not support 
a direct eﬀ ect of risperidone on human platelet function, plasma coagulation, and 
ﬁ brinolysis [89]. However, atypical agents possess a high aﬃ  nity for the serotonin 
receptor type 5HT2A, and serotonin-induced platelet aggregation may be aﬀ ected 
[90]. Evidence also exists that lupus anticoagulant and anticardiolipin antibody 
levels may be raised in patients taking conventional antipsychotic agents [91] and 
clozapine [92]. Venous stasis can be exacerbated by excessive sedation. Moreover, 
a recent meta-analysis has suggested a nearly 3-fold increased risk of peripheral 
edema associated with risperidone [93].
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METABOLIC ABNORMALITIES
Weight gain
Signiﬁ cant weight gain is observed during treatment of schizophrenic patients with 
clozapine and olanzapine, with an increase in body fat being mainly responsible 
for olanzapine-induced weight gain [94-97]. In general, weight gain is observed 
during the ﬁ rst 4–12 weeks of treatment with most atypical antipsychotics. After 
this initial phase, weight gain continues at a lower level or even stabilizes. Clo-
zapine and olanzapine cause weight gain that continues over a prolonged period 
[98]. Results of a meta-analysis showed a mean weight gain of 4.45 kg under treat-
ment with clozapine, 4.15 kg for olanzapine, 2.10 kg for risperidone and 0.04 kg 
for ziprasidone respectively [99,100]. Increased food intake is partly being held 
responsible for the weight gain in psychotic patients and is possibly a consequence 
of the antipsychotic drug’s interaction with neuronal dopamine-, serotonin- and 
histamine-receptors [101]. Antipsychotic agents block the 5-HT2 receptor system 
resulting in a decreased serotoninergic transmission and thereby causing obesity.
Changes of glucose homeostasis
A retrospective cohort study showed that among patients with schizophrenia the 
prevalence of type 2 diabetes mellitus (T2DM) was over 20, with no signiﬁ cant 
diﬀ erence between atypical and conventional antipsychotics [102]. A more detailed 
analysis showed that during treatment with conventional antipsychotics the risk 
of diabetes was three times higher compared to the general population. Clozapine 
appears to be associated with a 1.4-fold higher prevalence than conventional anti-
psychotics and for olanzapine the factor is approximately 1.3. Th e relative risk of 
developing T2DM seems to be slightly lower with quetiapine and risperidone. 
Since the introduction of atypical antipsychotics several case reports of new-onset 
diabetes and diabetic ketoacidosis have been published. In summary, 27 case re-
ports of new-onset diabetes were found for clozapine, 39 for olanzapine, four for 
risperidone and three for quetiapine [103]. In most patients, the hyperglycaemia 
occurred within 6 weeks after start of treatment with the antipsychotic drug [103], 
in two patients, one with severe hyperglycaemia and one with ketoacidosis, within 
1 week [104, 105]. Most cases of new-onset disturbances of the glucose homeosta-
sis were reversible after discontinuation of the antipsychotic medication. Koller 
et al. [106] analysed 69 case reports of quetiapine-associated hyperglycaemia and 
T2DM. In a large retrospective case–control study, patients taking olanzapine had 
a signiﬁ cant higher risk of developing T2DM than patients without olanzapine 
(odds ratio 5.8) or patients treated with conventional antipsychotics (odds ratio 
4.2) [107]. Possible mechanisms include weight gain, changes of insulin secretion, 
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development of peripheral insulin resistance and changes of cellular glucose uptake 
[108, 109]. Several authors suggest that the onset of diabetes during antipsychotic 
therapy is secondary to drug-induced weight gain [103], possibly both induced 
by histamine antagonism [110, 111]. However, the rapid onset of diabetes, the 
disappearance of hyperglycaemia after discontinuation of the drug and recurrence 
after reintroduction support the development of diabetes in patients on atypical 
antipsychotics being a drug-related eﬀ ect, especially with regard to olanzapine and 
clozapine.
Disturbances of lipid metabolism
Additionally to weight gain and diabetes, some atypical antipsychotics cause hyper-
triglyceridaemia [112]. Increased adiposity can result in excess free fatty acids (FFA) 
release from hypertrophic adipocytes leading to higher FFA concentrations. Th ese 
can induce muscle and hepatic insulin resistance, endothelial- and pancreatic-cell 
dysfunction and increased VLDL triglyceride production. A recent prospective 
study comparing the eﬀ ects of clozapine, olanzapine, risperidone and sulpiride 
on glucose and lipid metabolism in ﬁ rst-episode schizophrenia at baseline and 
8 weeks after inclusion showed that besides higher C-peptide, fasting insulin and 
insulin resistance index (IRI), cholesterol and triglyceride levels were signiﬁ cantly 
increased in the clozapine and olanzapine groups [113]. In a comparative study, 
treatment with various antipsychotics resulted in signiﬁ cantly elevated triglycer-
ide levels in 56 of clozapine, 39 of olanzapine and 21 of risperidone-treated 
patients compared to none of haloperidol and 8 of ﬂ uphenazine-treated patients 
[114]. Th e same study showed a reduction of HDL cholesterol during treatment 
with clozapine and olanzapine, whereas total cholesterol levels were signiﬁ cantly 
lower in risperidone- and ﬂ uphenazine-treated patients. Koro et al. [115] observed 
a threefold higher risk of hyperlipidaemia for conventional antipsychotics when 
compared with a control population without antipsychotic exposure. Atypicals 
treatment associated odds varied: olanzapine use was associated with a nearly ﬁ ve-
fold higher increase in the risk of developing hyperlipidaemia, whereas risperidone 
showed no signiﬁ cant diﬀ erence [115]. A more recent study described a negative 
eﬀ ect of olanzapine administration on total cholesterol and triglycerides, whereas 
favourable metabolic eﬀ ects were observed in ziprasidone-treated patients with 
regard to total cholesterol, LDL and HDL [108]. Th ese results were conﬁ rmed 
in another study with 1,493 patients [109]. An increase of serum lipid levels was 
already seen after 4 weeks of treatment with olanzapine or clozapine and was 
signiﬁ cantly correlated with increasing BMI. It is noteworthy that all of the infor-
mation presented were gathered from studies in patients with either schizophrenia 
(the great majority) or bipolar disorder. Whether patients with BPSD receiving 
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antipsychotics develop similar disturbances is still debated. Indeed, only few and 
relatively small studies have been published. In 2006 Rondanelli et al. [116] have 
studied 36 AD patients who were residing in nursing homes and receiving either 
risperidone, olanzapine or quetiapine. Th e results of the study suggest that the 
treatment with low-dose of atypical antipsychotics is not associated with weight 
gain or increase the risk of developing type II diabetes or abnormalities of lipid 
metabolism. Th e CATIE-AD, instead, has highlighted a clear eﬀ ect of all atypical 
antipsychotics under scrutiny to increase weight gain and BMI with olanzapine 
having the greatest eﬀ ect followed by risperidone [117]. In contrast, there was no 
apparent eﬀ ect on glucose levels, total cholesterol and triglycerides levels. Con-
sistent results were reported by a post hoc analysis of 1,267 patients with BPSD 
receiving olanzapine (1-20 mg/day) [118]. Th e estimated probability of gaining 
more than 7 of initial body weight was signiﬁ cantly greater in patients treated 
with olanzapine versus placebo (P < 0.001). Weight gain in olanzapine-treated 
patients was signiﬁ cantly greater in individuals with a baseline body mass index 
of less than 25 kg/m2. Th e same group of authors similarly concluded that as 
for the risk of diabetes, seven olanzapine clinical trials showed no statistically 
signiﬁ cant association with antipsychotic use [119]. Finally, a study on 95 patients 
with dementia receiving mostly olanzapine and risperidone showed no eﬀ ect on 
any of the parameters of the metabolic syndrome based on the NCEP-ATPIII 
criteria [120].
EXTRAPYRAMIDAL EFFECTS
Conventional antipsychotics have been historically linked to a substantial incidence 
of extrapyramidal symptoms (EPS). Th e use of atypical antipsychotics is gener-
ally associated with a lower risk of EPS compared to conventional agents [121]. 
Diﬀ erent pharmacological mechanisms have been hypothesized including higher 
aﬃ  nity for serotonin 5HT2A than dopamine D2 receptors, faster dissociation from 
D2 receptors, selective aﬃ  nity for mesolimbic rather than nigrostriatal D2 recep-
tors, partial agonism and intrinsic anticholinergic activity. Atypical antipsychotics 
diﬀ er in their relative risk of EPS, with risperidone associated with the highest 
risk and clozapine and quetiapine with the lowest [122]. With regard to acute 
EPS, such as acute dystonia, akathisia and parkinsonism, various meta-analyses 
have documented an advantage for atypical antipsychotics, although in most cases 
the comparator was the high-potency agent haloperidol [123, 124]. Diﬀ erences 
in EPS risk were less marked when atypical antipsychotics were compared with 
low-potency conventional agents [125]. Concerning tardive dyskinesia, the limited 
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available evidence indicates that the use of atypical antipsychotics is associated with 
an incidence of 1 per year compared with 5 for conventional agents [126]. In 
this respect, a systematic review of 11 studies lasting 1 year or longer in patients with 
schizophrenia-spectrum disorders treated with atypical antipsychotics has clearly 
documented that these agents have a reduced risk for tardive dyskinesia [127]. As 
age is a risk factor for the development of tardive dyskinesia, older patients may 
be at even greater risk than the general adult population. In a study in patients 
highly vulnerable to tardive dyskinesia, including middle-aged and older adults, 
the use of atypical antipsychotics was associated with a signiﬁ cantly lower risk of 
developing tardive dyskinesia compared with conventional agents [128]. Although 
EPS with atypical antipsychotics may be less frequent and severe than with con-
ventional agents, it should be acknowledged that most studies investigating this 
aspect focused on patients with psychiatric diagnoses other than dementia. Th e 
few randomized controlled studies evaluating the eﬀ ect of newer antipsychotics 
in patients with dementia were too short (6 to 12 weeks) to provide any valuable 
information. A better understanding of the risk for EPS associated with various 
antipsychotics in patients with dementia has resulted from two retrospective co-
hort studies in elderly patients with dementia [129, 130]. In the ﬁ rst investigation, 
a dose-dependent increased risk of parkinsonism was documented among older 
adults with dementia prescribed atypical antipsychotics [129]. Interestingly, the 
risk of developing parkinsonism was similar among patients dispensed a high-dose 
atypical antipsychotics, usually risperidone, and those dispensed a higher potency 
conventional antipsychotic. Another cohort study investigated drug-induced 
movement disorders other than parkinsonism and found that the risk of develop-
ing tardive dyskinesia and other drug-induced movement disorders during treat-
ment with an atypical antipsychotic was not statistically diﬀ erent from that with 
a conventional agent [130]. Few studies have approached the issue considering a 
surrogate end-point like falls, either cumulative or only those injurious ending 
into an hospitalization for femur fracture. A relatively small study of very short 
duration conducted among patients in residential care facilities in Australia has 
documented that despite fewer EPS, atypical antipsychotics were not associated 
with fewer falls relative to conventional agents [131]. A recent study from the 
SAGE study group would indicate that in a cohort of patients with Parkinson’s 
disease, the use of risperidone and also clozapine are associated with an increased 
risk of falling similar to that of conventional antipsychotics [132]. Th ese data are 
in agreement with the results of the study by Liperoti et al. on the risk of femur 
fracture [133]. After control for potential confounders the risk of hospitalization 
for femur fracture was equally increased for atypical (OR 1.37) and conventional 
antipsychotics (OR 1.35).
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HYPERPROLACTINEMIA
Conventional antipsychotics may cause hyperprolactinemia by blocking dopamine 
D2 receptors on pituitary lactotroph cells, thereby removing the tonic inhibition on 
prolactin release provided by dopamine secreted by the tuberoinfundibular neurons 
in the hypothalamus [134]. With exception of risperidone and amisulpride, newer 
antipsychotics have a weak potential to cause elevation of plasma prolactin levels. 
Plasma prolactin increase is generally dose related and is more common in women, 
while is independent of age [135]. Hyperprolactinemia may be asymptomatic or 
can cause a wide range of clinical symptoms. Resulting from either the direct 
eﬀ ects of prolactin on body tissues (galactorrhea, gynecomastia) or endocrine-
related secondary eﬀ ects (sexual and reproductive dysfunction in the short-term 
and osteoporosis in the longer term) [136]. Th ere are conﬂ icting data on whether 
hyperprolactinemia is associated with an increased risk of breast cancer [134, 136]. 
As previously mentioned, hyperprolactinemia has been hypothesized as one of the 
possible mechanism for cerebrovascular eﬀ ects induced by antipsychotics.
CONCLUSIONS
Th e burden of dementia in Western Countries has dramatically increased in recent 
years and will increase even further in the years to come. Despite the growing num-
ber of elderly patients who will be aﬀ ected by cognitive deterioration and related 
psychotic/behavioral symptoms in the future, critical aspects of the management 
remain unsolved. Diﬀ erences between two antipsychotic types and even among 
individual medications clearly exist in the risk of speciﬁ c adverse events, such as 
extrapyramidal and metabolic eﬀ ects. Clinicians should consider individual safety 
proﬁ le of diﬀ erent antipsychotic drugs whenever they decide to start a treatment. 
Th e lowest dosage and the shortest duration of use is recommended for both 
conventional and atypical antipsychotics in elderly subjects with dementia.
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ABSTRACT
Purpose: To estimate one-year prevalence, one-year incidence and indication of 
use of AD drug treatment in general practice of Southern Italy during the years 
2003-2004.
Methods: Among 142,346 individuals registered in the lists of 119 general prac-
titioners of Southern Italy, we identiﬁ ed users of diﬀ erent AD types: tricyclic 
antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and other 
antidepressants. Annual prevalence of AD use was measured as the number of 
individuals receiving at least one AD prescription in the years 2003-2004, divided 
by the number of patients registered in the GP lists. One-year incidence of AD 
treatment was calculated as the number of new users of AD, divided by the num-
ber of total patients free from AD prescriptions in the previous year.
Results: Overall, one-year prevalence of AD use was 5.08 (95 Conﬁ dence Inter-
val: 4.97-5.20) per 100 inhabitants in the year 2003, with a 20 increase in 2004 
(6.00, 5.88-6.13). Prevalence of SSRI use markedly increased from 3.80 (3.73-3.90) 
in 2003 to 4.51 (4.40-4.61) in 2004. Th e incidence rates of SSRI, TCA and other 
antidepressant use were 2.11 (2.03-2.19), 0.38 (0.35-0.41) and 0.53 (0.49-0.57), 
respectively.
Depressive disorders were the main indication of use of any AD user (mostly for 
SSRI users), followed by anxious disturbances.
Conclusions: SSRIs, particularly those recently marketed, have been increasingly 
used during the last years, mainly to treat aﬀ ective disorders.
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INTRODUCTION
In Europe, according to a recent investigation 1 which estimated the prevalence of 
psychiatric diseases in the general population, a “lifetime” prevalence of aﬀ ective 
disorders of 11.1 was reported. Primary care providers play a crucial role in the 
management of these disorders, as suggested by surveys 2-3 showing that depressive 
symptoms are present in nearly 70 of patients who visit general practitioners. 
Antidepressant (AD) pharmacotherapy represents a key therapeutic strategy in the 
management of outpatients with major depression, and the introduction of selec-
tive serotonin reuptake inhibitors (SSRIs) into the market, since the late 80’s, has 
progressively changed AD prescribing patterns, both in Italy and in most Western 
Countries. According to a national Italian report on drug consumption4, SSRIs 
have been the most prescribed medications among neuropsychiatric drugs in the 
year 2004 (with a 18 increase with respect to the previous year). It is possible, 
however, that the wide and continuously increasing utilization of SSRIs might be 
partly related to the fact that these drugs are indicated not only in the treatment 
of major depression, but also in the treatment of a broad range of conditions, such 
as obsessive-compulsive disorders, panic attacks, generalised anxious disorders, 
eating disorders, somatoforms disorders, premenstrual syndrome disorders 5. 
Although several investigations6-8 on AD prescribing patterns in primary care of 
Northern Italy have been previously carried out, these studies were limited by the 
lack of data on clinically relevant information, such as indication of use.
In order to ﬁ ll this gap, the aims of this study were: a) to measure one-year 
prevalence, one-year incidence and distribution of AD use in general practice of 
Southern Italy; b) to characterise AD users, with particular regard to indication 
of use. Secondary objective of this investigation was to compare our data with 
national ﬁ gures on drug consumption, in order to verify the reliability of this 
general practice database in performing drug-utilization studies.
METHODS
Data source
Data were extracted from the Arianna database during the years 2003-2004. Such 
a database, set up by the Health-Service Agency of the city of Caserta in the 
year 2000, currently contains information on a population of almost 300,000 
individuals living in the catchments area of Caserta and registered in the lists of 
225 general practitioners (GPs). Such a sample of physicians accounts for 73.7 
(225/305) of total GPs who practice in the same area. Participating GPs record data 
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during their daily clinical practice through dedicated software, and, monthly, send 
complete and anonymous clinical data of their patients to the Arianna Database. 
Information collected include patient demographics, drug prescriptions that are 
coded according to the Anatomical Th erapeutic Chemical classiﬁ cation system 
(ATC), and medical diagnoses coded by the ninth edition of International Clas-
siﬁ cation of Diseases (ICD-9).
All participating GPs received extensive training in data collection techniques. 
Routine quality checks include the analysis of several parameters such as miss-
ing patient codes, the number of daily ﬁ lled prescriptions and the proportion of 
prescriptions correctly linked to medical diagnoses, and monthly continuity of 
data submission. Any variations within deﬁ ned ranges are investigated and back-
submitted to each participating GP, in order to receive an immediate feedback 
about data quality and completeness. GPs failing to meet these standard quality 
criteria are not retained within the analyses, according to basic standards in the 
conduct of pharmacoepidemiological studies 9. So far, the Arianna database has 
been shown to provide accurate and reliable information. 10-11
Study population
Overall, 119 GPs that continuously sent data to Arianna database during the years 
2003-2004 were selected for this investigation. Among 142,346 individuals registered 
in their lists, users of ADs, deﬁ ned as individuals receiving at least one AD (ATC: 
N06A) prescription during the observation years, were identiﬁ ed. Patients were in-
cluded into the study irrespective of whether AD treatment was initiated by GPs or 
by specialists working in the public or private sector, in this case leading thereafter 
to GP prescriptions. In fact, in Italy the system works in such a way that outpatients 
receiving prescriptions in the public or private sector by specialists get the medi-
cines free of charge through GP prescriptions. Th e following cohorts of AD users 
were identiﬁ ed according to the drug type being used: (1) tricyclic antidepressants 
(TCAs) (N06AA); (2) selective serotonin reuptake inhibitors (SSRIs) (N06AB); (3) 
other ADs: venlafaxine (N06AX16), reboxetine (N06AX18), mianserin (N06AX03), 
mirtazapine (N06AX11), trazodone (N06AX05) and nefazodone (N06AX06). Since 
February 2003, all antidepressant medications are totally reimbursed by Health Na-
tional System in Italy. As a consequence, the study ﬁ nding are free from the biases 
deriving from reimbursement restriction. After identiﬁ cation of AD users, the fol-
lowing information was retrieved using the Arianna database: patients’ demograph-
ics, AD-related data (including product name, dispensed quantity and indication of 
use) recorded during the years 2003-4, concomitant medications prescribed at the 
ﬁ rst AD prescription date (index date), and concurrent diseases, for whom a drug 
prescription was issued prior to the index date.
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One-year prevalence and incidence of antidepressant use
Annual prevalence of AD treatment was calculated as the number of AD drug 
users divided by the number of subjects alive and registered in the GPs’ lists in the 
observation year. We deﬁ ned ‘‘new user’’ as a patient receiving a ﬁ rst AD prescrip-
tion during the year 2004, without any recorded AD prescription in the previous 
year. Th e incidence rate was measured as the number of ‘‘new users’’ divided by the 
number of subjects free from antidepressant drug use in the previous year. Both 
prevalence and incidence were expressed as rates per 100 inhabitants, together 
with 95 Conﬁ dence Interval (CI).
Statistical analysis
Chi-Square test for categorical variables and Student t-test for continuous variables, 
with a signiﬁ cance level of P < 0.05, were used for assessing the diﬀ erences among 
users of various AD types. Statistical analyses were performed using STATA 6.0 
(STATA Corporation, Texas, USA).
RESULTS
One-year prevalence of antidepressant medication use
Prevalence of AD use per 100 inhabitants, stratiﬁ ed by age groups and calendar 
years, is shown in Figure 1. On a total sample of 142,346 individuals registered 
in the lists of 119 GPs, prevalence of use was 5.08 (95 CI: 4.97-5.20) per 100 
Figure 1. Prevalence of use of antidepressant medications during the years 2003-2004, stratifi ed by age groups.
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inhabitants in the year 2003, with a 20 increase in 2004 (6.00, 5.88-6.13). 
Prevalence was higher for females (2003: 6.64, 6.46-6.82; 2004: 7.82, 7.63- 8.01), 
and increased with increasing age in both years. Concerning diﬀ erent AD types, 
prevalence of SSRI use was higher than TCA use (2003: 0.80, 0.76-0.84; 2004: 
0.89, 0.84-0.94) and other ADs (2003: 1.16, 1.11-1.21; 2004: 1.33, 1.28-1.40) and, 
diﬀ erently from the other two groups, tended to dramatically increase during the 
two study years (2003: 3.80, 3.73-3.90; 2004: 4.51, 4.40-4.61). In Figure 2, the 
one-year prevalence of AD use for medications accounting for more than 90 of 
total AD prescriptions is shown. Th e three AD drugs with the highest prevalence 
of use in both years were SSRIs: citalopram (2003: 1.85, 1.78-1.92; 2004: 1.52, 1.46-
1.59), paroxetine (2003: 1.15, 1.11-1.21; 2004: 1.35, 1.29-1.41) and sertraline (2003: 
0.72, 0.68-0.77; 2004: 0.86, 0.81-0.90). Amitriptyline and venlafaxine were the 
most used medications among TCA and other ADs, respectively. Th e prevalence 
of ﬁ rst ﬁ ve medications appears to increase within the two study years, except for 
citalopram. Th e prevalence of escitalopram (0.86, 0.81-0.91), marketed in Italy 
since 2004, ranges in the third position among AD medications in this year. Th e 
41 of escitalopram users switched to this drug after stopping other ADs in the 
previous year.
Figure 2. Prevalence of use (per 100 inhabitants) of mostly prescribed antidepressant medications* during the years 2003-04.
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One-year incident treatment with antidepressant medications
Overall, one-year incidence rate of AD treatment was 3.06 (2.97-3.15) per 100 
inhabitants during the year 2004 (Figure 3). Th e incidence rate was higher for 
females (3.93, 3.79-4.08) and, again, increased with increasing age. Th e incidence 
rates of SSRI, TCA and other AD use were respectively 2.11 (2.03-2.19), 0.38 (0.35-
0.41) and 0.53 (0.49-0.57) per 100 inhabitants. Figure 4 highlights the distribu-
tion of new treatments with diﬀ erent AD types. In general, SSRIs accounted for 
almost two thirds of total new treatments with ADs, while the remaining was 
equally distributed between TCA and other ADs. Compared to younger patients, 
however, a larger proportion of elderly people (23.7) started a new treatment 
with AD, other than SSRI and TCA, and in particular with trazodone.
Clinical characteristics of antidepressant users
On a total sample of 142,346 subjects, 11,418 (8.0) received at least one prescrip-
tion of any AD medication during the study years: 8,671 received SSRI (75.9), 
1,869 TCA (16.4) and 2,795 other AD prescription (24.5), at least once. In 
Table 1, demographic and clinical characteristics of AD users, stratiﬁ ed by not 
mutually exclusive cohorts, are listed. Patients taking other ADs were signiﬁ cantly 
(P< 0.05) older than users of TCA and SSRI. In particular, 80 of other AD 
users older than 85 years received trazodone. A higher (P < 0.05) proportion of 
Figure 3. One-year incidence of antidepressant treatment in the year 2004, stratifi ed by age groups and gender.
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Figure 4. Distribution of new treatments with antidepressant medications in 2004, stratifi ed by age and drug type.
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Legend: TCA= Tricyclic antidepressant; SSRI= Selective serotonin reuptake inhibitor;
Other ADs= antidepressant medications, other than TCA and SSRI (venlafaxine, trazodone, reboxetine, mianserin, mirtazapine and nefazodone); 
More than 1 class= patient starting a treatment with more than 1 AD medication belonging to diff erent classes. Categories are mutually 
exclusive.
Table 1. Demographic and clinical characteristics of antidepressant drug users* during the years 2003-2004, stratifi ed by drug type.
Variables
TCA
N=1,869 (%)
95% CI
SSRI
N=8,671 (%)
95% CI
Other ADs
N=2,795 (%)
95% CI
Mean age ± Standard Deviation, y 53.6±17.2 54.1±18.2 59.0±18.6
Gender
Females 1,330 (71.2) 69.0-73.1 5,768 (66.5) 65.5-67.5 1,800 (64.4) 62.6-66.1
Males 539 (28.8) 26.8-30.9 2,903 (33.5) 32.4-34.4 995 (35.6) 33.8-37.3
Indication of use**
Depressive disorders 937 (50.1) 47.8-52.3 5,831 (67.2) 66.2-68.2 1,789 (64.0) 62.2-65.7
Anxious disturbances 257 (13.8) 12.2-15.3 918 (10.6) 9.9-11.2 300 (10.7) 9.6-11.9
Bipolar disorders 159 (8.5) 7.3-9.8 795 (9.2) 8.5-9.7 219 (7.8) 6.8-8.8
Headache 150 (8.0) 6.8-9.3 95 (1.1) 0.8-1.3 13 (0.5) 0.2-0.7
Psychotic disorders 111 (5.9) 4.9-7.1 467 (5.4) 4.9-5.8 182 (6.5) 5.6-7.4
Psychiatric disturbances associated 
with somatic disorders
36 (1.9) 1.3-2.6 111 (1.3) 1.0-1.5 79 (2.8) 2.2-3.5
Dementia 17 (0.9) 0.5-1.4 112 (1.3) 1.0-1.5 84 (3.0) 2.4-3.7
Neuropathic pain 29 (1.6) 1.0-2.2 22 (0.3) 0.1-0.3 1 (0.04) 0.01-0.2
Not reported 173 (9.3) 8.0-10.6 320 (3.7) 3.3-4.1 128 (4.6) 3.8-5.4
Legend: TCA= Tricyclic antidepressant; SSRI= Selective serotonin reuptake inhibitor; Other ADs= antidepressant medications, other than TCA 
and SSRI (venlafaxine, trazodone, reboxetine, mianserin, mirtazapine and nefazodone).
*Patients receiving at least 1 antidepressant medication prescription during the years 2003-4. Antidepressant drug types are not mutually 
exclusives.
** Indication of use that was recorded at the fi rst antidepressant prescription date, by drug type.
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TCA users were females compared to SSRI users and other AD users. Depres-
sive disorders, including neurotic depression, were the main indication of use of 
any AD, followed by anxious disturbances and bipolar disorders. Interestingly, 
patients aﬀ ected by depressive disorders accounted for 67.2 of SSRI users, a 
proportion signiﬁ cantly (P < 0.05) higher than TCA users (50.1). On the other 
hand, patients treated with TCA (8.0) were signiﬁ cantly (P < 0.05) more aﬀ ected 
by headache, mostly due to amitriptyline, than SSRI (1.1) and other antidepres-
sant users (0.5).
DISCUSSION
One-year prevalence, incidence and distribution of antidepressants
Th e results of this study indicated a strikingly increasing prevalence of AD medi-
cation use in a general practice of Southern Italy during the years 2003-2004. Th is 
increase appears to be mostly related to SSRI.
Percudani et al 6-7 reported a one-year prevalence of AD use of 4.43 per 100 
inhabitants among 404,238 individuals living in Lombardy, a region of Northern 
Italy, during the year 2001. Since AD medication use has been progressively rising 
in the last years in Italy, due partly to SSRI reimbursement without restrictions, 
our results seem to be in line with this previous Italian investigation. In addition, 
our ﬁ ndings are comparable with Italian national data on drug consumption for 
2004 4. Similarly to our investigation, national data highlighted that citalopram, 
sertraline and paroxetine were the three most used ADs in Italy in 2004, with 
citalopram showing a 20 reduction compared to 2003.
On the other hand, our study shows the high prevalence of use of escitalopram 
that is the S-enantiomer of citalopram, marketed in Italy only at the beginning 
of 2004, thus conﬁ rming again data from Italian national report 4. Th is ﬁ nding 
conﬁ rms the trend of new marketed drugs to be widely prescribed in general 
practice, immediately after their introduction in drug market.12 As expected, SS-
RIs accounted for almost two thirds of total one-year incident treatments with 
AD medications, with these agents mainly used in treating aﬀ ective disorders. 
Although these ﬁ gures seem in line with the background-frequency of psychiatric 
disorders that, theoretically, should be treated with AD agents, speciﬁ c studies 
are warranted to precisely quantify the degree of coherence between the true 
frequency of these conditions and the frequency of AD use. Clearly, these analyses 
are complicated by the fact that not all these conditions are of suﬃ  cient severity 
to justify pharmacotherapy. According to our data, however, their wide range of 
indications of use might play only a minor role in choosing SSRI as antidepressant 
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therapy. Indeed, in line with previous European investigations, SSRI have been 
increasingly used to treat mainly aﬀ ective disorders. 5,13
Interestingly, a lower proportion of people older than 65 years started a new 
AD therapy with SSRI or TCA, compared to younger patients. On the other 
hand, a relevant proportion of elderly people initiated a new AD treatment with 
trazodone, in line with another Italian study 14, reporting a dramatically increased 
use of this drug in patients older than 85, in the year 2001. Th is large utilization 
of trazodone in elderly people might raise clinical issue, in view of the propensity 
of this antidepressant to cause orthostatic hypotension, and possibly thereby to 
increase the risk of falls and hip fractures, in these patients.15
Characteristics of antidepressant users
Th e main ﬁ nding of our analysis is that the increase of SSRI use does not seem 
to be explained by a large number of prescriptions due to indications other than 
depression. Only 10 of SSRI users was treated because of anxious disturbances, 
and, in addition, a higher proportion of patients on SSRI were aﬀ ected by depres-
sive disorders compared to TCA users. Such data seem to be in contrast with Italian 
national data showing that 41.5 of SSRI prescriptions were related to neurotic 
disturbances. Th is disagreement, however, might be partly explained by diﬀ erent 
diagnostic categories being deﬁ ned in our study and in that national report. Th is 
discrepancy highlights the need to adopt more eﬃ  cient and internationally ac-
cepted tools and standards, targeted to better identify and code mental disorders 
in general practice setting. A number of previously published papers 16-18 strongly 
supported the use of International Classiﬁ cation of Mental Disorders-Primary 
Health Care (ICD-10 PHC), a special edition of the ICD-10 that is addressed to 
general practitioners. Another study ﬁ nding is the signiﬁ cantly higher proportion 
of TCA users who were treated because of headache, compared to users of SSRI 
and other ADs. Th is result is explained by the use of amitriptyline. According 
to Italian Summary of Product Characteristic of amitriptyline, “prophylaxis of 
migraine and chronic recurrent headaches” is listed among approved indications 
of use.
Strengths
To our knowledge, this is the ﬁ rst investigation targeted to assess the antidepres-
sant medication use in general practice of Southern Italy.
Th e availability of clinical data in Caserta database allowed us to perform 
clinical characterisation of AD users in general practice, thus providing useful 
information on the indication of use of AD.
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Limitations
Th is analysis was not aimed to evaluate any clinical outcome. In addition, such an 
investigation was performed using data concerning only two years, 2003 and 2004, 
collected from a restricted area of Southern Italy. It is therefore possible that these 
ﬁ ndings might not be fully generalized to the whole Italian general practice. How-
ever, the comparison with Italian national report on drug consumption supported 
the reliability of this database in providing information about AD drug utilization 
in Italy. We used outpatient prescription data and we had no information whether 
the antidepressant drug prescriptions were actually ﬁ lled and taken. Th is limit 
should be taken into account since around half of the medicines prescribed for 
people with chronic conditions are not ultimately taken.19 Finally, this study was 
performed using computerized medical records from general practice. According 
to Kaye et al 20, the observed ﬁ ndings may not pertain directly to patients treated 
in other settings (e.g., psychiatric inpatients or individual in nursing homes). Since 
a relevant proportion of individuals living in residential settings receive AD drugs, 
the prevalence rates might have underestimated the use of these agents, especially 
in certain age groups, such as very old people, who are more likely to be admitted to 
these facilities.21 To avoid an additional underestimation, only GPs who continu-
ously provided data to Arianna database during the whole observation period were 
included into the study. Sensitivity analysis did not show any signiﬁ cant diﬀ erence 
in prescribing behaviour between GPs enrolled into the study and the others.
In conclusion, the AD use has been continuously increasing in general prac-
tice of Southern Italy in the last years, largely reﬂ ecting increasing use of newer 
agents, in particular SSRI. Nevertheless, such an increased use does not seem to be 
explained by large number of prescriptions due to indications other than depres-
sion. Indeed, aﬀ ective disorders remain the main indication of use, particularly 
for SSRI.
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ABSTRACT
Background: Competing hypotheses have been formulated about a possible as-
sociation between selective serotonin reuptake inhibitors (SSRIs) and ischemic 
stroke. However, the relationship between antidepressant drug use and ischemic 
stroke is still unclear. Aim of the study was to assess the association between use 
of diﬀ erent types of antidepressants and the risk of ischemic stroke in elderly 
outpatients.
Methods: A population-based, nested, case-control study was conducted in 
persons 65 years and older in the Integrated Primary Care Information (IPCI) 
database (1996-2005). Cases were all patients with a validated ﬁ rst ischemic stroke. 
Controls were matched on year of birth, sex and index date. Exposure to antide-
pressants was divided in current, past and non-use and further categorized by type 
(SSRI, tricyclic [TCA], other antidepressants), dose and duration. Conditional 
logistic regression was used to compare the risk of ischemic stroke between users 
of antidepressants and non-users.
Results: Overall, 996 incident ischemic strokes were identiﬁ ed. Current use of 
SSRIs was associated with a signiﬁ cantly increased risk as compared to non-use 
(OR: 1.55; 95 CI: 1.07-2.25) in elderly, particularly when used longer than 4 
months. No associations were observed for current use of TCAs and other AD. 
Conclusion: Compared to non use, only SSRI use appears to be associated with 
an increased risk of ischemic stroke in elderly patients, particularly as short term 
eﬀ ect.
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BACKGROUND
Antidepressant drugs (ADs) are widely used in elderly people for indications such 
as depressive symptoms, anxiety disorders and neuropathic pain [1-2].
Th e selective serotonin reuptake inhibitors (SSRIs) are considered the ﬁ rst-
choice for the elderly with depressive symptoms, as these drugs are supposed 
to have similar eﬃ  cacy to other antidepressants but better tolerability [3]. Re-
cently, the eﬀ ects of SSRIs on cerebral circulation have garnered attention after 
preliminary reports suggested an association between SSRI exposure and risk 
of abnormal bleeding, including hemorrhagic stroke [4-6]. SSRIs decrease the 
intracellular contents of serotonin in platelets by blocking serotonin transporter 
5-HTT, thus inhibiting platelet function. Th is anti-platelet eﬀ ect of SSRIs may 
ultimately increase the risk of hemorrhage, such as intracranial bleeding [7]. Th e 
same mechanism might theoretically protect against arterial thrombotic events, 
including ischemic stroke [7]. Previous investigations documented a signiﬁ cant 
reduction in the risk of myocardial infarction associated with SSRI use [8-9]. On 
the other hand, SSRIs may cause vasoconstriction in cerebral arteries as a result 
of serotoninergic activation which may lead to ischemic stroke [10-11]. To date 
the net eﬀ ect of SSRIs on the risk of ischemic and hemorrhagic stroke remains 
unclear.
Several studies explored the association between hemorrhagic stroke and SSRI 
and other antidepressant drug use but failed to show any signiﬁ cant associations 
[12-14]. Little is known about the risk of ischemic stroke in elderly persons using 
antidepressants, although approximately 80 of total strokes are ischemic ones 
in these patients [15].An Italian study did not ﬁ nd an increased risk of cerebro-
vascular adverse eﬀ ects in elderly patients who were treated with antidepressants, 
but did not diﬀ erentiate between ischemic and hemorrhagic stroke [16]. Two 
studies did demonstrate an increased risk of ischemic stroke for SSRIs but did not 
consider the elderly speciﬁ cally [17] or were limited to hospitalized stroke only 
and not considering other antidepressants and indication of use [18]. Altogether, 
the epidemiologic evidence about antidepressant use and risk of ischemic stroke 
is inconclusive.
Th us, the aim of this study was to assess the association between the use of 
various antidepressant drug types and the risk of a ﬁ rst-ever ischemic stroke in 
community-dwelling elderly persons.
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METHODS
Setting
We employed a population-based, nested, case-control study. Data for this study 
were retrieved from the Integrated Primary Care Information (IPCI) database. 
Th e IPCI database is a longitudinal general practice research database set up in 
1992 and containing data from electronic medical records from a group of 150 
Dutch general practitioners’ (GPs) practices. In the Netherlands, all persons have 
their own GP who serves as the gatekeeper to medical care and ﬁ les all relevant 
medical details on their patients from primary care visits, hospital admissions and 
visits to outpatient clinics. A detailed description of the database has been previ-
ously reported [19]. Brieﬂ y, IPCI contains the medical records of approximately 
800,000 patients with an age and gender distribution representative of the Neth-
erlands. Th e electronic records contain coded and anonymous data on patient 
demographics, reasons for visits, signs, symptoms and medical diagnoses (using 
the International Classiﬁ cation for Primary Care [20]) from GPs and specialists, 
hospitalizations, as well as drug prescriptions. Drug prescriptions include product 
name, anatomical therapeutic chemical (ATC) classiﬁ cation, dispensed quantity, 
dosage regimen and coded indication. To maximize completeness of the data, GPs 
participating in the IPCI project are not allowed to maintain a system of paper-
based records, aside from the electronic medical records. Th e system complies with 
European Union guidelines on the use of medical data for medical research and 
has been proven valid for pharmaco-epidemiological research [21]. Th e Scientiﬁ c 
and Ethical Advisory Board of the IPCI project approved the study.
Study population
Th e study started on January 1, 1996, and ended on December 31, 2005. Th e source 
population comprised all individuals 65 years and older with at least 1 year of data 
registered in the database. All individuals were followed from the study entry date 
until one of the following events, whichever came ﬁ rst: transient ischemic attack 
(TIA), stroke, death, moving out of the practice area, or end of the study period. 
Patients who had a recorded diagnosis of TIA or stroke in the medical history 
prior to the study entry were excluded. Patients with a diagnosis of cerebral tumor, 
either before or during the study period, were also excluded.
Case Identifi cation and Ascertainment
Cases were all patients with a ﬁ rst-ever ischemic stroke that occurred during the 
study period. Th e case identiﬁ cation and ascertainment included two phases. First, 
we applied a broad search on patient clinical diary and summaries of specialist 
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letters, using coded diagnoses and key words for free text. Second, the electronic 
medical records of all potential cases of cerebrovascular accidents were manually 
reviewed by two medically trained researchers (G.T. and E.F.S), who were blinded 
to the exposure. Patients were classiﬁ ed as having a TIA, a hemorrhagic stroke, 
an undeﬁ ned stroke, or an ischemic stroke. Ischemic stroke was considered if the 
diagnosis was conﬁ rmed by a CT-scan or explicitly mentioned by a consulting 
specialist or listed among discharge diagnoses. Th e date of initial symptoms (e.g. 
dizziness, unexplained falling, and headache) was considered as the index date. 
Only if a stroke was preceded by a TIA occurring less than one month before, 
TIA was taken as the index date. Otherwise, a TIA was not considered in order to 
avoid case misclassiﬁ cation. TIA, however, was used as a censoring point to avoid 
protopathic bias since some patients with TIA may receive treatment with anti-
depressants subsequently [22]. In case of disagreement between the two assessors 
in classifying the cases and identifying the index date, a consensus was found via 
discussion. For each case, all persons in follow-up at the time of the index date and 
of the same age and sex as the case served as a control in the statistical analyses.
Exposure defi nition
Information on antidepressant drug use was obtained from the prescription ﬁ les. 
We created antidepressant exposure categories based on drug type, and recency, 
dose and duration of use. Th e legend duration was calculated as the total number 
of units per prescription divided by the prescribed daily number of these units. 
Antidepressant drugs were grouped according to the mechanism of action into: 1) 
Selective serotonin reuptake inhibitors (SSRIs): paroxetine, ﬂ uoxetine, citalopram, 
ﬂ uvoxamine and sertraline; 2) Tricyclic antidepressants (TCAs): clomipramine, 
amitriptyline, dothiepin, imipramine, trimipramine, lofepramine, maprotiline, 
doxepin, nortriptyline, desipramine, bupropion, moclobemide, opipramol, 
dosulepin and reboxetine; 3) Other antidepressants: venlafaxine, mirtazapine, 
mianserine, nefazodone and trazodone. A combination category was considered 
for concomitant use of more antidepressants belonging to diﬀ erent classes. We 
performed a secondary analysis in which we grouped antidepressant drugs based 
on the aﬃ  nity to the serotonin transporter [14]: 1) high aﬃ  nity (paroxetine, 
ﬂ uoxetine, sertraline, and clomipramine); 2) intermediate aﬃ  nity (citalopram, 
ﬂ uvoxamine, amitriptyline, dothiepin, imipramine, and venlafaxine); 3) low aﬃ  n-
ity (trimipramine, lofepramine, maprotiline, doxepin, nortriptyline, desipramine, 
bupropion, moclobemide, opipramol, dosulepin, reboxetine, mirtazapine, mian-
serine, nefazodone and trazodone). Exposure to diﬀ erent types of antidepressants 
was further divided into current, past and never use. Drug use was deﬁ ned as 
current if the prescription length covered the index date or ended less than 30 days 
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(carry-over eﬀ ect) prior. Past use meant that the last prescription ended more than 
30 days prior to the index date. Patients were deﬁ ned as non users if antidepressant 
prescriptions were never recorded prior to the index date. To be able to study 
the dose-eﬀ ect, we expressed daily dosing regimens as the prescribed number of 
deﬁ ned daily dosages (DDD), as deﬁ ned by the World Health Organization (see 
website: http://www.whocc.no/atcddd/indexdatabase/). Duration of antidepres-
sant use was calculated as the cumulative number of prescription days during the 
follow-up period. Th e duration was divided into short term use if ≤180 days and 
long term use if >180 days, as the median duration of any antidepressant use was 
180 days.
Covariates
As potential confounders, we considered age, sex, and calendar time (matching 
factors), smoking cigarettes, presence of cardiovascular disease (heart failure, 
hypertension, angina, history of myocardial infarction, peripheral arterial disease, 
atrial ﬁ brillation, phlebitis/thrombophlebitis), neuropsychiatric diseases (Parkin-
son’s disease, dementia, and migraine), chronic obstructive pulmonary disease 
(COPD), diabetes mellitus, lipid metabolism disorders, coagulation/platelet 
abnormalities, malignant tumors, pneumonia (within 3 months prior to the index 
date). We also considered chronic use of diuretics, digoxin, ACE-inhibitors, angio-
tensin receptor blockers, calcium-channel blockers, beta-blockers, lipid-lowering 
drugs, vasodilators and concomitant use (within 3 months prior to index date) of 
low dose aspirin, anticoagulants, antibiotics, systemic corticosteroids, NSAIDs, 
benzodiazepines, antipsychotic drugs, and opioids. Depression itself may be a risk 
factor for stroke and therefore confounding by indication cannot be easily ruled 
out [23]. To address this issue, two medically trained researchers (G.T. and E.F.S.) 
manually assessed the indication of use of antidepressant drugs from the free 
text of the medical records. Reasons for use were classiﬁ ed as depression, anxiety, 
headache, neuropathic pain, and other/unspeciﬁ ed disorders. Th is approach was 
taken for all exposed cases and for a randomly selected sample of the exposed 
controls (N=425).
Data Analysis
Relative risks of ischemic stroke plus 95 conﬁ dence intervals [CIs] were 
estimated by calculating odds ratios by using conditional logistic regression 
analysis. We performed adjustment for all covariates that were associated with 
ischemic stroke at the univariate analyses. In these analyses current and past use 
of diﬀ erent types of antidepressants (SSRI, TCA and other antidepressants) were 
compared to non-use. To compare directly the risk for ischemic stroke among 
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diﬀ erent antidepressant types, we performed an additional analysis with current 
use of TCA as comparator. A secondary analysis was carried out considering as 
exposure categories antidepressants with high, intermediate and low aﬃ  nity to 
the serotonin transporter. A linear trend across strata of increasing aﬃ  nity to the 
serotonin transporter was tested by including aﬃ  nity as an ordinal variable in 
the logistic regression model. A sensitivity analysis was conducted in which we 
removed the carry over eﬀ ect of 30 days. Among current users of antidepressants, 
we further calculated odds ratios for the risk of ischemic stroke with individual 
medications, daily dosage (≤ 0.5 and > 0.5 DDD), and cumulative duration of use 
(≤ 180 days and >180 days). Stratiﬁ ed analyses were conducted to study age and 
history of ischemic vascular disease as eﬀ ect modiﬁ ers. To evaluate the presence of 
confounding by indication we also performed an analysis according to the type of 
antidepressant and the indication of use.
Antidepressant drugs may be prescribed to treat symptoms of cerebral ischemic 
disorders occurring shortly before stroke, thus some cases of ischemic stroke could 
be mistakenly attributed to antidepressant exposure (i.e. protopathic bias). To 
further assess the possible eﬀ ect of protopathic bias on the association between 
antidepressants and ischemic stroke, we performed sensitivity analyses in which 
all patients, who started antidepressant treatment within 30, 60 and 90 days before 
the index date, were excluded. All analyses were conducted in SPSS/PC, version 13 
(SPSS Inc, Chicago, Ill). Th e level of signiﬁ cance for all statistical tests was 2-sided 
P < 0.05.
RESULTS
Th e source population for this study comprised 70,392 individuals of 65 years and 
older. Of them, 1,176 (1.7) were excluded because of cerebral tumors (n= 138) or 
history of cerebrovascular event (n=1,038) prior to the study entry. Th e ﬁ nal study 
population comprised 69,216 elderly persons (43 males, average age: 72.7±7.6 
years). Within this population, 1,354 (2.0) persons experienced a ﬁ rst-ever stroke 
(ischemic, hemorrhagic and undeﬁ ned subtypes) during the study period, of 
which 996 (74) were classiﬁ ed as incident ischemic stroke. Per case there were on 
average 493 age and sex matched controls available as a comparator. Demographic 
and clinical characteristics of cases and controls are reported in Table 1. Co-mor-
bidities like hypertension, coronary heart diseases, atrial ﬁ brillation, coagulation 
abnormalities, diabetes mellitus, COPD, and dementia, and concomitant use of 
corticosteroids, anticoagulants and opioids were associated with ischemic stroke. 
Among cases, 151 (15.2) received at least one antidepressant drug at any time 
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Table 1. Demographic and clinical characteristics of cases compared to age and sex matched non-cases.
Current Use Cases
N=996 (%)
Controls (%) Crude OR*
(95% CI)
Age groups (years) Matching factor
65-74 321 (32.2) 233,006 (47.4)
75-84 447 (44.9) 220,358 (44.9)
≥ 85 228 (22.9) 37,912 (7.7)
Gender Matching factor
Males 416 (41.8) 187,250 (38.1)
Females 580 (58.2) 304,026 (61.8)
Smoking cigarettes 55 (5.5) 27,274 (5.6) 1.19 (0.90-1.58)
Cardiovascular diseases
Hypertension 386 (38.8) 143,231 (29.1) 1.56 (1.37-1.77)
Angina 141 (14.2) 51,312 (10.4) 1.30 (1.08-1.55)
History of myocardial infarction 57 (5.7) 17,059 (3.5) 1.62 (1.24-2.12)
Peripheral arterial disease 27 (2.7) 10,616 (2.2) 1.20 (0.82-1.77)
Atrial fi brillation 59 (5.9) 16,314 (3.3) 1.65 (1.27-2.15)
Heart failure 135 (13.6) 30,468 (6.2) 1.87 (1.55-2.25)
Phlebitis/thrombophlebitis 34 (3.4) 13,642 (2.8) 1.21 (0.86-1.71)
Other diseases potentially related to stroke
Lipid metabolism disorders 53 (5.3) 38,440 (7.8) 0.79 (0.59-1.04)
Coagulation/platelet abnormalities 10 (1.0) 1,937 (0.4) 2.47 (1.32-4.61)
Obesity 9 (0.9) 5,920 (1.2) 0.87 (0.45-1.69)
Chronic obstructive pulmonary disease (COPD) 145 (14.6) 53,773 (10.9) 1.34 (1.12-1.60)
Diabetes mellitus 163 (16.4) 49,321 (10.0) 1.76 (1.49-2.08)
Tumours (except for cerebral ones) 107 (10.7) 48,122 (9.8) 1.06 (0.87-1.30)
Pneumonia (within 3 months prior to ID) 3 (0.3) 1,311 (0.3) 0.96 (0.31-2.99)
Neuropsychiatry diseases
Parkinson’s diseases 7 (0.7) 3,651 (0.7) 0.81 (0.30-1.71)
Dementia 45 (4.5) 12,451 (2.5) 1.44 (1.06-1.95)
Migraine 11 (1.1) 5,632 (1.1) 1.16 (0.64-2.10)
Prior use of cardiovascular medications
Diuretics 7 (0.7) 1,948 (0.4) 1.56 (0.74-3.29)
Digoxin 1 (0.1) 395 (0.1) NA
ACE-inhibitors 2 (0.2) 1,509 (0.3) NA
Sartanes 1 (0.1) 651 (0.1) NA
Calcium-channel blockers 3 (0.3) 1,106 (0.2) 1.26 (0.41-3.93)
Beta-blockers 9 (0.9) 2,483 (0.5) 1.84 (0.95-3.57)
Lipid-lowering drugs 1 (0.1) 1,056 (0.2) NA
Vasodilators 2 (0.2) 612 (0.1) NA
Aspirin 4 (0.4) 1,687 (0.3) 1.15 (0.43-3.07)
Anticoagulants 15 (1.5) 1,585 (0.3) 4.29 (2.56-7.18)
Concomitant use of psychotropic drugs
Benzodiazepines 4 (0.4) 1,462 (0.3) 1.20 (0.45-3.21)
Antipsychotic drugs 1 (0.1) 140 (0.1) NA
Opioids 3 (0.3) 154 (0.1) 9.09 (2.87-28.4)
Concomitant use of other drugs
Systemic corticosteroids 3 (0.3) 285 (0.1) 4.74 (1.51-14.83)
Antibiotics 3 (0.3) 711 (0.1) 2.10 (0.68-6.55)
NSAIDS 3 (0.3) 1,122 (0.2) 1.22 (0.39-3.81)
* Conditional logistic regression analysis;
NA= not applicable as too few cases
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prior to the ﬁ rst ischemic stroke: 29 (2.9) were current users of SSRI, 17 (1.7) 
of TCA and 6 (0.6) of other antidepressants. Compared to non-use, current 
use of SSRIs was associated with an increased risk of ischemic stroke (OR: 1.55; 
95 CI: 1.07-2.25), while no signiﬁ cant associations were found for current use 
of TCA (OR: 1.18; 95 CI: 0.73-1.91) or other antidepressants (OR: 1.01; 95CI: 
0.45-2.25) (Table 2). Past use of either SSRI or TCA showed an increase in the risk 
of ischemic stroke as well. Compared to current use of TCA the risk of ischemic 
stroke with current use of SSRIs (OR: 1.32; 95CI: 0.72-2.40) or other Ads (OR: 
0.86; 95CI: 0.34-2.18) was not statistically signiﬁ cant diﬀ erent. Among current 
users, SSRIs were used at a higher dosage (on average, 1±0.05 DDD per day) and 
for longer periods (on average 270 days) than TCAs (on average 0.5±0.1 DDD 
and 158 days) and other antidepressants (on average 0.8±0.1 DDD and 245 days). 
Th ese diﬀ erences in mean dosage and duration of use across antidepressant types 
lowered if considering depressed patients only (SSRI: 1±0.05 DDD, 259 days; 
TCA: 0.8±0.1 DDD, 211 days; and other antidepressant: 0.8±0.1 DDD, 248 days). 
Table 2. Risk of ischemic stroke with use of diff erent antidepressant groups, stratifi ed by dosage** and duration** of use
Exposure category
Cases
 N=996 (%)
Controls N=491,276 
(%)
Crude OR
(95% CI)
Adjusted* OR
(95% CI)
Non Use 844 (84.7) 437,718 (89.1) 1.00 1.00
Current Use
SSRI 29 (2.9) 9,410 (1.9) 1.67 (1.15-2.42) 1.55 (1.07-2.25)
≤1 DDD 26 8,508 1.65 (1.03-2.44) 1.52 (0.98-2.26)
>1 DDD 3 902 1.92 (0.62-5.99) 1.78 (0.57-5.54)
≤ 180 days 16 3,468 2.26 (1.36-3.78) 2.07 (1.24-3.46)
> 180 days 13 5,942 1.22 (0.70-2.11) 1.14 (0.65-1.97)
TCA 17 (1.7) 7,155 (1.5) 1.24 (0.77-2.01) 1.18 (0.73-1.91)
≤1 DDD 16 6,658 1.25 (0.76-2.06) 1.18 (0.72-1.93)
>1 DDD 1 477 1.22 (0.17-8.67) 1.19 (0.17-8.46)
≤ 180 days 13 4,938 1.37 (0.79-2.37) 1.27 (0.73-2.20)
> 180 days 4 2,217 0.98 (0.37-2.61) 0.96 (0.0.36-2.56)
Other ADs 6 (0.6) 2,995 (0.6) 1.06 (0.48-2.38) 1.01 (0.45-2.25)
≤1 DDD 6 2,595 1.21 (0.54-2.71) 1.15 (0.51-2.56)
>1 DDD - 400 NA NA
≤ 180 days 2 1,397 0.75 (0.19-3.00) 0.71 (0.18-2.83)
> 180 days 4 1,598 1.35 (0.51-3.62) 1.28 (0.48-3.44)
Combination - 284 (0.01) NA NA
Recent/Past use
SSRI 49 (4.9) 17,219 (3.5) 1.49 (1.11-2.00) 1.39 (1.03-1.86)
TCA 43 (4.3) 13,729 (2.8) 1.64 (1.21-2.24) 1.53 (1.12-2.08)
Others 8 (0.8) 2,766 (0.6) 1.46 (0.73-2.94) 1.35 (0.67-2.72)
Combination - - NA NA
*Analysis was adjusted for hypertension, angina, history of myocardial infarction, atrial fi brillation, heart failure, coagulation/platelet 
abnormalities, COPD, diabetes mellitus, dementia, concomitant use of anticoagulants, systemic corticosteroids and opioids.
** As cut off  point for dosage and duration categories, the median values for all current users of antidepressant were considered.
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Th ere was no dose eﬀ ect on the risk of ischemic stroke for current users of any 
antidepressant type. However, we did observe a duration eﬀ ect, where shorter use 
(i.e. ≤180 days) of SSRIs was associated with a larger risk increase (OR: 2.07; 95 
CI: 1.24-3.46) than longer use (i.e. >180 days, OR: 1.14; 95CI: 0.65-1.97). Con-
sidering the aﬃ  nity to the serotonin transporter, a signiﬁ cant increase in the risk 
of ischemic stroke was observed only for the current users of antidepressants with 
high aﬃ  nity to the serotonin receptor (OR: 1.43; 95 CI: 1.00-2.15), compared 
to non users. Th e linear trend test of increasing aﬃ  nity and the risk of ischemic 
stroke was statistically signiﬁ cant (p < 0.05) (Table 3). Th e indication of use was 
validated and assessed in all the cases (N=152) and in a sample of controls (N=425), 
who were currently or formerly exposed to an antidepressant drug. Among the 52 
cases, 36 (69) were currently treated with antidepressants because of depressive 
symptoms, and two thirds of these subjects received SSRIs (Table 4). For patients 
with depression as an indication for treatment, the risk of ischemic stroke with 
SSRIs use (OR: 1.99; 95 CI: 1.20-3.30) was higher than that with TCAs (OR: 
1.07; 95 CI: 0.43-2.65), although the diﬀ erence was not statistically signiﬁ cant. 
We still observed a risk increase with current use of SSRIs if the indication was 
not depression, but the OR was lower and not statistically signiﬁ cant (OR: 1.50; 
95 CI: 0.54-4.19). We performed a stratiﬁ ed analysis on presence of ischemic 
cardiovascular disease and on age, which showed that these factors did not modify 
Table 3. Risk of ischemic stroke associated to diff erent antidepressant groups (classifi ed according to affi  nity for serotonin reuptake receptor), 
compared to non-use
AD exposure based on serotonin 
transporter affi  nity
Cases
 N=996 (%)
Controls N=491,276 
(%)
Crude OR
(95% CI)
Adjusted* OR
(95% CI)
Non-Use 844 (84.7) 437,718 (89.1) 1.00 1.00
Current Use
High affi  nity 1 24 (2.4) 8,752 (1.8) 1.55 (1.05-2.27) 1.43 (1.00-2.15)
Intermediate affi  nity 2 21 (2.1) 7,863 (1.6) 1.40 (0.91-2.16) 1.30 (0.84-2.00)
Low affi  nity 3 6 (0.6) 2,926 (0.6) 1.05 (0.47-2.34) 0.98 (0.44-2.19)
Combination 1 (0.1) 303 (0.1) NA NA
Recent/Past Use
High affi  nity 1 43 (4.3) 15,978 (3.3) 1.44 (1.05-1.96) 1.34 (0.98-1.83)
Intermediate affi  nity 2 49 (4.9) 14,873 (3.0) 1.70 (1.27-2.27) 1.57 (1.18-2.10)
Low affi  nity 3 8 (0.8) 2,863 (0.6) 1.38 (0.68-2.77) 1.29 (0.64-2.59)
Combination - - NA NA
* Analysis was adjusted for hypertension, angina, history of myocardial infarction, atrial fi brillation, heart failure, coagulation/platelet 
abnormalities, COPD, diabetes mellitus, dementia, concomitant use of anticoagulants, systemic corticosteroids and opioids.
Legend:
1. Paroxetine, fl uoxetine, sertraline, clomipramine;
2. Citalopram, fl uvoxamine, amitriptyline, dothiepin, imipramine, venlafaxine;
3. Trimipramine, lofepramine, maprotiline, doxepin, nortriptyline, desipramine, bupropion, moclobemide, opipramol, dosulepin and 
reboxetine, mirtazapine, mianserine, nefazodone and trazodone.
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the eﬀ ect of the association between antidepressant and ischemic stroke (data 
not shown). To test for protopathic bias, we excluded patients who received the 
ﬁ rst prescription of antidepressant within 30, 60 and 90 days prior to the index 
date. Compared to non-use, the risk in current users was only somewhat diluted 
(from 1.55 to 1.42 for SSRI; from 1.18 to 1.01 for TCA; from 1.01 to 1.07 for other 
antidepressants). Although our analysis was underpowered to assess the risk of 
each individual drug, sertraline (4 exposed cases, OR: 2.03; 95 CI: 0.76-5.44) 
and paroxetine (18 exposed cases, OR: 1.59; 95 CI: 1.00-2.55) were associate with 
the greatest risks of ischemic stroke.
DISCUSSION
To our knowledge, this is the ﬁ rst observational study that explored speciﬁ cally 
the association between antidepressant drug use and the risk of ischemic stroke 
in a cohort of elderly patients. Th e results show that in comparison to non use, 
current use of SSRIs confers a signiﬁ cantly increased risk of ischemic stroke (adj. 
OR: 1.55; 95 CI: 1.07-2.25), especially during the ﬁ rst 6 months of treatment. 
Table 4. Risk of ischemic stroke associated with current use of diff erent antidepressant types and diff erent indications of use, with non use as 
reference (OR=1.00)
Antidepressant exposure by
indication of use
Cases
N=152 (%)
Control N=425 
(%)
Adjusted* OR (95% CI)
Current use of SSRI
Depression 24 (15.8) 43 (10.1) 1.99 (1.20-3.30)
Others 5 (3.3) 13 (3.1) 1.50 (0.54-4.19)
Current use of TCA
Depression 7 (4.6) 23 (5.4) 1.07 (0.43-2.65)
Others 10 (6.6) 29 (6.8) 1.38 (0.68-2.81)
Current use of Other AD
Depression 5 (3.3) 16 (3.8) 0.67 (0.23-1.96)
Others 1 (0.1) 5 (1.2) 1.00 (0.13-8.05)
Recent/Past use of SSRI
Depression 32 (21.1) 97 (22.8) 1.30 (0.86-1.96)
Others 17 (11.2) 31 (7.3) 1.73 (0.94-3.19)
Recent/Past use of TCA
Depression 13 (8.6) 31 (7.3) 1.58 (0.86-2.88)
Others 30 (19.7) 124 (29.2) 1.09 (0.72-1.65)
Recent/Past use of Other AD
Depression 5 (3.3) 18 (4.2) 0.93 (0.34-2.53)
Others 3 (2.0) 4 (0.9) 2.32 (0.52-10.36)
* Analysis was adjusted for hypertension, angina, history of myocardial infarction, atrial fi brillation, heart failure, coagulation/platelet 
abnormalities, COPD, diabetes mellitus, dementia, concomitant use of anticoagulants, systemic corticosteroids and opioids
Legend: Others= neuropathic pain, headache, anxiety disorders, other or unspecifi ed psychiatric disorders.
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Th is increased risk instead does not appear to be dose-dependent. We did ﬁ nd a 
linear risk increase with increasing aﬃ  nity to the serotonin transporter. Past use of 
both SSRIs and TCAs was associated with ischemic stroke as well.
Th e results of our study are mostly in line with the very few reports that have 
previously explored aspects of the association between SSRI use and stroke 
[16-18]. Barbui et al found no diﬀ erence in the risk of cerebrovascular accidents 
between SSRI and TCA use (adj. OR: 1.31; 95 CI: 0.87-1.97) but could not dif-
ferentiate between ischemic and hemorrhagic stroke [16]. A Danish study, which 
analyzed hemorrhagic and ischemic stroke separately, but considered only events 
leading to hospital admission, found that past use but not current use of SSRIs 
was associated with an increased risk of ischemic stroke (adj. OR: 1.3; 95 CI: 
1.0-1.5 vs. non-use) [18]. In this study the analytic strategy could have resulted 
in a misclassiﬁ cation of the index date and, as a result, a misclassiﬁ cation of the 
exposure. We did found an association between past use of both SSRIs and TCAs 
and the risk of ischemic stroke. Th is ﬁ nding could point at a potential eﬀ ect of 
confounding by indication on our results. Depression itself is a known risk factor 
of cerebrovascular disorders in young patients [23-24], while the role of depres-
sion as predictor of stroke in elderly patients remains very controversial [24]. To 
deal with confounding by indication, Chen et al recently conducted a nested case-
control study among patients with depression in a large population-based, U.S. 
medical claims database [17]. In line with our study, the risk of ischemic stroke for 
current users of SSRIs was signiﬁ cantly higher as compared to non-use (adj. OR: 
1.55; 95 CI: 1.00-2.39), while the increase in the risk in current users of TCAs 
(OR: 1.59; 95CI: 0.89-2.83) or other antidepressants (OR: 1.33; 95CI: 0.81-2.17) 
was not statistically signiﬁ cant. Also, in our study, when we selected exclusively 
depressed elderly (depression as the indication for treatment), only SSRI use was 
associated with an increased risk of stroke. TCA or other antidepressants show no 
association whatsoever. Th is ﬁ nding argues against the inﬂ uence of confounding 
by indication. Possible mechanisms supporting a potential causal association be-
tween exposure to SSRIs and ischemic stroke have been previously hypothesized. 
Serotoninergic activation secondary to SSRI use can induce a vasoconstrictive 
eﬀ ect that is mediated by the 5-hydroxytryptamine-2 (5HT-2) receptor on smooth 
muscle cells [25-26]. A recent review about the cerebrovascular eﬀ ects of SSRIs 
pointed out that use of these medications may increase the risk of ischemic stroke 
by triggering thromboembolism through its vasoconstrictive eﬀ ect in patients with 
large cerebral arteries atherosclerosis [7]. A signiﬁ cant linear trend between the 
risk of ischemic stroke and the aﬃ  nity to the serotonin transporter was evident in 
our study. Also, paroxetine and sertraline, antidepressants showing the highest af-
ﬁ nity to the serotonin transporter [27], seemed to confer a greater risk of ischemic 
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stroke. Th ese ﬁ ndings support the hypothesis that a serotoninergic activation may 
play a role in the association between ischemic stroke and SSRI use. Th e eﬀ ect of 
SSRIs was predominantly observed within the ﬁ rst six months of therapy, which 
could point at an immediate eﬀ ect of SSRIs and depletion of susceptibles during 
continued use.
Strength and limitations
Th e strength of this study is the availability of information on many confounders 
and details on antidepressant use. Moreover, we were able to review the medi-
cal records of all potential cases to identify the real incident, ﬁ rst-ever ischemic 
strokes. However, several limitations warrant caution. As in any observational 
study, selection bias, information bias and residual confounding should be consid-
ered as alternative explanations for the study ﬁ nding. Selection bias was minimal 
as all data were obtained from prospectively collected medical records that are 
maintained for patient care purposes. To minimize the potential eﬀ ect of infor-
mation bias by misclassiﬁ cation of the outcome a two-step case validation was 
undertaken and, for the same purpose, TIA itself was not considered as a study 
endpoint, due to high probability of misclassiﬁ cation for this event. However, if a 
stroke was preceded by a TIA occurring less than one month before, the case was 
retained and the onset of TIA was taken as the index date.
To exclude all patients with history of cerebrovascular events at the study entry, 
we required at least one year of data registered in the database as inclusion criteria. 
Nevertheless, we could have missed information on prior cerebrovascular events 
without sequelae occurring long time before the study entry. Misclassiﬁ cation of 
exposure cannot be excluded since we used outpatient prescription data and had no 
information about whether the drug prescriptions were actually ﬁ lled and taken. 
Non-adherence to antidepressant medication may be a relevant issue particularly 
in older patients, although a U.K. study reported that the level of adherence did 
not diﬀ er across various antidepressant types in community dwelling elderly [28]. 
Not ﬁ lling of prescriptions or non-adherence most likely results in non-diﬀ erential 
misclassiﬁ cation of the exposure, in which case our study underestimates the actual 
risk. Moreover, we may have missed specialist prescriptions of antidepressants. 
Many risk factors for ischemic stroke were considered in our study. Despite this, 
residual confounding due to unmeasured confounders or severity of (underlying) 
disease cannot be excluded. It is however unlikely that highly prevalent and strong 
risk factors were missed in our study. Finally, since the study considered only com-
munity dwelling elderly, the ﬁ ndings may not be generalized to elderly inpatients 
or those living in nursing homes. Likewise, exclusion of patients with prior TIA 
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or stroke prevents the generalizability of the results to elderly patients with a prior 
history of cerebrovascular events.
In summary, our study shows that among elderly people living in the com-
munity current use of SSRI may increase the risk of ischemic stroke, especially 
within the ﬁ rst 6 months of treatment. Further studies employing larger samples 
are needed to conﬁ rm these results and to conclusively establish the eﬀ ect of the 
aﬃ  nity to the serotonin transporter. Meanwhile, it seems advisable that SSRI 
treatment is carefully tailored and that a close monitoring is established in the 
ﬁ rst few weeks of treatment.
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SUMMARY
Th e present article reviews and discusses critically the issue of drug interactions 
involving antidepressants in the elderly. With the progressive aging of the popula-
tion, late-life depression will increase in importance as a public health problem 
and prescriptions of antidepressants will presumably grow so thus enhancing the 
likelihood of drug interactions. After considering the general mechanisms and the 
various factors predisposing elderly subjects to drug interactions, the interaction 
potential for each class of antidepressant drugs will be examined, in order to help 
the prescribing physician in the selection of the most appropriate agent for an 
elderly patient receiving concomitant medications. Some general recommenda-
tions to prevent or minimize the occurrence of adverse drug interactions in elderly 
patients with depression will be given. Potential intervention strategies, targeted 
to adequately supply health professionals with information on the risks of clini-
cally relevant drug interactions are deeply discussed.
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INTRODUCTION
Depression is the most common psychiatric disorder in late life. Although major 
depression has been reported to occur in approximately 3 of individuals aged 
>65 years, the prevalence of depressive symptoms in the elderly is estimated to 
range between 15 and 30 [1, 2]. Geriatric depression may cause disability and 
mortality and increases health care costs. Untreated depression in older people 
results in patient suﬀ ering, increased rates of death from medical illnesses and sui-
cide, medical morbidity, inappropriate institutionalization and caregiver burden 
[2, 3]. Among drugs used to treat depressive disorders, newer antidepressants, in 
particular selective serotonin reuptake inhibitors (SSRIs), are considered as ﬁ rst-
line drugs in the treatment of late-life depression, due to a more a more favorable 
tolerability, safety proﬁ le and a relatively lower potential for drug interactions as 
compared to older compounds [2-4]. Th e pharmacological treatment of geriatric 
depression can be diﬃ  cult because age-related physiological changes and comor-
bid medical conditions may alter drug response and, therefore, predispose older 
subjects to adverse eﬀ ects. In addition, as a result of coexisting chronic illnesses, 
elderly depressive patients often take many medications simultaneously, and this 
increases the likelihood of adverse events due to drug interactions. Th e potential 
for drug interactions may therefore guide selection of an appropriate antidepres-
sant, especially in old age. In this respect, comprehensive reviews of antidepressant 
drug interactions in the elderly have been published [5, 6].
Th e purpose of this article is to discuss critically drug interactions involving 
antidepressants in the elderly in the attempt to provide necessary information to 
prevent or minimize their occurrence. In addition to the basic mechanisms and 
factors predisposing elderly subjects to drug interactions, the interaction potential 
for each class of drugs will be examined, in order to help the prescribing physi-
cian in the selection of the most appropriate antidepressant for an elderly patient 
receiving concomitant medications.
GENERAL MECHANISMS OF DRUG INTERACTIONS
A drug interaction occurs when the eﬀ ectiveness or toxicity of a drug is altered by 
the concomitant administration of another drug. Drug interactions can be classi-
ﬁ ed as either pharmacokinetic or pharmacodynamic. However, many interactions 
are multifactorial in nature and may involve a complex sequence of events both at 
pharmacokinetic and pharmacodynamic level.
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Pharmacokinetic interactions
Pharmacokinetic interactions consist of changes in the absorption, distribution, 
metabolism or excretion of a drug and/or its metabolites, or the quantity of active 
drug that reaches its site of action, after the addition of another chemical agent. 
Most pharmacokinetic interactions with antidepressants drugs occur at metabolic 
level and generally results from inhibition or induction of the hepatic cytochrome 
P450 isoenzymes (CYPs) responsible for the biotransformation of individual 
antidepressants as well as concomitantly prescribed medications [7]. Th e activity 
of CYPs is genetically determined and may be inﬂ uenced by pathophysiological 
and environmental factors, including concomitant administration of other drugs. 
Over the past few years the diﬀ erent substrates, inhibitors and inducers of CYP 
isoenzymes in man have been identiﬁ ed [8]. As reported in Table 1, the major 
CYP enzymes involved in the metabolism of currently available antidepressants 
include CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. In ad-
dition, some newer antidepressants may also act as inhibitors of one or more of 
these isoenzymes (Table 2). Th is information may be of great value for clinicians 
Table 1. CYP enzymes responsible for the biotransformation of currently available antidepressants
Antidepressants CYP enzymes
Tricyclic antidepressants (hydroxylation)
Trycyclic antidepressants (demethylation)
Citalopram/Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Venlafaxine
Duloxetine
Mirtazapine
Reboxetine
Bupropion
CYP2D6
CYP1A2, CYP2C19, CYP3A4
CYP2C19, CYP2D6, CYP3A4
CYP2D6, CYP2C9
CYP1A2, CYP2D6
CYP2D6, CYP3A4
CYP3A4
CYP2D6, CYP3A4
CYP1A2, CYP2D6
CYP1A2, CYP2D6, CYP3A4
CYP3A4
CYP2B6
Table 2. Inhibitory eff ect of newer antidepressants on CYP enzymes
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4
Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Venlafaxine
Duloxetine
Mirtazapine
Reboxetine
Bupropion
0
0
+
+ + +
+
+
0
0
0
0
0
0
0
+ +
+ +
+
+
0
0
0
0
0
0
0
+/++
+ + +
+
+
0
0
0
0
0
+
0/+
+ + +
+
+ + +
+/++
+
++
+
+
++
0
0
+/++
+ +w
+
+
+
0
0
0
0
0 = minimal or no inhibition; + = mild inhibition; + + = moderate inhibition; + + + = potent inhibition
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in anticipating and eventually avoiding potential interactions. Co-administration 
of two substrates of the same enzyme, or co-administration of a substrate with an 
inhibitor or an inducer, entails the possibility of a drug interaction. As a conse-
quence, plasma concentrations of the co-administered drugs may be increased or 
decreased, resulting in clinical toxicity or diminished therapeutic eﬀ ect. Dosage 
adjustments may then be required to avoid adverse eﬀ ects or therapeutic failure. 
For the reasons that will be mentioned in next section, the entity of these kinetic 
changes is likely to be higher in the elderly. Metabolic drug-drug interactions 
may initially be studied in vitro in order to predict the potential importance in 
vivo. However, not of all theoretically possible drug interactions that are predicted 
from in vitro studies will occur in vivo, and some may not be clinically signiﬁ cant 
anyway. Th e most relevant aspects that must be taken into account when evaluat-
ing the potential occurrence, extent and clinical signiﬁ cance of a metabolic drug 
interaction include drug-related factors such as potency and concentration of the 
inhibitor/inducer, therapeutic index of the substrate, extent of metabolism of the 
substrate through the aﬀ ected enzyme, presence of active or toxic metabolites, 
patient-related factors such as individual inherent enzyme activity (e.g. phenotyp-
ing/genotyping information), risk level for each individual to experience adverse 
eﬀ ects (e.g. the elderly), and epidemiological factors such as the probability of the 
interacting drugs being used concurrently [9]. In general, it is likely to expect 
a clinically signiﬁ cant interaction when a drug with a low therapeutic index is 
co-administered with a potent inhibitor or inducer of the major pathway of its 
metabolism. By contrast, as most drugs have several metabolic pathways, the 
inhibition of an enzyme playing a marginal role in the overall clearance of a given 
drug may have a limited impact on its disposition, presumably resulting only in 
a minimal increase in plasma concentrations, since another isoform may provide 
suﬃ  cient secondary metabolic pathways. Pharmacokinetic drug interactions with 
antidepressants may also involve drug transporters, in particular P-glycoprotein 
(P-gp). P-gp is a multidrug eﬄ  ux transporter, highly expressed in the intestine, 
brain, liver and kidney, which acts as a natural defence mechanism against several 
substrates by limiting their absorption from the gut and penetration to the brain 
and promoting their elimination in the bile and urine [10]. Like CYPs, the activity 
of P-gp can be inhibited or induced by other agents, altering the level of substrate 
drug in circulation. Recent in vitro evidence suggests that some newer antide-
pressants, namely paroxetine, sertraline, citalopram and venlafaxine, may inhibit 
P-gp [11]. In theory, as many substrates for P-gp, such as digoxin, cyclosporin 
and various chemotherapeutic agents, have a narrow therapeutic range and are 
widely used in the elderly, coadministration with these antidepressants may result 
in adverse drug reactions. However, a recent population-based assessment of the 
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potential interaction between SSRIs and digoxin in eldery patients has indicated 
that this mechanism is unlikely to be of major clinical signiﬁ cance [12].
PHARMACODYNAMIC INTERACTIONS
Pharmacodynamic interactions take place at receptor sites and occur between 
drugs with similar or opposing mechanisms of action, resulting in additive, syn-
ergistic or antagonistic eﬀ ects. Th e potential for pharmacodynamic interactions 
diﬀ er markedly between the various classes of antidepressants depending on the 
respective mechanism of action and receptor proﬁ le. In general, older compounds, 
such as TCAs or MAOIs, acting on a broad range of receptors or enzymes have 
a greater potential to interact pharmacodynamically with other medications af-
fecting the same system(s) than newer agents with a more speciﬁ c mechanisms of 
action [13].
FACTORS PREDISPOSING ELDERLY PATIENTS TO DRUG INTERACTIONS
Drug interactions in the elderly are usually more frequent and more severe com-
pared with younger subjects [14, 15]. In fact, the large interindividual variability 
in drug response resulting from genetic, pathophysiological and environmental 
factors aﬀ ecting pharmacokinetics and pharmacodynamics is further ampliﬁ ed in 
the elderly because of the eﬀ ect of age-related changes, comorbid disorders and 
polypharmacy. As a consequence, any given dose of a given drug may produce a 
diﬀ erent, and sometimes unexpected, response in elderly patients and, therefore, 
predispose them to adverse eﬀ ects and drug interactions.
Polypharmacy
Geriatric depression is often associated with chronic medical illnesses, such as 
diabetes, ischemic heart disease, postroke, dementia, Parkinson’s disease, as well 
as other psychiatric disorders. Based on this, elderly depressed patients often take 
many medications simultaneously and this may multiply adverse eﬀ ects through 
drug interactions, both pharmacokinetic and pharmacodynamic. Several studies 
in diﬀ erent settings have unequivocally indicated that the number of prescrip-
tions (and not the age) is the best predictor of adverse drug reactions [16-18]. Th e 
incidence of undesirable interactions rises exponentially when multiple drugs are 
administered [19]. Moreover, elderly patients often use to self-medicate with over-
the-counter preparations and natural remedies (herbal products). In this respect, 
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there is an increased awareness about potential adverse drug interactions involving 
herbal medicines especially in older adults [20-21].
Age-related changes in pharmacokinetics and pharmacodynamics
Aging is characterized by the progressive loss of organ system functional reserve 
and this may result in changes in pharmacokinetics and pharmacodynamics. 
Many age-related physiological changes are known to aﬀ ect drug absorption, 
distribution, metabolism and excretion [22]. While drug absorption is generally 
not signiﬁ cantly inﬂ uenced by age, changes in body composition may aﬀ ect drug 
distribution in the elderly. In particular, the decrease in total body mass with age 
is associated with an increase in the proportion of body fat. Th ese alterations may 
lead to increased volume of distribution of lipid-soluble drugs, as antidepressants, 
that tend to accumulate and persist longer in the body. Th e most relevant age-
related pharmacokinetic modiﬁ cations involve drug elimination, through hepatic 
metabolism and/or renal excretion. In fact, hepatic metabolic capacity and renal 
function decline progressively with age, thereby resulting in a decreased elimi-
nation of many drugs. Th e decline in drug metabolism is mainly explained by 
changes in liver blood ﬂ ow and liver mass, while it is still controversial if there is 
an age-dependent decrease in microsomal enzyme activity [23, 24]. Unfortunately, 
these age-related changes in hepatic drug metabolism are unpredictable and dif-
ﬁ cult to estimate. Changes in renal clearance are comparatively more predictable, 
as glomerular ﬁ ltration rate decreases by approximately 10 per decade after 20 
years of age. Th e reduced drug clearance may lead to higher and more variable 
steady-state plasma concentrations. As pharmacological eﬀ ects, including the 
inihibitory/inducing eﬀ ects on drug-metabolizing enzymes, are often concentra-
tion dependent, the likelihood of drug interactions is increased in the elderly. 
Published reports of pharmacokinetics of older and newer antidepressants in 
elderly have been reviewed [25-27]. In general, though methodological issues and 
confounding factors may complicate the interpretation of data, either no change or 
reduction in clearance has been documented. To compensate for such physiologic 
changes, reductions of one third to half of the usual initial dose are recommended 
in elderly patients [26]. Although age-related pharmacodynamic changes may be 
even more important than pharmacokinetic modiﬁ cations, the pharmacodynamic 
alterations have been less extensively investigated. With aging, the response to 
a drug on its target organ may be modiﬁ ed. Consequently, elderly patients are 
usually more sensitive to the eﬀ ects of any given serum drug concentration. Even 
if the pharmacokinetics of a drug are not modiﬁ ed, an elderly patient may require 
a smaller dosage because of a change in pharmacodynamic sensitivity. With regard 
to psychoactive drugs, structural, electrophysiological and biochemical changes 
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involving brain neurons and neurotransmission have been documented in the 
elderly [22]. Th ese alterations may theoretically increase cerebral vulnerability 
and increase the risk for pharmacodynamically mediated drug interactions. In 
addition to age-related physiological changes, other genetic, pathological and 
environmental factors may contribute to variability in the pharmacokinetics and 
pharmacodynamics of each drug in an elderly patient, thereby increasing the 
likelihood of serious drug interactions. In particular, diseases of organs that alter 
the physiological mechanisms subserving the various pharmacokinetic phases may 
further compromize the elimination of drugs.
INTERACTION POTENTIAL OF VARIOUS ANTIDEPRESSANTS IN THE ELDERLY
Antidepressants drugs currently available diﬀ er in their potential for drug in-
teractions, as summarized in Table 3. For more comprehensive information, the 
reader is referred to earlier reviews of drug interactions involving older and newer 
antidepressants [13, 28-34].
Table 3. Comparison of the potential for drug interactions among various classes of antidepressants in the elderly.
Antidepressant drugs Potential for drug interactions in the elderly
Monoamine oxidase inhibitors -  elevated risk of potentially fatal pharmacodynamic interactions, particularly with 
tyramine-rich foods, sympathomimetic drugs and other antidepressants
Tricyclic antidepressants -  susceptible to enzyme inhibition by inhibitors of CYP2D6 (aff ecting mainly 
hydroxylation) and by inhibitors of CYP1A2, CYP2C19 and CYP3A4 (aff ecting mainly 
demethylation) and to enzyme induction by various anticonvulsants
-  high potential for pharmacodynamic interactions, particularly with anticholinergic 
drugs and medications aff ecting the central nervous and the cardiovascular system
Selective serotonin reuptake 
inhibitors
- diff erential inhibition at selective CYP isoenzymes
 fl uoxetine potently inhibits CYP2D6 and moderately CYP2C9 and CYP3A4
 paroxetine potently inhibits CYP2D6
  fl uvoxamine potently inhibits CYP1A2 and CYP2C19 and moderately CYP2C9 and 
CYP3A4
 sertraline is a weak to moderate inhibitor of CYP2D6
 citalopram/escitalopram are weak inhibitors of CYP isoenzymes
-  low potential for pharmacodynamic interactions, but possible involvement 
in pharmacodynamic interactions with other serotonergic drugs (serotonin 
syndrome) and incresed risk of bleeding with nonsteroidal anti-infl ammatory drugs, 
corticosteroids, oral anticoagulants and antiplatelet drugs (including low-dose aspirin)
Serotonin and noradrenaline reuptake 
inhibitors
- duloxetine is a moderate inhibitor of CYP2D6
-  low potential for pharmacodynamic interactions, but possible involvement in 
pharmacodynamic interactions with other serotonergic drugs (serotonin syndrome)
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Monoamine Oxidase Inhibitors (MAOIs)
Monoamine oxidase inhibitors (MAOIs) are rarely used today in the treatment of 
depression due to their high potential for severe pharmacodynamic interactions 
[28, 29]. Potentially fatal hypertensive crises may occur when nonselective MAOIs 
are coadministered with foods containing tyramine or other pressor amines, sym-
pathomimetic agents and TCAs [28]. In addition, a serious and life-threatening 
toxic reaction, known as “serotonin syndrome” has been reported in patients re-
ceiving nonselective MAOIs in combination with highly serotonergic drugs such 
as an SSRI, clomipramine or tryptophan [35].
Tricyclic antidepressants (TCAs)
Despite proven eﬃ  cacy, tricyclic antidepressants (TCAs) are generally reserved as 
alternative agents for treating late-life depression [2-4]. Th e clinical use of TCAs in 
the elderly may be particularly problematic due to their anticholinergic, sedative 
and cardiovascular side eﬀ ects. Among cardiovascular adverse events, orthostatic 
hypotension is of particular concern in the elderly as it may lead to falls and hip 
fractures, cerebrovascular accidents and myocardial ischaemia. Moreover, TCAs 
have a relatively narrow therapeutic index as a result of dose- and concentration-
dependent central nervous system and cardiac toxicity. In addition to tolerability 
and safety problems, the use of these agents in geriatric patients is further compli-
cated by a relatively high potential for drug interactions with a variety of concomi-
tantly prescribed medications. TCAs have a variety of pharmacological actions and 
may therefore interact pharmacodynamically with compounds acting on the same 
target(s). TCAs inhibit the neuronal reuptake of noradrenaline and serotonin, 
bind to multiple receptors types (M1 cholinergic receptors, H1-histamine recep-
tors, α1-adrenoceptors), and inhibit fast sodium channels. Based on this, TCAs 
should be avoided or used with extreme caution in elderly patients treated with 
anticholinergics and with drugs aﬀ ecting the central nervous and cardiovascular 
systems [6, 13]. Concomitant administration of TCAs with other medications 
possessing antimuscarinic activity, such as phenothiazines and antiparkinsonian 
agents, may induce additive central and peripheral anticholinergic eﬀ ects, includ-
ing memory impairment, dry mouth, blurred vision and constipation. In geriatric 
patients, the interaction could also precipitate confusional states, acute glaucoma, 
adynamic ileus and urinary retention. TCAs may potentiate the sedative eﬀ ects of 
alcohol and other central nervous system (CNS) depressants such as barbiturates, 
benzodiazepines, anthistamines, and antipsychotics, thereby impairing psycho-
motor and cognitive function, particularly dangerous in an elderly population. 
Undesirable interactions may also occur when TCAs are used in combination 
with a variety cardiovascular drug (e.g. antiarrhythmics, antihypertensives and 
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oral anticoagulants). TCAs are also susceptible to clinically relevant pharmacoki-
netic interactions when coprescribed with substantial inhibitors of CYP enzymes 
involved in their biotransformation [36]. Th ese include CYP1A2 inhibitors such as 
ﬂ uvoxamine and ciproﬂ oxacin, CYP2D6 inhibitors such as quinidine, ﬂ uoxetine, 
paroxetine and bupropion, and CYP3A4 inhibitors such as nefazodone, some azole 
antifungals and some macrolide antibiotics [37]. Inhibition of CYP enzymes may 
cause an increase in plasma concentrations of TCAs, possibly resulting in serious 
adverse reactions, such as anticholinergic eﬀ ects, arrhythmias, convulsions and 
delirium. Th ese eﬀ ects are presumably more common and more serious in elderly 
patients because of age related changes in pharmacokinetics and pharmacody-
namics. By contrast, co-administration with enzyme inducers, namely various 
anticonvulsants, may lead to decreased concentrations of TCAs and, therefore, 
attenuate their eﬀ ects.
Selective Serotonin Reuptake Inhibitors (SSRIs)
Owing to their eﬃ  cacy, good tolerability and relative safety, the selective serotonin 
reuptake inhibitors (SSRIs) have become the most frequently prescribed antide-
pressants. Th e published clinical evidence suggests that SSRIs are ﬁ rst-line agents 
for treating geriatric depression [2-4]. Th e use of SSRIs in the elderly is associated 
with the possibility of clinically relevant pharmacokinetic interactions with other 
medications due to their inhibitory eﬀ ect on CYP enzymes. Th e diﬀ erential eﬀ ects 
of various SSRIs on CYPs are well characterized in vitro [37, 38]. Th e various 
SSRIs available diﬀ er considerably in proﬁ les with regard to inhibition of CYP 
enzymes in vitro and this may guide selection of an appropriate compound in the 
individual patient (Table 2). Based on this, it would appear that the potential for 
individual SSRIs to interact with other drugs is greater for ﬂ uvoxamine, ﬂ uoxetine 
and paroxetine and lower for sertraline, citalopram and escitalopram. In view of 
these considerations, caution is required when adding an SSRI to a multi-drug 
regimen in the elderly. In fact, as the inhibitory eﬀ ect on CYPs is concentration 
dependent, the potential for drug interactions is presumably higher in the elderly, 
especially for compunds whose elimination is aﬀ ected by age, such as citalopram 
and paroxetine, and for those which exhibit nonlinear kinetics, such as ﬂ uoxetine 
and paroxetine [6]. For drugs with long half-lives, e.g. ﬂ uoxetine and its active 
metabolite, the interaction potential may persist for weeks after treatment discon-
tinuation. Conversely, it is unlikely that other drugs may cause clinically relevant 
changes in the pharmacokinetics of SSRIs. Substantial inhibitors or inducers of 
CYPs responsible for the biotransformation of the various SSRIs may aﬀ ect their 
elimination leading to modiﬁ cations in plasma concentrations. However, as these 
drugs have a wide therapeutic index, the consequences of these changes are unlikely 
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to be clinically relevant [30]. Due to their selective mechanism of action, SSRIs 
are usually considered at relatively low risk for pharmacodynamically mediated 
interaction. However, SSRIs may interact adversely with other drugs aﬀ ecting 
serotoninergic transmission, such as MAOIs, TCAs, triptophan, with possibile 
occurrence of a potentially fatal serotonin syndrome [35]. According to postmor-
tem forensic investigation, elderly patients, particularly those with atherosclerotic 
cardiovascular disease or preexisting heart disease, appear to be at high risk for this 
syndrome [39]. In addition, recent epidemiological evidence suggests that SSRI 
use is associated with an increased incidence of upper gastrointestinal bleeding. 
Th e prevention of serotonin uptake of from circulation into platelets induced 
by SSRIs, leading to reduced platelet aggregation and prolonged bleeding time, 
may be the underlying biological mechanism for this eﬀ ect. Patients at particular 
risk of gastrointestinal bleeding include elderly persons and subjects receiving 
other bleeding risk-increasing medications such as nonsteroidal anti-inﬂ amma-
tory drugs, corticosteroids, oral anticoagulants and antiplatelet drugs (including 
low-dose aspirin) [40]. Examples of potentially clinically signiﬁ cant interactions 
between SSRIs and other medications commonly used in the elderly are given 
below. SSRIs are frequently prescribed in combination with other CNS drugs. 
Patients with depression refractory to treatment with a single agent are sometimes 
tried on combination therapy. While this practice may prove therapeutically ad-
vantageous in selected cases, its potential beneﬁ ts should be weighed against the 
risk of adverse eﬀ ects resulting from a wide range of interactions. Apart from the 
possibility of a serotonin syndrome when coadministered with other serotonergic 
antidepressants, various SSRIs may cause a remarkable elevation of plasma TCAs 
levels, through inhibition of CYPs [6, 13]. Concomitant administration of SSRIs 
with novel antipsychotics is relatively common, but may occasionally results in 
clinically important interactions. In this respect, paroxetine and ﬂ uoxetine have 
been reported to produce a clinically relevant increase in plasma concentrations 
of risperidone, presumably through inhibition of CYP2D6, whereas ﬂ uvoxamine 
may cause a signiﬁ cant elevation of plasma concentrations of clozapine and, to a 
lesser extent, olanzapine which are both substrates of CYP1A2 [41-45]. Compared 
with TCAs, SSRIs are less likely to produce additive CNS depressant eﬀ ects when 
taken together with benzodiazepines and other CNS depressants. Fluvoxamine 
has been reported to inhibit the CYP1A2-mediated metabolism of tacrine, a 
cholinesterase inhibitor used for the treatment of Alzheimer’s dementia, possibly 
increasing its hepatotoxicity [46]. Clinically relevant drug interactions between 
SSRIs and drugs used to treat concomitant cardiovascular disorders, in particular 
oral anticoagulants, beta-blockers and digoxin, have been occasionally documented 
in elderly patients. Case reports and literature reviews have suggested that SSRIs, 
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in particular ﬂ uvoxamine and ﬂ uoxetine, may interact with the oral anticoagulant 
warfarin to cause bleeding [47-51]. SSRIs may increase the risk of hemorrhage 
during warfarin treatment by two mechanisms. First, SSRIs may reduce platelet 
aggregation by depleting platelet serotonin levels, directly increasing the risk of 
bleeding, as earlier mentioned [40]. Second, some SSRIs, particularly ﬂ uvoxamine 
and ﬂ uoxetine, may inhibit the CYP2C9-mediated oxidative metabolism of the 
more biologically active (S)-enantiomer of warfarin [50, 51]. However, a recent 
population study has not (failed to) documented a signiﬁ cant risk of gastroin-
testinal bleeding in elderly patients taking warfarin who had recently started a 
treatment with various antidepressants including ﬂ uoxetine and ﬂ uvoxamine 
[52]. Coadministration of ﬂ uoxetine with metoprolol or propranolol has occa-
sionally resulted in serious adverse events such as bradycardia or heart block [53, 
54]. Inhibition of CYP2D6-mediated oxidative metabolism of beta-blockers by 
ﬂ uoxetine is the most likely explanation for this interaction. Isolated case reports 
have described a remarkable elevation of serum digoxin concentrations along with 
signs of toxicity in elderly patients after coadminitration of ﬂ uoxetine or parox-
etine [55, 56]. With regard to this, a large population-based, case-control study, in 
elderly patients has documented a slightly increased risk of hospital admissions for 
digoxin toxicity following initiation of SSRI therapy with no diﬀ erence among the 
various compounds [12]. Interestingly, a similar risk was also found with TCAs or 
benzodiazepines compounds with no known pharmacokinetic interactions with 
digoxin. Finally, few cases of theophylline toxicity have been reported in elderly 
patients following addition of ﬂ uvoxamine [57, 58]. Th e potent inhibitory eﬀ ect of 
ﬂ uvoxamine on CYP1A2, main isoenzyme involved in theophylline metabolism, 
provides an explanation for this interaction.
Serotonin and noradrenaline reuptake inhibitors
Venlafaxine and duloxetine are serotonin and noradrenaline reuptake inhibitors 
(SNRIs). As SSRIs, they have a low aﬃ  nity for multiple receptors. While venla-
faxine has a weak inhibitory eﬀ ect on the activity of the various CYP enzymes, 
duloxetine is a moderate inhibitor of CYP2D6 [59]. As a precaution, elderly 
patients taking duloxetine in addition to substrates of CYP2D6 with a narrow 
therapeutic index should be carefully monitored. Like all antidepressants that 
inhibit serotonin reuptake, SNRIs may interact pharmacodynamically with other 
serotonergic compounds and cause a “serotonin syndrome”.
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Other antidepressants
Mirtazapine
Mirtazapine is a dual-action antidepressant whose eﬀ ect appears to be related to 
the enhancement of central noradrenergic and serotonin 5-HT1 receptor-mediated 
serotonergic neurotransmission. Mirtazapine is a weak inhibitor of the various 
CYP enzymes and has a very low potential for pharmacokinetic interactions with 
other drugs [60]. However, given its aﬃ  nity for histaminergic receptors, mirtazap-
ine may potentiate the sedative eﬀ ects of coprescribed CNS depressants.
Reboxetine
Reboxetine is a selective noradrenaline reuptake inhibitor and it has a low aﬃ  nity 
for cholinergic, histaminergic and α1-adrenergic receptors. Due to its weak inhibi-
tory aﬃ  nity for CYPs enzymes, it is unlikely that reboxetine may cause clinically 
signiﬁ cant pharmacokinetic interactions with other medications. On the other 
hand, due to the potentiation of noradrenergic neurotransmission, reboxetine 
should be used with caution in elderly patients in association with cardiovascular 
drugs [34].
Bupropion
Bupropion is an antidepressant which inhibits the neuronal reuptake of nora-
drenaline and dopamine. Its metabolism is not completely characterized, but one 
of its acitve products is metabolized by CYP2D6. In vitro and in vivo studies have 
shown that bupropion is a moderate inhibitor of CYP2D6 [34]. As bupropion 
increases dopaminergic activity the potential exists for interactions with other 
dopaminergic agents.
St. John’s wort (Hypericum perforatum)
St. John’s wort (Hypericum perforatum) is one of the most commonly used herbal 
antidepressants. Th is herbal extract, available in several countries as a dietary 
supplement, is eﬀ ective in mild-to-moderate depression and has an encouraging 
safety proﬁ le [20, 21]. As with other natural products, St. John’s wort is increas-
ingly used in the elderly [62]. Recent evidence indicates that St. John’s wort is a 
potent inducer of CYP3A4 (and possibly other CYPs) and P-glycoprotein and 
may therefore be involved in clinically relevant interactions with prescribed drugs 
[63, 64]. In this respect, interaction studies and case reports have documented 
that St. John’s wort may cause a remarkable decrease in plasma concentrations of 
a number of medications including amitrptyline, cyclosporine, digoxin, indina-
vir, irinotecan, methadone, simvastatin, tacrolimus, theophylline, warfarin and 
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oral contraceptives, thereby reducing their eﬃ  cacy. In addition, combined use 
of St. John’s wort with serotonergic antidepressants (e.g. sertraline, paroxetine, 
nefazodone and venlafaxine) may result in symptoms characteristic of serotonin 
syndrome, presumably to a central pharmacodynamic mechanism [20, 21].
PREVALENCE OF CLINICALLY RELEVANT ANTIDEPRESSANT DRUG 
INTERACTIONS IN THE ELDERLY
From a public health perspective the issue of antidepressant drug interactions in 
the elderly is of great clinical relevance if we consider that the number of prescrip-
tions of these compounds is generally growing in the population, particularly in 
old age [65]. In this respect, newer antidepressants are often used to treat psychi-
atric conditions other than depression (e.g. anxiety disorders) and are increasingly 
prescribed among general practitioners [66]. Moreover, the recommended dura-
tion of treatment tend to increase so thus elevating the likelihood of copresription 
with other medications. Based on these considerations, drug interactions with 
antidepressants are certainly common in the elderly. However, the prevalence 
of clinically important interactions is not well documented. While the risk of 
potentially harmful drug interactions is well recognized with older antidepressants 
and has contributed to a gradual decline in their utilization in psychiatric prac-
tice, the clinical signiﬁ cance of drug interactions with newer compounds remains 
poorly deﬁ ned despite millions of exposures. Th e question of the prevalence of 
clinically relevant drug interactions involving antidepressants has been debated 
in recently published articles [67, 68]. According to De Vane [67], antidepressant 
drug interactions are potentially, but rarely clinically signiﬁ cant. With regard to 
this, major concern about drug interactions with newer antidepressants derives 
from the possibility that SSRIs as well as other recently marketed compounds 
may cause pharmacokinetic interactions through their in vitro ability to inhibit 
various CYPs. Th ese metabolically-based interactions may be easily predicted 
from in vitro studies. However, the corrent models for extrapolation of in vitro 
data to the in vivo situation have several limitations, so not all of them will occur 
in clinical practice [69]. Moreover not all inhibitory drug interactions occurring 
in vivo are clinically signiﬁ cant. Various factors may contribute to minimize their 
clinical consequences including compensatory mechanisms (e.g. the presence 
of alternative metabolic pathways) and a wide therapeutic index of the aﬀ ected 
drug. Indeed, evidence for some antidepressant drug interactions is based on 
anecdotal case report or extrapolation of the results of pharmacokinetic studies 
conducted in healthy volunteers to patients. Consistent with this, epidemiological 
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and post-marketing surveillance data do not conﬁ rm a high prevalence of serious 
antidepressant-induced drug interactions [67].
Although clinically important interactions with newer antidepressants are 
likely to be unusual and severe adverse interactions are presumably rare events, it 
should be emphasized that elderly patients represent a population at risk for drug 
interactions. For the reasons earlier reported, the clinical consequences of a drug 
combination may be ampliﬁ ed in old age. Th erefore, even if the risk is not well 
documented at epidemiological level, the choice of a pharmacological agent with 
a low potential for drug interactions appears as the most rational strategy in the 
elderly.
PREVENTION AND MANAGEMENT OF ANTIDEPRESSANT DRUG 
INTERACTIONS IN THE ELDERLY
Preventing the use of medications where there is the potential for serious drug in-
teractions or minimizing their clinical manifestations is essential to ensure patient 
safety. Some general recommendations may be given to prevent or minimize the 
occurrence of adverse drug interactions in elderly patients with depression.
- Th e need for multiple drug therapy should be continuously evaluated and 
drugs that are no longer needed should be discontinued.
- Basic understanding of the mechanisms of drug interactions and the various 
factors predisposing elderly patients to adverse drug interactions may be useful 
for safe prescribing.
- Knowledge of the interaction potential of individual agents (especially with 
respect to pharmacodynamic eﬀ ects and inhibition of CYP isoenzymes) may 
guide selection of an appropriate compound which is less likely to interfere 
with already taken medication(s).
- Clinical manifestations of most drug interactions, in particular those with a 
pharmacokinetic mechanism, can be prevented or compensated for by appro-
priate dosage adjustments based on clinical observation. Each elderly patient 
should be treated individually and monitored carefully during antidepressant 
therapy.
Correct and comprehensive information is a prerequisite for both prevention 
and adequate management of drug interactions. However, despite the relevant 
burden of drug-drug interactions, particularly in elderly population, prescribing 
physicians seem to be generally unaware of potential risks associated with con-
comitant prescription of medications that are frequently used in general practice, 
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as many newer antidepressants. A plausible explanation to such a poor awareness 
about drug interactions among health professionals might be related to the fact 
that current information provided to clinicians through standard information 
sources appear to be inconsistent, incomplete and outdated, in some cases reﬂ ect-
ing scientiﬁ c uncertainty and lack of documentation. Th e Summary of Product 
Characteristics (SPC) is the primary source of information concerning potential 
drug-drug interactions for health care professionals. However, due to obvious 
space limitations, potential drug-drug interactions cannot be listed exhaustively 
and critically evaluated for their clinical relevance. In this respect, a very low 
agreement on the risk for clinically relevant drug interactions has been reported 
between the SPC and other standard drug-related information sources such as the 
Drugdex System (Th omson Micromedex, Greenwood Village, Colo) [70]. Apart 
from accuracy and coherence of information sources, another critical issue is how 
to provide health professionals with wise and updated information on drug inter-
actions. Potential intervention strategies, targeted to adequately supply prescribers 
with information on the risks of clinically relevant drug-drug interactions may be 
represented by computerized drug interaction alerts and active participation of 
pharmacists [71]. Th ere is good evidence that electronic decision support systems, 
such as automated drug interaction alerts, being immediately integrated in the 
prescribing process, can dramatically increase clinicians’ recognition of interact-
ing drug pairs (including antidepressant drugs) by upward to 50, thus leading 
to reduce the number of prescriptions with potentially hazardous combinations 
[72-73]. Finally, the pharmacists might have a predominant role in the manage-
ment of drug-related issues, including drug-drug interactions, through screening, 
prevention and education strategy that are addressed to general population, in 
collaboration with physicians and other health professionals. Consistent with this, 
some studies have documented the eﬀ ective contribution of pharmacists to the 
management of drug therapies in patients with depression both in primary care 
and hospital settings [74-75].
CONCLUSION
Drug treatment of depression in old age is associated with an increased risk of ad-
verse pharmacokinetic and pharmacodynamic drug interactions. Due to comorbid 
medical conditions, elderly patients often take many medications simultaneously. 
In addition to polypharmacy, age-related physiological changes may modify drug 
response and, therefore, predispose elderly subjects to adverse eﬀ ects and drug 
interactions. Th e risk of potentially harmful drug interactions is well documented 
Gianluca BW.indd   174 25-May-09   11:23:30 AM
175
Antidepressant drugs in elderly: use and safety 
with older antidepressants and has contributed to a gradual decline in their uti-
lization in clinical practice. By virtue of a more selective mechanism of action, 
newer antidepressants have a relatively low potential for pharmacodynamic drug 
interactions. However, the possibility of the serotonin syndrome should be taken 
into account when drugs aﬀ ecting serotonergic transmission, such as SSRIs or 
SNRIs are coadministered with other serotonergic agents. On the other hand, 
newer agents have a diﬀ erential potential for pharmacokinetic interactions due 
to their inhibitory eﬀ ects on various CYP enzymes. Within the group of SSRIs, 
ﬂ uoxetine and paroxetine are potent inhibitors of CYP2D6, while ﬂ uvoxamine 
inhibits markedly CYP1A2. Duloxetine and bupropion are moderate inhibitors 
of CYP2D6. Although metabolic interactions with antidepressants are rarely 
involved in serious toxicity, are often predictable and can be managed by standard 
clinical practice, the use antidepressants with low inhibitory activity on diﬀ erent 
CYP enzymes appears particulary suitable in an elderly population. Correct and 
comprehensive information is a prerequisite for both prevention and adequate 
management of drug interactions with antidepressants in the elderly.
FUTURE PERSPECTIVE
With the progressive aging of the population, late-life depression is likely to 
become more and more important as a public health problem and prescriptions 
of antidepressants will presumably grow so thus increasing the likelihood of drug 
interactions. In recent years, diﬀ erent in vitro techniques have been developed and 
have become widely used as screening tools to predict potential for metabolic drug 
interactions before a drug reaches the clinical phases of development. Reﬁ nement 
of this methodology will certainly improve the predictive power. Th is informa-
tion might be therefore applied not only in drug discovery (through design and 
selection of new agents devoid of undesirable interaction potential) and in drug 
development (though rational identiﬁ cation of drug interactions to be assessed 
in the clinical setting), but also in making informed decisions when adding 
or withdrawing comedications in routine clinical practice. Systematic studies 
are needed to test the clinical relevance of drug interactions and the complex 
nature of multiple medication use in routine clinical practice. In this respect, 
epidemiological studies and large post-marketing database are the most clinically 
relevant guide to drug combinations likely to cause adverse reactions. Correct and 
comprehensive information is a prerequisite for both prevention and adequate 
management of drug interactions. Intervention strategies to prevent potentially 
harmful drug interactions both in primary and secondary have been developed 
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including computerized drug interaction alerts and active participation of phar-
macists. Future research should focus on improving these strategies in accurately 
and precisely identifying adverse drug interactions in the elderly.
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ABSTRACT
Aim of this study was to evaluate prevalence of use and prescribing pattern of Anti-
Parkinson Drugs (APDs) in general practice of Southern Italy. Among 120,000 
individuals registered in the lists of 93 general practitioners of Southern Italy, we 
estimated one-year prevalence and incidence of APD use in the years 2003-2005. 
Overall, prevalence of APD use remained stable over the years and it strongly 
increased in subjects over 70 years of age. L-Dopa with a dopa decarboxylase 
inhibitor was the most frequently prescribed APD, although the use of both ergot 
and non-ergot derivative DAs has increased, particularly, in the elderly. A high 
proportion of APD users (15-20) received only one prescription during the study 
period.
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INTRODUCTION
Parkinson’s disease (PD) is a chronic neurodegenerative disorder, with an estimated 
prevalence ranging from 66 to 257 per 100,000 inhabitants in Italy [1,2]. To date, 
Levodopa (L-Dopa) has been largely demonstrated to be the most eﬀ ective drug 
in Parkinson’s disease (PD) treatment, although this medication is associated with 
limiting and poorly tolerated motor and non-motor side eﬀ ects, particularly, in the 
advanced stages of the disease [3]. Other anti-Parkinson drugs (APDs) are com-
monly used in clinical practice either as monotherapy or as adjunctive therapy 
with L-Dopa, to delay or reduce its motor and non-motor complications and to 
maximise drug eﬀ ectiveness [4-6]: dopamine agonists (ergot and non-ergot deriva-
tives), anticholinergic drugs, amantadine, selegiline and catecol-O-methyltraserase 
(COMT) inhibitors. When they were ﬁ rst introduced, the indication for dopamine 
agonists (DAs) was as adjunctive therapy with L-Dopa in advanced PD, with the 
aim of reducing dyskinesias, by decreasing L-Dopa daily dosage [7]. In the last 
decade, however, these medications have been increasingly used as monotherapy 
in early PD to delay the start of L-Dopa treatment [8,9]. Dopamine agonists are 
divided into ergot and non-ergot-derivative medications. Ergot-derivatives, per-
golide and cabergoline are also used to treat hyperprolactinemic disorders, while 
non-ergot derived pramipexole and ropinirole are also approved for use in restless 
leg syndrome [10]. Since 2002, however, a number of case reports and observa-
tional studies have highlighted the risk of valvular heart disease associated with 
ergot-derivative DA use [11-13]. Anticholinergic drugs are not widely prescribed 
in PD, with the exception of young onset tremor dominant PD, due to the high 
frequency of adverse drug reactions (ADRs), like xerostomya, urinary retention, 
confusional state, hallucinations and cognitive impairment, mostly in older people 
[14]. Amantadine is NMDA-receptor antagonist that shows a good eﬃ  cacy in 
reducing L-Dopa-induced diskynesia [15], while selegiline is an irreversible MAO-
B inhibitor with symptomatic eﬀ ect in10 of de novo patients [16]. Th e most 
recently marketed APDs are COMT inhibitors that are used in combination with 
L-Dopa [17]. During the last decade, several studies have been performed to explore 
anti-Parkinson drug utilization in diﬀ erent settings [18-21]; however, the majority 
estimated prevalence of PD using the drug tracer methodology [19,20]. In an Ital-
ian cross-sectional study [18], L-dopa was the most commonly used APD (but in 
association with other APDs in older onset idiopathic PD), followed by dopamine 
agonists and anticholinergic agents. Apart from this study, recent investigations 
aimed at assessing APD prescribing patterns in Italy are lacking. Th is investigation 
was performed to measure the prevalence of APD use and to analyse the prescrib-
ing pattern of these medications in general practice in the south of Italy.
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METHODS
Data source
Data were extracted from the Arianna database during the years 2003-2005. Th is 
database was set up by the Local Health Agency of Caserta in the year 2000. It 
currently contains information on a population of almost 300,000 individuals 
living in the catchment area of Caserta and registered in the lists of 225 general 
practitioners (GPs). Th is sample of physicians accounts for 73.7 (225/305) of the 
total number of GPs who practice in the same area. Participating GPs record data 
during their daily clinical practice through dedicated software, and, once a month 
send complete and anonymous data concerning their patients to the Arianna 
Database. Information collected includes patient demographics, drug prescrip-
tions (reimbursed by Health National System) coded according to the Anatomical 
Th erapeutic Chemical (ATC) classiﬁ cation system, and medical diagnoses coded 
by the ninth edition of International Classiﬁ cation of Diseases (ICD-9). All par-
ticipating GPs received extensive training in data collection techniques. A number 
of data quality checks are routinely performed, including the analysis of several 
parameters such as missing patient codes, the number of prescriptions ﬁ lled daily 
and the regularity of their monthly of data submission. Any variation within 
deﬁ ned ranges is investigated and returned to each participating GP, in order to 
receive immediate feedback about data quality and completeness. GPs failing to 
meet these standard quality criteria are dropped from epidemiological investiga-
tions, according to basic standards in the conduct of pharmaco-epidemiological 
studies [22]. So far, the Arianna database has been shown to provide accurate and 
reliable information on drug utilization [23-25].
Study population
Ninety three GPs that regularly sent data to the Arianna database during the 
years 2003-2005 were selected for this study. Among 119,393 individuals registered 
in their lists at 30 December 2005, users of Anti-Parkinson Drugs (APDs) were 
identiﬁ ed; these were deﬁ ned as individuals receiving at least one APD (ATC: 
N04) prescription during the study period. Patients were included in the study 
irrespective of whether APD treatment was initiated by GPs or by specialists 
working either in the public or private sector, leading in this case thereafter, to 
prescriptions provided by GPs that is the most common situation with APDs. 
Indeed in Italy, outpatients receiving prescriptions from specialists in the public 
or private sector subsequently receive their drugs free of charge through prescrip-
tions the are provided by GP. Th e following cohorts of APD users were identiﬁ ed 
according to the drug type that was used: (1) Levodopa, alone or in combination 
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with Dopa Decarboxylase Inhibitor (DDCI); (2) Ergot derivative dopamine 
agonists (bromocriptine, pergolide and cabergoline); (3) Non-ergot derivative 
dopamine agonists (pramipexole and ropinirole) and (4) Anticholinergic agents 
(trihexyphenidyl, biperidene, metixene, procyclidine and bornaprine). Other 
APDs, such as selegiline, COMT inhibitors, amantadine and apomorphine were 
not included in the analysis since either the National Health System does not re-
imburse them in Italy or, alternatively, these medications are dispensed directly in 
hospital setting, thus bypassing general prescription. After identiﬁ cation of APD 
users, the following information was retrieved using the Arianna database: pa-
tients’ demographics, APD prescription data (including product name, dispensed 
quantity and indication of use) recorded during the years 2003-5. Th e ﬁ rst APD 
prescription date was considered as index date.
Outcome defi nition
Annual prevalence of APD treatment was calculated, overall and by drug type, as 
the number of APD users per year divided by the number of subjects alive and 
registered in the GPs’ lists during the observation years.
We deﬁ ned ‘‘new user’’ as a patient receiving a ﬁ rst APD prescription during 
the years 2004 or 2005, without any recorded APD prescription in the previous 
year. One-year incidence of APD use was measured as the number of ‘‘new users’’ 
divided by the number of subjects who did not receive an APD prescription in the 
previous year. Both prevalence and incidence were calculated for APDs, overall 
and by drug type, and were expressed as rates per 100,000 inhabitants, together 
with 95 Conﬁ dence Interval (CI).
An analysis was performed to speciﬁ cally evaluate APD prescribing pattern 
in treatment of PD, taking into account only those patients who received more 
than one APD prescription during the study period with a medical diagnosis of 
idiopathic, secondary or unspeciﬁ ed PD. Within each drug type, the proportion 
of patients that was treated with monotherapy or add-on therapy with diﬀ erent 
APD classes was evaluated separately.
Statistical analysis
Chi-Square test for categorical variables and Student t-test for continuous vari-
ables, with a signiﬁ cance level of P < 0.05, were used for assessing the diﬀ erences 
among users of various APD types at the index date. Statistical analyses were 
performed using STATA 6.0 (STATA Corporation, Texas, USA).
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RESULTS
In Table 1, main characteristics of APD type users are described. As expected, 
Levodopa (plus a DDCI) was the most frequently used APD (620 patients) dur-
ing the study years, followed by anticholinergic drugs (434). Users of these last 
medications were signiﬁ cantly younger (p < 0.05) compared to other APD users. 
Use of any APD type was equal between the sexes and no diﬀ erences were shown 
among various APD classes.
Table 1. Characteristics of APD users (at least 1 prescription) within the study years
Variables
L-Dopa
N= 620
Ergot derivatives 
DA
N= 211
Non-Ergot 
derivatives DA
N= 214
Anticholinergic agents
N= 434
Median age, years 78 72 73 56
Gender (%)
Males 300 (48.4) 97 (46.0) 103 (48.1) 221 (50.9)
Females 320 (51.6) 114 (54.0) 111 (51.9) 213 (49.1)
N. User of APD Px*(%)
1 Px 92 (14.8) 41 (19.4) 14 (6.5) 90 (20.7)
2 Px 48 (7.7) 14 (6.6) 5 (2.3) 58 (13.4)
3 Px 29 (4.7) 5 (2.4) 7 (3.3) 34 (7.8)
>3 Px 451 (72.7) 151 (71.6) 188 (87.9) 252 (58.1)
Legend: DA= dopamine agonists. Use of diff erent drug types is not mutually exclusive.
* In this analysis, APD users have been stratifi ed by the number of APD prescriptions (Px) that they received within study years.
A relatively high proportion of APD users received only one prescription during 
the study years: 20.7 of anticholinergic agent users, 19.4 of ergot derivatives 
DA users and slightly lower proportion (14.8) of Levodopa (plus a DDCI) users. 
On the contrary, the proportion of non-ergot derivative DA user receiving only 
one prescription within study years was very low (6.5).
Overall, prevalence of APD use appeared to be stable over the years (in 2005: 
601 per 100,000 inhabitants; 95 Conﬁ dence Interval: 559.1-646.9), with a strik-
ingly increasing trend in advanced age: 2,142 (1,963-2,337) per 100,000 in subjects 
older than 65 years, in 2005 (Figure 1).
However, after excluding anticholinergic agents from the analysis, the preva-
lence of APD use signiﬁ cantly decreased in each study year: 392 (358-439) per 
100,000 in 2005.
Th e one-year prevalence of use of APD classes is reported in Figure 2. Th e 
prevalence of use of L-Dopa (plus a DDCI) was markedly higher than other APD 
classes and it did not change during the study years: 307 (278-340) per 100,000 
inhabitants in 2005.
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On the other hand, prevalence of use of both ergot and non-ergot derivative 
DA continuously increased during the study years, going from 59 (47-74) per 
100,000 in 2003 to 95 (79-114) in 2005, and from 93 (77-112) to 130 (111-152).
A peculiar trend in the prevalence in the use of anticholinergic agents was 
shown during the study period, with a peak in 2004: 229 (203-258) per 100,000. 
Figure 1. Prevalence of APD use per 100,000 inhabitants, stratifi ed by age groups and calendar years.
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Figure 2. Prevalence of APD use^ per 100,000 inhabitants, due to Parkinson’s disease or Parkinsonism, stratifi ed by drug types and calendar 
years.
0
50
100
150
200
250
300
350
L-D
opa
Erg
ot d
eriv
ativ
e D
A
Non
-erg
ot d
eriv
ativ
e D
A
Ant
ich
olin
erg
ic a
gen
ts
2003 2004 2005
^ In this analysis, only patients receiving more than 1 APD prescription have been included.
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Compared to 2004, the prevalence of anticholinergic agents decreased, particu-
larly in patients over the age of 70 years in 2005 (308, 232-409 vs 446, 353-565), 
while it was reduced to a lesser extent in those ≤ 70 years old: 155 (133-180) versus 
196 (171-225).
Th e one-year incidence of treatment with diﬀ erent APD types in the years 
2004-2005, stratiﬁ ed by age groups, is reported in Figure 3. One-year incidence 
of APD use was, 113 (96-134) per 100,000 inhabitants in 2004 and 161 (140-185) 
in 2005. With the exception of anticholinergic drugs, rates of new treatment with 
APD were very low in patients <70 years old during the observation years.
In older patients, the highest incidence of use was reported for L-Dopa (plus a 
DDCI) that markedly increased from 2004 (307 per 100,000; 95 CI: 232-404) 
to 2005 (453; 360-569). Even though the incidence of L-Dopa (plus a DDCI) use 
more than doubled, compared to ergot and non-ergot derivative DA, new treat-
ments with these medications seemed to increase moderately during the study 
years, as well.
Th e prescribing pattern of diﬀ erent APD types did not change remarkably dur-
ing the study years, as shown in Figures 4 a-d. Among L-Dopa (plus a DDCI) 
users, however, a reduction of monotherapy use (71 in 2003 vs. 63 in 2005) 
is highlighted, partly due to the increased proportion of patients that are more 
recently being treated using combined therapy with an ergot-derivative DA (8 in 
2003 vs. 12 in 2005) and non-ergot derivative DA (14 in 2003 vs. 18 in 2005).
Figure 3. One-year incidence of treatment^ with APD in the years 2004-2005, stratifi ed by drug type, age groups and calendar year.
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With regard to dopamine-agonists, almost 50 of both ergot and non-ergot de-
rivative users received concomitant treatment with L-Dopa (plus a DDCI), while 
the remaining proportion was treated with these medications as monotherapy or 
with both DA subtypes.
With regard to anticholinergic agents, almost 90 of users were treated as 
monotherapy, with the remaining proportion of patients being treated mainly 
with combined treatment with Levodopa.
Figure 4 a-d. Prescribing pattern* of L-Dopa (a), ergot derivative DA (b), non-ergot derivative DA (c) and anticholinergic agents (d), stratifi ed 
by calendar year
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DISCUSSION
To our knowledge this is the ﬁ rst observational study that was targeted to ex-
plore the pattern of use of anti-Parkinson drugs in Southern Italy. Earlier Italian 
analyses [18, 26-28] looked primarily at APD use as drug tracer to estimate PD 
prevalence.
Another recent investigation [17] evaluated APD prescribing pattern in North-
ern Italy and it reported L-Dopa (plus a DDCI) as being the most frequently used 
APD, followed by dopamine agonists and anticholinergic agents, in agreement 
with our results.
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*In this analysis, only patients receiving more than 1 APD prescription, have been included. Combination with other drug types was defi ned as 
at least 1 prescription of APD and 1 of other drugs belonging to diff erent APD types that were registered within 3 months period.
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A crude prevalence of 257 per 100,000 for PD was estimated in an area of 
Southern Italy through a door-to-door survey [2]. In our study, we calculated 
a prevalence of APD use of 601 per 100,000 (95 CI: 559-647). Large use of 
APD for indications other than PD, particularly with regards to anticholinergic 
drugs, might partly explain such a diﬀ erence. It is well known that anticholinergic 
agents are prescribed by GPs to treat extrapyramidal side eﬀ ects induced by other 
medications, like neuroleptics [29]. Indeed, prevalence of APD use was strongly 
reduced to 392 (358-439) per 100,000, in our study, after excluding anticholinergic 
drugs from the analysis.
Moreover, a signiﬁ cant proportion of APD users received only one prescription 
(about 15) in our study, in part due to misdiagnosed Parkinsonism or patient’s 
death, thus contributing to the overestimation of the prevalence of APD use. 
In addition, this ﬁ nding might suggest that both GPs and specialists commonly 
prescribe a trial of dopaminergic medications and assess response rather than carry 
out more complex diagnostic procedures.
An earlier Italian investigation reported that 18 of APD users also only re-
ceived one prescription [30].
Interestingly, we found that both ergot and non-ergot derivative dopamine ago-
nists were increasingly used during the study years, in line with another European 
investigation [21]. However, an increased risk of valvular heart disease associated 
with pergolide and cabergoline use has been reported since 2002 [11,12] and this 
has also recently been conﬁ rmed [13,31].
Concerning the prescribing pattern of anti-Parkinson drugs, some critical 
points identiﬁ ed in our analysis merit discussion, on the basis of international 
[32,33] and Italian [34] guidelines for the treatment of PD and parkinsonisms.
As previously mentioned, the use of dopamine agonists, measured as one-year 
incidence, has been increasing during the last years; however, such an increase 
related mainly to older people, apparently in contrast with guidelines that suggest 
DA use at early stage of PD.
On the other hand, more than 20 of DA users were treated concomitantly 
with ergot and non-ergot derivative medications; such a proportion might be, 
however, overestimated since we considered a polytherapy as prescriptions of both 
DA types that were registered within 3 months period.
Anticholinergic drugs were prominently prescribed as monotherapy even 
though these medications are not recommended in PD treatment due to the high 
frequency of adverse events, particularly in the elderly; however, the high propor-
tion of patients (about 20) receiving only one prescription of these medications 
during the study years would suggest their wide utilization in indications, other 
than PD [29].
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Limitations
Some study limitations warrant caution. First, certain APDs, such as amantadine, 
apomorphine, COMT inhibitor and selegiline, were not taken into account in 
this investigation, since either Italian National Health System does not reimburse 
them or, alternatively, these medications are directly dispensed in hospital setting. 
In both cases, prescriptions of these medications cannot be retrieved through a 
general practice database. Second, we used outpatient prescription data and we 
had no information whether the APD prescriptions were actually ﬁ lled and taken. 
Th is limitation should be taken into account since approximately half of the drugs 
prescribed for people with chronic conditions are not actually taken [35]. Th is 
investigation provides new insight into the APD prescribing pattern in a large 
Local Health Unit of Southern Italy. Th erefore, data may not exactly reﬂ ect other 
Countries or an Italian national trend. Nevertheless, previous investigations [23-
25] seem to support comparability and reliability of data derived from this general 
practice database in conducting drug utilization studies. A further nationwide 
study might be performed to evaluate the APD prescribing pattern by geographi-
cal area in Italy.
In conclusion, the study ﬁ ndings highlight that L-Dopa is strikingly the most 
widely used anti-parkinson drug in general practice in Southern Italy, in spite of 
the fact almost 15 of users receive only one prescription. On the other hand, 
a progressively increasing use of both ergot and non-ergot derivative dopamine 
agonists has been reported, particularly in older people, during the last years. 
More attempts should be tried to achieve a widespread diﬀ usion of treatment 
guidelines on Parkinson’s disease and other extrapyramidal disorders also among 
general practitioners.
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To the Editor:
Dopamine agonist (DA) agents are widely prescribed in the treatment of Parkin-
son’s Disease (PD). In the last years, some concerns have been raising about the as-
sociation between the use of pergolide, an ergot-derived DA, and the development 
of ﬁ brotic valvular heart disease, particularly, when it is administered at high doses 
over long periods [1]. Recently, two epidemiologic investigations have shown that 
also another ergot-derived DA, cabergoline, would be associated with an increased 
risk of heart valvular ﬁ brosis [2-3]. Both ergot derived DAs would induce ﬁ brotic 
valvular damage through preferential activation of the 5-hydroxytryptamine 2B (5-
HT2B) receptor expressed on heart valves, thus inducing a prolonged mitogenic 
eﬀ ects in cardiac ﬁ bromyoblasts [4]. On the other hand, such a risk would not be 
increased among patients treated with other Ergot derived DA (bromocriptine and 
lisuride) and DA that are not ergot derived (pramipexole and ropinirole), since 
these medications have respectively antagonistic properties and low aﬃ  nity to the 
human 5-HT2B receptor [5]. In light of these new scientiﬁ c evidences, clinicians 
who decide to start a therapy with ergot-derived DAs in patients with PD should 
pay more attention to concomitant cardiovascular diseases. To characterise the 
users of both ergot and not ergot-derived DAs in clinical practice, with particular 
regard to cardiovascular diseases, we carried out an analysis using a general practice 
database of Caserta-1 Local Health Unit. Such a database contains all antiparkin-
son drug prescriptions ﬁ lled by GPs or by specialists in the catchments area of 
Caserta. Indeed, outpatients receiving prescriptions in the public or private sector 
by specialists get the medicines free of charge through GP prescriptions in Italy. 
Among almost 120,000 subjects registered in the lists of 93 general practitioners 
enrolled in this database, we selected one-year incident users of ergot- (cabergoline, 
lisuride, pergolide and bromocriptine) and not ergot-derived DA (pramipexole 
and ropinirole) that were aﬀ ected by PD during the years 2004-2005. Incident 
users were deﬁ ned as patients receiving at least one DA prescription in the years 
2004 or 2005 without any DA prescription recorded in the previous year. Within 
study sample, we identiﬁ ed all diagnoses of cardiovascular (CV) disease and CV 
medication prescriptions that were registered prior to the ﬁ rst prescription date of 
ergot and not ergot-derived DA users. Data on prescriptions and clinical diagnoses 
are recorded into this database starting from 2002. Th erefore, at least two years of 
observational time prior to ﬁ rst DA prescription date was available to deﬁ ne and 
characterise all incident users. Overall, 144 and 102 patients with PD that started a 
therapy with ergot and not ergot-derived DA, respectively, were identiﬁ ed during 
the study years. Demographic and clinical characteristics of DA agonist users are 
reported in Table 1. Our ﬁ ndings show that almost 70 of incident users of Ergot 
derived DA are older than 65 years (despite this percentage is lower than Not-
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Ergot derived DA users), in contrast with international guidelines [6]. Th e burden 
of CV diseases appears to be a clinically relevant issue in DA users, as expected. 
However, a higher proportion (20) of Ergot derived DA users are aﬀ ected by 
more than 3 concomitant CV diseases than Not Ergot derived users (8). In 
particular, patients who start a therapy with Ergot DAs are more likely (p < 0.05) 
to be aﬀ ected by heart failure, compared to Not Ergot users. Th e occurrence of 
valvular heart disease due to ergot derived DA use might dramatically worsen the 
clinical conditions in patients with heart failure [7]. In line with these results, a 
signiﬁ cantly higher proportion (p < 0.05) of patients starting a treatment with 
Ergot-derived DAs concomitantly received 3 or more cardiovascular medications, 
compared to Not Ergot derived DA users. Overall, incident users of Ergot derived 
Characteristics of Ergot and Not Ergot derived Dopamine agonist users (at least 1 prescription) with Parkinson’s disease during the study years
Variables
Ergot derived DA
N= 144 (%)
Non-Ergot derived DA
N= 102 (%)
Median age, years 73.0 71.5
Age groups
<65 years 47 (32.6) 25 (24.5)
≥ 65 years 97 (67.4) 77 (75.5)
Gender (%)
Males 64 (44.4) 52 (51.0)
Females 80 (55.6) 50 (49.0)
Cardiovascular (CV) disease^:
None 51 (35.4) 32 (31.4)
1 disease 34 (23.6) 37 (36.3)
2 diseases 30 (20.8) 24 (23.5)
≥ 3 diseases 29 (20.1) 9 (8.8)
Hypertension 80 (55.6) 62 (60.8)
Coronary heart disease 32 (22.3) 15 (14.7)
Peripheral arterial disease 14 (9.7) 7 (6.9)
Cardiac arrhythmias 14 (9.7) 5 (4.9)
Heart failure 15 (10.4) 2 (2.0)
Concomitant CV medications^: Number
None 48 (33.3) 23 (22.5)
1 drug type 16 (11.1) 26 (25.5)
2 drug types 20 (13.9) 18 (17.6)
≥ 3 drug types 60 (41.7) 35 (34.3)
Concomitant CV medications^: Type
Digoxin 19 (13.2) 5 (4.9)
Anti-hypertensive medications 86 (59.7) 64 (62.8)
Lipid-lowering drugs 22 (15.3) 15 (14.7)
Vasodilators 29 (20.1) 12 (11.8)
Platelet aggregation inhibitors 67 (46.5) 46 (45.1)
Legend: Ergot derived DA (dopamine agonists)= cabergoline =121 (84.0%), pergolide=4 (2.8%), lisuride=6 (4.2%), and bromocriptine=13 
(9.0%); Not Ergot derived DA = ropinirole and pramipexole. ^ Prior to the fi rst prescription date. Chi-Square test for categorical variables, 
with a signifi cance level of p<0.05, was used for assessing the diff erences among users of Ergot and Not-Ergot derived DAs.”
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DA (almost 85 of these being cabergoline users) seem to have a more severe 
cardiovascular proﬁ le, compared to Not Ergot derived DA users. Th is ﬁ nding 
should be considered in light of the warning on the heart valvular ﬁ brosis risk 
associated with Ergot DA use in PD patients.
Clinicians should evaluate the burden of cardiovascular disease of PD patients 
before starting therapy with ergot derived dopamine agonists, in order to prevent 
further cardiovascular damage.
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ABSTRACT
Objectives: To assess the association between ergot and non-ergot derived dop-
amine agonists (DAs) and newly diagnosed cardiac valve regurgitation in patients 
with Parkinson’s disease.
Methods: New users of DAs or levodopa (L-Dopa) for Parkinson’s disease were 
identiﬁ ed from THIN (UK), Health Search-Th ales (Italy), and IPCI (NL) gen-
eral practice databases between 1996 and 2007. Cases of newly diagnosed valve 
regurgitation were detected and validated by an expert panel, blinded to exposure 
status. Crude incidence rates have been calculated for each drug class. A nested 
case-control design was used to assess the association between use of DAs and the 
outcome. All eligible controls were matched to the cases on age, gender, index date 
and database. Relative risks for current users of either ergot or non ergot derived 
DA were compared to L-Dopa use. Adjusted relative risks were estimated as odds 
ratio (OR) using conditional logistic regression, while adjusting for covariates 
univariately associated with the outcome.
Results: Th e study population included 8,451 and 10,306 new users of DAs or 
L-Dopa, respectively. During follow-up, 85 deﬁ nite cases were identiﬁ ed. Crude 
incidence rates were 29.7 (20.1-42.3), 13.1 (8.6-19.1), and 12.3 (8.6-17.1) per 10,000 
person-years for patients starting on ergot-, non-ergot derived DA and L-Dopa, 
respectively.
Compared to L-Dopa use, use of ergot-derived DAs was associated with a 
signiﬁ cantly increased risk of newly-diagnosed valve regurgitation (OR: 4.44; 
95CI: 2.43-8.10). Th is increase in risk was observed for cabergoline (OR: 5.10; 
95CI: 2.67-9.76) and pergolide use (OR: 4.04; 95CI: 1.53-10.72), and in those 
exposed longer than 6 months.
Conclusions: Use of either pergolide or cabergoline for more than 6 months 
was associated with an increased risk of newly diagnosed valve regurgitation in 
patients with Parkinson disease. Th ere was no evidence for an increased risk with 
the use of non-ergot derived DAs.
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INTRODUCTION
Th e prevalence of Parkinson’s disease (PD) in persons above 65 years is 1.8 in 
Europe [1]. To date, Levodopa (L-Dopa) is the most eﬀ ective drug for the treat-
ment of Parkinson’s disease [2]. In the last decade, however, dopamine agonists 
(DAs) have been increasingly used as monotherapy in early PD to delay the start 
of L-Dopa treatment [3-4]. Other indications for use of DAs include hyperpro-
lactinemia and restless leg syndrome.
Since 2002, a number of case reports of ﬁ brotic valvular heart disease during 
the use of the ergot-derived DA pergolide were published, particularly for high 
dose and longer duration of pergolide use [5-9]. On echocardiography, patients 
had mild to severe cardiac valve regurgitation, often involving more than one 
valve [10-12]. Several cross-sectional echocardiographic studies in patients with 
Parkinson’s disease showed that the prevalence of valve regurgitation was higher in 
patients who were treated with ergot derived DAs (see Appendix). Schade was the 
ﬁ rst to look at symptomatic/diagnosed valve problems on a large scale in the UK 
General Practice Research Database by conducting a nested case-control study in a 
large UK electronic medical record database [13]. As a consequence of the growing 
evidence on the risk of cardiac valve regurgitation pergolide was withdrawn from 
the US market, while in Europe cabergoline as well as pergolide are now second 
line treatment for Parkinson’s disease [14]. Fibrotic heart valve damage is thought 
to occur through preferential activation of serotonin 5-HT2B receptor expressed on 
heart valves [15]. Cabergoline and pergolide are potent agonists of these receptors, 
which may explain the observed eﬀ ect on valves. However, mitral tenting and 
valvulopathy have also been occasionally observed with non-ergot DAs [12,17] 
as well as with ergot DAs that are only partial agonists of 5-HT2B receptors (e.g., 
bromocriptine) [18]. Previous epidemiologic [13, 19-21] and echocardiographic 
studies [14] showed that ergot-derived dopamine agonists are associated with 
cardiac valve regurgitation but they lacked the power and exposure variability to 
examine multiple individual dopamine agonists.
Th e aim of our study was to determine the comparative risks of newly diagnosed 
valve regurgitation associated with ergot and non-ergot derived DAs in a cohort of 
patients treated for Parkinson’s disease.
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METHODS
Data Sources
To gain statistical power and heterogeneity in exposure, for this study we combined 
data from three diﬀ erent European population-based general practice databases, 
which are described below.
The Health Improvement Network (THIN)
THIN is a database of electronic primary care medical records from the United 
Kingdom. General practitioners are trained to record their medical records using 
a dedicated computer system. Data recorded in THIN include demographics, de-
tails from general practitioner’s visits, such as medical diagnoses and prescriptions 
(with BNF-code and MULTILEX code), diagnoses from specialist referrals and 
hospital admissions that are recorded using READ codes or free text, laboratory 
tests, and lifestyle characteristics, with electronic medical records that date back to 
1985. Currently, the database has 2.7 million active patients registered within 358 
participating practices. Data from THIN have been demonstrated to be valid for 
pharmacoepidemiology research and undergo diﬀ erent levels of quality control 
[22]. Th e Ethical committee (MRec) approved this study protocol.
Health Search-Thales Database (HSD)
Th e HSD is an Italian database of electronic primary care medical records. It was 
established in 1998 by the Italian College of General Practitioners. HSD currently 
contains data from computer-based patient records from over 900 GPs (cover-
ing a total of around 1.600,000 patients) located throughout Italy. Th ese GPs 
voluntarily agreed to collect data for the database and attend speciﬁ c training 
courses. Th e database includes information on the age and gender of the patient, 
and drug prescription information, clinical events and diagnoses, hospital admis-
sion, and causes of death. All diagnoses are coded according to the International 
Classiﬁ cation of Diseases, 9th Revision, Clinical Modiﬁ cation (ICD-9 CM). Drug 
names are coded according to the anatomical therapeutic chemical (ATC) clas-
siﬁ cation system. To be included in the study, GPs must meet standard quality 
criteria pertaining to: levels of coding, prevalence of well-known diseases, and 
mortality rates. Th e HSD complies with European Union guidelines on the use 
of medical data for research. Th e HSD has been the data source for a number of 
peer-reviewed publications on the prevalence of disease conditions, drug safety 
and prescription patterns in Italian primary care [23-24]. Approval for use of data 
was obtained from the Italian College of Primary Care Physicians.
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Integrated Primary Care Information (IPCI)
Th e IPCI database is a longitudinal general practice research database set up in 
1992 and containing data from electronic medical records from a group of 360 
Dutch general practitioners (GPs). In the Netherlands, all persons have their 
own general practitioner who serves as the gatekeepers to medical care and ﬁ les 
all relevant medical details on their patients from primary care visits, hospital 
admissions and visits to outpatient clinics. Details of the database have been 
previously described [25]. Brieﬂ y, the database contains the medical records of ap-
proximately 1,000,000 patients with an age and gender distribution representative 
of the Netherlands. Th e electronic records contain coded and anonymous data 
on patient demographics, reasons for visits (in free text), signs and symptoms, 
diagnoses (using the International Classiﬁ cation for Primary Care [26] and free 
text) from general practitioners and specialists, referrals, hospitalizations, as well 
as drug prescriptions, including product name, ATC classiﬁ cation, dispensed 
quantity, dosage regimen and indication. To maximize completeness of the data, 
general practitioners participating in the IPCI project are not allowed to maintain 
a system of paper-based records, aside from the electronic medical records. Th e 
system complies with European Union guidelines on the use of medical data for 
medical research and has been proven valid for pharmaco-epidemiological research 
[27]. Th e Scientiﬁ c and Ethical Advisory Board of the IPCI project approved the 
study.
Study population
Th e study population comprised all individuals from the three databases, who had 
at least one year of valid data and who received a ﬁ rst prescription for a dopamine 
agonist or levodopa for the treatment of Parkinson’s disease. All individuals were 
followed from the date of study entry (ﬁ rst prescription of the study drug starting 
from January 1st, 1996) until one of the following events, whichever came ﬁ rst: 
newly diagnosed valvulopathy (valve regurgitation, stenosis or prolapse or mixed 
valve disorder), death, moving out of the practice area, last data drawdown, or 
end of the study period (December 31st, 2007). Occurrence of valve stenosis or 
prolapse during the follow up was considered as a censoring factor as valve regur-
gitation could no longer be reliably assessed in these patients. From the cohort 
we excluded all persons, who at any time prior to the study entry, were diagnosed 
with rheumatic heart disease, congenital heart disease, dilated or hypertrophic 
cardiomyopathies, arrhythmogenic right ventricular cardiopathy, pericardial, 
pleural, pulmonary or retroperitoneal ﬁ brosis, endocarditis, myocarditis, or car-
cinoid syndrome, or who had been treated with fenﬂ uramine, dexfenﬂ uramine 
or amiodarone. Th ese drugs are known to potentially induce ﬁ brotic reactions 
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[28-29]. All patients with a history of cardiac valve replacement or valvulopathy 
prior to study entry were excluded as well.
Case ascertainment and validation
Th e primary study outcome was newly diagnosed cardiac valve regurgitation. 
Th e case identiﬁ cation and ascertainment process included three phases. First, we 
identiﬁ ed all potential cases within the cohort by searching on diagnosis codes and 
free text in the electronic medical records. Second the electronic medical records 
for all potential cases were manually reviewed by two medical doctors to exclude 
obvious false positive cases (KV and GT). For the remaining potential cases from 
all the three databases additional information (i.e. GP’s conﬁ rmation, specialist 
letters or additional free text) was requested.
Th ird, a representative sample of the potential cases was judged as either case or 
no case by an endpoint adjudication committee which included six expert medical 
doctors (GT, RS, GB, MM, GM, AC and WH). Th is committee developed a 
validation algorithm which was applied independently by two medical doctors. 
Case validation was based on careful manual review of the entire clinical diary 
and additional free text plus specialist and discharge letters. Cases were considered 
deﬁ nite if the diagnosis of cardiac valve regurgitation was clearly mentioned and 
conﬁ rmed by echocardiography or cardiac catheterization or if it was reported by 
a specialist. In case of disagreement in the case validation, consensus was reached 
through discussion. If cases of unspeciﬁ ed valvulopathy or cardiac valve replace-
ment were identiﬁ ed and further information to validate the case was missing, 
the case was classiﬁ ed as not assessable. Th e endpoint adjudication committee 
deﬁ ned the primary index date as the date of ﬁ rst diagnosis of valve regurgitation. 
A secondary index date was deﬁ ned as the ﬁ rst date of related symptoms (dyspnea, 
edema, syncope, arrhythmia, or chest pain). Blinding to exposure was guaranteed 
throughout the entire validation process. For the nested case control analysis each 
case was matched to all eligible controls within the study cohort in the respective 
database with the same age (±2 year) and sex. Controls were assigned the same 
primary and secondary index date as the case.
Exposure
We included in the study new users of either L-Dopa or DAs. New users of DAs 
were further classiﬁ ed as ergot-derived (pergolide, cabergoline, bromocriptine, 
lisuride and dihydroergocryptine mesylate) or non-ergot derived (pramipexole, 
ropinirole, apomorphine) compounds. Piribedil, rotigotine, metergoline, quina-
golide were rarely or not used at all for the treatment of PD in the study cohort. 
New users of L-Dopa, alone or combined with a decarboxylase inhibitor, had not 
Gianluca BW.indd   206 25-May-09   11:23:47 AM
207
Anti-Parkinson drugs in elderly: use and safety
been treated with DAs anytime prior. Since L-Dopa has never been associated 
with an increased risk of valve regurgitation, L-Dopa users served as a reference 
cohort to calculate the background incidence rate of cardiac valve regurgitation in 
patients with PD. Th e start of DA use in L-Dopa users was considered as a censor-
ing factor to avoid overlapping person time between the two cohorts. Information 
on DA or L-Dopa use was obtained from the prescription ﬁ les of the respective 
databases. We calculated the legend duration by dividing the total number of 
units per prescription by the prescribed daily number of these units (IPCI/THIN) 
or the deﬁ ned daily dose (HSD). Th e ﬁ rst type of drug at cohort entry was used 
for calculation of incidence rates. To estimate the association between study drugs 
and cardiac valve regurgitation in the nested case control analysis, we created 
exposure categories based on drug type, timing and duration of use. Drug use was 
deﬁ ned as current if the prescription duration covered the index date or ended 
≤180 days (to account for the carry-over eﬀ ect) prior [13]. Drug use was classiﬁ ed 
as past if the last prescription ended more than 180 days prior to the index date. 
Among current users of study drugs, we studied the risk of valve regurgitation 
for the most widely prescribed compounds, by diﬀ erent dose (<0.5, 0.5-1 and >1 
deﬁ ned daily dosage) and cumulative durations of use (≤ 6 and > 6 months). We 
considered the deﬁ ned daily dosages (DDDs), as deﬁ ned by the World Health 
Organization (see website: http://www.whocc.no/atcddd/indexdatabase/). As in 
the HSD there was no information on the dosing regimen, this database could not 
be used for the assessment of the eﬀ ect of dose.
Covariates
As potential confounders, we considered age, sex, database and calendar time 
(matching factors), presence of cardiovascular disease (heart failure, hypertension, 
coronary heart disease, history of cerebrovascular disorders, peripheral arterial dis-
ease, aortic aneurysm, arrhythmias, venous thromboembolism), autoimmune dis-
orders (rheumatoid arthritis, systemic lupus erythematosus, inﬂ ammatory bowel 
disease and others), and other chronic diseases, such as dementia, gastrointestinal 
disorders, chronic obstructive pulmonary disease (COPD), chronic renal failure, 
diabetes mellitus, obesity, and lipid metabolism disorders. We also considered the 
use of anti-Parkinson drugs other than L-Dopa and DAs (selegiline, amantadine, 
tolcapone, entacapone, and anticholinergic drugs).
To describe the characteristics of the two study cohorts, all covariates were 
assessed prior to study entry (ﬁ rst prescription of either L-Dopa or DA). In the 
nested case control analysis, covariates were assessed prior to the index date (date 
of newly diagnosed valve regurgitation).
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Data analysis
For each database we described and compared demographic and clinical charac-
teristics of DA and L-dopa users at study entry by using chi-square tests or t-tests 
for categorical and continuous variables, respectively. Patient characteristics were 
also compared between databases in order to evaluate baseline diﬀ erences. For 
each database and each study drug we measured follow-up time, expressed as 
person-years (PYs). An intention to treat analysis was carried out to estimate the 
crude incidence rate of valve regurgitation in each study cohort, and for ergot 
and non ergot DAs separately, considering the ﬁ rst drug being used during the 
entire study period (i.e. not censored for treatment switch or discontinuation). 
Relative risks of cardiac valve regurgitation were estimated by calculating odds 
ratios (OR) using conditional logistic regression analysis, while adjusting for all 
covariates that were associated signiﬁ cantly (p <0.10) with the study outcome 
in the univariate analysis. ORs (plus 95 conﬁ dence intervals [CIs]) were cal-
culated for current use of DAs altogether and for ergot and non-ergot derived 
DAs separately, compared to any use of L-Dopa (current and past use together). 
We chose this comparator under the assumption that the risk does not diﬀ er 
between current and past use of L-Dopa. Among current users we tested the linear 
trend across the products ranked on their aﬃ  nity for the 5-HT2B receptor (from 
highest to lowest: cabergoline, pergolide, apomorphine, pramipexole, ropinirole 
and L-Dopa), by including 5-HT2B receptor aﬃ  nity as an ordinal variable in the 
conditional logistic regression model. Bromocriptine that has agonistic as well as 
antagonistic eﬀ ects (partial agonist) and lisuride that is an antagonist were not 
included in this analysis [16]. To inspect the eﬀ ect of diagnostic suspicion bias 
that might have resulted in diﬀ erential work up of exposed cases after the alert 
on the risk of cardiac valve regurgitation with pergolide use that was published 
in 2003, we conducted a subgroup analysis including only cases and controls for 
whom the diagnosis (primary index date) was made before September 2003. Since 
patients with cardiac disease who undergo frequent examinations may have more 
opportunity to be diagnosed with valve regurgitation (e.g. myocardial infarction 
history and heart failure) we conducted sensitivity analyses in which patients with 
a history of these diseases were excluded. Other sensitivity analyses have been 
performed to inspect the issues of potential protopathic bias (using the date of 
ﬁ rst related symptom as index date that is the secondary index date) and misclas-
siﬁ cation of exposure (varying the period to account for the carry-eﬀ ect in the 
exposure window from 180 to 365, 90 and 0 days). All analyses were conducted 
in SPSS/PC, version 13 (SPSS Inc, Chicago, Ill). Th e level of signiﬁ cance for all 
statistical tests was 2-sided P < 0.05, unless otherwise speciﬁ ed.
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RESULTS
Th e source population from the three electronic health record databases included 
overall 4,690,813 persons (Figure 1). We identiﬁ ed 35,897 (0.8) patients who 
started a new treatment with either DA or L-Dopa during the study period. From 
this study sample, we then excluded all the patients who were treated for indi-
cations other than Parkinson’s disease (N=15,547, 43.3), or who had prevalent 
cardiac valvulopathy (N=502, 1.4) or at least another exclusion criteria (N=1,098, 
3.1) prior to cohort entry.
Th e ﬁ nal study cohort consisted of 8,451 new users of DAs and 10,306 new 
users of L-Dopa. On average, L-Dopa users were followed for 2.6 years and DA 
users for 3.3 years, with a similar follow up for users of ergot or non-ergot derived 
compounds. As ﬁ rst medication, cabergoline (N=1,172, follow-up=3,478 Person-
Years (PYs)), pergolide (N=711, 3,207 PYs) and bromocripitine (N=272, 1,398 PYs) 
were the most widely prescribed ergot DAs, while pramipexole (N=2,580, 6,552 
PYs), apomorphine (N=1,555, 5,914 PYs) and ropinirole (N=1,893, 5,858 PYs) were 
the most frequently used non-ergot DAs. Th ere were major diﬀ erences in drug 
Figure 1. Selection of incident cases of valve regurgitation in patients with Parkinson’s disease from the source populations
Broad search through codes and 
free text 
35,897 new users of either DA or L-Dopa
Validated cases:
- 85 definite
- 6 not assessable
Source populations: 
479,949 (IPCI) + 2,600,000 (THIN) + 1,610,864 (HSD)= 
4 690 813
158 potential incident 
cases of valve 
regurgitation  
57 excluded cases:
25 stenosis, 16 prolapse and 16 
other causes (history of reumathic 
valve disorder, endocarditis, 
congenital valve disorders) 
Final study 
cohort: 18,757
Manual validation from 
scientific board 
Excluded patients:  
Prevalent cardiac valve disorders: 502
Other exclusion criteria: 1,098 15,547 excluded due to 
indications of use other 
h PD
479,9 9 (IPCI) + 2,600,00  (THIN) + 1,610,8 4 (HSD)= 4,690,813
15,5   due to
indications f use other an PD
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prescribing data between the countries. Apomorphine was almost exclusively used 
in UK (THIN), while ropinirole and pramipexole were extensively prescribed in 
Italy (HSD). Cabergoline was not used for Parkinson’s disease in Th e Netherlands 
(IPCI) since this medication is approved only for the treatment of hyperpro-
lactinemia. Various patient characteristics diﬀ ered signiﬁ cantly between dopamine 
agonist and levodopa users and between the databases (Table 1). New users of DA 
were younger compared to new users of L-dopa (mean ages: 65-73 years versus 
73-81 years), and both DA and L-dopa users were signiﬁ cantly (p<0.05) older in 
Italy than in UK and NL. No diﬀ erences in gender distribution were observed 
between DA and L-Dopa in Italy and NL, while in the UK males were more 
often using dopamine agonists than levodopa (p<0.05). Concerning co-morbidity, 
L-Dopa users were more likely to be aﬀ ected by cardiovascular diseases, such as 
heart failure, hypertension and cerebrovascular disorders, than DA users, and 
signiﬁ cant diﬀ erences in the frequency of co-morbidities were observed across 
the databases. In the study cohort we identiﬁ ed 85 (0.5) deﬁ nite cases of newly 
diagnosed cardiac valve regurgitation (Fig.1, Tables 1-2). Details, on the type and 
the valves that were involved, are reported in Table 1. Six cases were judged as 
non-assessable (lack of additional information) and were therefore not included 
in the analysis. On the basis of the intention to treat analysis, patients who started 
with an ergot-derived DA had a higher crude incidence rate (29.7 per 10,000 PYs) 
of valve regurgitation, compared to patients starting on either L-dopa (12.3 per 
10,000 PYs) or non-ergot derived DAs (13.1 per 10,000 PYs). Th is diﬀ erence was 
consistent across the databases, although the absolute rates diﬀ ered (Table 2).
Case control analysis
A total of 6,362 controls could be matched to the 85 cases of valve regurgitation by 
age (±2 years), gender, database and index date. Th e mean age of the cases was 85. 
Cases had more cardiovascular diseases than controls. However, only arrhythmias 
and hypertension were univariately (p< 0.10) associated with cardiac valve regur-
gitation. In the pooled analysis, as compared to persons using L-Dopa, the risk of 
cardiac valve regurgitation was signiﬁ cantly increased among patients who were 
currently exposed to ergot-derived DA (adjusted OR: 4.44; 95 Conﬁ dence Inter-
val: 2.43-8.10), but not in those exposed to non-ergot derived DA (adj. OR: 1.32; 
95 CI: 0.70-2.52) (Table 3). Th e risk was strikingly higher in patients who were 
cumulatively exposed to ergot-derived DAs for 6 months and more (adj. OR: 6.58; 
95 CI: 3.37-11.84) (Table 4). No signiﬁ cant diﬀ erences in the prescribed daily 
dose (standardized to deﬁ ned daily dose (DDD) units) were observed between 
current users of ergot (mean dosage: 0.93±0.1 DDD) and non-ergot (0.91±0.1 
DDD) derived DAs. Th e risk increased linearly (p<0.001) with increasing dosages 
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Table 1. Characteristics of new users of either dopamine agonist or L-Dopa for Parkinson’s disease in diff erent databases
HSD (Italy) IPCI (Netherlands) THIN (United Kingdom)
DA
N= 4,685 (%)
L-Dopa
N=6,093 (%)
DA
N=232 (%)
L-Dopa
N=447 (%)
DA
N=3,534 (%)
L-Dopa
N=3,766 (%)
Mean age ± SE 72.6 ± 0.2 80.8 ±0.1 66.0 ± 0.9 72.7 ± 0.6 65.0 ± 0.2 76.3 ± 0.2
Gender
Males 2,136 (45.6) 2,759 (45.3) 104 (44.8) 204 (45.6) 2,682 (75.9) 1,992 (52.9)
Females 2,549 (54.4) 3,334 (54.7) 128 (55.2) 243 (54.4) 852 (24.1) 1,774 (47.1)
Potential cases of valve 
regurgitation
54 (1.2) 50 (0.9) 2 (0.9) - 32 (1.0) 22 (0.6)
Validated cases 30 (0.6) 24 (0.5) 2 (0.9) - 23 (0.7) 12 (0.3)
Defi nite 30 22 2 - 20 11
Not assessable - 2 - - 3 1
Defi nite case: N (%)
Type of lesion
Valve regurgitation 30 20 (99.1) 2 (100.0) 18 (90.0) 11 (100.0)
Mixed valve disorder - 2 (0.9) 2 (10.0) -
Valve aff ected
Mitralis 8 (25.8) 3 (13.6) 1 (50.0) 9 (45.0) 7 (63.6)
Aortic 6 (19.4) 5 (22.7) 7 (35.0) 1 (9.1)
Pulmonary - -
Tricuspid 1 (3.2) 2 (9.1) 2 (10.0) 1 (9.1)
More than one valve 15 (50.0) 12 (54.5) 1 (50.0) 2 (10.0) 2 (18.2)
Covariates
Other anti-Parkinson drugs 828 (17.7) 375 (6.2) 64 (27.6) 55 (12.3) 742 (21.0) 512 (13.6)
Cardiovascular co-morbidities
Heart Failure 99 (2.1) 174 (2.9) 7 (3.0) 28 (5.6) 84 (2.4) 204 (5.4)
Coronary heart disease 302 (6.4) 451 (7.4) 9 (3.9) 10 (2.2) 299 (8.5) 259 (6.9)
Hypertension 1,941 (41.4) 2,669 (43.8) 33 (14.2) 83 (18.6) 2,219 (62.8) 2,549 (67.7)
Arrhythmias 239 (5.1) 367 (6.0) 12 (5.2) 23 (5.1) 170 (4.8) 282 (7.5)
History of cerebro-vascular 
disorders
477 (10.2) 944 (15.5) 14 (6.0) 35 (7.8) 298 (8.4) 670 (17.8)
Peripheral arterial disease 42 (0.9) 55 (0.9) 3 (1.3) 6 (1.3) 94 (2.7) 89 (2.4)
Venous thromboembolism 24 (0.5) 48 (0.8) - - 89 (2.5) 121 (3.2)
Aortic aneurism 22 (0.5) 36 (0.6) 2 (0.9) 3 (0.7) 33 (0.9) 37 91.0)
Other co-morbidities
Diabetes 657 (14.0) 1,015 (16.7) 22 (9.5) 54 (12.1) 694 (19.6) 435 (11.6)
Lipid metabolism disorders 870 (18.6) 976 (16.0) 33 (14.2) 52 (11.6) 1,122 (31.7) 864 (22.9)
Obesity 126 (2.7) 103 (1.7) 2 (0.9) 5 (1.1) 168 (4.8) 99 (2.6)
Chronic renal failure 83 (1.8) 145 (2.4) 1 (0.4) 3 (0.7) 28 (0.8) 22 (0.6)
COPD 837 (17.9) 1,008 (16.5) 14 (6.0) 23 (5.1) 768 (21.7) 806 (21.4)
Gastrointestinal disorders 1,264 (27.0) 1,537 (25.2) 57 (24.6) 83 (18.6) 1,105 (31.3) 1,183 (31.4)
Dementia 747 (15.9) 772 (12.7) 2 (0.9) 28 (6.3) 30 (0.8) 205 (5.4)
Autoimmune co-morbidities
SLE 13 (0.3) 14 (0.2) 2 (0.9) - 3 (0.1) 6 (0.2)
RA 31 (0.7) 50 (0.8) 6 (2.6) 13 (2.9) 38 (1.1) 58 (1.5)
IBD 23 (0.5) 27 (0.4) 4 (1.7) 2 (0.2) 34 (1.0) 48 (1.3)
Other autoimmune disorders 234 (5.0) 242 (4.0) 4 (1.7) 5 (1.1) 82 (2.3) 125 (3.3)
Legend: Other anti-Parkinson drugs= amantadine, selegiline, anticholinergic drugs, tolcapone, entacapone; COPD= chronic obstructive 
pulmonary disease; SLE= systemic lupus erythematosus; RA=rheumatoid arthritis; IBD=infl ammatory bowel disease.
Gianluca BW.indd   211 25-May-09   11:23:47 AM
Chapter 4
212
for ergot-derived DA users. However, a signiﬁ cant increase in the risk was reported 
not only for those receiving dosages higher than 1 DDD (13.90; 4.16-46.44), but 
also for those who received dosages lower than 0.5 DDD (6.97; 1.98-24.48). For 
non-ergot derived DAs no such a trend was observed (Table 4).
Considering the individual compounds, the risk of valve regurgitation was sig-
niﬁ cantly increased for users of cabergoline (adj. OR: 5.10; 95 CI: 2.67-9.76) and 
pergolide (adj. OR: 4.04; 95 CI: 1.53-10.72) (Table 3). Th ere was a signiﬁ cant (p 
< 0.001) linear trend between the risk of cardiac valve regurgitation and aﬃ  nity to 
Table 2. Incidence rate (IR) of valve regurgitation per 10,000 Person-Years of follow-up by exposure to dopamine agonist or L-Dopa.
Drug Exposure*
Pooled analysis HSD THIN IPCI
Cases
Follow-up 
(P/Y)
Crude IR
(95% CI)
Crude IR
(95% CI)
Crude IR
(95% CI)
Crude IR
(95% CI)
Dopamine agonist (DA)** 52 27,790
18.7
(14.1-24.3)
19.0
(13.1-25.5)
17.4
(11.0-26.4)
36.7
(7.3-1-17.6)
Ergot derived DA 28 9,437
29.7
(20.1-42.3)
21.4
(12.5-34.5)
52.7
(27.9-91.2)
57.1
(11.4-183.0)
Non-Ergot derived DA 24 18,353
13.1
(8.6-19.1)
17.1
(10.0-27.5)
9.6
(4.7-17.5)
-
L-Dopa
33 26,768
12.3
(8.6-17.1)
13.4
(8.6-19.9)
11.7
(6.2-20.2)
-
Legend: Ergot-derived DA= Cabergoline, pergolide, bromocriptine, dihydroergocryptine mesylate, lisuride, metergoline; Non-ergot-derived 
DA: pramipexole, ropinirole, apomorphine, piribedil, rotigotine, quinagolide.
* Treatment at the cohort entry. ** DA users may have switched to L-Dopa.
Table 3. Risk of valve regurgitation with dopamine agonist use as compared to L-Dopa use
Cases
 N=85 (%)
Controls
 N=6,362 (%)
Crude* OR
(95% CI)
Adjusted** OR
(95% CI)
Current and past use of L-Dopa 33 (38.8) 3,053 (48.0) 1.00 1.00
Current Use^
Ergot derived DA^^ 20 (23.5) 477 (7.5) 3.90 (2.16-7.05) 4.44 (2.43-8.10)
Cabergoline 16 398 4.74 (2.50-8.99) 5.10 (2.67-9.76)
Pergolide 6 106 3.27 (1.26-8.47) 4.04 (1.53-10.72)
Bromocriptine 1 15 1.85 (0.23-15.16) 2.60 (0.31-21.56)
Non Ergot derived DA^^ 16 (18.8) 1,195 (18.8) 1.26 (0.67-2.37) 1.32 (0.70-2.52)
Pramipexole 4 455 1.63 (0.79-3.38) 1.73 (0.83-3.61)
Ropinirole 11 709 0.86 (0.30-2.48) 0.95 (0.33-2.74)
Apomorphine 2 87 2.04 (0.41-10.10) 1.91 (0.37-9.79)
Combination of ergot and non-ergot derived DAs 2 (2.4) 66 (1.0) 3.50 (0.80-15.41) 4.12 (0.93-18.28)
Past use
Ergot derived DA 7 (8.2) 606 (9.5) 1.18 (0.50-2.76) 1.29 (0.55-3.05)
Non-Ergot derived DA 7 (8.2) 947 (14.9) 0.63 (0.25-1.58) 0.65 (0.26-1.63)
Combination of more classes - 18 (0.3) - -
Legend: OR=Odds Ratio, DA=Dopamine agonists, L-Dopa= Levodopa. * Conditional logistical regression analysis (age, sex, database and 
index date as matching factors). ** Adjusted for hypertension and arrhythmias. ^ Current use means use within 180 days before the index date; 
past use means that use ended more than 180 days before. ^^ No mutually exclusive use within the class of Ergot derived DA or Non-Ergot 
derived DA
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the 5HT2b receptor. Th ese ﬁ ndings were conﬁ rmed if the analyses were performed 
in the single databases. IPCI had two cases only and therefore we could not look 
at the analysis limited to this speciﬁ c database. Various sensitivity analyses were 
conducted to look at the robustness of the results. When the ﬁ rst date of speciﬁ c 
symptom was used as the index date, the study results did not materially change 
(current use of Ergot derived DA: OR=5.11; 95 CI=2.61-10.02; current use of non 
Ergot derived DA: 1.10; 0.51-2.38). Patients who had stopped using either ergot 
or non-ergot derived DAs more than six months prior to the diagnosis of valve 
regurgitation (i.e. past users) did not have an increased risk. History of myocardial 
infarction and heart failure were no eﬀ ect modiﬁ ers of the association between 
ergot-derived DA use and valve regurgitation. Exclusion of patients with a his-
tory of myocardial infarction or heart failure yielded similarly increased risks for 
ergot-derived DAs. Varying the exposure risk window to account for potential 
carry-over eﬀ ects did not change the results for ergot derived dopamine agonists. 
Using current use of levodopa as comparator instead of current or past did not 
change the results substantially
Of the 85 case patients with cardiac-valve regurgitation identiﬁ ed in this study, 
4 (4.7) patients were subsequently aﬀ ected by newly diagnosed heart failure, 
while 16 (18.8) died within 2 years from the date of valve regurgitation diagnosis. 
Among the controls, 79 (1.2) subjects were newly diagnosed with heart failure 
and 566 (8.9) died after two years from the index date.
Table 4. Risk of cardiac valve regurgitation for current users of dopamine agonist use compared to levodopa use, stratifi ed by dosage and 
duration
Cases
 N=85
Controls
 N=6,362
Crude RR**
(95% CI)
Adjusted*^ RR
(95% CI)
Current or past use of Levodopa 33 3,053 1.00 1.00
Daily dose eff ect *
Ergot derived DA
<0.5 DDD 5 63 6.27 (1.84-21.34) 6.97 (1.98-24.48)
0.5-1 DDD - 35 - -
> 1 DDD 5 46 11.43 (3.52-37.08) 13.90 (4.16-46.44)
Non-Ergot derived DA
<0.5 DDD 4 228 1.80 (0.52-6.24) 1.81 (0.51-6.42)
0.5-1 DDD 1 82 1.28 (0.16-10.12) 1.41 (0.18-11.26)
> 1 DDD - 130 - -
Duration eff ect
Ergot derived DA
< 6 months 4 194 1.86 (0.63-5.49) 1.95 (0.66-5.73)
6 months or more 16 283 5.42 (2.82-10.43) 6.58 (3.37-11.84)
Non-Ergot derived DA
< 6 months 9 556 1.49 (0.69-3.23) 1.49 (0.68-3.26)
6 months or more 7 639 1.12 (0.48-2.62) 1.26 (0.54-2.99)
*excluding HSD for which the daily dose was not available
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DISCUSSION
Th is multi-country database study found that the use of ergot-derived dopamine 
agonists is associated with an increased risk of incident cardiac valve regurgitation 
among patients with Parkinson’s disease from three diﬀ erent countries. Th e risk 
increased with increasing dosage of ergot-derived dopamine agonists and was most 
pronounced in persons using the drugs for at least six months. Th is increase in risk 
was shown only for cabergoline and pergolide. We did not observe any increase in 
the risk of valve regurgitation for the use of non-ergot derived DAs pramipexole, 
ropinirole and apomorphine, although the odds ratio for Pramipexole was elevated. 
Our ﬁ ndings conﬁ rm previous evidence from case-reports and observational stud-
ies [14]. In a similar way to our study, Schade et al performed a nested case-control 
study, using electronic heath care data from the UK General Practice Research 
Database, and documented a dose-dependent increased risk of cardiac valve regur-
gitation for exposure to cabergoline or pergolide [13]. Our incidence rate of valve 
regurgitation in ergot derived DA users with Parkinson’s disease was similar to the 
estimate from Schade et al (30 per 10,000 PYs). Th is rate contrasts with the high 
prevalence rates reported from cross sectional echocardiographic studies. In these 
studies 1 of patients with Parkinson’s disease taking ergot-derived DA had severe 
valvulopathy [14]. Th e diﬀ erence may be explained by the fact that many patients 
with valvulopathy remain without symptoms and do not get diagnosed quickly 
[14]. Most of the previously performed studies included only a small number of 
patients and explored the eﬀ ect of a limited number of DAs. By combining the 
data from three diﬀ erent databases in three diﬀ erent countries, we could better as-
sess the comparative risk of valve regurgitation for individual ergot and non-ergot 
DAs and rank on the basis of receptor aﬃ  nity. Th ere are mechanistic grounds to 
believe that not all DAs are equally likely to play a role in the development of 
cardiac valve regurgitation. Preferential activation of the 5-hydroxytryptamine 2B 
(5-HT2B) receptor, which is expressed on heart valves, has been shown to induce 
prolonged mitogenic eﬀ ects in cardiac ﬁ bromyoblasts, thus potentially leading to 
heart valve ﬁ broplasia and regurgitation [15-16]. In line with this hypothesis, we 
found an increased risk of valve regurgitation only for pergolide and cabergoline 
which are both potent agonists of the 5-HT2B receptor [30]. Patients who had 
stopped using ergot derived DAs more than 6 months prior to the diagnosis of 
valve regurgitation were not associated with an increased risk of valve regurgita-
tion in our study. According to this ﬁ nding, the eﬀ ect of ergot DAs on the valve 
regurgitation may be reversible, as previously suggested [5,7,9].
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Strengths and limitations of the study
Th e strength of this study was the availability of a large amount of data drawn 
from three electronic health record databases from three diﬀ erent countries. Th ese 
data sources oﬀ ered us the opportunity to take into account the heterogeneity 
of diﬀ erent populations and diﬀ erent prescribing patterns of DAs in a cohort of 
patients with Parkinson’s disease. Furthermore, it allowed us to evaluate the eﬀ ect 
of individual ergot and non-ergot derived DAs on the risk of valve regurgita-
tion. However, some possible limitations warrant cautious interpretation of the 
results. As for all observational studies, selection bias, information bias due to 
misclassiﬁ cation of outcome or exposure, and residual confounding should be 
considered as alternative explanations for our study ﬁ nding. Selection bias was 
minimal as all data were obtained from prospectively collected medical records 
that are maintained for patient care purposes, irrespective of any research question. 
Diagnostic suspicion bias could be of concern, since pergolide was discussed as a 
possible cause of cardiac valvulopathy before the end of the study period. Th e Brit-
ish Committee on Safety of Medicines published an alert on pergolide-associated 
valvulopathy in September 2003 [31] and this alert may have led to an increased 
use of diagnostic measures in patients receiving pergolide and other ergot derived 
DAs in order to detect valvulopathies. To investigate this potential source of bias, 
we conducted a subgroup analysis involving only 28/85 (32.0) patients in whom 
cardiac valve regurgitation had been diagnosed before September 2003. Th is 
analysis did not substantially change our results. Likewise, diﬀ erential work up 
and detection probability can be expected in patients with heart failure or a history 
of myocardial infarction since they are more likely to receive an echocardiographic 
test. We demonstrated however that exclusion of these cases did not alter the study 
ﬁ ndings. Misclassiﬁ cation of exposure may have occurred due to non-compliance, 
despite the fact that all the study medications are on prescription basis only and 
entry into the cohort was based on a prescription. However, this misclassiﬁ cation 
is likely to be non-diﬀ erential and would therefore lead to underestimation of the 
true eﬀ ect. We may have missed specialist prescribed medication but the extent of 
this is likely to be equal for all Parkinson drugs. Finally exposure misclassiﬁ cation 
may have occurred because of incorrect exposure window and errors in the index 
date. Sensitivity analyses in which we varied the exposure window did not substan-
tially change the results. Notably, deﬁ ning the date of ﬁ rst symptoms as the index 
date rather than the date of diagnosis tended to make the results even stronger. 
Misclassiﬁ cation of the outcome may have occurred due to lack of inclusion of 
false negative (undiagnosed cases with valve regurgitation) or inclusion of false 
positive cases. Th e eﬀ ect of the false negatives (inclusion as controls) is probably 
limited since the prevalence of severe valvulopathy is 1 in users of anti-Parkinson 
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drugs. Th e eﬀ ect of false positives is considered to be limited due to the extensive 
case validation process. Th e eﬀ ect of false positives is considered to be limited due 
to the extensive case validation process. Unmeasured confounding can never be ex-
cluded, though it is unlikely that strong risk factors for cardiac valve regurgitation 
may have gone undetected. Th erefore, the strong eﬀ ect of ergot derived DA that 
was observed in our study is unlikely to be explained by unmeasured or residual 
confounding. Finally, there was heterogeneity in the prevalence of co-morbidity 
between the databases due to diﬀ erences in coding schemes and health care struc-
ture. Th e association between valve regurgitation and ergot derived dopamine 
agonists was highest in UK and NL (despite limited number of exposed case) and 
lowest in Italy, but it was consistently documented in all databases. Future research 
should speciﬁ cally explore the risk of valvular regurgitation in association with the 
use of individual ergot-derived DAs in patients with hyperprolactinemia, who are 
treated at much lower dosages than patients with Parkinson’s disease. Only few 
echocardiographic studies, including a limited study sample, have been conducted 
in these patients so far. All of them reported no increase in risk for clinically 
relevant valvulopathy with pergolide or cabergoline use in patients with prolac-
tinoma or other endocrine diseases [32-37]. A recent echocardiographic study 
documented an increased risk of valvulopathy in users of bromocriptine. We only 
identiﬁ ed one case and 15 controls that were currently exposed to bromocriptine. 
Although we pooled data from three diﬀ erent electronic medical record databases, 
our study was probably underpowered to detect any eﬀ ect for bromocriptine, and 
therefore an increase in the risk also for this drug cannot be excluded, as recently 
documented in an echocardiographic study [38].
In conclusion, our study shows that treatment with either pergolide or caber-
goline was associated with a dose and duration dependent increased risk of newly 
diagnosed valve regurgitation in patients with Parkinson disease. Th ere was no 
evidence of such an increase in risk with the use of non ergot derived dopamine 
agonists.
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APPENDIX
Publications of observational investigations on the risk of valve regurgitation in 
association with dopamine agonist use in patients with Parkinson’s disease.
First author, 
journal, year*
Study Design Outcome Exposure Main fi ndings
Steiger M1,
J Neural Transm, 
2009
Systematic review Cardiac valve 
regurgitation
Pergolide, cabergoline, and 
non-ergot-derived DA in 
PD patients
The use of ergot-derived 
DAs in patients with PD was 
associated with increased risk 
for cardiac valve regurgitation
Oeda T2,
J Neural Transm, 
2009
Nested case control 
study
Valvular heart disease Ergot-derived dopamine 
agonists
Use of pergolide or 
cabergoline is an independent 
risk factor for developing 
valvular heart disease
Tan L3,
Movement 
Disorders, 2009
Echocardiographic
study
Valvular heart disease Use of bromocriptine The risk of both mild 
regurgitation and moderate-
severe regurgitation was 
increased with increasing 
cumulative dose of 
bromocriptine
Yamashiro K4,
Movement 
Disorders, 2008
Echocardiographic 
study
Cardiac valve 
regurgitation
Low dose dopamine 
agonists
The frequency of mild or 
above mild regurgitation 
of the aortic valve was 
signifi cantly higher in the 
cabergoline group
Rasmussen VG5,
J Inter Med, 2008
Echocardiographic 
study
Valvular regurgitation Ergot and non-etgot 
derived DA use in PD
Ergot derived DA was 
associated with moderate 
valve regurgitation
Zadikoff  C6,
Can J Neurol Sci, 
2008
Retrospective, 
population-based 
cohort study
Hospital admissions 
for VHD or HF
Pergolide use in PD Pergolide is associated with 
a higher risk of hospital 
admission for VHD or HF, 
particularly with 1-4 years 
treatment
Zanettini R7,
NEJM, 2007
Echocardiographic 
study
Valvular regurgitation Pergolide, cabergoline, and
non–ergot-derived DA in 
PD patients
Pergolide and cabergoline 
are associated with clinically 
important valve regurgitation
Corvol JC8,
Archives Neurology, 
2007
Echocardiographic 
study
Moderate to severe 
regurgitation
Pergolide use in PD 
patients for longer than 
three months
Pergolide use in PD patients 
is associated with valve 
regurgitation and correlates 
with cumulative dose
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Simonis G9,
Movement 
Disorders, 2007
Meta-analysis of 
observational studies
Heart valve disease Ergot and non-etgot 
derived DA use in PD
Valvular heart disease occurs 
not only in patients treated 
with pergolide, but also 
in patients treated with 
cabergoline at a comparable 
frequency
Schade R10,
NEJM, 2007
Nested case control 
study, using GPRD
Newly diagnosed 
cardiac-valve 
regurgitation
Levodopa, romocriptine, 
cabergoline, pergolide, 
lisuride, pramipexole, and 
ropinirole
Pergolide and cabergoline are 
associated with an increased 
risk of newly diagnosed 
cardiac-valve regurgitation
Dewey RB11,
Arch Neurol, 2007
Echocardiographic 
study
Valve functionality 
score
Pergolide vs non-ergot DA 
use in PD
Pergolide contributes to 
cardiac valve regurgitation as 
long term use for PD.
Kenangil G12,
Clinical Neurology 
and Neurosurgery, 
2007
Echocardiographic 
study
Valvular regurgitation Cabergoline and pergolide 
use in PD patients
Ergot derived DA are 
associated with moderate 
valvular regurgitation
Junghanns S13,
Movement 
Disorders, 2007
Echocardiographic 
study
Valvular regurgitation Pergolide, cabergoline,
ropinirole, pramipexole 
use in PD
ergot DA is associated with 
higher prevalence of VHD 
compared to non-ergot DA
Kim J14,
Movement disorders, 
2006
Echocardiographic 
study
Valvular thicknesses Bromocriptine and 
pergolide use in PD 
patients
No increase in the frequency 
of valvulopathy with 
bromocriptine or pergolide
Ruzicka E15,
J Neurol, 2006
Echocardiographic 
study
Restrictive valvular 
regurgitation
Pergolide use in PD 
patients
No cases of restrictive
valvular heart disease in PD 
patients treated with
pergolide (3mg per day).
Peralta C16,
Movement 
Disorders, 2006
Echocardiographic 
study
Valvular regurgitation Ergot and non ergot DA use 
in PD patients
No diff erences in valvular 
regurgitation risk between 
ergot and non ergot DA
Yamamoto M17,
Neurology, 2006
Echocardiographic 
study
Valvular 
abnormalities
Ergot and non ergot DA use 
in PD patients
The frequency of valvulopathy 
is increased in the cabergoline 
group
Waller EA18,
Mayo Clin Proc, 2005
Echocardiographic 
study
Valvular heart disease Pergolide use in PD The frequency of aortic 
regurgitation appears to be 
increased in patients taking 
pergolide. This increase may 
be dose dependent.
Baseman DG19,
Neurology, 2004
Echocardiographic 
study
Valvular regurgitation Pergolide use in PD Pergolide may injure cardiac 
valves, resulting most 
commonly in tricuspid 
regurgitation.
Van Camp G20,
Lancet, 2004
Echocardiographic 
study
Restrictive valvular 
heart disease
Pergolide use in PD 
patients
Restrictive valvular heart 
disease is not a rare
fi nding in patients treated 
with pergolide
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GENERAL DISCUSSION
Prescribing of psychotropic drugs to elderly with neuropsychiatric disorders is 
challenging due to limited scientiﬁ c evidence on the eﬀ ectiveness as well as prob-
lematic tolerability and large potential of dug-drug interactions. Rational use of 
psychotropic drugs may improve the quality of life and the functional status of 
elderly patients with neuropsychiatric diseases. However, currently psychotropic 
medications are often misused and overused in these patients [1]. Th e availability 
and secondary use of databases with longitudinal electronic health records of 
millions of persons oﬀ er the opportunity to get better insight into real life psy-
chotropic drug use and the risks and beneﬁ ts of those medications in community 
dwelling elderly persons.
In this chapter, the main ﬁ ndings of this research and the main methodological 
issues of pharmaco-epidemiological studies are discussed to facilitate a proper 
interpretation of the results described in this thesis.
MAIN FINDINGS
Use and safety of antipsychotic drugs in elderly
Typical antipsychotics (sometimes referred to as ﬁ rst generation antipsychotics, 
conventional antipsychotics, or neuroleptics) are a class of psychotropic drugs that 
were developed in the 1950s. Chlorpromazine was the ﬁ rst typical antipsychotic to 
enter clinical use. Typical antipsychotics are used in elderly population to treat acute 
and chronic psychoses, mania, agitation, and other geriatric psychiatric disorders. 
Generally, these medications are divided on the basis of their chemical structure 
into butyrophenones, phenotiazines, and substituted benzamides. Fatal and life-
threatening arrhythmias and severe extrapyramidal adverse events that are a cluster 
of symptoms consisting of akathisia, parkinsonisms, and dystonias represent the 
main limitations on the use of typical antipsychotics in elderly. For this reason, new 
antipsychotics (atypicals) were developed with a supposedly better safety proﬁ le. 
Atypical antipsychotics have been marketed since the 1990s starting with clozapine. 
Th e atypicality of this newer class consists of diﬀ erent eﬃ  cacy in the treatment of 
negative symptoms (i.e. catatonia, apathy) of schizophrenia and the lower risk of 
extrapyramidal adverse events, compared to conventional antipsychotics. For these 
reasons, the use of atypical antipsychotics has been rapidly expanding worldwide, 
particularly in elderly, even for unlicensed indications of use.
We found that the use of atypical antipsychotics increased approximately ﬁ ve 
times between 1999 and 2002 in Italy, mostly because of their increased use in the 
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treatment of behavioral and psychotic disorders of dementia (BPSD). Th is indica-
tion was also the main reason for oﬀ -label use. Th ese ﬁ ndings are in line with 
data from the UK where use of atypical antipsychotics increased nearly six-fold 
between 1997 and 2001 [2]. In the U.S., olanzapine and risperidone were the most 
commonly prescribed antipsychotic drugs, already in 1997 [3].
Safety warnings
Since 2004, regulatory agencies started to release warnings about the potential 
risks of atypical antipsychotics in BPSD in particular. Th e Committee on Safety 
of Medicines (CSM) highlighted a 3-fold increased risk of cerebrovascular events 
in elderly with dementia, who were treated with either risperidone or olanzapine 
in March 2004 [4]. Th is risk was identiﬁ ed from a pooled analysis of placebo-
controlled clinical trials. In April 2005, another warning was issued by the Food 
and Drug Administration (FDA) to inform health professionals about the results of 
a pooled analysis of 17 RCTs reporting a 1.7 times increased risk of all-cause mortal-
ity associated with atypical antipsychotic use in elderly dementia patients [5]. In 
June 2008, the FDA extended this warning also to the typical antipsychotics [6].
Eff ects of safety warning on drug utilization
We and others studied the eﬀ ect of the safety warnings on the utilization of the 
antipsychotics in elderly population. A Canadian study demonstrated that the 
safety alerts had slowed down the increase in prescription of atypical antipsychotic 
drugs in patients with dementia, but it had not changed the overall prescription 
rate of antipsychotics [7]. In our study in Italy, we also demonstrated a signiﬁ cant 
decrease in the use of atypical agents in elderly demented patients between 2003 
and 2005. Like in Canada, the overall prescription rate of antipsychotics was not 
reduced. Haloperidol was the most frequently prescribed antipsychotic to elderly 
patients with dementia in Italy. However, the scientiﬁ c evidence on the eﬃ  cacy 
of this typical antipsychotic in the management of behavioural and psychotic 
symptoms of dementia is controversial [8-9]. In our study more than 3 of the 
community dwelling elderly received at least one antipsychotic drug prescription 
in 2005, and 40 of them were treated for dementia and related disorders. Our 
and the Canadian study indirectly documented the switch between atypical and 
typical antipsychotics, as a result of the safety warnings on cerebrovascular adverse 
events and risk of death that addressed the atypicals initially. Th e eﬀ ect of the 
most recent alerts that concerned the conventional antipsychotics as well should 
be evaluated.
Ongoing randomized clinical trials comparing atypicals and conventional anti-
psychotics will provide more evidence on the best choice in these patients. Mean-
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while observational studies have been done by us and other groups to compare 
the safety risks associated with the atypical and typical antipsychotic use drugs in 
elderly and demented elderly in particular.
Observational safety studies on cerebrovascular events
Following the safety alerts, several observational studies were done to address the 
potential risk of cerebrovascular adverse events associated with antipsychotic use 
in elderly [10-16]. In summary, these studies suggested no diﬀ erence in the risk of 
stroke with atypicals compared to conventional antipsychotics, whereas the risk 
of stroke was higher during use than non-use for both classes. We also conducted 
a retrospective cohort study, comparing the risk of stroke in elderly using either 
conventional or atypical antipsychotics versus non users. For this study we used 
the Health Search/Th ales database, which is an electronic health record database 
that stores medical information on about 1.5 of the total Italian population. 
We demonstrated that the use of any antipsychotic as compared to non-use was 
associated with an increased risk for ﬁ rst-ever stroke. Interestingly, the risk for 
stroke with phenothiazines was two-fold higher than the risk with atypical anti-
psychotic use. Th is ﬁ nding would support a diﬀ erential eﬀ ect across subgroups 
of conventional antipsychotics. In light of this ﬁ nding, the safety of subgroups of 
conventional antipsychotics should be evaluated separately, contrary to what was 
generally done in previous investigations.
Observational safety studies on mortality
Th e increased mortality warning was ﬁ rst launched in 2005; this warning resulted 
in various observational studies. All the studies conﬁ rmed that antipsychotic drug 
use is associated with an increased risk of all-cause mortality compared to non use. 
Conventional antipsychotics have a similar, if not higher risk of mortality than 
atypical agents [17-23].
We conducted a subsequent study to further evaluate the risk of all-cause mor-
tality in association with antipsychotic use. A case control study was conducted 
that was nested in a cohort of elderly demented patients. For this study, we used 
the Integrated Primary Care Information (IPCI) database, which is a Dutch 
electronic health record database containing information from 500 general practi-
tioners distributed all over Th e Netherlands and with a current population of ap-
proximately 1.1 million patients. In a cohort of 2,385 community dwelling elderly 
with dementia, we found no diﬀ erence in the risk of death between atypical and 
typical antipsychotics; however, both antipsychotic classes were associated with a 
signiﬁ cant and dose-related increase in risk of all-cause mortality when compared 
to non-use. Due to the limited sample size of the dementia cohort we did not 
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have enough power to study speciﬁ c causes of death in our study. Th e FDA alert 
mentioned that cerebrovascular events (CVEs), pneumonia and arrhythmias were 
the most frequently reported causes of death in elderly demented patients treated 
with antipsychotic drugs. While the association between antipsychotic drug use 
and cerebrovascular adverse events as well as arrhythmias or sudden cardiac death 
has been extensively explored [24-28], epidemiologic evidence on the risk of fatal 
and non-fatal pneumonia with antipsychotic use in elderly is currently missing. To 
ﬁ ll this gap, we performed a case control study nested in a cohort of community 
dwelling elderly, using data from the IPCI database again but not restricting to 
elderly patients with dementia only to increase the power. In a cohort of 2,560 el-
derly, who were newly treated with antipsychotic drugs, it was shown that the use 
of either atypical or typical antipsychotics was associated with a dose-dependent 
increase in the risk of community acquired pneumonia. According to our ﬁ ndings, 
one case of pneumonia would occur respectively in every 29 patients treated with 
atypical antipsychotics and in every 73 patients who are treated with typical anti-
psychotics. Atypical antipsychotics were also associated with a higher risk of fatal 
pneumonia, despite the limited number of fatal cases that were exposed to atypical 
antipsychotics (N=7) in our study. Although our design was diﬀ erent, the conclu-
sions of our study are in line with those of a previous Dutch investigation [29]. Th e 
possible mechanisms by which exposure to antipsychotics could be associated with 
the development of pneumonia remain speculative. Excessive sedation as a result 
of histamine-1 receptor blocking in the central nervous system is a well-known 
cause of swallowing problems, which could facilitate aspiration pneumonia [30]. 
In line with this hypothesis, our study showed a higher risk of pneumonia for 
atypical antipsychotics and phenothiazines compared to butyrophenones, which 
have the lowest aﬃ  nity for antihistaminergic receptor H1.
Use and safety of antidepressant drugs in elderly
Utilization of antidepressants
SSRIs are currently considered as ﬁ rst-line drugs in the treatment of late-life 
depression, due to similar eﬃ  cacy but more favorable tolerability. Th is has con-
tributed to the increasing use of SSRI in both adults and elderly persons in Europe 
and other countries in the last decade [31-33].
To provide an updated picture on the use of antidepressants, we performed a 
drug utilization study, using the Arianna database. Th is database was set up by the 
Local Health Service of Caserta (Southern Italy) in 2000 and currently contains 
electronic health records from more than 300,000 persons that are registered by 
one of the 225 participating general practitioners. Th e prevalence of antidepres-
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sant drug use increased in all age groups during the years 2003-2004, mostly as a 
result of the increase in use of SSRIs. In 2004, 9.9 of patients aged 65-74, 13.8 
of those aged 75-84, and 12.4 of those ≥ 85 years were treated with antidepres-
sants. SSRIs accounted for about two-thirds of all newly initiated antidepressant 
treatments in the elderly and were mainly prescribed for the treatment of late 
life depression, which is in line with guideline recommendations. We also found 
that newly marketed drugs (such as escitalopram) ranked high in frequency of 
use, which conﬁ rms that new drugs have quick uptake in general practice [34]. 
A substantial proportion of elderly persons received trazodone as ﬁ rst line an-
tidepressant, probably in light of its sedative properties. Th is may raise clinical 
problems in view of the propensity of this antidepressant to cause orthostatic 
hypotension, which is associated with falling, fractures and cerebrovascular events 
in elderly patients [35].
Drug-drug interactions
Both TCAs and SSRIs and other antidepressants carry the risk of pharmacokinetic 
and pharmacodynamic drug-drug interaction (DDI), especially in elderly. In gen-
eral, a drug interaction occurs when the eﬀ ectiveness or toxicity of a drug is altered 
by the concomitant administration of another drug. A review was conducted to 
discuss drug-drug interactions with antidepressants and methods to prevent them 
in elderly patients.
Th ere are important factors that predispose elderly to suﬀ er from DDI with 
antidepressants in general. First, age-related changes in pharmacokinetics and 
pharmacodynamics negatively inﬂ uence drug elimination through hepatic me-
tabolism and/or renal excretion. Second, as a result of coexisting chronic illnesses, 
elderly depressive patients often take many concomitant medications.
SSRIs have a potential for pharmacokinetic interactions due to their inhibi-
tory eﬀ ect on cytochrome P450 (CYP P450) enzymes. Th e diﬀ erential eﬀ ects of 
various SSRIs on CYPs are well characterized in vitro. Fluvoxamine, ﬂ uoxetine 
and paroxetine have the largest potential for interaction [36]. Older compounds, 
such as tricyclic antidepressants or monoamine oxidase inhibitors, which act on a 
broad range of receptors, have a greater potential for pharmacodynamic DDI than 
newer agents with a more speciﬁ c mechanisms of action [37].
TCAs inhibit the neuronal reuptake of noradrenaline and serotonin, bind to 
multiple receptors types (M1 cholinergic receptors, H1-histamine receptors, α1-
adrenoceptors), and inhibit fast sodium channels. Based on this, TCAs should 
be avoided or used with extreme caution in elderly patients treated with anticho-
linergics or with drugs aﬀ ecting the central nervous and cardiovascular systems 
[38]. Concomitant administration of TCAs with other medications possessing 
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antimuscarinic activity, such as phenothiazines and antiparkinsonian agents, may 
induce central and peripheral anticholinergic eﬀ ects, including memory impair-
ment, dry mouth, blurred vision, constipation, confusional states, and urinary 
retention. Furthermore, TCAs may potentiate the sedative eﬀ ects of other central 
nervous system (CNS) depressants such as barbiturates, benzodiazepines, anthis-
tamines, antipsychotics, thereby impairing psychomotor and cognitive function 
in elderly population. Undesirable interactions may also occur when TCAs are 
used in combination with a variety of cardiovascular drug (e.g. anti-arrhythmics, 
antihypertensives and oral anticoagulants).
Awareness about the risks of drug-drug interactions with individual antidepres-
sant may lower the potential of DDI in elderly patients that are treated with these 
psychotropic drugs.
Cerebrovascular safety of antidepressants
Th e potential eﬀ ects of SSRIs and other antidepressants on cerebral circulation 
and platelets have received a lot of attention after preliminary reports suggested an 
association between SSRI exposure and risk of bleeding, including hemorrhagic 
stroke [39-41]. Several observational studies explored the association between SSRI 
use and hemorrhagic stroke but could not show any signiﬁ cant associations [42-
44]. Although an association with hemorrhagic stroke could not be conﬁ rmed, 
there is contrasting evidence on the association with ischemic stroke. Given the 
serotonin depleting eﬀ ect of SSRIs on platelets, a protective eﬀ ect of SSRIs against 
thrombotic event might be anticipated [45]. To investigate the eﬀ ect of SSRIs on 
ischemic stroke, we conducted a cohort study in Dutch elderly outpatients using 
the IPCI database. A signiﬁ cant increase in the risk of ischemic stroke was found 
for current use of SSRIs, compared to non use (adj. OR: 1.55; 95 CI: 1.07-2.25), 
particularly in the beginning of the treatment, though the association was not 
dose-dependent. Past use of either SSRIs or TCAs was associated with ischemic 
stroke as well, in line with a Danish study [46]. Our ﬁ nding supports the possibil-
ity that depressive symptoms, which is the main reason for use of antidepressants 
in elderly, act as a confounder on the association between antidepressants and 
stroke. To deal with confounding by indication, Chen et al recently conducted a 
nested case control study within patients with depression in a large population-
based U.S. medical claims database [47]. Th eir ﬁ ndings, however, were in line 
with ours, the risk of ischemic stroke was increased only for current users of SSRIs 
(adj. OR: 1.55; 95 CI: 1.00-2.39). Possible mechanisms supporting the causal as-
sociation between exposure to SSRIs and ischemic stroke have been hypothesized. 
Serotoninergic activation secondary to SSRI use may induce a vasoconstrictive 
eﬀ ect that is mediated by the 5-hydroxytryptamine-2 (5HT-2) receptor on smooth 
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muscle cells [48-49]. A recent review on the cerebrovascular eﬀ ects of SSRIs 
showed that SSRIs use may increase the risk of ischemic stroke by triggering a 
thromboembolic phenomenon in patients with cerebral atherosclerosis through 
its vasoconstrictive eﬀ ect in large cerebral arteries [45]. In our study we support 
this hypothesis as we found a signiﬁ cant linear trend between the aﬃ  nity to the 
serotonin transporter and the risk of ischemic stroke.
Use of and safety of anti-Parkinson drugs in elderly
Utilization of anti-Parkinson drugs
Levodopa (L-Dopa) is the most eﬀ ective drug in Parkinson’s disease (PD) treatment, 
but it is associated with limiting and poorly tolerated motor and non-motor side 
eﬀ ects, especially in the advanced stages of the disease [50]. Other anti-Parkinson 
drugs are commonly used as monotherapy or as adjunctive therapy with L-Dopa, 
to delay or reduce its use and the occurrence of motor and non-motor complica-
tions while maximizing treatment eﬀ ectiveness [51]. Th ese other drugs include 
ergot and non-ergot derived dopamine agonists (DAs), anticholinergic drugs, 
amantadine, selegiline and catechol-O-methyltransferase (COMT) inhibitors. 
Due to lack of recent data on APD use in Europe, we explored the prescribing 
pattern of anti-Parkinson drugs in the Arianna database in Southern Italy during 
the years 2003-2005. In our study, the prevalence of Parkinson drug use was 6.0 
per 1,000 persons per year. We observed that L-dopa was the most widely pre-
scribed Parkinson drug in this area. Th is was in line with other European studies 
[52-53]. Almost 20 of either L-Dopa or ergot derived DA users received only 
one prescription. Th is ﬁ nding suggests that physicians commonly prescribe a trial 
of dopaminergic medications to diagnose Parkinson’s disease rather than carrying 
out more complex diagnostic procedures.
In the same setting, we looked at the characteristics of patients and we observed 
that the burden of existing cardiovascular disease diﬀ ers between new users of 
ergot-derived DAs. Th is ﬁ nding should be considered in light of the warnings on 
the risk of ﬁ brotic heart valve disorder associated with the use of pergolide and 
cabergoline in patients with Parkinson’s disease.
Risk of fi brotic heart valve disease with anti-Parkinson drugs
Starting from 2002, ﬁ rst a number of case reports, and subsequently several 
cross-sectional ecocardiographic studies and one retrospective database study have 
highlighted the risk of valvular heart disease associated with ergot derivative DA 
use [54-57]. As a consequence of the growing evidence on the risk of ﬁ brotic heart 
valve disease (i.e. valve regurgitation), pergolide was withdrawn from the U.S. 
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market, and pergolide as well as cabergoline are now second line treatments for 
Parkinson’s disease in Europe, and their use requires monitoring [58]. Th is risk of 
valve regurgitation seems to be dose-dependent and may be potentially reversible 
with the withdrawal of drug treatment. Due to the limited sample size of previous 
studies, however, the comparative risk of individual ergot and non-ergot derived 
DAs need further assessments using large amount of exposed persons.
With the aim to better investigate the relationship between ﬁ brotic heart valve 
disorder and use of ergot/non-ergot DA use, we undertook an observational inves-
tigation using information from three electronic health record database (Health 
Search/Th ales from Italy, IPCI from Th e Netherlands and THIN from UK). Th e 
results of our multicentre study showed that the use of ergot-derived DAs longer 
than 6 months was associated with an increased risk of newly diagnosed valve 
regurgitation in a cohort of patients with Parkinson’s disease from three diﬀ erent 
Countries. Th e risk increased with the increasing dosage, although a signiﬁ cant 
increase was observed already in those users of ergot derived DA that received 
dosage lower than 0.5 DDD. Th is increase in the risk could be demonstrated 
only for cabergoline and pergolide. On the contrary, we did not observe any 
increase in the risk for the use of non-ergot derived DA pramipexole, ropinirole 
and apomorphine, despite more than doubled prevalence of exposure to these 
drugs in controls, compared to ergot-derived DAs. Th ese ﬁ ndings are in line with 
previous evidence from echocardiographic and epidemiologic studies [58]. So far, 
only one case control study had been conducted using electronic medical records 
[57]. In line with this paper, we found a crude incidence rate of valve regurgitation 
of 30 per 10,000 PYs for users of ergot-derived DAs. Furthermore, we observed 
a signiﬁ cant linear trend of the aﬃ  nity to 5HT2b receptor for current users of the 
study drugs in the risk of valve regurgitation, thus conﬁ ming a major role for 
the pharmacological action on this receptor in the drug-induced ﬁ brotic heart 
valve disorders [59]. Further research is needed to evaluate the comparative risk of 
valve regurgitation with the use of individual ergot derived DA in patients with 
hyperprolactinemia, who are treated with much lower dosage of ergot derived DA 
and on average are much younger than patients with Parkinson’s disease.
METHODOLOGICAL CONSIDERATIONS
Study setting
A shift of long term management of mental illness from psychiatric hospitals to 
the community took place in European Countries in the past 20 years. As a result, 
general practitioners (GPs) have been increasingly involved in the pharmacologi-
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cal management of neuropsychiatric disorders in the elderly [60-62]. In several 
European countries (e.g. UK, Netherlands, Spain, and Italy) citizens have their 
own GP, who serves as the gatekeeper to medical care. Th ese GPs ﬁ les all relevant 
medical details on their patients from primary care visits, hospital admissions 
and visits to outpatient clinics. Th e primary care setting is therefore suitable for 
population-based epidemiologic investigations on the use and safety of psycho-
tropic drugs. In all the observational studies presented in this thesis, data have 
been drawn from three general practice databases that are located in two diﬀ erent 
Countries (Italy and Th e Netherlands):
a) Th e Health Search/Th ales database, which was set up by the Italian College of 
General Practitioners (SIMG) in 1998, currently contains information on more 
than 1 million patients, who are registered with one of the participating 800 
GPs. Th e GPs are distributed homogeneously all over Italy. Th is database has 
been validated and used frequently for epidemiological studies [63-65].
b) Th e Arianna database is a longitudinal general practice database from South-
ern Italy, which was set up in 2000. It currently contains information on a 
population of almost 300,000 individuals (225 GPs) living in the catchments 
area of Caserta. Th is database has been used for some epidemiological studies 
[66-67].
c) Th e Integrated Primary Care Information (IPCI) database is a Dutch lon-
gitudinal general practice research database, which was set up in 1992. To 
date, IPCI contains data from electronic medical records of approximately 1 
million of patients from a group of 500 Dutch GPs. Th e IPCI database has 
been validated and used in more than 50 publications on the drug safety and 
eﬀ ectiveness [68-70].
d) Th e Health Information Network (THIN) that is a database of primary care 
medical records from the United Kingdom.
Currently, the database has 2.7 million active patients registered within 358 par-
ticipating practices. Data from THIN have been demonstrated to be valid for 
pharmacoepidemiology research [71].
Databases were chosen for logistical and accessibility reasons, and ﬁ nally, in 
the safety studies, for availability of information and size. In the study on the as-
sociation between valvular regurgitation and dopamine agonist use in Parkinson’s 
disease, databases were combined to proﬁ t from the heterogeneity of drug pre-
scribing patterns across countries and to increase the sample size. Secondary use 
of electronic medical records stored in these databases brings various advantages. 
First these longitudinal databases allow for enumeration of the source population 
and provide a good denominator for utilization studies and disease rates. Secondly, 
the availability of information in the records of all patients avoids selection bias, 
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which often is a problem if ﬁ eld studies need to be conducted. Th irdly, most 
databases allow for long follow-up, which will even increase with time. Fourthly, 
these database, have real life clinical information on a large number of patients, 
including information on diseases, symptoms, signs, drug prescriptions, labora-
tory and diagnostic instrumental tests, hospital and specialist referral and death. 
Another advantage of using these databases is the possibility to go back to the GP 
to ask for additional information (i.e. letters from specialist and GPs’ conﬁ rma-
tion of diagnoses).
On the other hand, some limitations of these data sources should be acknowl-
edged as well. First, information is collected in the outpatient setting only and as a 
consequence the study ﬁ ndings (especially those from drug utilization studies) may 
not directly pertain to patients that are treated in diﬀ erent settings, like hospital 
or nursing homes and long term care facilities. Second, the use of medications, 
which are not prescribed by GPs, is not consistently and completely registered. 
As a consequence, missing information on over the counter medications and 
prescriptions that are issued directly from psychiatric local health services should 
be always taken into account, when interpreting results of the research presented 
in this thesis. Th ird due to the non-random assignment of drugs, channeling, 
resulting in confounding by indication always occurs.
Observational studies: bias and confounding
Studying the relationship between psychotropic drug use and new onset of adverse 
events in electronic heal record databases is extremely challenging due to a variety 
of potential biases and confounders. In all observational studies, various types 
of bias, e.g. selection bias, protopathic bias, information bias and confounding 
by indication, may inﬂ uence the study ﬁ ndings, as brieﬂ y discussed below. Th e 
primary study design that was adopted in almost all the epidemiologic studies 
focusing on drug safety was the nested-case control study. Th ese case control 
studies were nested cohorts of either speciﬁ c drug users (i.e. antipsychotic or 
anti-Parkinson drugs), elderly or demented elderly. Nesting was done to reduce 
potential for confounding by indication. Case control studies are more eﬃ  cient 
in studying dose, duration and exposure responses than cohort studies, whereas 
their validity is the same when using already recorded information from electronic 
medical records.
Th e potential for selection bias was minimal in our studies as all data were 
obtained from prospectively collected medical records that are maintained for 
patient care purposes on a population based level. In each country from which the 
databases were used, there is no threshold to access GPs and patients are registered 
independent of disease status.
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Information bias can occur as result of misclassiﬁ cation of either exposure or 
outcome. To minimize the potential eﬀ ect of information bias by misclassiﬁ ca-
tion of the outcome a two-step case validation process was undertaken for all the 
studied outcomes (all-cause mortality, stroke, pneumonia and valvular regurgita-
tion). First, all the potential cases were identiﬁ ed through broad searches of coded 
diagnoses and narratives in the electronic medical record of the study patients. 
Second, the electronic medical records of all potential cases were reviewed and 
validated manually by at least two expert and trained medical doctors, who were 
blinded to the exposure.
In all the observational studies presented in this thesis, misclassiﬁ cation of ex-
posure is possible since we used outpatient prescription data and had no informa-
tion about actual ﬁ lling and use of the medications. Around half of the medicines 
prescribed for people with chronic conditions are ultimately not taken in the US 
[72]. Although this percentage may be lower in the EU where geerally patients do 
not have to pay for their medications, this misclassiﬁ cation is most likely equal 
(non-diﬀ erential) between cases and controls and, therefore, the actual risk may 
have possibly been underestimated. To deal with misclassiﬁ cation due to irregular 
intake we performed various sensitivity analyses in our studies by varying the 
exposure window. Two main epidemiologic issues were frequently encountered 
in our studies and they merit a careful and extensive discussion: confounding by 
indication and protopathic bias.
Confounding by indication is a commonly used term that refers to an extrane-
ous determinant of the outcome parameter that is present if a perceived high risk 
or poor prognosis is an indication for intervention. Th e indication is a confounder 
because it correlates with the intervention and is a risk indicator for the illness 
[73]. Confounding by indication is likely in the studied associations, since the 
choice of psychotropic drug is often associated with the prognosis or condition 
of a patient, which in itself can be a risk factor for stroke, pneumonia or death. 
Confounding by indication was addressed in the design (restriction, matching) 
and analysis phases of all studies.
In the study on the risk of all-cause mortality with antipsychotic drug use, we 
restricted the study population to elderly patients with dementia only. Dementia 
itself is a strong risk factor of death in the elderly population [74] and behavioral 
and psychotic symptoms requiring antipsychotic treatment may themselves be 
predictors of mortality within older demented patients. Th is means that there 
is a strong potential for confounding by severity, when comparing the risk of 
death between current users of antipsychotics and non users [75]. In the analysis 
phase, we dealt with confounding by indication by stratifying or adjusting for the 
indication of use in the multivariate regression models. In the study on the risk of 
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ischemic stroke in users of antidepressants our basic strategy was adjustment and 
stratiﬁ cation for indication. In the study on anti-Parkinson drugs and valvular 
regurgitation we compared patients with the same indication (restriction) using 
levodopa as reference group, and we adjusted for many covariates.
Due to the use of electronic health records, we could consider (adjust or match 
for) many risk factors. However, residual confounding is always possible due 
to insuﬃ  ciently or selectively registered covariates (i.e. smoking and alcohol or 
severity of disease). Only strong and highly prevalent risk factors would be able 
to explain the ﬁ ndings of our studies and it is unlikely that these covariates have 
been omitted.
Protopathic bias occurs when a drug is used to treat prodromic symptoms of 
the study outcome, thereby it may appear that the drug is causing the outcome 
[76]. For example, SSRIs are frequently prescribed for the treatment of late life 
depression, which may represent a manifestation of subtle cerebrovascular disor-
ders resulting to stroke in the elderly [77].Similarly, severe pneumonia may induce 
delirium and trigger subsequent antipsychotic drug use in elderly patients [78]. In 
both situations, wrong assessment of the date of onset could result in protopathic 
bias, thus mistakenly attributing stroke and pneumonia onset respectively to SSRI 
and antipsychotics. To deal with this protopathic bias, we performed sensitivity 
analyses excluding from the exposure category those patients who started the 
therapy within a short period prior to the occurrence of the outcome.
CONCLUDING REMARKS
What this thesis adds
Th is thesis shows that secondary use of data from electronic health record data-
bases is a very valuable tool to evaluate both the use and the safety of psychotropic 
medications in elderly as well as the eﬀ ects of risk minimization strategies or 
health regulatory warnings. Th is type of epidemiologic investigations may be 
of great interest for various stakeholders ranging from clinicians to patients and 
regulators at national and international level. Th ese data allow for monitoring 
of new compounds, safety warnings, changes in the reimbursement criteria, and 
other health policy interventions on the prescribing pattern of neuropsychiatric 
medications in advanced age.
In the research presented in this thesis, we showed the increases in use of sec-
ond generation antidepressants (SSRI) and antipsychotics (atypical agents) and 
the eﬀ ects of regulatory warnings on the utilization patterns of antipsychotics. 
Use of psychiatric medications is not without risk in the elderly, and therefore 
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we explored the extent of some of these safety issues. Regarding the safety of 
antipsychotics, we demonstrated that no signiﬁ cant diﬀ erences exist in the risk 
of all-cause mortality between atypical and conventional antipsychotic drugs in 
elderly demented patients and of fatal/non fatal pneumonia in community dwell-
ing elderly. However, both atypical and conventional antipsychotics seem to be 
associated with a dose-dependent increase of those risks compared to non-use. 
Regarding the risk of stroke which was the cause of the ﬁ rst safety warnings on 
the oﬀ -label use of atypical antipsychotics in elderly patients with dementia, we 
documented an increased risk for both atypical and typical antipsychotic use, 
compared to non-use. Th e study on the association between use of antidepressants 
and ischemic stroke showed that use of SSRI does not reduce the risk of ischemic 
stroke, as previously hypothesized, while could be associated with a slight increase 
in the risk, especially using those drugs with the highest aﬃ  nity to the serotonin 
transporter. Th e safety study on the association between anti-Parkinson drugs 
and newly diagnosed valvular regurgitation conﬁ rmed that only the treatment 
with either pergolide or cabergoline longer than 6 months was associated with 
an increased risk in patients with Parkinson disease. Th e increase in the risk was 
dose dependent. Aggregation of data from multiple databases provided us with 
amounts of data enough to observe that there was no evidence of such an increase 
in risk with the use of non ergot derived dopamine agonists.
Future directions
Th is thesis shows both the potential and pitfalls of secondary use of electronic 
health records for assessing utilization and safety of psychotropic drug use in the 
elderly. A great need exists to better describe and explore the use and the eﬀ ects 
of these drugs in elderly, due to their wide use in real practice setting and little 
clinical trial evidence availability. Future research on psychotropic drugs in elderly 
should therefore take three diﬀ erent directions:
1. Encouraging research on special geriatric populations, such as elderly living 
in nursing home and long term care facilities, for whom electronic medical 
information is currently limited;
2. Exploring and testing new methodologies for assessing not only the safety but 
also the eﬀ ectiveness of these drugs through the use of electronic health record 
databases;
3. Identifying the best strategies for the aggregation of data coming from multiple 
electronic health record databases in studies on rare outcomes and exposures.
In Europe there is a general deﬁ ciency of evidence about drug use and eﬀ ects in 
special geriatric populations, such as the oldest old (patients aged 85 and older) and 
frail medically ill elderly patients who are commonly nursing home residents [79]. 
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Th is may partly be explained by the fact that currently very little electronic health 
record data is available from these settings. Future research in Europe should be 
aimed at unlocking information from these settings for research. In such a way the 
use and safety of psychotropic drugs in nursing home settings could be properly 
described and monitored, which is the setting in which these medications are 
often misused and overused [1].
Th e research that is shown in this thesis was aimed at exploring the prescribing 
pattern and the most relevant safety issues of the most widely used psychotropic 
drugs in the community dwelling geriatric population. Ideally, a more comprehen-
sive assessment would need to be done combining all safety issues and weighing 
these against the eﬀ ectiveness of psychotropic drugs. New methodologies are war-
ranted and in development to evaluate also the drug eﬀ ectiveness and quantify the 
overall beneﬁ t-risk proﬁ le of available medications [80]. Use of electronic medical 
record databases seem key in these assessments since they reﬂ ect reality rather 
than artiﬁ cial clinical trials circumstances and allow for longer term follow-up. 
Th e ﬁ eld of eﬀ ectiveness assessment in these databases is currently a ﬁ eld of high 
attention due to the high potential for confounding by indication, and the future 
should show whether valid estimations are possible while using a non-randomized 
approaches [81]. In case of severe rare clinical outcomes, a single electronic health 
record database may not provide suﬃ  cient subjects and heterogeneity in exposure 
to conduct a full comparative pharmacoepidemiologic drug safety study. For this 
reason we tried to combine data from diﬀ erent electronic health record to study 
the association between dopamine agonist use and cardiac valve regurgitation. 
Although aggregation of data from multiple databases is ambitious, currently it 
is challenging, especially in Europe, due to the diﬀ erences in terminology and 
language systems being adopted as well as the diﬀ erences in quality and type of 
gathered information. Th is strategy however may provide the statistical power to 
study rare adverse events and rare drug exposures. Th e best methodologies for 
analyzing aggregated data that are drawn from diﬀ erent sources should be sought 
in the future.
REFERENCES
 1. Alexopoulos, G.S., et al., Using antipsychotic agents in older patients. J Clin Psychia-
try, 2004. 65 Suppl 2: p. 5-99; discussion 100-102;
 2. Ashcroft, D.M., et al., Variations in prescribing atypical antipsychotic drugs in pri-
mary care: cross-sectional study. Pharmacoepidemiol Drug Saf, 2002. 11(4): p. 285-9.
 3. Hermann, R.C., et al., Prescription of antipsychotic drugs by oﬃ  ce-based physicians 
in the United States, 1989-1997. Psychiatr Serv, 2002. 53(4): p. 425-30.
Gianluca BW.indd   238 25-May-09   11:24:04 AM
239
General Discussion
 4. News, C.o.S.o.M.L. Atypical antipsychotic drugs and stroke. . 9 March 2004 [cited 
September 15th, 2005]; Available from: http://www.mca.gov.uk/aboutagency/reg-
framework/csm/csmhome.htm.
 5. Advisory, F.P.H. Deaths with Antipsychotics in Elderly Patients with Behavioural 
Disturbances. April 2005 [cited April 10th, 2005]; Available from: http://www.fda.
gov/cder/drug/advisory/antipsychotics.htm.
 6. news, F. FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs. 
June 16, 2008 [cited June 24th, 2008]; Available from: http://www.fda.gov/bbs/top-
ics/NEWS/2008/NEW01851.html.Kamble, P., et al., Antipsychotic drug use among 
elderly nursing home residents in the United States. Am J Geriatr Pharmacother, 
2008. 6(4): p. 187-97.
 7. Valiyeva, E., et al., Eﬀ ect of regulatory warnings on antipsychotic prescription rates 
among elderly patients with dementia: a population-based time-series analysis. Cmaj, 
2008. 179(5): p. 438-46.
 8. Lonergan, E., J. Luxenberg, and J. Colford, Haloperidol for agitation in dementia. 
Cochrane Database Syst Rev, 2002(2): p. CD002852.
 9. Lee, P.E., et al., Atypical antipsychotic drugs in the treatment of behavioural and 
psychological symptoms of dementia: systematic review. Bmj, 2004. 329(7457): p. 
75.
 10. Herrmann, N., M. Mamdani, and K.L. Lanctot, Atypical antipsychotics and risk of 
cerebrovascular accidents. Am J Psychiatry, 2004. 161(6): p. 1113-5.
 11. Gill, S.S., et al., Atypical antipsychotic drugs and risk of ischaemic stroke: population 
based retrospective cohort study. Bmj, 2005. 330(7489): p. 445.
 12. Liperoti, R., et al., Cerebrovascular events among elderly nursing home patients 
treated with conventional or atypical antipsychotics. J Clin Psychiatry, 2005. 66(9): p. 
1090-6.
 13. Finkel, S., et al., Risperidone treatment in elderly patients with dementia: relative risk 
of cerebrovascular events versus other antipsychotics. Int Psychogeriatr, 2005. 17(4): p. 
617-29.
 14. Layton, D., et al., Comparison of incidence rates of cerebrovascular accidents and 
transient ischaemic attacks in observational cohort studies of patients prescribed ris-
peridone, quetiapine or olanzapine in general practice in England including patients 
with dementia. J Psychopharmacol, 2005. 19(5): p. 473-82.
 15. Percudani, M., et al., Second-generation antipsychotics and risk of cerebrovascular 
accidents in the elderly. J Clin Psychopharmacol, 2005. 25(5): p. 468-70.
 16. Barnett, M.J., H. Wehring, and P.J. Perry, Comparison of risk of cerebrovascular 
events in an elderly VA population with dementia between antipsychotic and nonan-
tipsychotic users. J Clin Psychopharmacol, 2007. 27(6): p. 595-601.
 17. Wang, P.S., et al., Risk of death in elderly users of conventional vs. atypical anti-
psychotic medications. N Engl J Med, 2005. 353(22): p. 2335-41.
 18. Schneeweiss, S., et al., Risk of death associated with the use of conventional versus 
atypical antipsychotic drugs among elderly patients. Cmaj, 2007. 176(5): p. 627-32.
 19. Gill, S.S., et al., Antipsychotic drug use and mortality in older adults with dementia. 
Ann Intern Med, 2007. 146(11): p. 775-86.
Gianluca BW.indd   239 25-May-09   11:24:04 AM
Chapter 5
240
 20. Kales, H.C., et al., Mortality risk in patients with dementia treated with antipsychotics 
versus other psychiatric medications. Am J Psychiatry, 2007. 164(10): p. 1568-76; quiz 
1623.
 21. Hollis, J., et al., Risk of death associated with antipsychotic drug dispensing in resi-
dential aged care facilities. Aust N Z J Psychiatry, 2007. 41(9): p. 751-8.
 22. Raivio, M.M., et al., Neither atypical nor conventional antipsychotics increase 
mortality or hospital admissions among elderly patients with dementia: a two-year 
prospective study. Am J Geriatr Psychiatry, 2007. 15(5): p. 416-24.
 23. Liperoti R, L.K., Mor V, Bernabei R, Gambassi G, Risk of death associated with 
atypical and conventional antipsychotics among nursing home residents with demen-
tia (in press). Arch Intern Med.
 24. Straus, S.M., et al., Antipsychotics and the risk of sudden cardiac death. Arch Intern 
Med, 2004. 164(12): p. 1293-7.
 25. Giles, T.D. and R.K. Modlin, Death associated with ventricular arrhythmia and 
thioridazine hydrochloride. Jama, 1968. 205(2): p. 108-10.
 26. Jackson, T., L. Ditmanson, and B. Phibbs, Torsade de pointes and low-dose oral 
haloperidol. Arch Intern Med, 1997. 157(17): p. 2013-5.
 27. Hennessy, S., et al., Cardiac arrest and ventricular arrhythmia in patients taking anti-
psychotic drugs: cohort study using administrative data. Bmj, 2002. 325(7372): p. 
1070.
 28. Ray, W.A., et al., Antipsychotics and the risk of sudden cardiac death. Arch Gen 
Psychiatry, 2001. 58(12): p. 1161-7.
 29. Knol, W., et al., Antipsychotic drug use and risk of pneumonia in elderly people. J 
Am Geriatr Soc, 2008. 56(4): p. 661-6.
 30. Schindler, J.S. and J.H. Kelly, Swallowing disorders in the elderly. Laryngoscope, 
2002. 112(4): p. 589-602.
 31. Solai, L.K., B.H. Mulsant, and B.G. Pollock, Selective serotonin reuptake inhibitors 
for late-life depression: a comparative review. Drugs Aging, 2001. 18(5): p. 355-68.
 32. Isacsson, G., et al., Selective serotonin reuptake inhibitors have broadened the utilisa-
tion of antidepressant treatment in accordance with recommendations. Findings from 
a Swedish prescription database. J Aﬀ ect Disord, 1999. 53(1): p. 15-22.
 33. Lawrenson, R.A., et al., Th e treatment of depression in UK general practice: selective 
serotonin reuptake inhibitors and tricyclic antidepressants compared. J Aﬀ ect Disord, 
2000. 59(2): p. 149-57.
 34. Garrison, G.D. and G.M. Levin, Factors aﬀ ecting prescribing of the newer antide-
pressants. Ann Pharmacother, 2000. 34(1): p. 10-4.
 35. Poon, I.O. and U. Braun, High prevalence of orthostatic hypotension and its cor-
relation with potentially causative medications among elderly veterans. J Clin Pharm 
Th er, 2005. 30(2): p. 173-8.
 36. Hemeryck, A. and F.M. Belpaire, Selective serotonin reuptake inhibitors and cyto-
chrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab, 2002. 
3(1): p. 13-37.
 37. Spina E, P.E., Newer and older antidepressants: A comparative review of drug interac-
tions. CNS Drugs, 1994. 2: p. 479497.
 38. Spina E, Scordo MG. Clinically signiﬁ cant drug interactions with antidepressants in 
the elderly. Drugs & Aging 2002; 19 299-320
Gianluca BW.indd   240 25-May-09   11:24:04 AM
241
General Discussion
 39. Skop, B.P. and T.M. Brown, Potential vascular and bleeding complications of treat-
ment with selective serotonin reuptake inhibitors. Psychosomatics, 1996. 37(1): p. 
12-6.
 40. Ottervanger, J.P., et al., Bleeding attributed to the intake of paroxetine. Am J Psychia-
try, 1994. 151(5): p. 781-2.
 41. Layton, D., et al., Is there an association between selective serotonin reuptake inhibi-
tors and risk of abnormal bleeding? Results from a cohort study based on prescription 
event monitoring in England. Eur J Clin Pharmacol, 2001. 57(2): p. 167-76.
 42. de Abajo, F.J., et al., Intracranial haemorrhage and use of selective serotonin reuptake 
inhibitors. Br J Clin Pharmacol, 2000. 50(1): p. 43-7.
 43. Barbui, C., et al., Antidepressant drug prescription and risk of abnormal bleeding: a 
case-control study. J Clin Psychopharmacol, 2009. 29(1): p. 33-8.
 44. Kharofa, J., et al., Selective serotonin reuptake inhibitors and risk of hemorrhagic 
stroke. Stroke, 2007. 38(11): p. 3049-51.
 45. Ramasubbu, R., Cerebrovascular eﬀ ects of selective serotonin reuptake inhibitors: a 
systematic review. J Clin Psychiatry, 2004. 65(12): p. 1642-53.
 46. Bak, S., et al., Selective serotonin reuptake inhibitors and the risk of stroke: a 
population-based case-control study. Stroke, 2002. 33(6): p. 1465-73.
 47. Chen, Y., et al., Risk of cerebrovascular events associated with antidepressant use in 
patients with depression: a population-based, nested case-control study. Ann Pharma-
cother, 2008. 42(2): p. 177-84.
 48. Bonvento, G., E.T. MacKenzie, and L. Edvinsson, Serotonergic innervation of the 
cerebral vasculature: relevance to migraine and ischaemia. Brain Res Brain Res Rev, 
1991. 16(3): p. 257-63.
 49. Muhonen, M.G., et al., Eﬀ ects of serotonin on cerebral circulation after middle 
cerebral artery occlusion. J Neurosurg, 1997. 87(2): p. 301-6.
 50. Lewitt, P.A., Levodopa for the treatment of Parkinson’s disease. N Engl J Med, 2008. 
359(23): p. 2468-76.
 51. Lees, A., Alternatives to levodopa in the initial treatment of early Parkinson’s disease. 
Drugs Aging, 2005. 22(9): p. 731-40.
 52. Askmark, H., K. Antonov, and S.M. Aquilonius, Th e increased utilisation of dop-
amine agonists and the introduction of COMT inhibitors have not reduced levodopa 
consumption--a nation-wide perspective in Sweden. Parkinsonism Relat Disord, 
2003. 9(5): p. 271-6.
 53. Criado-Alvarez JJ, R.-B.C., Martínez-Hernández J, González-Solana I, Use of an-
tiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson 
disease Rev Neurol, 1998 27(157): p. 405-8.
 54. Peralta, C., et al., Valvular heart disease in Parkinson’s disease vs. controls: An echocar-
diographic study. Mov Disord, 2006. 21(8): p. 1109-13.
 55. Pinero, A., P. Marcos-Alberca, and J. Fortes, Cabergoline-related severe restrictive 
mitral regurgitation. N Engl J Med, 2005. 353(18): p. 1976-7.
 56. Zanettini, R., et al., Valvular heart disease and the use of dopamine agonists for 
Parkinson’s disease. N Engl J Med, 2007. 356(1): p. 39-46.
 57. Schade, R., et al., Dopamine agonists and the risk of cardiac-valve regurgitation. N 
Engl J Med, 2007. 356(1): p. 29-38.
Gianluca BW.indd   241 25-May-09   11:24:04 AM
Chapter 5
242
 58. Simonis, G., J.T. Fuhrmann, and R.H. Strasser, Meta-analysis of heart valve abnor-
malities in Parkinson’s disease patients treated with dopamine agonists. Mov Disord, 
2007. 22(13): p. 1936-42.
 59. Jahnichen S, Horowski R, Pertza H. Agonism at 5-HT2B receptors is not a class eﬀ ect 
of the ergolines. Eur J Pharmacol 2005; 513: 225-228.
 60. Strum R, M.L., Wells KB, Provider choice and continuity for the treatment of depres-
sion. Med Care, 1996. 34: p. 723-734.
 61. Kiraly, B., K. Gunning, and J. Leiser, Primary care issues in patients with mental 
illness. Am Fam Physician, 2008. 78(3): p. 355-62.
 62. Macmahon, D., D. Brooks, and R. Smith, Parkinson’s: integrating the primary and 
secondary care guidelines. Practitioner, 2000. 244(1609): p. 370-8.
 63. Filippi A, Sabatini A, Badioli L, Samani F, Mazzaglia G, Catapano A, Cricelli C. Eﬀ ects 
of an automated electronic reminder in changing the antiplatelet drug-prescribing 
behavior among Italian general practitioners in diabetic patients: an intervention trial. 
Diabetes Care 2003; 26: 1497-1500.
 64. Cricelli C, Mazzaglia G, Samani F, Marchi M, Sabatini A, Nardi R, Ventriglia G, 
Caputi AP. Prevalence estimates for chronic diseases in Italy: exploring the diﬀ erences 
between self-report and primary care databases. J Public Health Med 2003; 25: 254-
257.
 65. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Triﬁ rò G, Cricelli C, 
Brignoli O, Caputi AP. Patterns of persistence with antihypertensive medications in 
newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary 
care. J Hypertens 2005; 23: 2093-100
 66. Alacqua M, Triﬁ rò G, Cavagna L, Caporali R, Montecucco CM, Moretti S, Tari DU, 
Galdo M, Caputi AP, Arcoraci V. Prescribing pattern of drugs in the treatment of 
osteoarthritis in Italian general practice: the eﬀ ect of rofecoxib withdrawal. Arthritis 
Rheum. 2008 Apr; 59: 568-74.
 67. Triﬁ rò G, Alacqua M, Corrao S, Moretti S, Tari DU, Galdo M; UVEC Group, 
Caputi AP, Arcoraci V. Lipid-lowering drug use in Italian primary care: eﬀ ects of 
reimbursement criteria revision. Eur J Clin Pharmacol. 2008; 64: 619-25
 68. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk 
of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 
2004; 292: 1955-60.
 69. van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PV, Boon 
WM, van Bemmel JH. Th e introduction of computer-based patient records in Th e 
Netherlands. Ann Intern Med. 1993; 119: 1036-41.
 70. Vlug AE, van der Lei J, Mosseveld BM, et al. Post-marketing surveillance based on 
electronic patient records: the IPCI project. Methods Inf Med 1999; 38: 339-44.
 71. Lewis J, Schinnar R, Bilker W, Wang X, Strom B. Validation studies of the health 
improvement network (THIN) database for pharmacoepidemiology research. Phar-
macoepidemiol & Drug Safety 2007; 16: 393-401. Meal A, Leonardi-Bee J, Smith C, 
Hubbard R, Bath-Hextall F. Validation of THIN data for non-melanoma skin cancer. 
Qual Prim Care. 2008; 16: 49-52.
 72. Haynes, R.B., K.A. McKibbon, and R. Kanani, Systematic review of randomised tri-
als of interventions to assist patients to follow prescriptions for medications. Lancet, 
1996. 348(9024): p. 383-6.
Gianluca BW.indd   242 25-May-09   11:24:04 AM
243
General Discussion
 73. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of varia-
tion in the use of epidemiologic terminology. Am J Epidemiol 1999; 149: 981-3.72.
 74. Tschanz, J.T., et al., Dementia: the leading predictor of death in a deﬁ ned elderly 
population: the Cache County Study. Neurology, 2004. 62(7): p. 1156-62.
 75. Walsh, J.S., H.G. Welch, and E.B. Larson, Survival of outpatients with Alzheimer-
type dementia. Ann Intern Med, 1990. 113(6): p. 429-34.
 76. Horwitz, R.I. and A.R. Feinstein, Th e problem of “protopathic bias” in case-control 
studies. Am J Med, 1980. 68(2): p. 255-8.
 77. Krishnan, K.R., Depression as a contributing factor in cerebrovascular disease. Am 
Heart J, 2000. 140(4 Suppl): p. 70-6.
 78. Marrie, T.J., Community-acquired pneumonia in the elderly. Clin Infect Dis, 2000. 
31(4): p. 1066-78.
 79. Desai, A.K., Use of psychopharmacologic agents in the elderly. Clin Geriatr Med, 
2003. 19(4): p. 697-719.
 80. Lynd LD, O’brien BJ. Advances in risk-beneﬁ t evaluation using probabilistic simu-
lation methods: an application to the prophylaxis of deep vein thrombosis. J Clin 
Epidemiol. 2004; 57: 795-803
 81. Schneeweiss S. Developments in post-marketing comparative eﬀ ectiveness research. 
Clin Pharmacol Th er. 2007 Aug; 82(2): 143-56.
Gianluca BW.indd   243 25-May-09   11:24:04 AM
Gianluca BW.indd   244 25-May-09   11:24:04 AM
C H A P T E R  6
Summary of thesis
Gianluca BW.indd   245 25-May-09   11:24:13 AM
Gianluca BW.indd   246 25-May-09   11:24:17 AM
247
6.1.  Summary
Th e world’s population in the older ages continues to increase and two billions of 
persons over 65 years are expected by 2050. Likewise, the burden of neuropsychi-
atric disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), 
increases as well. Late life neuropsychiatric disorders are disabling conditions that 
result in a lower quality of life of elderly patients and their caregivers, earlier 
institutionalization, and excess mortality. Amelioration of these conditions can be 
achieved with rational prescribing of psychotropic drugs in these patients, but this 
is challenging due to the limited scientiﬁ c evidence on the eﬀ ectiveness, restricted 
tolerability and potential of dug-drug interactions of available medications.
Th e increasing amount of electronic health records oﬀ ers the opportunity to gen-
erate a constantly updated picture on psychotropic drug use in clinical practice and 
to provide a better insight on the risks of those medications in geriatric population.
Th e general objective of the research described in the present thesis was to 
obtain a better understanding of the use and safety of antipsychotic (chapter 2), 
antidepressant (chapter 3), and anti-Parkinson drugs (chapter 4) in community 
dwelling elderly patients.
Antipsychotic drugs
In a population-based Italian study, we found a rather stable one-year prevalence 
of antipsychotic use (1.4) during the years 1999-2002. However, the use of 
atypical antipsychotics increased approximately ﬁ vefold during the study years 
(0.7 per 1,000 in 1999 vs. 3.4 per 1,000 in 2002). Th is growth was mostly due 
to their growing use in the treatment of behavioral and psychotic disorders of 
dementia, which was the main reason for oﬀ -label use (chapter 2.1). A number of 
alerts were launched by health regulatory agencies on the risks of cerebrovascular 
events and all-cause mortality in association with the oﬀ -label antipsychotic use in 
elderly demented patients, starting in 2003. In the Italian primary care setting, we 
documented a signiﬁ cant decrease in the use of atypical agents in elderly patients 
with dementia after the issuing of safety alerts, although the overall prescription 
rate of antipsychotics was not reduced in these patients. Despite the decrease, 
however, more than 3 of Italian community dwelling elderly patients received 
at least one antipsychotic drug prescription in 2005, and around 40 of them 
being treated for dementia and related disorders (chapter 2.2). In the chapter 
2.3, we undertook a retrospective cohort study in the same setting and we ob-
served a similarly increased risk of ﬁ rst-ever stroke with use of either typical or 
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atypical antipsychotics, compared to non use, in elderly persons. Such a risk was 
however more than two-fold higher for phenothiazines than atypical agents. We 
thereafter explored the risk of all-cause mortality with the antipsychotic use in 
elderly demented patients, employing a nested case control approach with data 
from the Dutch longitudinal general practice database, IPCI (chapter 2.4). We 
documented a dose-dependent increase in the risk of death for users of either 
atypical or typical antipsychotic, in comparison to non users. No diﬀ erences in 
the mortality risk were reported between use of atypical and typical agents in 
community dwelling elderly with dementia.
In the IPCI database, we also investigated the risk of fatal and non-fatal com-
munity acquired pneumonia in elderly persons. We observed a dose-dependent 
increased risk for pneumonia in current users of either atypical or typical antipsy-
chotics, compared to past use of antipsychotics. Fatal pneumonia was associated 
with atypical agents only, although our analysis was underpowered. Th e risk of 
pneumonia increased linearly with the increasing aﬃ  nity to histaminergic H1 
receptor from antipsychotic classes (chapter 2.5).
In chapter 2.6, we performed a comprehensive review on the safety of atypical 
and typical antipsychotics in elderly demented patients. Results from meta-analyses 
of clinical trials and observational studies report overall a similarly increased risk 
in all-cause mortality and cerebrovascular adverse events in users of both atypical 
and conventional antipsychotics. When prescribing antipsychotics, speciﬁ c safety 
issues to consider are the pro-arrhythmic activity and extrapyramidal symptoms 
for conventional antipsychotics, and the metabolic eﬀ ects (i.e. increased risk of 
diabetes and obesity) for the atypical agents.
Antidepressants
Regarding antidepressant drugs, we ﬁ rst conducted a drug utilization study in 
Southern Italy. Th e prevalence of antidepressant use increased in all age groups 
during the years 2003-2004, as a result of a dramatic increase in the prescriptions 
for SSRIs. In 2004, 9.9 of patients aged 65-74, 13.8 of those aged 75-84, and 
12.4 of those ≥ 85 years were treated with antidepressants. SSRIs accounted for 
about two-thirds of incident treatments with antidepressants in elderly patients. 
In line with guideline recommendations, SSRIs were mainly prescribed for the 
treatment of late life depression (chapter 3.1). Using the IPCI database, we found 
that SSRI and other antidepressants have no protective eﬀ ect against ischemic 
stroke in elderly, as previously postulated (chapter 3.2). Compared to non-use, 
use of SSRIs, and particularly of those with the highest aﬃ  nity to serotonin trans-
porters, may be associated with a slight increase in the risk of ischemic stroke in 
geriatric population, early after the start of therapy.
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We then carried out a review of the current evidence on drug-drug interactions 
with antidepressant medications in elderly patients, focusing on the available 
prevention strategies (chapter 3.3). TCAs, SSRIs as well as other new antidepres-
sants are potentially involved in the development of both pharmacokinetic and 
pharmacodynamic harmful drug-drug interactions. Correct and comprehensive 
information is a prerequisite for both prevention and adequate management of 
drug interactions with antidepressants in the elderly. Electronic decision support 
systems, such as automated drug interaction alerts, can dramatically reduce the 
number of concomitant prescriptions of antidepressants and other medications 
with potentially hazardous combinations.
Anti-Parkinson drugs
With respect to anti-Parkinson drugs, we ﬁ rst documented that levodopa was 
the most frequently prescribed medication for Parkinson’s disease in Southern 
Italy during the years 2003-2005. However, almost 20 of either levodopa or 
ergot-derived dopamine agonist users received only one medication (chapter 4.1). 
In light of the growing evidence on the risk of ﬁ brotic heart valve disorder with 
the use of pergolide and other ergot-derived dopamine agonists, we then evaluated 
the cardiovascular proﬁ le of parkinsonian patients, who were newly treated with 
either ergot or non-ergot derived dopamine agonists (DAs) in the same setting 
(chapter 4.2). We found that the burden of cardiovascular diseases is a relevant 
concern in incident users of ergot-derived DAs. Our last study was a study on the 
eﬀ ect of ergot and non-ergot derived DAs on the risk of valvular regurgitation. 
For this study the data from three databases (Health Search/Th ales from Italy, 
THIN from UK, and IPCI fron Th e Netherlands) were combined. We conﬁ rmed 
that a dose dependent increase in the risk of symptomatic valvular regurgitation 
was associated with the treatment with either pergolide or cabergoline longer than 
6 months in a cohort of patients with Parkinson disease. Aggregation of data 
from multiple databases provided us with enough amounts of data to observe that 
there was no increase in risk with the use of individual non-ergot derived DAs 
(chapter 4.3).
In the general discussion in chapter 5, the main ﬁ ndings of the research are 
summarized and some methodological issues are discussed in depth to facilitate 
the interpretation of the results. Finally, some recommendations for future re-
search are reported.
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6.2.  Samenvatting
Het percentage ouderen neemt naar verwachting wereldwijd toe tot een aantal van 
2 miljard 65-plussers in 2050. Hand in hand met de toenemende vergrijzing zal ook 
het aantal patiënten met neuropsychiatrische aandoeningen, zoals Parkinson en 
Alzheimer, toenemen. Deze ouderdomsziekten zijn invaliderende aandoeningen 
die gepaard gaan met een afgenomen kwaliteit van leven, institutionalisering op 
jonge(re) leeftijd en een verhoogde mortaliteit. De ziektelast kan worden vermin-
derd door gebruik van psychotrope geneesmiddelen. Problemen zijn echter dat er 
weinig studies zijn gedaan naar werkzaamheid van pyschotrope geneesmiddelen in 
ouderen, dat de tolerantie vaak slecht is en er een hoge kans is op interacties met 
andere medicijnen.
Hoewel er weinig klinische studies naar werkzaamheid en veiligheid zijn gedaan 
is er wel veel ervaring in de praktijk opgedaan doordat deze mensen vaak wel 
worden behandeld. Door de grote hoeveelheid zorggegevens die tegenwoordig in 
geautomatiseerde vorm in databases worden bewaard, is het nu mogelijk om op 
basis van deze data te bestuderen wat het gebruik van deze pyschotrope genees-
middelen in ouderen is en wat de potentiele gezondheids risico’s zijn.
Het doel van het in dit proefschrift beschreven onderzoek was daarom om meer 
inzicht te krijgen in het gebruik en de veiligheid van antipsychotica (hoofdstuk 2), 
antidepressiva (hoofdstuk 3) en anti-Parkinson middelen (hoofdstuk 4) in niet 
geinstitutionaliseerde ouderen.
Antipsychotica
We bestudeerden het gebruik van antipsychotica vooral in Italie. Daarbij toonden 
we aan dat de jaar prevalentie van antispychotica gebruik redelijk constant was in 
de periode 1999-2002 (1.4). Ondanks deze stabiele prevalentie was het gebruik 
van de nieuwere atypische antipsychotica vijf keer toegenomen (0.7 per 1.000 in 
1999 vs. 3.4 per 1.000 in 2002) en nam het gebruik van de conventionele antipsy-
chotica dus af. De toename in gebruik van de atypische antipsyhotica was vooral 
te wijten aan het toenemende gebruik ervan in gedragsstoornissen en psychoses 
die optreden bij dementie. Deze toepassing is niet in overeenstemming met het 
registratiebesluit en wordt daarom als oﬀ -label geclassiﬁ ceerd (hoofdstuk 2.1).
Vanaf 2003 hebben verscheidene overheden waarschuwingen doen uitgaan over 
het risico op beroertes als gevolg van het gebruik van antipsychotica in demente 
ouderen. We hebben bestudeerd welke eﬀ ecten deze waarschuwingen hadden op 
het voorschrijven van antipsychotica in ouderen. -We hebben waargenomen dat 
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in de Italiaanse huisartsenpraktijken het gebruik van atypische antipsychotica bij 
ouderen met dementie signiﬁ cant is afgenomen na de waarschuwingen hoewel het 
totale antipsychoticagebruik gelijk gebleven is, 3 van de ouderen krijgt tenminste 
één antispychoticum van de huisarts. Ongeveer 40 hiervan werd voorgeschreven 
voor dementie en gerelateerde aandoeningen (hoofdstuk 2.2).
In hoofdstuk 2.3 beschrijven we een retrospectief cohort onderzoek dat werd 
uitgevoerd door gebruik te maken van de Health Search Database, een database 
met elektronische medische dossiers van huisartsen in Italie. Hierbij vonden we 
dat er in vergelijking met niet-gebruikers een toegenomen risico is op hersen-
bloeding bij het gebruik van typische en atypische antipsychotica in ouderen. 
Vervolgens hebben wij het overlijdensrisico bij gebruik van antipsychotica in 
ouderen onderzocht middels een genest patiënt-controle onderzoek in een Neder-
landse longitudinale database met elektronische medische dossiers, namelijk IPCI 
(hoofdstuk 2.4). Hierin zagen we dat het risico op overlijden hoger is tijdens 
gebruik van antipsychotica en ook nog dosis afhankelijk is. Het verhoogde risico 
was gelijk voor gebruikers van atypische en typische antipsychotica, terwijl de 
waarschuwingen van de overheden zich eigenlijk alleen hadden gericht op de 
atypische antipsychotica. Als vervolg op het onderzoek naar mortaliteit waarin 
bleek dat veel mensen overleden aan een pneumonie, hebben we een additioneel 
onderzoek in dezelfde IPCI database gedaan naar de relatie tussen gebruik van 
antipyschotica en het risico op fatale en niet-fatale longontsteking. Hierin zagen 
we dat het gebruik van antipsychotica leidt tot een dosis-gerelateerde toename van 
het risico op pneumonie. Fataal aﬂ opende longontstekingen waren vooral geasso-
cieerd met het gebruik van atypische antipsychotica. Het risico op het krijgen van 
een longontsteking nam rechtlijnig toe met de aﬃ  nitieit van antipsychotica voor 
histaminerge H1 receptoren waarmee een mogelijk mechanisme tussen gebruik 
van deze middelen en de eﬀ ecten kan worden voorgesteld (hoofdstuk 2.5).
In hoofdstuk 2.6 hebben wij de beschikbare literatuur over de veiligheid van ty-
pische en atypische antipsychotica in demente ouderen, samengevat. Meta-analyses 
van klinische en observationele studies laten over het algemeen een vergelijkbare 
toename zien van het risico op mortaliteit en cerebrovasculaire bijwerkingen in 
conventionele en atypische antipsychoticagebruikers. Bij het voorschrijven van 
conventionele antipsychotica moet daarnaast nog rekening gehouden worden met 
een aantal speciﬁ eke additionele veiligheidsrisicos, namelijk artimiëen, extrapyra-
midale symptomen en metabole eﬀ ecten (e.g. toegenomen risico op diabetes en 
obesitas).
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Antidepressiva
Om antidepressiva te onderzoeken hebben we allereerst het gebruik hiervan in 
kaart gebracht. De prevalentie van antidepressivagebruik in Zuid Italie nam toe 
in 2003-2004 door een sterke toename van het gebruik van selectieve serotonine 
inhibitoren (SSRIs). In 2004 werden 9,9 van de patiënten tussen de 65 en 74 
jaar, 13.8 van de patiënten tussen de 75 en 84 jaar en 12.4 van de patiënten van 
85 jaar en ouder behandeld met antidepressiva. SSRIs werden voorgeschreven in 
ongeveer tweederde van de nieuwe antidepressiva behandelingen. SSRIs werden 
vooral voorgeschreven voor depressie op oudere leeftijd, hetgeen in overeenstem-
ming is met bestaande richtlijnen (hoofdstuk 3.1).
Het gebruik van antidepressiva is in verband gebracht met hersenaandoeningen, 
maar er is geen uitsluitsel of het risico nu verlaagd (beroerte) of juist verhoogd 
(hersenbloeding) is. Op basis van de IPCI database hebben wij aangetoond dat, 
in tegenstelling tot eerdere berichtgeving, SSRIs en ander antidepressivumgebuik 
geen beschermend eﬀ ect hebben op beroertes in ouderen (hoofdstuk 3.2). In 
vergelijking met niet-gebruikers is het gebruik van SSRIs mogelijk geassocieerd 
met een kleine toename van het risico op een beroerte in de geriatrische bevolking, 
vooral vlak na de start van de behandeling.
Vervolgens hebben wij de literatuur samengevat over interacties tussen anti-
depressiva en andere geneesmiddelen (hoofdstuk 3.3). TCA’s, SSRI’s en andere 
nieuwe antidepressiva zijn mogelijk betrokken bij het ontstaan van schadelijke 
pharmacokinetische en pharmacodynamische interacties tussen medicijnen. Een 
goede informatieverstrekking en surveillance is daarom een vereiste zowel voor 
preventie alswel adequeate behandeling van interacties tussen antidepressiva en 
andere medicijnen in ouderen.
Anti-Parkinson medicatie
Met betrekking tot anti-Parkinson medicatie hebben we in een geneesmiddel 
gebruik studie allereerst vastgesteld dat levodopa het meest gebruikte medicament 
was voor de ziekte van Parkinson in Zuid Italië in 2003-2005. Opvallend was dat 
veel gebruikers van dopamine agonisten slechts één voorschrift kregen (hoofdstuk 
4.1).
Er is toenemend bewijs dat dopamine agonistsen die afgeleid zijn van ergot 
derivaten, zoals pergolide en cabergoline, het risico op ﬁ brotische hartklepaf-
wijkingen verhogen. Daarom hebben we in eerste instantie onderzocht wat het 
cardiovasculaire proﬁ el was van Parkinson patiënten die voor het eerst behan-
deld werden met ergot- en niet-ergot-gederiveerde dopamine agonsiten (DA’s) 
(hoofdstuk 4.2). We vonden dat nieuwe gebruikers van ergot-gederiveerde DA’s 
een hoger basis risico hebben op het ontstaan van cardiovasculaire aandoeningen, 
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dit is belangrijk indien vergelijkende studies worden gedaan. Onze laatste studie 
betreft de vergelijking het risico op valvulaire regurgitatie tussen gebruikers van 
ergot- en niet-ergot-gederiveerde dopamine agonisten en levodopa gebruikers. 
Voor deze studie hebben wij data van drie databases (Health Search uit Italië, 
THIN uit Engeland en IPCI uit Nederland) gecombineerd. In deze studie werd 
bevestigd dat personen die langdurig pergolide of cabergoline gebruiken voor 
Parkinson een verhoogd risico hebben op symptomatische valvulaire regurgitatie 
in vergelijking met mensen die levodopa gebruiken. Er was geen bewijs voor een 
toegenomen risico bij gebruik van niet-ergot-gederiveerde dopamine agonisten 
(hoofdstuk 4.3).
In de algemene discussie in hoofdstuk 5 worden de belangrijkste bevindingen 
samengevat en wordt verder ingegaan op enkele methodologische zaken om de 
interpretatie van de resultaten te vergemakkelijken. Als laatste volgen er enkele 
aanbevelingen voor toekomstig onderzoek.
Gianluca BW.indd   254 25-May-09   11:24:18 AM
255
A C K N O W L E D G M E N T S
Looking behind at the last years, I consider myself as very lucky since I was in-
tegrated in three beautiful “scientiﬁ c families” in Messina (Sicily), Florence and 
Rotterdam.
All of them contributed equally in supporting me all over this incredible trip 
aimed at performing my research thesis.
In 2003, I started to work in the laboratory of Pharmacology at the University 
of Messina, doing in vivo experiments. Here, prof. Caputi, you have been the 
ﬁ rst one that enthusiastically talked to me about pharmacovigilance and phar-
macoepidemiology. Hence, you easily convinced me to come out from the lab 
and introduced me in the world of clinical pharmacology. While sitting in the 
canteen of the Pharmacology institute, you said: “once in the future you’ll thank 
me for that”. Now it’s time to thank you from my heart. I want to thank you also 
because you gave me the possibility to educate myself ﬁ rst in Florence and then 
in Rotterdam.
Working in Messina oﬀ ered me the opportunity to collaborate with other valuable 
researchers, namely prof. Eddy Spina, Dr. Enzo Arcoraci, Dr. Loredana Alacqua, 
Dr. Rodolfo Savica Somehow all of you are owners of small pieces of this thesis 
and I thank you for the time, the eﬀ orts and the patience that you dedicated me 
during my research. From Messina, I want to thank some other colleagues, such 
as Alessandra Russo, Antonella Catania, and Giovanni Polimeni, who have been 
particularly close to me depite the large geographical distance.
Without data, research does not exist. I thank you Dr. Michele Tari and Dr. 
Salvatore Moretti for providing us with data from Local Health Unit of Caserta-1, 
which have been used in some of the investigations included in this thesis.
During my research period, I had the fortune to collaborate with other excellent 
Italian scientists, such as prof. Giovanni Gambassi, Dr. Nicola Vanacore and Dr. 
Corrado Barbui. Th ank you for the enthusiasm and the outstanding scientiﬁ c 
knowledge that you shared with me.
My second “working family” is in Florence and is called Health Search. Here I 
undertook part of the research of this thesis and I spent one year and a half of 
Gianluca BW.indd   255 25-May-09   11:24:18 AM
256
Acknowledgments
my life. First of all, I want to thank you, Giampiero. You taught me the basics 
for conducting scientiﬁ c research and you are “responsible” for my moving to 
Rotterdam. Th en, I want to thank you Iacopo. You always made me feel part of 
the family. Francesco (Grappino), Serena, Emiliano, Flora, Giovannina, thank 
all of you very much for your help and friendship, despite my thousand phone 
calls. And thank you Dr. Claudio Cricelli and Dr. Carlo Niccolai, you oﬃ  cially 
represent the Italian College of General Practitioners, which oﬀ ered me the op-
portunity to perform some of the studies described in this thesis.
My third scientiﬁ c family is in Rotterdam, at the Department of Medical Infor-
matics of the Erasmus University Medical Center, where I was adopted since 2005. 
Th ere is a person that trusted me and my working skills since the beginning, this 
person is prof.dr. Miriam Sturkenboom! Th ank you, Miriam for your brilliant 
scientiﬁ c supervision as well as for the immense psychological support and the 
empathy when listening to my typically Italian complaints on Dutch weather and 
food, and thanks also for your advices in all the critical situations that I faced with 
in the last four years. If we call you “Grande Madre” is not just by coincidence.
Th ank you “brothers in science” Seppe and Roelof, and “sisters in science” Vera, 
Sandra, Emine, and, in particular, minha amiga Ana, my zusje Fatma and Precy, 
who tolerated my mood changes and my Italian jokes while sharing the room. All 
of you made my working time more pleasurable. Dear brother Seppe thank you 
also for all the eﬀ orts (unfortunately, not always succesful!) in stimulating social 
interactions and for your support during the last hectic period.
At the Department of Medical Informatics, I had the pleasure to collaborate with 
other valuable scientists, such as Dr. Jeanne Dieleman, Dr. Eva van Soest, and Dr. 
Katia Verhamme and with whom I shared my last stressful deadlines. Th ank all of 
you for the eﬀ orts and the energy that you dedicated to my thesis.
Also in Rotterdam I had the privilege to “feed” my scientiﬁ c culture with fruitful 
and amazing discussions (sometimes accomplished by nice glasses of wine!) on 
diﬀ erent methodologies and lines of research. Th ank you for that, prof.dr. Johan 
van der Lei, Dr. Jan Kors, Dr. Erik Van Mullingen, and prof.dr. Bruno Stricker.
Some persons represent the soul of the Department of Medical Informatics. 
Th ey work hard and with enthusiasm, giving us the opportunity to conduct the 
research. Dank je wel Desiree, Tineke, Carmen, Sander, and Marcel, Mees, Ria, 
collega Ann, and Kris (you saved the data from my crashed computer and we 
shared several “gezellige avonden genietend van karafj es rode wijn”. Dziękuję!).
Gianluca BW.indd   256 25-May-09   11:24:18 AM
257
Acknowledgments
During my staying in Rotterdam, I was delighted to be in touch with an extraordi-
nary number of people coming from diﬀ erent Countries. With some of them I got 
particularly along. Th ank you for the friendship and constant help, Oscarillo and 
Lourdes, Francesca (Chicchen), Cristina, Nuno, Mehlika, Gino and Alexia and all 
the other friends from the Radiology Band. And thanks to all the other precious 
Dutch and “Mediterranean” friends with whom I had the pleasure to share lovely 
Italian dinners and other pleasant activities. I enjoyed also the company of other 
friends that moved from Th e Netherlands to other Countries, such as Francesca 
(Pugliese), Stifano, Marco, Alessandro, Francesco, Spyros and Toshika. It was a 
pleasure to meet all of you!
A part this thesis, Rotterdam gave me another gift, Carmen! Th ank you for the 
lovely attentions. Although I met you at the end of my PhD, I do want to share 
fully with you the happiness for this achieved goal and for all the next ones that I 
will share with you.
To complete my thesis I decided to leave my Country. Sometimes I even felt 
guilty for that. I love very much Sicily, its heart-warming sun, sea, and people. I 
extremely missed all of that. I missed even more my family and friends.
Th anks to my uncles, aunts, cousins and friends that supported me from Italy 
(also sending me delicious food or nostalgic gifts) and visited me in Th e Nether-
lands. I will never forget the Christmas dinner with my family in Rotterdam.
Grazie Papà e Franco, without your constant psychological support, probably I 
wouldn’t have reached the end of this PhD. I dedicate this thesis to both of you. 
Hopefully, this can reward you for my absence.
I regret my Mother is not here, but I’m sure, she accomplished me step by step 
during this incredible trip. Dear Mother, you transferred to me your love and your 
enthusiasm for the Research and the Science. All my successes will be always our 
successes.
Gianluca BW.indd   257 25-May-09   11:24:18 AM
Gianluca BW.indd   258 25-May-09   11:24:18 AM
259
P H D  P O R T F O L I O
Name: Gianluca Triﬁ rò
Erasmus MC Department: Medical Informatics
Collaboration: University of Messina, Messina – Italy
Promotors: Prof. M.C.J.M. Sturkenboom and Prof A.P. Caputi
1. PHD TRAINING
Research skills
Statistics and methodology
2002-2006  Post-graduation Degree in Clinical Pharmacology at the University 
of Messina, Messina, Italy.
2006-2008  Master of Science in Clinical Epidemiology, Netherlands Institute 
for Health Sciences, Erasmus University, Rotterdam, Th e Nether-
lands.
Oral Presentations
2008  24th International Conference on Pharmacoepidemiology & 
Th erapeutic Risk Management, Copenaghen – Denmark. Fatal 
and Non−Fatal Pneumonia Associated with Atypical and Typical 
Antipsychotic Use in Elderly Patients.
  II meeting “Th e contribution of Alzheimer evaluation centres 
in the management of patients with dementia”, Italian National 
Health Institute, Rome, Italy. “Prescribing pattern of antipsychotic 
drugs in Italian general population: Focus on dementia in the years 
2000-2005”.
  8th Annual Meeting of International Society of Pharmacovigilance, 
Buenos Aires – Argentina. Data mining on large health record da-
tabases for detecting adverse reactions: which events to monitor?
2007  8TH Congress Of European Association For Clinical Pharmacol-
ogy And Th erapeutics (EACPT), Amsterdam – the Netherlands. 
“Did the marketing of new antiepileptic drugs (AEDs) change the 
prescribing pattern of AEDs in Italy?”
Gianluca BW.indd   259 25-May-09   11:24:18 AM
260
PhD Portfolio
2006  XV National Conference of Italian NeuroPsychoPharmacology 
Society (SINPF). Genova, Italy. “Monitoring models for neurop-
sychiatry medications: limits and advantages of databases”.
  XV National Conference on the “EVALUATION OF DRUG 
UTILIZATION AND SAFETY: EXPERIENCES IN ITALY”, 
Italian National Health Institute, Rome, Italy. “Risk of mortality 
associated with the use of antipsychotic drugs. A population-based 
study”
Seminars and workshop
2008-2009  Advanced topics in Pharmacoepidemiological methods, special 
skill workshop, International Conference on Pharmacoepidemiol-
ogy and Th erapeutic Risk.
2006-2008  Research seminars, Department of Epidemiology and Medical 
Informatics, Erasmus MC, Rotterdam, Th e Netherlands.
2006-2008  Dutch National meeting of Medical informatics PhD
Teaching
2005-2008  Supervising and teaching medical students at the University of 
Messina, Messina, Italy.
2006-2007  Teaching on the drug prescribing at the Local Health Unit of 
Caserta, Italy.
2005-2007  Teaching at the Master course on the drug management for health 
professionals at the Local Health Units of Palermo, Enna, Messina 
– Italy.
Others
2008-current  Work package Leader of the European project “Exploring and 
Understanding Adverse Drug Reactions by integrative mining of 
clinical records and biomedical knowledge (EU-ADR)”
2006-current  Referee activities for various international journals (Pharma-
coepidemiology and Drug Safety, Expert Opinion on Drug Safety, 
Psychiatric Services, Epilepsy Research, Neuroepidemiology).
2007  Expert in the Seventh Research Framework Programme for Euro-
pean Union (‘FP7-HEALTH-2007-Drug Safety’).
Gianluca BW.indd   260 25-May-09   11:24:18 AM
261
A B O U T  T H E  A U T H O R
Th e author of this thesis was born in Messina (Italy) on 30th January, 1978. After 
obtaining a grammar diploma with full grades at the Liceo Classico “F. Maurolico” 
in Messina in 1996, he started to study Medicine and Surgery at the University 
of Messina, for which he graduated cum laude in 2002. In 2005, he started to 
work as a PhD student at the Department of Medical Informatics of Erasmus 
Medical Center (EMC) in collaboration with the Department of Clinical and Ex-
perimental Medicine and Pharmacology of the University of Messina. Meanwhile, 
in 2006 he obtained the Postgraduate degree cum laude in Clinical Pharmacology 
at the University of Messina. In 2008, he obtained a Master of Science degree in 
Clinical Epidemiology at the National Institute of Health Sciences (Nihes) in Th e 
Netherlands.
Aside the research that is presented in this thesis, he is currently involved in the 
scientiﬁ c management of the European Project “Exploring and Understanding 
Adverse Drug Reactions by integrative mining of clinical records and biomedical 
knowledge (EU-ADR)” that is coordinated by the Department of Medical Infor-
matics of the EMC. Furthermore, he collaborates as expert in pharmacoepidemi-
ology with the Research Institute “IRCCS Centro Neurolesi - Bonino-Pulejo”, 
Messina (Italy) and the Health Search/Th ales database of the Italian College of 
General Practitioners (SIMG), Florence (Italy). From SIMG he received in 2006 
a grant for a project that was funded by Italian Drug Agency: “Evaluation of 
prescribing pattern and safety proﬁ le of antidepressant and antipsychotic medica-
tions in Italian general practice”. In 2007, he was expert in the Seventh Research 
Framework Programme for European Union (call ‘FP7-HEALTH-2007-Drug 
Safety’).
Additionally, he is a scientiﬁ c collaborator for the update and management of 
the website on pharmacovigilance (www.farmacovigilanza.org) owned to Clinical 
Pharmacology section of Italian Society of Pharmacology.
Gianluca BW.indd   261 25-May-09   11:24:18 AM
Gianluca BW.indd   262 25-May-09   11:24:18 AM
263
B I B L I O G R A P H Y
PUBLICATIONS INCLUDED IN THIS THESIS:
Antipsychotic drugs in elderly: use and safety
Triﬁ rò G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic 
prescribing pattern among Italian general practitioners: a population-based study 
during 1999-2002 years. Eur J Clin Pharmacol. 2005 Mar;61(1):47-53.
Triﬁ rò G., Sini G., Sturkenboom M, Vanacore N, Mazzaglia G, Caputi AP, 
Cricelli C, Brignoli O, Aguglia E, Biggio G, Samani F. Prescribing pattern of anti-
psychotic drugs in Italian general population: focus on elderly dementia during 
the years 2000-2005. Submitted for publication
Sacchetti E, Triﬁ rò G, Caputi AP, Turrina C, Spina E, Cricelli C, Brignoli O, Sessa E, 
Mazzaglia G. Risk of stroke with typical and atypical anti-psychotics: a retrospective 
cohort study including unexposed subjects. J Psychopharmacol. 2008; 22:39-46.
Triﬁ rò G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom 
MC. All-cause mortality associated with atypical and typical antipsychotics in 
demented outpatients. Pharmacoepidemiol Drug Saf. 2007;16:538-44.
Triﬁ rò G., Sen E.F., Gambassi G., Achille P. Caputi, Bagnardi V, Brea J, Sturken-
boom M.C.J.M.. Fatal and non fatal community acquired pneumonia associated 
with antipsychotic drug use in elderly patients. Submitted for publication.
Triﬁ rò G, Spina E, Gambassi G. Safety of antipsychotics in elderly patients with 
dementia: atypical and conventional agents have the same risks? Pharmacological 
research. Pharmacol Res. 2009; 59:1-12.
Antidepressant drugs in elderly: use and safety
Triﬁ rò G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, Caputi AP, Arcoraci 
V and UVEC group. Antidepressant drugs: prevalence, incidence and indication 
of use in general practice of Southern Italy during the years 2003-2004. Pharma-
coepidemiol Drug Saf. 2007; 16:552-9.
Gianluca BW.indd   263 25-May-09   11:24:18 AM
264
Bibliography
Spina E and Triﬁ rò G. Preventing drug interactions with antidepressants in the 
elderly. Aging Health 2007; 3(2): 231-243. Review.
Triﬁ rò G, Dieleman J, Sen Elif F, Gambassi G, Brea J, Sturkenboom MCJM. 
Risk of ischemic stroke associated with antidepressant drug use in elderly persons. 
Submitted for publication
Anti-Parkinson drugs in elderly: use and safety
Triﬁ rò G, Savica R, Morgante L, Vanacore N, Tari M, Moretti S, Galdo M, Spina 
E, Caputi AP, UVEC group and Arcoraci V. Prescribing pattern of Anti-Parkinson 
drugs in Southern Italy: cross-sectional analysis in the years 2003-5. Parkinsonism 
Relat Disord. 2008;14(5):420-5.
Triﬁ rò G, Morgante L, Tari M, Arcoraci V, Savica R. Burden of cardiovascular 
diseases in elderly with Parkinson’s disease who start a dopamine agonist agent. J 
Am Geriatr Soc. 2008; 56:371-3.
OTHER PUBLICATIONS:
1. Savica R, Longo M, La Spina P, Pitrone A, Calabrò R.S., Triﬁ rò G, Cotroneo 
M, Granata F, Musolino R. Cerebellar stroke in elderly patient with Basilar Artery 
Agenesia: a case report. Journal of Stroke and Cerebrovascular Diseases (in press).
2. Alacqua M, Triﬁ rò G, Spina E, Moretti S, Tari DU, Bramanti P, Caputi 
AP, and Arcoraci V. Newer and older antiepileptic drug use in Southern Italy: a 
population based study during the years 2003-2005. Epilepsy Research (in press).
3. Polimeni G, Russo A, Catania MA, Aiello A, Oteri A, Triﬁ rò G, Calapai G, 
Sautebin L, Iacobelli M, Caputi AP. Drug safety information through the internet: 
the experience of an Italian website. Drug Saf. 2009; 32(3):245-53.
4. Alacqua M, Triﬁ rò G, Cavagna L, Caporali R, Montecucco CM, Moretti 
S, Tari DU, Galdo M, Caputi AP, Arcoraci V. Prescribing pattern of drugs in 
the treatment of osteoarthritis in Italian general practice: Th e eﬀ ect of rofecoxib 
withdrawal. Arthritis Rheum 2008; 59:568-574.
5. Mazzaglia G, Yurgin N, Boye KS, Triﬁ rò G, Cottrell S, Allen E, Filippi A, 
Medea G, Cricelli C. Prevalence and antihyperglycemic prescribing trends for 
Gianluca BW.indd   264 25-May-09   11:24:18 AM
265
Bibliography
patients with type 2 diabetes in Italy: a four year descriptive study from national 
primary care data. Pharmacol Res 2008; 57:358-63.
6. Triﬁ rò G, Alacqua M, Corrao S, Moretti S, Tari DU, Galdo M; UVEC Group, 
Caputi AP, Arcoraci V. Lipid-lowering drug use in Italian primary care: eﬀ ects of 
reimbursement criteria revision. Eur J Clin Pharmacol 2008; 64:619-25.
7. Triﬁ rò G, Alacqua M, Corrao S, Tari M, Arcoraci V. Statins for the primary 
prevention of cardiovascular events in elderly patients: a picture from clinical prac-
tice without strong evidence from clinical trials. J Am Geriatr Soc 2008; 56:175-7.
8. Alacqua M, Triﬁ rò G, Arcoraci V, Germanò E, Magazù A, Calarese T, Di Vita 
G, Gagliano C, Spina E. Use and tolerability of newer antipsychotics and antide-
pressants: a chart review in a paediatric setting. Pharm World Sci 2008; 30:44-50.
9. Savica R, Beghi E, Mazzaglia G, Innocenti F, Brignoli O, Cricelli C, Caputi 
AP, Musolino R, Spina E, Triﬁ rò G. Prescribing patterns of antiepileptic drugs in 
Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol 
2007; 14:1317-21.
10. Triﬁ rò G, Spina E, Savica R, Beghi E, Innocenti F, Mazzaglia G, Brignoli 
O, Cricelli C, Caputi AP. Prescribing pattern of anti-epileptic drugs in Italy: a 
population-based study. 8th Congress of the EACPT. Monduzzi Editore, pp. 43-
46, 2007.
11. Triﬁ rò G, Corrao S, Alacqua M, Moretti S, Tari M, Caputi AP, Arcoraci V; 
UVEC Group. Interaction risk with proton pump inhibitors in general practice: 
signiﬁ cant disagreement between diﬀ erent drug-related information sources. Br J 
Clin Pharmacol 2006; 62:582-90.
12. Triﬁ rò G. Drug-drug interactions and statin therapy. South Med J 2006; 
99:1325-6.
13. Filippi A, Sessa E, Pecchioli S, Triﬁ rò G, Samani F, Mazzaglia G. Homecare 
for patients with heart failure in Italy. Ital Heart J 2005; 6:573-7.
14. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Triﬁ rò G, Cricelli 
C, Brignoli O, Caputi AP. Patterns of persistence with antihypertensive medica-
Gianluca BW.indd   265 25-May-09   11:24:18 AM
266
Bibliography
tions in newly diagnosed hypertensive patients in Italy: a retrospective cohort 
study in primary care. J Hypertens 2005; 23:2093-100.
15. Piacentini N, Triﬁ rò G, Tari M, Moretti S, UVEC group, Arcoraci V. Statin-
macrolide interaction risk: a population-based study throughout a general practice 
database. Eur J Clin Pharmacol 2005;61:615-20.
16. Triﬁ rò G, Calogero G, Menniti Ippolito F, Cosentino M, Giuliani R, Con-
forti A, Venegoni M, Mazzaglia G, Caputi AP. Adverse drug events in emergency 
department population: a prospective Italian study. Pharmacoepidemiol Drug Saf 
2005; 14:333-40.
17. Filippi A, Sessa E, Triﬁ rò G, Mazzaglia G, Pecchioli S, Caputi AP, Cricelli C. 
Oral anticoagulant therapy in Italy: prescribing prevalence and clinical reasons. 
Pharmacol Res 2004; 50:601-3.
Gianluca BW.indd   266 25-May-09   11:24:18 AM
